Sonic hedgehog signalling in chronic renal allograft nephropathy and peripheral immunity by Wakelin, Sonia Jane.
Sonic hedgehog signalling in chronic renal allograft
nephropathy and peripheral immunity
Sonia Jane Wakelin
A thesis submitted for the degree ofDoctor ofPhilosophy
University of Edinburgh, 2005
Edinburgh University Medical School
Abstract
The highly conserved Sonic hedgehog (Shh) signalling pathway has been shown to
play an important role in the determination of cell fate and proliferation during
development. Whilst the role of Shh signalling in the embryo has become
increasingly well understood, the possible roles for Shh signalling in the adult are
less clear. Recent reports in the literature have lent support to roles for Shh signalling
in both remodelling processes and the maintenance of peripheral immunity.
Chronic renal allograft nephropathy (CAN) is a major cause of long-term renal
failure in kidney allograft recipients. It is characterised by interstitial fibrosis, tubular
atrophy, vasculopathy and a mononuclear cell infiltration. The inflammatory cell
infiltrate consists ofmainly macrophages and T cells, and macrophage infiltration
and activity correlate directly with graft survival. Transforming Growth Factor Beta
(TGF-13) and Vascular Endothelial Growth Factor (VEGF) are among a number of
factors produced by activated macrophages and both growth factors have been
demonstrated to be upregulated in CAN. That Shh signalling may play a role in CAN
is suggested by recent suggestions in the literature that the Shh signalling pathway
expression is upregulated in other fibrotic conditions, notably idiopathic pulmonary
fibrosis and in murine models ofpulmonary fibrosis. Furthermore, both TGF-P and
VEGF have been shown to be upregulated by Shh signalling. Thus, the first
hypothesis central to this thesis was that Shh signalling pathway components are
expressed in and relevant to normal and CAN kidney. The results presented
demonstrate that, although Shh is expressed in normal renal epithelium, this
expression is lost in CAN, a finding in contrast to observations in models of lung
fibrosis. Possible reasons for this loss of expression are further investigated using
cultures of a renal tubular epithelial cell line (ACHN) and primary cultures ofmurine
epithelial cells.
Another recently identified area in which Shh signalling may be important in the
adult is peripheral immunity, with recent reports demonstrating that the addition of
recombinant Shh to cultures of activated CD4+ T cells modulates the proliferation
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and cytokine effector function of these cells. Furthermore, that macrophages express
the receptor for Shh, Ptc, and that certain macrophage products including TGF-P and
VEGF have been shown to be upregulated by Shh signalling lends support to a
possible role for Shh signalling in macrophages, an area which has, to date, not been
explored. Thus, the second hypothesis underlying the work presented in this thesis
was that Shh signalling plays a role in peripheral immunity. In particular, the role of
Shh signalling in macrophages and CD4+ T cells has been investigated. The findings
presented suggest that recombinant Shh modulates the cytokine effector function of
macrophages but that the predominant effects observed are most likely to be due to
low levels of endotoxin contamination present within the recombinant proteins
utilised to explore the effects of Shh in vitro. Shh also modulated the cytokine
effector function, but not the proliferation of activated CD4+ T cells, a finding partly
in keeping with previous reports in the literature. However, in contrast to previous
reports, blockade of Shh signalling failed to abrogate either the proliferation or
cytokine effector response of activated CD4+ T cells. Possible reasons for this
disparity are discussed. Taken together, the findings from these investigations
highlight possible roles for Shh signalling in adult kidney and peripheral immunity
but emphasize the need for good quality, commercially available reagents to
investigate the pathway. The current lack of such reagents precludes firm
conclusions regarding possible roles for Shh signalling in peripheral immunity and
the kidney or, indeed, roles relevant to the inflammatory processes seen in CAN.
3
Declaration
I hereby declare that this thesis has been composed solely by myself and has not been
accepted in any previous application for candidature for a higher degree. All work
presented in this thesis was, unless acknowledged, initiated and executed by myself.




Firstly, I am grateful to Professor James Garden and Mr John Forsythe from the
Edinburgh Royal Infirmary Department of Surgery and Transplant Unit. Without
their interest and support, this PhD would not have been possible. I am also grateful
to Dr Sarah Howie whose patience, moral support and tireless optimism as a
supervisor have been invaluable throughout this PhD. I would like to thank Professor
Jonathan Lamb for his enthusiasm, encouragement and ideas during the early part of
my PhD and I would also like to thank those who have provided financial support for
the work presented in this thesis. Specifically in this regard, I would like to thank
Edinburgh Royal Infirmary Department of Surgery and Transplant Unit whose
funding initiated this work; the Royal College of Surgeons ofEdinburgh; the Chief
Scientist Office and the Wellcome Trust for supporting me as a Wellcome Trust
Clinical Research Training Fellow.
Many thanks are due to all those in the MRC Centre for Inflammation Research who
have been able to offer a wealth of experience and invaluable advice throughout this
PhD. I am grateful to all those who have offered technical advice and, specifically, to
Shonna McCall for her invaluable flow cytometry and cell sorting expertise.
Last, but by no means least, I would like to thank Kevin for his love, support and
patience throughout this PhD. I would also like to thank my parents for their love and
encouragement and Cleo and Lucy for their moral support.
5
"We can judge ourprogress by the courage ofour questions and the depth ofour
answers, our willingness to embrace what is true rather than whatfeels good"








LIST OF FIGURES 17
LIST OF TABLES 23




1.2 The Sonic Hedgehog Signalling Pathway 28
1.2.1 Introduction 28
1.2.2 The Shh Signalling Pathway 29
1.2.3 Cyclopamine 33
1.2.4 The Gli family of transcription factors 33
1.2.5 Targets of Hh signalling 35
1.2.6 Other players in the Shh pathway 37
1.2.7 Shh signalling in the kidney 38
1.2.8 Shh signalling and the immune system 40
1.2.9 Inflammation and repair 42
1.3 Chronic Renal Allograft Nephropathy (CAN) 47
1.3.1 Introduction 47
1.3.2 Aetiology 48
1.3.3 Histopathological Changes in CAN 50
1.3.4 Macrophages and macrophage products in CAN 52
1.4 Macrophage Activation 55
1.4.1 Introduction 55
1.4.2 The Innate Immune System 55
1.4.3 The Toll-Like Receptors 56
1.4.4 The Macrophage Effector Response 59
7
1.5 T Cell Activation 63
1.5.1 Introduction 63
1.5.2 Antigen presentation 63
1.5.3 T cell receptor mediated activation 65
1.5.4 The CD4+ T cell effector response 68
1.6 Hypotheses 71
Chapter 2
MATERIALS AND METHODS 73
2.1 Materials 74
2.1.1 Media 74
2.1.2 Cell Separation and Stimulation Reagents 75
2.1.3 Flow Cytometry Reagents 76
2.1.4 Immunoassay Reagents 76
2.1.5 Immunohistochemistry Reagents 77
2.1.6 Molecular Biology Reagents 78
2.1.7 Protein Analysis Reagents 78
2.2 Methods 80
2.2.1 Macrophage experiments using human peripheral blood monocyte-
derived macrophages 80
2.2.1.1 Isolation of peripheral blood mononuclear cells (PBMCs) for monocyte
isolation 80
2.2.1.2 Macrophage purification and culture 80
2.2.1.3 Macrophage stimulation experiments 81
2.2.2 T cell experiments using human peripheral blood-derived T cells 82
2.2.2.1 Isolation of peripheral blood mononuclear cells (PBMCs) for CD4+ T
cell isolation 82
2.2.2.2 CD4+ T cell purification and culture 82
2.2.2.3 CD4+ T cell stimulations using anti-CD3s and anti-CD28 antibodies
84
2.2.2.4 Mixed leukocyte reactions (MLRs) 85
2.2.2.5 Proliferation assay 85
2.2.3 Renal Epithelial Experiments 86
2.2.3.1 AC1TN Cell Line Management 86
2.2.3.2 Murine primary renal epithelial cell (REC) culture 86
2.2.4 Protein Analysis 87
2.2.4.1 Flow Cytometry 87
2.2.4.2 Enzyme Linked Immunosorbent Assay (ELISA) 87
8
2.2.4.3 Cytometric Bead Arrays (CBA) 88
2.2.4.4 Immunohistochemistry 91
2.2.4.5 Western Blotting 95
2.2.5 Molecular Biology 97
2.2.5.1 RNA Extraction 97
2.2.5.2 Reverse Transcription ofRNA to cDNA 98
2.2.5.3 Standard PCR 98
2.2.5.4 Real Time PCR 101
2.2.6 Endotoxin Assay 103
2.2.7 MTT Assay 103
Chapter 3
SONIC HEDGEHOG IS DIFFERENTIALLY EXPRESSED IN NORMAL
KIDNEY AND CHRONIC RENAL ALLOGRAFT NEPHROPATHY 105
3.1 Introduction 106
3.2 The hallmarks of CAN 109
3.3 TGF-p and VEGF are expressed in CAN 113
3.4 Shh is expressed in normal adult human kidney 115
3.5 Ptc, but not Shh, is expressed in CAN 118
3.5.1 Immunohistochemistry 118
3.5.2 Real-time PCR 118
3.6 Shh and Ptc expression are not apparent in renal biopsy specimens ... 122
3.7 Discussion 125
3.7.1 Shh is expressed in normal adult human kidney but not CAN 125




THE EFFECT OF IMMUNOSUPPRESSIVE AGENTS AND CELL DAMAGE
ON SONIC HEDGEHOG EXPRESSION IN RENAL EPITHELIAL CELL
CULTURES 135
4.1 Introduction 136
4.2 The effect of the immunosuppressive agents ciclosporin and
dexamethasone on Shh expression in ACHN cells 138
4.2.1 Ciclosporin upregulates Shh expression in ACHN renal epithelial cells
138
4.2.2 Evaluating the toxicity of ciclosporin and dexamethasone to ACHN
renal epithelial cells 143
4.3 Shh release from ACHN cells 145
4.3.1 ELISA 145
4.3.2 Western blotting 146
4.3.2.1 Shh protein is detected in ACHN cells by Western blotting 146
4.3.2.2 Shh is not detected in the supernatant of cells treated with ciclosporin
or dexamethasone 149
4.4 Primary murine renal epithelial cell cultures 150
4.4.1 Primary renal epithelial cell (REC) cultures 151
4.4.2 Shh and Ptc expression in REC cultures 154
4.5 Shh expression by and release from REC cultures in response to
ciclosporin and dexamethasone 156
4.6 Damage fails to modulate Shh release from RECs 159
4.6.1 Oxidative cell damage 159
4.6.2 Ultraviolet B irradiation-induced damage 163
4.7 Discussion 165
4.7.1 The effect of immunosuppressive agents on Shh expression in renal
tubular epithelium 166




THE EFFECT OF SONIC HEDGEHOG ON HUMAN MACROPHAGE
EFFECTOR FUNCTION 175
5.1 Introduction 176
5.2 Shh signalling in human macrophages 177
5.2.1 Shh signalling pathway components are expressed in human
macrophages 177
5.2.2 Ptc expression is upregulated in response to recombinant Shh (rShh) 181
5.3 rShh modulates the effector function of macrophages 184
5.3.1 rShh differentially modulates the Vascular Endothelial Growth Factor
and Transforming Growth Factor-|3 expression by macrophages 184
5.3.2 rShh differentially modulates the cytokine and chemokine expression by
macrophages 189
5.4 Inhibiting Shh signalling using cyclopamine differentially abrogates the
macrophage response to rShh 195
5.5 Inhibition of CD14 modulates the macrophage response to rShh 201
5.6 Endotoxin Considerations 207
5.6.1 Endotoxin quantification 208
5.6.1.1 LAL chromogenic endpoint assay 208
5.6.1.2 LAL kinetic assay 211
5.6.2 The administration of LPS with equivalent endotoxic activity does not
induce the same magnitude of response as rShh 211
5.7 Polymixin B abrogates the macrophage response to rShh 215
5.7.1 The use of PMB-agarose beads to remove contaminating LPS 215
5.7.2 The use ofPolymixin B as a culture additive 216
5.8 rShh and low concentrations of LPS are sensitive to heat 220
5.9 Discussion 222
5.9.1 Shh signalling pathway expression in macrophages 222
5.9.2 rShh and macrophage effector function 225
5.9.3 The effect of cyclopamine 227




THE EFFECT OF SONIC HEDGEHOG ON T CELL EFFECTOR FUNCTION
232
6.1 Introduction 233
6.2 Shh signalling and the effector function of depletion-purified, anti-
CD3s/anti-CD28 activated, CD4+ T cells 234
6.2.1 Isolation and depletion purification ofhuman CD4+ T cells 234
6.2.2 Shh and CD4+ T cell proliferation 237
6.3 Shh signalling and the effector function of depletion-purified CD4+ T
cells in the presence of an antigen presenting cell 242
6.4 The effect of Shh blockade on T cell effector function 246
6.4.1 Blocking Shh signalling in anti-CD3/anti-CD28 activated, depletion-
purified CD4+ T cells fails to modulate T cell effector function 246
6.4.2 Blocking Shh signalling in MLR cultures fails to modulate T cell
effector function 250
6.5 Shh signalling and the effector function of CD4+ T cells purified using
positive CD4+ selection 253
6.6 Shh and cell sorted CD3+CD4+ cells 260
6.7 Discussion 265
6.7.1 Shh and T cell effector function 265
6.7.2 The Nature of the Stimulus 269
6.7.3 Summary 273






APC Antigen Presenting Cell
AP-1 Activator protein 1
AR Acute rejection
ATN Acute Tubular Necrosis
BCC Basal Cell Carcinoma
BMP Bone morphogenetic protein
BSA Bovine Serum Albumin
CAN Chronic renal allograft nephropathy
CBA Cytometric bead array
CBP CREB binding protein
CD Cluster of differentiation
CHO Chinese Hamster Ovary
Ci Cubitus interruptus
CMV Cytomegalovirus
CNS Central Nervous System
Cos-2 Costal-2
COUPTF-II Chicken Ovalbumin Upstream Promotor Transcription Factor-II
C-Shh Carboxy terminal form of Shh













ELISA Enzyme Linked Immunosorbent Assay
FCS Fetal Calf Serum
FFPE Formalin-fixed, paraffin-embedded
FGF Fibroblast growth factor
Fu Fused
GDF Growth and differentiation factor
GM-CSF Granulocyte macrophage colony stimulating factor
GRO Melanoma growth stimulatory activity
HBSS Hanks buffered saline solution
Hh Hedgehog
Hip Hedgehog interacting protein
HLA Human Leukocyte Antigen
HRP Horseradish peroxidase
HSP Heat shock protein
HSPGs Heparan sulphate proteoglycans
3H-TdR Tritiated methyl thymidine
HUVECS Human umbilical cord endothelial cells
IBE Immortalised brain capillary endothelial cells




IGF-1 Insulin-like growth factor-1
Ihh Indian Hedgehog
IKK IkB kinase complex
IMDM Iscove's Modified Dulbecco's Medium





IRG-1 Immune-responsive gene 1
ITAM Immunoreceptor Tyrosine-based ActivationMotif
JNK Jun N-terminal kinase
LAL Limulus Amebocyte Lysate
LDH Lactate dehydrogenase assay
LDL Low density lipoprotein
LPS Lipopolysaccharide
LRW LAL reagent water
Mai MyD88 adapter-like
MAPK Mitogen-activated protein kinases
MCP-1 Monocyte chemotactic protein-1
MHC Major histocompatibility complex
MIG Monokine induced by gamma-interferon
MIP Macrophage inflammatory protein
MLR Mixed leukocyte reaction
MMC Mitomycin C
MMF Mycophenolate mofetil
mRNA Messenger Ribonucleic Acid
NF-kB Nuclear factor kB
NFAT Nuclear factor of activated T cells
N-Shh Amino terminal form of Shh
OD Optical density
PAMPs Pathogen associated molecular patterns
PBMCs Peripheral blood mononuclear cells
PBS Phosphate buffered saline
PCR Polymerase chain reaction
PCT Proximal convoluted tubule










PRRs Pattern Recognition Receptors
Ptc Patched
RANTES Regulated on activation normal T cell expressed and secreted
RAP Receptor associated protein
REC Renal epithelial cell
rShh Recombinant Sonic Hedgehog
RT-PCR Reverse transcription polymerase chain reaction
Shh Sonic hedgehog
Smo Smoothened
SSD Sterol sensing domain
TCR T cell receptor
TGF-|3 Transforming Growth Factor-P
Th T helper
TIRAP TIR domain-containing adapter protein
TLR Toll-like receptor
Tm Annealing temperature
TNFa Tumour necrosis factor alpha
TOLLIP Toll-interacting protein
UVB Ultraviolet B
VCAM-1 Vascular cell adhesion molecule - 1





FIGURE 1.1: The Sonic Hedgehog Signalling Pathway 30
FIGURE 1.2: The TLRs and their Agonists 58
Chapter 3
FIGURE 3.1: CAN is characterised by an inflammatory cell infiltrate, tubular
atrophy, allograft vasculopathy and glomerular sclerosis Ill
FIGURE 3.2: CAN is characterised by fibrosis 112
FIGURE 3.3: TGF-p and VEGF expression are evident in CAN 114
FIGURE 3.4: Shh, but not Ptc, is expressed in normal adult human kidney 117
FIGURE 3.5: Ptc, but not Shh is expressed in CAN 120
FIGURE 3.6: Shh and Ptc mRNA expression in normal kidney and CAN 121
FIGURE 3.7: Shh and Ptc expression are not apparent in renal biopsy
specimens 124
Chapter 4
FIGURE 4.1: Shh expression is upregulated by ciclosporin in ACHN cells 141
FIGURE 4.2: Shh expression is differentially modulated by ciclosporin and
dexamethasone in ACHN cells 142
17
FIGURE 4.3: Evaluation of ciclosporin and dexamethasone cytotoxicity on ACHN
cells using MTT 144
FIGURE 4.4: Western blots ofACHN cell lysates 148
FIGURE 4.5: Immunohistochemical phentoyping of Renal Epithelial Cell (REC)
cultures 153
FIGURE 4.6: Renal Epithelial Cells express Shh, but not Ptc 155
FIGURE 4.7: The expression of Shh in Renal Epithelial Cells is not modulated by
ciclosporin or dexamethasone 158
FIGURE 4.8: Evaluation of hydrogen peroxide cytotoxicity on RECs using
MTT 162
Chapter 5
FIGURE 5.1: Representative flow cytometry data demonstrating purities of
macrophages used for macrophage experiments 179
FIGURE 5.2: The Shh signalling components Ptc, Smo, Gli 1 and Gli 2 are
expressed in human PBMC-derived macrophages 180
FIGURE 5.3: Ptc expression is upregulated in macrophages in response to
rShh 182
FIGURE 5.4: rShh differentially modulates macrophage VEGF expression 187
FIGURE 5.5: rShh fails to modulate TGF-P production by macrophages 188
18
FIGURE 5.6: rShh upregulates the production of IL-6, IL-8, MCP-1, IP-10, MIG
and RANTES by macrophages cultured in the presence of serum 191
FIGURE 5.7: rShh fails to modulate the production of IL-1|3, IL-12p70, TNFa or
IL-10 by macrophages cultured in the presence of serum 192
FIGURE 5.8: rShh upregulates the production of IL-6, IL-8, MCP-1, IP-10, MIG
and RANTES by macrophages cultured in the absence of serum 193
FIGURE 5.9: rShh fails to modulate the production of IL-ip, IL-12p70, TNFa or
IL-10 by macrophages cultured in the absence of serum 194
FIGURE 5.10: Cyclopamine inhibits the rShh-mediated upregulation of IL-6 and
MCP-1 in macrophages cultured in the presence of serum 197
FIGURE 5.11: Cyclopamine fails to modulate the rShh-mediated upregulation of
RANTES, MIG and IP-10 in macrophages cultured in the presence of serum 198
FIGURE 5.12: Cyclopamine inhibits the rShh-mediated upregulation of IL-6 and
MCP-1 in macrophages cultured in the absence of serum 199
FIGURE 5.13: Cyclopamine fails to modulate the rShh-mediated upregulation of
RANTES, MIG and IP-10 in macrophages cultured in the absence of serum 200
FIGURE 5.14: CD14 blockade inhibits the rShh-mediated upregulation of IL-6, IL-
8, MCP-1, IP-10, MIG and RANTES by macrophages cultured in the presence of
serum 204
FIGURE 5.15: CD14 blockade inhibits the rShh-mediated upregulation of IL-6, IL-
8, MCP-1, IP-10, MIG and RANTES by macrophages cultured in the absence of
serum 205
19
FIGURE 5.16: Evaluation of the functional CD14 blocking antibody, 61D3, on
macrophages adhered on plastic for 6 days 206
FIGURE 5.17: rShh contains endotoxic activity 210
FIGURE 5.18: rShh induces a greater upregulation in cytokines and chemokines
compared to LPS of equivalent endotoxic activity in the presence of serum 213
FIGURE 5.19: rShh induces a greater upregulation in cytokines and chemokines
compared to LPS of equivalent endotoxic activity in the absence of serum 214
FIGURE 5.20: Polymixin B abrogates the rShh-mediated upregulation of cytokines
and chemokines in the presence of serum 218
FIGURE 5.21: Polymixin B abrogates the rShh-mediated upregulation of cytokines
and chemokines in the absence of serum 219
FIGURE 5.22: rShh and low concentrations of LPS are heat-sensitive 221
Chapter 6
FIGURE 6.1: Representative flow cytometry data demonstrating purities of CD4+ T
cells isolated using depletion techniques 237
FIGURE 6.2: rShh fails to modulate the proliferation of resting or activated
depletion-purified CD4+ T cells 240
FIGURE 6.3: rShh upregulates the production of IFNy, TNFa, IL-10, IL-6 and IL-2
from suboptimally activated CD4+ T cells 241
FIGURE 6.4: rShh fails to modulate the production of IFNy, TNFa, IU10, IL-6, IL-
4 and IL-2 from optimally activated CD4+ T cells 242
20
FIGURE 6.5: rShh fails to modulate the proliferation ofT cells in mixed leukocoyte
reactions (MLRs) 245
FIGURE 6.6: rShh fails to modulate the cytokine effector function ofT cells in
MLRs 246
FIGURE 6.7: The proliferation of suboptimally and optimally activated depletion-
purified CD4+ T cells is not modulated by inhibition of Shh signalling 251
FIGURE 6.8: The cytokine effector function of suboptimally and optimally
activated depletion-purified CD4+ T cells is not modulated by inhibition of Shh
signalling 250
FIGURE 6.9: MLR proliferation is not modulated by inhibition of Shh
signalling 252
FIGURE 6.10: The cytokine effector function ofCD4+ T cells in an MLR is not
modulated by inhibition of Shh signalling 253
FIGURE 6.11: Representative flow cytometry data demonstrating purities of CD4+
T cells isolated using positive selection techniques 257
FIGURE 6.12: rShh fails to modulate the proliferation of resting or activated
positively-selected CD4+ T cells 258
FIGURE 6.13: rShh upregulates the production of IFNy, TNFa, IL-10, IL-6 and IL-
2 from suboptimally activated CD4+ T cells 259
FIGURE 6.14: rShh fails to modulate the production of IFNy, TNFa, IL-10, IL-6,
IL-4 and IL-2 from optimally activated CD4+ T cells 260
21
FIGURE 6.15: rShh fails to modulate the proliferation of resting or activated cell-
sorted CD4+ T cells 263
FIGURE 6.16: rShh upregulates the production of IFNy, TNFa, IL-10, IL-6 and EL-
2 from suboptimally activated cell-sorted CD4+ T cells 264
FIGURE 6.17: rShh upregulates the production of IFNy, TNFa, IL-10, IL-6 and IL-
2 from optimally activated cell-sorted CD4+ T cells 265
22
List of Tables
TABLE 1: Cytometric Bead Arrays (CBAs) 90
TABLE 2: RT-PCR Primers 100
TABLE 3: Real-Time Primer and Probe Sequences 102
23
List of Appendices
APPENDIX 1: Megalin is expressed on the apical surface of proximal convoluted
tubular cells 344
APPENDIX 2: Megalin fails to be expressed in CAN 345
APPENDIX 3: Ptc expression is upregulated in macrophages in response to
LPS 346
APPENDIX 4: The inhibitory effects of cyclopamine and polymixin B are not
additive 347
APPENDIX 5: Cyclopamine fails to modulate the response of cell-sorted CD4+ T
cells to Shh 348






The themes underlying the work presented in this thesis have arisen as a result of
several key reports investigating novel roles for developmental signalling pathways
in adult physiology and pathophysiology. The Sonic hedgehog signalling pathway is
one such pathway. It is known to have a role in a variety of developmental processes
but, more recently, its expression has been demonstrated in adult tissues prompting
speculation regarding its role in the adult. Three key publications formed the basis to
the work presented in this thesis and these have been discussed in detail below.
Together, they highlight possible roles for Shh signalling in inflammation, fibrosis
and peripheral immunity, roles that have, to date, been little explored. The work
investigating the role of Shh signalling in inflammation and fibrosis has, as will be
seen below, focussed on its possible role in the context of lung inflammation and
fibrosis. Although it is well established that Shh signalling plays a role in the
developing lung, more recent evidence has shown that that Shh signalling is also
upregulated in the epithelium in fibrotic lung conditions in the mouse and human.
This, together with recent evidence suggesting that Shh signalling components are
expressed on peripheral immune cells including T cells and macrophages, and,
further, that signalling through the pathway appears to modulate the proliferation and
cytokine profile of CD4+ T cells, suggests that Shh signalling may be important at
the epithelium-immune cell interface and may play a role in linking the innate and
adaptive immune systems. Indeed, Shh signalling has the potential to be involved in
a number ofpathologies and, specifically, highlights possible roles for Shh signalling
in other conditions characterised by inflammatory cell infiltration and fibrosis.
In this regard, the kidney provides an interesting area for further study. Little is
known about Shh signalling in the adult kidney although the developing kidney, like
the developing lung, is influenced by hedgehog signalling. Furthermore, a number of
chronic renal diseases show evidence of fibrosis. In this regard however, the
transplanted kidney affected by chronic renal allograft nephropathy (CAN) is of
specific interest. As discussed further below, fibrosis is one of the histopathological
hallmarks ofCAN and the fibrosis is associated with an inflammatory cell infiltrate
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comprising macrophages and T cells. Given that Shh signalling may be upregulated
in fibrotic conditions, that Shh signalling has been shown recently to be relevant to T
cell effector function and that macrophages express the receptor for Shh and may
thus be able to respond to a Shh signal, these factors highlight a possible role for Shh
signalling at the epithelial-immune cell interface and in CAN. Like fibrotic
conditions of the lung, CAN occurs even in the face of strong immunosuppressive
therapy, thus highlighting the need for further exploration into the mechanisms
contributing to its development and potentially presenting the Shh signalling
pathway as a possible target for therapeutic intervention.
Thus, it is the possible role in CAN and contribution to peripheral immune
mechanisms relevant to the epithelium-immune cell interface that the work presented
in this thesis has sought to evaluate. Specifically, and based on the recent reports in
the literature investigating the role of Shh signalling in lung fibrosis and peripheral
immunity, this work has sought to investigate 2 central avenues of enquiry. Firstly,
the possible importance of Shh signalling in the normal adult kidney and the kidney
affected by CAN is explored. In the second part of the thesis, and relevant to
interactions that may be occurring at the epithelium-immune cells interface, the role
of Shh signalling in the effector function ofmacrophages and CD4+ T cells has been
evaluated.
In this first introductory chapter, the background leading up to the work presented in
this thesis will be discussed. In the first part, general discussion of the Shh signalling
pathway and the recent work concerning its roles in fibrotic lung disease and
peripheral immunity will be reviewed. This will then be followed by an introduction
to the poorly understood process ofCAN. Given that macrophages and T cells are
central to innate and adaptive immune responses and that recent reports suggest that
Shh signalling may be relevant and important to the effector function of these cells,
the concepts ofmacrophage and T cell activation are introduced in the final part of
this chapter.
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1.2 The Sonic Hedgehog Signalling Pathway
1.2.1 Introduction
The Hedgehog (Hh) family of proteins has an important role in determining both cell
fate and proliferation during development. Discovered in Drosophila, the hedgehog
gene was initially identified during a screening process for embryonic patterning
defects1. The family derives its name from a mutant form ofDrosophila which,
during its embryonic development, has prominent changes (denticles) in regions
normally associated with bare cuticle. The Hh pathway is highly conserved through
evolution and there are 3 vertebrate homologues ofDrosophila Hh; Sonic hedgehog
(Shh), Indian hedgehog (Ihh) and Desert hedgehog (Dhh)2"4. All have roles during
embryogenesis but, of these, Shh is the best characterised. During development, Shh
signalling plays a crucial role in the regulation of embryonic patterning most notably
in the neural tube, limbs, gut and lung4"7. The contribution of Ihh is most notable
during the formation and growth of the limb, where it regulates the pace of
o q % t
chondrocyte differentiation ' . Ectopic expression of Ihh delays hypertrophy and
subsequent replacement of cartilage with bone . Ihh also plays a role in gut
organogenesis4'10, vasculogenesis and hematopoiesis1'. Roles for Dhh include control
• *12of gonad and germ line development and peripheral nerve sheath formation .
In humans, Shh is located on the distal long arm of chromosome 7 (7q36). Targeted
disruption of Shh signalling results in embryonic lethality13. Mutations of the Shh
gene result in holoprosencephaly14, a syndrome incorporating a variety of facial and
cranial defects such as cyclopia. Defects in distal limb structures and the foregut are
also evident15. The latter include oesophageal atresia and stenosis, tracheo-
oesophageal fistula, gut malrotation, reduced smooth muscle, annular pancreas,
imperforate anus and lung hypoplasia7,16. Similar features develop in animals
exposed to the teratogen and Shh antagonist, cyclopamine17, and in patients with




Aside from its role in developmental patterning, Shh also acts as a growth factor in a
large number of different cell types including CNS precursors11, haematopoietic stem
19 20 21 • 22cells , T cells ' and epithelial cells , an effect at least partly mediated via a
decrease in cyclic-AMP-dependent protein kinase A (PKA) activity23. Indeed,
mutations leading to the constitutive activation of the Shh signalling pathway have
been linked to the development of a number ofmalignancies including sporadic24'25
26 27 28and familial ' basal cell carcinomas, medulloblastoma and rhabdomyosarcoma.
1.2.2 The Shh Signalling Pathway
The Shh signalling pathway is outlined in Figure 1.1. Shh, like its Drosophila
counterpart, Hh, is synthesised in a 45 kDa precursor form. Autoproteolytic cleavage
in the endoplasmic reticulum results in the formation of a biologically active 19kDa
amino terminal form (N-Shh) and a 25kDa carboxy-terminal region (C-Shh)3'29. The
signalling activity of Shh resides in the amino terminal6'30,31 whereas the 25kDa
'X')
carboxy-terminal region acts as a cholesterol transferase , responsible for the
covalent linking of cholesterol to the carboxy terminus ofN-Shh during the
autoproteolysis step29'32'33. Although it is not known why cholesterol is covalently
linked to the carboxy terminus ofN-Shh, it has been proposed that its function is to
allow N-Shh to remain attached to the cell surface therefore promoting short-range
signalling between neighbouring cells and, thus, spatially restricting the localisation
of the Hh signal32'34. Furthermore, it may be that the cholesterol modification assists
in localising Hh to lipid rafts within the membrane35'36, thus helping to concentrate
Hh ligands, increasing the likelihood of ligand/receptor interaction and directing
intracellular transport within epithelium and/or the sequestration of Shh within
cells37'38. In Drosophila, the cholesterol modification seems to be required to target
cleaved Hh to a delivery system. This system includes Dispatched, a protein similar
to Ptc required for the release ofHh from the secreting cell, and Tout velu, an
enzyme involved in heparan sulphate biosynthesis required for the efficient transport
of, and response to, the Hh protein signal37'38. In the absence ofDispatched, the
levels ofHh remains high in Hh producing cells. However, Hh is not released from




The Sonic Hedgehog Signalling Pathway
Shh is synthesised in a 45 kDa precursor form. Autoproteolytic cleavage in the
endoplasmic reticulum results in the formation of a biologically active 19kDa amino
terminal form (N-Shh). Ptc is the receptor for Shh and binds Shh with high affinity. In
the absence of Shh stimulation, Ptc represses the activity of a further protein
Smoothened (Smo) and this repression of Smo by Ptc prevents the activation of the
Gli family of transcription factors (Figure 1.1a). When Shh binds to Ptc, the repression
by Ptc on Smo is lifted, thus allowing Smo signalling and the activation of the
downstream transcriptional targets of Shh signalling through the Gli transcription
factors (Figure 1.1b).
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In addition to the cholesterol modification, a second lipid modification,
palmitoylation of the N terminus, occurs after the cholesterol modification and may
enhance the signalling activity of Shh . Further work from in vitro assays suggests
that neither cholesterol nor palmitoyl modification increases the affinity of Hh
proteins for Ptc. However, both processes appear to increase the specific activity of
the Hh protein39.
The receptor for Shh is the product of a tumour suppressor gene, Ptc40, originally
identified as the gene responsible for Gorlin's syndrome, an autosomal dominant
disorder characterised by multiple basal cell carcinomas, medulloblastoma and
ovarian fibromas and other developmental anomalies27, \ The Ptc gene product is a
transmembrane protein with 12 membrane-spanning domains and 2 extracellular
loops42'43. Ptc is expressed in all known targets ofHh signalling27,44 and binds Shh
with high affinity4 . In the absence of Shh stimulation, Ptc represses the activity of a
further protein Smoothened (Smo)45,46 which has marked structural similarity to the
G-protein coupled receptors46. Smo is required to transduce the Shh signal45"47 and,
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in Drosophila, is required for all Hh signalling . In the absence of a Shh signal, the
repression of Smo by Ptc prevents activation of the downstream targets of Shh
signalling49. Together, Ptc and Smo form a receiving unit for Shh27,40 although it
appears that only Ptc is capable of binding to Shh, since, in the absence of Ptc, Shh
fails to bind Smo40'50. When Shh binds to Ptc, the repression by Ptc on Smo is lifted,
thus allowing Smo signalling and the activation of the downstream transcriptional
targets of Shh signalling. In mice lacking Ptc activity, the Hh signalling pathway
response genes are constitutively activated in target tissues by the permanent
activation of Smo11. This results in a neoplastic state characterised by proliferating,
undifferentiated cell populations27,41. Activating mutations in Smo and Shh have been
shown to result in similar phenotypes to those seen when Ptc expression is
absent24,51.
The exact mechanism by which Ptc exerts its effects on Smo has yet to be
determined although it has been proposed that the inhibition of Smo by Ptc requires
them to be in close proximity . Early studies suggested a simple stoichiometric
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regulation of Smo by Ptc. Indeed, initial cell culture experiments based on
overexpression experiments proposed that Ptc and Smo may interact directly to form
a complex40'45. The experiments further suggested that when Hh binds to Ptc, the
complex undergoes conformational change resulting in the activation of Smo.
However, other studies investigating a possible stoichiometric relationship have not
ST
been supportive of such an interaction . Experiments in Drosophila have revealed
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that Ptc and Hh colocalise to intracellular vesicles in Hh-responding cells . Oher
studies in mammalian tissue culture studies have shown that soluble recombinant
Shh protein can be internalised by cells transfected with Ptc54. Some authors posit
that both Ptc and Hh are targeted to the lysosome55, at least in some cells. Others
have proposed that the internalisation process is dynamin-dependent54 suggesting
that internalisation is mediated via clathrin-coated pits54. Some evidence, however,
lends support for a role for caveolae in the internalisation process. Indeed, Ptc has
been shown in vitro to associate with caveolin-156. Other authors though do not
concur with a role for caveolin in Ptc internalisation, viewing it instead as a means of
delivering Ptc to the plasma membrane56. Lipid rafts have also been implicated in
both Ptc internalisation and the interaction of Ptc with Smo. Indeed, Hh has been
demonstrated to accumulate in lipid rafts35. Smo also localises to lipid rafts but
whether the association ofPtc and Smo occurs before or after lipid raft integration is
not yet clear57.
Other insights into the nature of the relationship between Smo and Ptc have come
from studies in Drosophila lending support to more indirect models of Smo
regulation by Ptc. Indeed, the findings from a number of studies have suggested that,
although Hh and Ptc colocalise in Hh-responding cells, Smo and Ptc do not
colocalise in responding cells58'59, thus supporting a more indirect interaction
between Ptc and Smo. Indirect models proposed include a catalytic regulation by Ptc
and evidence in favour of this comes from studies demonstrating a 45:1 ratio of
Smo:Ptc resulting in 80% reduction in Smo activity53. Other studies have posited that
Ptc may act by regulating Smo trafficking within the cell60'61. Indeed, Smo
downregulation appears to be dependent on the Ptc sterol sensing domain (SSD)60'61
supporting a role for Ptc in the trafficking of Smo through a membrane
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compartment11. Other proposed mechanisms of inhibition include the possibility that
Ptc might control Smo function by influencing its interaction with cellular small
molecules62.
1.2.3 Cyclopamine
Cyclopamine is a plant steroid alkaloid derived from Veratrum californicum. Ewes
that consume this plant give birth to lambs with features ofholoprosencephaly63 and
the administration of cyclopamine to vertebrate embryos produces a phenotype
consistent with loss ofHh signalling15. In NIH-3T3 cells transiently transfected with
both luciferase reporter and Smo complementary DNA, overexpression of Smo
induced reporter expression 10-fold, an effect suppressed by 5-20pM cyclopamine,
providing in vitro evidence for an inhibitory effect of cyclopamine on Smo activation
and, thus, Shh signalling. Since the discovery that cyclopamine inhibits Shh
signalling, it has been used extensively in both in vitro and in vivo experiments to
abrogate Shh signalling64"6 . Although the precise mode of action of cyclopamine has
not been determined, cyclopamine appears to inhibit the cellular response to the Hh
signal by inhibiting activated Smo in a Shh and Ptc-independent manner17'64'69,
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possibly through binding directly to the heptahelical domain of Smo . The activation
status of Smo appears to be critical in determining whether cyclopamine will inhibit
Hh pathway activation as evidenced by experiments demonstrating little effect of
cyclopamine on the reporter expression induced by the oncogenic Smo mutants
W539L24 and S5 3 725. In the former study, all activating Smo mutants were
cyclopamine resistant, the level of resistance correlating positively with increased
potency, consistent with a model in which cyclopamine affects the balance between
activity states of Smo64.
1.2.4 The Gli family of transcription factors
In Drosophila, transcription in the Hh signalling pathway is mediated by the zinc
finger transcription factor Cubitus interruptus (Ci), a protein with 3 key functional
domains. These domains include an amino-terminal region involved in
transcriptional repression71, a zinc finger domain that binds to DNA72 and a carboxy-
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terminus that mediates activation of transcription71. Ci forms a complex in the
cytoplasm of the cell with 2 other proteins, Fused (Fu) and Costal-2 (Cos-2). Fu is a
serine-threonine kinase and positive mediator of the hedgehog signal whereas Cos-2
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acts to inhibit its effects . Cos-2 is responsible for the binding of the complex to
microtubules74. Proteolysis of the Ci gives rise to an amino-terminal containing
region (Ci75) and a carboxy terminus. Ci-75 contains the zinc finger domain, which
migrates to the nucleus and represses hedgehog target gene transcription74. Hh
signalling in Drosophila inhibits cleavage of full-length Ci and, thus, the Ci-Fu-Cos-
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2 complex dissociates from the tubules . Conversely, activated Ci binds to the
transcriptional coactivator, CREB-binding protein (CBP), allowing the expression of
Hh target genes .
In vertebrates, there are three known homologues of Ci constituting the Gli family of
transcription factors77'78. The roles of the individual Gli family members have yet to
be fully delineated, a process hampered by the partial redundancy and overlapping
domains of Gli expression. Nevertheless, results from a number of different studies
have shown that different Gli members appear to be responsible for different
no
activator and repressor functions .
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Glil was initially identified as a potential oncogene in human glioblastoma .
Subsequently, the family of vertebrate Gli genes that includes Glil, 2 and 3 was
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cloned and found to be expressed in many organs during development . Of the Gli
transcription factors, Glil appears to act solely as an activator inducing the
upregulation of target genes81 and functioning in a similar manner to Ci78. In tissue
culture cells or transgenic embryos, overexpression of Glil can induce the
transcription ofHh target genes in the absence of Hh activity23'82. Overexpression of
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Glil also contributes to the transformation ofprimary cells and occurs in
glioblastomas79, basal cell carcinomas (BCCs)84, osteosarcomas,
rhabdomyosarcomas and B cell lymphomas85'86. Given these effects, it is interesting
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to know that mice that lack Glil are phenotypically normal .
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In contrast to the activating functions ofGlil, Gli 2 and 3 have both activating and
repressive domains88. Gli2 plays a critical role in neural, lung and skeletal
development89,90 and mice with mutations in GU2 die at birth and exhibit a variety of
developmental defects including abnormal floorplate, skeletal and lung
development91. In vivo evidence for an activating role ofGli2 comes from mouse
OQ
mutants lacking the zinc finger regions and in transgenic flies and frog embryos,
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Gli2 is a weak activator . Deletion of the N-terminal domain of the protein,
however, turns Gli 2 into a strong activator, capable of inducing normally Shh-
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dependent cell types .
Although capable of acting as both an activator and a repressor, the main role for
Gli3 appears to be as a repressor ofHh targets as well as of Shh itself92. This
repression is mediated by proteolytic cleavage of full-length Gli3 into a repressor
form. The Gli3 mutant phenotype lends further support for a repressive role for Gli3.
Loss ofGli3 results in dorsal brain defects and limb Polydactyly that are associated
with ectopic activation of the Shh pathway and human mutations in the Gli3 gene
cause Greig syndrome, a condition characterised by syndactyly and facial
anomalies93, and Pallister-Hall syndrome, an autosomal dominant disease
incorporating a spectrum of defects such as Polydactyly, syndactyly, imperforate
anus, anteverted nares and other facial abnormalities94. Shh signalling functions to
inhibit the formation of the repressor form ofGli395 with removal ofGli3 function in
Shh mutants largely rescuing the Shh mutant defects demonstrating that, at least in
part, the Shh mutant phenotype is due to an excess ofGli3 repressor96.
1.2.5 Targets ofHh signalling
Hh signalling activates a number of target genes. Somewhat paradoxically, one of the
best recognised downstream targets ofHh signalling is Ptc itself97, with high levels
ofPtc expression commonly used to indicate a transcriptionally active Hh signalling
pathway98"100. It has been proposed that this upregulated Ptc expression in response
to Shh signalling serves to sequester Hh thereby limiting its action101 and, further,
that this negative regulatory mechanism may help to generate a Hh concentration
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gradient101. Glil is also a transcriptional target of Hh signalling and, like Ptc, is often
used to indicate a transcriptionally active Hh signalling pathway.
A number of other pathways appear to be activated by Hh signalling. Notably, in the
context of this thesis, these pathways include growth factors such as members of the
TGF-p superfamily, vascular endothelial growth factor (VEGF)102,103 and some of the
fibroblast growth factors104. Other targets ofHh signalling include members of the
Hox gene family, the transcription factor N-myc, cyclin D2, insulin-like growth
factor binding proteins, Deltex 1, osteopontin and plakoglobin105,106. Of these
downstream targets ofHh signalling, the growth factors TGF-P and VEGF are of
particular interest since they are directly relevant to avenues pursued during the
course of this thesis.
The TGF-P superfamily is a large family of secreted growth factors that affect many
developmental processes including growth and differentiation107"109. Members of the
family act downstream ofHh proteins in several developmental systems110"113. In
Drosophila, Hh signalling controls the expression of the long range morphogen and
TGF-P superfamily member, Decapentaplegic (Dpp)114, and it is believed that
activation ofDpp allows Hh to control patterning events in the imaginal
discs110'115,116. Hh signalling also controls the expression of Wingless51'11, another
morphogen family which interacts with Dpp to regulate both cell fate and
proliferation during development117. In vertebrates, the TGF-p superfamily includes
the 3 vertebrate isoforms of TGF-p, the activins and inhibins, growth and
differentiation factors (GDFs) and the bone morphogenetic proteins (BMPs)118. In
vertebrates, the closest homologues to Drosophila Dpp are the BMPs, BMP-2 and
BMP-4119. These 20-30kDa homodimeric proteins regulate many morphogenetic
events during embryonic development, playing an integral role in epithelial-
mesenchymal interactions119 and, as their name would suggest, functioning primarily
to induce chondrocytic and osteoblastic differentiation from mesenchymal
progenitors. Both BMP-2 and 4 have been shown to be regulated by Hh signalling111.
Shh induces ectopic expression ofBMP-2 when misexpressed in the chick
limb11 'and Hh signalling appears to act upstream ofBMP-4 signalling to induce the
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proliferation of primitive human blood cells19. Dynamo, a novel zebrafish member of
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the TGF-P superfamily is also upregulated by Shh . Interestingly, although
members of the TGF-P superfamily appear to be downstream targets ofHh
signalling, a direct association between Hh signalling and the regulation of any one
of the 3 isoforms ofTGF-P, has not been demonstrated. The same, however, may not
be true of the angiogenic factor and endothelial cell mitogen, VEGF. This growth
factor has been shown in a number of recently published studies to be a downstream
target ofHh signalling. Indeed, a direct association between Hh signalling and VEGF
has been proposed, a relationship that is discussed in Section 1.2.9 in more detail.
1.2.6 Other players in the Shh pathway
In addition to the Shh-Ptc axis described above, there is a growing body of evidence
to suggest that some effects attributed to Hh signalling may be mediated by a
pathway outwith the Shh-Ptc pathway described above121"123. Indeed, other receptors
have been reported to bind Shh. These include Ptc2, Hedgehog interacting protein
(Hip)124, vitronectin125 and megalin126'127.
The Ptc2 gene was identified in 1998128'129. It shares 60% amino acid identity with
Ptcl and has some characteristics similar to Ptc such as the extracellular loops that
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mediate the interaction with Hh . Furthermore, Ptc2 associates with Smo .
Nevertheless, the specific role of Ptc 2 in the Hh pathway remains unclear. It appears
to be coexpressed with Shh-producing cells and its transcription, unlike that ofPtc, is
independent of Hh signalling131. Indeed, the expression ofPtc2 is modulated by, but
not dependent on, Hh signalling. Furthermore, Ptc2 is not able to replace Ptc function
in tumour cells130 and during development in the mouse40, suggesting that Ptc and
Ptc2 have distinct and different functions.
Hip is a membrane-associated glycoprotein124 that binds to all 3 vertebrate
homologues ofHh with a similar affinity to that ofPtc. As with Ptc-expressing cells,
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Hip-expressing cells are located next to those expressing Hh . Hip, like Ptc and
Glil, is a transcriptional target of hedgehog signalling, induced by ectopic Hh
signalling and lost in Hh mutants124. The exact function ofHip remains to be fully
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elucidated. Interestingly, a Hip orthologue in Drosophila has not yet been
identified124 and Hip remains relatively poorly characterised. It appears to function in
a negative manner to attenuate a Hh signal since overexpression ofHip attenuates Hh
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signalling in mice . It remains to be seen whether downstream targets such as Gli
family members are directly modulated by Hip interactions. It may be that Hip
mediates effects outwith those of the relatively well-characterised Shh signalling
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pathway, a possibility highlighted recently by the work of Testaz et al .
Megalin, also known as gp330, is a 600kDa transmembrane protein belonging to the
Low Density Lipoprotein (LDL) receptor superfamily133'134. Megalin is expressed in
many epithelial cells including the proximal tubular cells and glomerular podocytes
of the kidney, type II pneumocytes, small intestinal epithelium, the visceral yolk sac
and the cytotrophoblast of the placenta, thyroid and parathyroid cells, endometrium,
oviduct, epididymis, ependymal cells, labyrinthine cells of the inner ear and the
ciliary epithelial cells of the eye135. Megalin requires the chaperone protein, receptor-
associated protein (RAP), in order to function optimally136. Although the significance
of the interaction is not entirely clear, a recent study has demonstrated that Shh is a
novel ligand for megalin126. Interestingly, in animals rendered deficient in megalin,
holoprosencephaly is also seen, lending support for megalin being a possible receptor
for Shh. Megalin-expressing cells were shown to internalise Shh through a
mechanism that could be inhibited by antagonists ofmegalin, namely anti-RAP and
anti-megalin antibodies126. Interestingly, in the same study, when chloroquine was
used to inhibit lysosomal proteinase activity, megalin-mediated N-Shh endocytosis
did not target Shh to the lysosomes, one of the mechanisms thought to be involved in
Ptc-mediated Shh degradation.
1.2.7 Shh signalling in the kidney
As outlined above, Shh signalling is integral to the development of a number of
organ systems. The developing kidney is no exception. Mice deficient in Shh
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develop a solitary kidney probably as a secondary consequence of the midline
defects occurring in the early mutant embryos. Deletions in the chromosome at the
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site containing Shh are associated with defects such as hydroureter, hydronephrosis
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and renal hypoplasia . Furthermore, Shh expression has been demonstrated in the
urothelium of the developing kidney4'138'139. In these studies, Shh expression was
restricted to the distal collecting ducts generated from the first branches of the
ureteric bud and the early El 1.5 ureter, the findings further confirmed in other
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studies using conditional loss of function models . Interestingly, high levels of Ptc
expression were observed in the mesenchymal cells adjacent to the Shh-expressing
epithelium of the collecting ducts and the ureter. At birth, Shh was shown to be
expressed in the inner medullary collecting ducts, the renal pelvic epithelium and the
ureteric epithelium, with concurrent Ptc expression in the mesenchyme of the
medulla and renal pelvis consistent with the possibility that Shh may serve as a
mitogen to promote proliferation of ureteral mesenchymal cells.
Aside from Shh itself, mutations in other components of the Shh signalling pathway
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can give rise to renal defects. Gli2-/-;Gli3+/- mice develop a horseshoe kidney
and, in humans, mutations in the Shh signalling pathway have been linked to the
renal anomalies associated with the VACTERL syndrome137, a disorder characterised
by vertebral defects, anal atresia, tracheooesophageal fistula, radial and renal
dysplasia, and limb abnormalities. Other downstream elements of the Hh signalling
cascade have also been implicated in renal development. For example, the recognised
targets of Hh signalling, BMPs 2 and 4 are also expressed in the developing kidney
as are mRNA transcripts for a number of other BMPs, including BMPs 3,5,6 and 7
which have been found to be expressed in the ureter, developing tubules, glomeruli
and metanephric mesenchyme throughout metanephric development140. Determining
the precise role for BMPs in renal development, however, is difficult. Indeed, for
example, BMP2 null mice die early and heterozygotes fail to display any obvious
renal phenotype141 thus making evaluation of the precise role for BMP2 difficult to
determine. BMP2 along with BMP7 is proposed to play a prominent role in the
regulation of branching morphogenesis in the developing kidney140'142. In embryonic
kidney explants and the IMCD-3 model of collecting duct morphogenesis, the
addition of recombinant BMP2 and BMP7 appears to regulate branching
morphogenesis142. BMP4 is expressed in the stromal cells around the Wolffian duct
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and stalk of the ureteric bud143 and may regulate ureteric bud formation. In explanted
embryonic metanephroi, the administration ofBMP4 reduces ureteric epithelial
branch formation and disrupts mesenchymal differentiation144. BMP4 may also be
involved in determining the anterior-posterior axis of the kidney145.
Aside from Shh, other Hh proteins appear to be relevant in renal development. For
example, Indian hedgehog signalling also appears to play a role in the developing
kidney where epithelial expression in differentiated tubular epithelium may serve to
signal to adjacent proliferating cells and maintain their undifferentiated state. It is
first detected in the murine metanephros at E14.5. By birth, Ihh is expressed in the
epithelium of the outer medulla and cortex146 with no expression in the collecting
ducts or ureter. Gene expression then increases with age, and is maximally expressed
in the adult146 where expression is observed in the proximal tubules.
1.2.8 Shh signalling and the immune system
That Shh signalling may play a role in the immune system has been suggested by
several lines of evidence. In 2000, Outram et al first demonstrated the presence of
components of the Hh cascade in the murine thymus and their involvement in T cell
maturation147. Extracts ofwhole murine thymus were shown to express mRNAs for
Shh, Ptcl, Ptc2, Smo, Glil, Gli2 and Gli3 and for the target of Hh signalling, BMP-
4147. Subsequent sorting of thymic cell populations demonstrated the expression of
Ptc and Smo, but not Shh, by thymocytes and the expression of Shh by thymic
epithelium, leading the authors to speculate that thymocytes may be able to respond
to, but not generate, a Shh signal147. In a further report by the same group,
immunohistochemistry studies confirmed the protein expression of Shh by the
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epithelial cells of the thymus and 85% of the thymocytes were found to express
Ptcl protein. Conversely, 35% of the thymocytes expressed Smo protein with the
most concentrated areas of expression corresponding to clusters of cells mixed with
thymic epithelial cells suggesting that Smo expression was highest in areas where Hh
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signalling pathway components were in close proximity for signalling to occur .
Only early T-cell progenitors and thymic epithelium were found to express the Gli
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genes Glil, 2 and 3 and these genes were not expressed in double positive and CD4+
thymocyte populations148, a finding supported by the findings of Bhardwaj et al who
demonstrated the expression ofPtcl and Smo, but not any of the Gli genes in human
peripheral CD3+ and CD 19+ lymphocytes19.
That active Hh signalling may occur in the thymus and influence early thymocyte
development was also demonstrated by Outram et al147. Culturing of thymocytes in
the presence of the anti-Hh antibody, 5E1 was shown to accelerate the progression of
double negative into double positive thymocytes147. Furthermore, culturing the
thymocytes in the presence of Shh arrested thymocyte differentiation at the CD25+
DN stage after TCRp rearrangement. Subsequently, Bhardwaj et al19 provided further
evidence to suggest that Shh signalling may be important in regulating the
proliferation and differentiation of haematopoietic precursor cells. Treatment of
highly purified primitive blood cells (CD34+ CD38"Lin") cells with exogenous Shh
induced the expansion of these cells whilst neutralisation of Shh signalling inhibited
cellular proliferation, maintaining the progenitors instead in an undifferentiated state.
Bhardwaj et al19 also demonstrated that the effect on proliferation is, at least in part,
mediated via BMP-4 since Noggin, a BMP-4 antagonist, was able to inhibit both
Shh-induced and BMP-4-induced proliferation of progenitor cells19.
In addition to the above roles proposed for Shh signalling in T cell development, 2
recent publications have explored the possible role for Shh signalling in peripheral T
cells in the adult. The studies from Edinburgh investigated the expression of Shh
signalling components and the role of Shh signalling in adult CD4+ T cells. In
contrast to the earlier findings in thymocytes in which Shh, Glil, Gli2 and Gli3 were
not expressed by thymocytes, depletion-purified CD4+ T cells were found to express
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Shh, Ptc and Glil in murine and human in vitro experiments ' . Lowrey et al
further demonstrated that the addition of exogenous recombinant Shh (rShh)
enhanced the proliferation of anti-CD3/antiCD28 activated murine CD4+ T cells, an
effect mediated via enhanced entry into the S/G2 proliferative phase of the cell cycle.
The findings in human CD4+ T cells20 were broadly in keeping with those in murine
CD4+ T cells21, although different activating conditions were used in the studies and
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enhanced proliferation in response to Shh was only seen in 50% human donors
studied. Both groups also reported on the abrogation of the proliferative response of
activated CD4+ T cells when endogenous Shh signalling was blocked using the
monoclonal antibody, 5E1. In the human study, this abrogation of proliferation was
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observed in only 50% donors studied. Stewart et al further investigated the effect of
both exogenous Shh administration and blockade of endogenous Shh signalling on
activated human CD4+ T cells. In these experiments, IFN-y, IL-2, IL-10 and IL-5
were shown to be upregulated by exogenous Shh administration, an effect observed
only in the 50% donors who demonstrated changes in proliferation. Furthermore,
blockade of endogenous Shh signalling resulted in the differential abrogation of
cytokine production by activated CD4+ T cells, with IFN-y and IL-2, but not IL-10
and IL-5, production being reduced by 5E1 treatment, an effect once again observed
only in those donors where an abrogation in proliferation was observed in response
to 5E1.
Much of the work to date investigating Hh signalling in the immune system has
focussed on development and, in this regard, T cell development has attracted the
most attention. Only more recently has interest focused on the adult peripheral
immune system with the publication of the 2 reports on adult CD4+ T cells outlined
above. Indeed, very little is known regarding the expression ofHh signalling
components in other adult immune cells. Of interest in this regard are the recent
findings of Stewart et al149 in which alveolar macrophages were shown to express Ptc
protein thus providing a possible mechanism through which T cells and macrophages
may be able to interact via the Shh signalling pathway.
1.2.9 Inflammation and repair
That Shh is important in the cell fate decisions and early developmental patterning in
the embryo is now well recognised. Much less is known about the possible role for
Hh signalling in the adult. Hh signalling pathway component expression is observed
in a number of organ systems in the adult, albeit at lower levels than those seen in the
embryo (Reviewed by McMahon et al5). The relevance of the expression of pathway
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components is, however, less clear. For certain adult processes, the role for Hh
signalling appears to have been clearly established. For example, Flh signalling has
been shown to be critical for hair regeneration in postnatal mice150. In other systems,
the role for Hh signalling is far from clear. It has been speculated that the role of the
developmental signalling pathways in the adult might be to recapitulate embryonic
processes when required151. Such recapitulation of embryonic process might be
called upon under conditions of damage, inflammation and repair where rudimentary
reparatory processes are often very similar in nature to those occurring during
embryonic development.
Interestingly in this regard, there are several lines of evidence to suggest that Hh
signalling may be reactivated or upregulated at sites of damage or injury and
examples of such upregulation can be found in a wide variety of organ systems
(Reviewed in Fitch et al, Appendix 6). For example, Ihh signalling is recognised to
be important during embryonic limb formation and growth where it regulates
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chondrocyte differentiation ' . In the adult, Ihh expression has been demonstrated to
be upregulated at bone fracture sites152"154 and Ihh mRNA is detected in mature and
hypertrophic chondrocytes of the fracture callus lending several authors to posit that
Ihh may play a role in fracture repair152. Furthermore, cyclical mechanical stress
greatly induced the expression of Ihh by chondrocytes suggesting that the Ihh gene is
mechanoresponsive155, and may thus play a role, not only in growth, but also repair
processes. Shh or Ihh may also directly modulate osteoblast behaviour since the
administration of recombinant Shh, commonly used in in vitro studies in place of
Ihh, to primary osteoblast cultures results in the formation ofmineralised bone
nodules, accelerating the expression and activity of alkaline phosphatase15 . These
results indicate that rShh may induce osteoprogenitor cells to differentiate and are
consistent with further reports to suggest that Hh may induce undifferentiated
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mesodermal cells to form bone in vivo ' .
In the adult gastrointestinal tract, Hh signalling plays a number of roles with
relevance to inflammation and repair. Proliferation of the gut progenitor cells occurs
in response to injury7 and Shh may play a role in determining the cell fate of such
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progenitor cells during the repair process. In the Xenopus stomach, Shh expression
closely correlates with cell proliferation and the development of the adult-type
epithelial phenotype159. Other authors have also suggested that Shh expression may
be required in the adult to maintain the structure and function of the gastric glands.
Indeed, Van den Brink et al67 posited that Shh may represent a fundic gland specific
soluble morphogen, loss ofwhich may contribute to intestinal transformation and the
development ofmalignancy. Furthermore, that injury may be linked with reactivation
of the Shh signalling pathway has been suggested by the work ofDimmler et al160 in
studies demonstrating that upregulated Shh transcription occurs in one (23132) of
three (23132, HGT-1 and AGS) gastric epithelial cell lines in response to reduced
pH. It remains to be seen however whether such activation of the Hh signalling
pathway in response to such injurious process occurs in vivo.
In experimental models in the lung, naphthalene can be used to deplete Clara cells.
This depletion is followed by the proliferation of progenitor cells and the
reestablishment of an intact epithelial barrier. Watkins et al161 demonstrated the
upregulation of Shh and Gli expression in response to this injury, with the peak in
expression occurring at the same time as the re-establishment of epithelial continuity.
Coincident with this upregulation an increase in the number of pulmonary
neuroepithelial cells was demonstrated, a finding of relevance given the recent
hypothesis that neuroepithelial cells may represent epithelial progenitor cells162.
Aside from the upregulated Shh expression seen in models of acute lung injury161,
upregulated Shh expression has also been demonstrated in chronic lung disease.
Stewart et al149 recently reported on the upregulation of Shh expression in areas of
remodelling epithelia overlying fibrosis both in the human condition idiopathic
pulmonary fibrosis and in an irritant-induced murine model of fibrosis. At these sites,
TGF-P and Shh expression appeared to colocalise, lending the authors to speculate
that, in the damaged lung, the two pathways may communicate.
The process of angiogenesis assumes a key role in the inflammatory process. Shh
signalling has been speculated to play an important role in angiogenesis as evidenced
by the results from a number of recent studies65,102'103. In 2001, Pola et al reported on
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the upregulation ofPtc by Shh in the coronary arteries and aortas ofmice102. In the
same study, using a hind-limb ischaemia model and a corneal angiogenesis model,
Shh was shown to upregulate neovascularisation and blood flow, an effect mediated
through increases in the number and diameter of new vessels formed. This effect
occurred in association with upregulated expression of VEGF and the angiopoietins
Angl and Ang2. Interestingly, in a further limb to the study, the administration of
Shh was shown to elicit different effects to those induced by VEGF administration.
In the corneal angiogenesis model, although both Shh and VEGF induced
angiogenesis, Shh induced long tortuous vessels of larger calibre compared to the
fine network of vessels induced in response to VEGF. Furthermore, in the hindlimb
ischaemia model, Shh, but not VEGF, effected capillary ingrowth. In a subsequent
paper by the same group, Shh and Ptc mRNA and protein expression were shown to
be increased in the first week following injury in the hind-limb ischaemia model103.
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As in the earlier study , the cells responsible for this upregulation were the
mesenchymal-derived fibroblasts and it was further noted that the pattern of
expression colocalised with the expression ofVEGF. Interestingly, VEGF was
upregulated in the ischaemic limb but this upregulation could be abrogated using the
5E1 antibody to block Hh signalling. This corroborates with the earlier reports of
Lawson et al163 which suggested that Shh acts upstream ofVEGF and that Hh
pathway activation may be a prerequisite for the postnatal angiogenic response to
muscle ischaemia.
The mechanism of VEGF upregulation in response to Shh remains to be elucidated.
Gli response elements are absent from the VEGF promotor region suggesting that the
upregulation induced by Shh is either indirect or mediated via a Gli-independent
mechanism. Gli-dependent and independent components of Shh-induced capillary
morphogenesis have also been proposed by Kanda et al65. Using recombinant Shh
administration to either human umbilical cord endothelial cells (HUVECs) or
immortalised brain capillary endothelial cells (IBE), this group established that Shh
could induce capillary morphogenesis. The authors failed to show a direct effect of
Shh on the proliferation or VEGF production of endothelial cells and the effect on
capillary morphogenesis appeared to be dependent on Shh-induced phosphoinositide-
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3-kinase (PI3K) activity although, interestingly, independent of Glil nuclear
translocation, a commonly used marker of Shh pathway activity. Whether, then, this
Gli-independent effect occurs through a different mediator such as the orphan
nuclear receptor, Chicken Ovalbumin Upstream Promotor Transcription Factor-II
(COUPTF-II), a Gli-independent downstream target of Hh signalling164 which also
has a role in the development of the primary vascular plexus165, has been posited103,
but remains to be established.
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1.3 Chronic Renal Allograft Nephropathy (CAN)
1.3.1 Introduction
For patients with end-stage renal disease, irrespective of aetiology, renal
transplantation is the treatment of choice. Following the first human renal allograft
transplant performed in Russia in the 1930s, knowledge regarding renal
transplantation and transplantation immunology has rapidly evolved. Although it was
soon recognised that compatibility between blood and tissue components was
important for successful transplantation, it was not until 1954 that the significance of
this was demonstrated when the first successful kidney transplant between identical
twins was performed. Some five decades later, overcoming tissue barriers between
donor and recipient remains a major obstacle to successful transplantation.
The introduction of ciclosporin in the 1980s had a significant impact on the early
prognosis of renal allografts and the subsequent development of newer agents and
improved regimes has resulted in 1-year graft survival rates exceeding 80 and 90-
95% for cadaveric and living related donors respectively166'167. Nevertheless, despite
the reduction in the number and severity of acute rejection episodes, the long-term
outcome of renal allografts has remained relatively constant168"170. Indeed, it is
notable that the long-term graft survival remains similar to that seen in the era prior
to the introduction of ciclosporin, with a predicted graft life of 7-8 years, irrespective
of the source of the allograft167'169'171. There is further enthusiasm for newer
immunosuppressive agents172 such as tacrolimus, mycophenolate mofetil (MMF) and
rapamycin but it remains to be seen whether these will have any significant impact
on the long-term outcome of renal transplants.
Chronic allograft nephropathy (CAN) is a significant cause of late graft loss
following renal allograft transplantation173"75. CAN is a poorly understood process
that occurs independently of immunosuppressive therapy and is not amenable to
treatment with conventional anti-rejection therapies. Clinically, CAN is manifested
by a progressive functional deterioration in allograft function. This is associated with
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a fall in creatinine clearance and an associated rise in serum creatinine secondary to a
decline in glomerular filtration rate176. In most instances, proteinuria occurs174 and
hypertension is common. Early diagnosis ofCAN is difficult since the clinical
sequelae of the condition usually occur some time after the histopathological
changes. Indeed, in prospective studies, mild histological changes in the graft
attributable to CAN could be demonstrated in 40-76% ofbiopsies of kidneys with
normal or near normal function173,177.
1.3.2 Aetiology
Chronic allograft nephropathy is a relatively new term for the changes occurring in
the failing allograft. Chronic rejection was initially the term used to describe the
changes reflecting the belief that a continuous immunological insult was responsible
for the pathology occurring in the chronically failing allograft. However, it is now
recognised that true chronic rejection represents only one possible cause for the
histopathological changes observed and CAN better describes what is likely to be a
172 178 179multifactorial process ' ' . Indeed, factors which may contribute to the
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development of CAN include humoral ' and cellular immune reactions and a
number of alloantigen-independent factors182,183, all ofwhich can contribute to the
histopathological changes seen in the chronically failing allograft.
That immune mechanisms are important in the development ofCAN is suggested by
2 key lines of evidence. Firstly, the number and/or intensity of acute rejection
episodes has been shown in a number of studies to correlate strongly with the later
184 187
development ofCAN " . Furthermore in this regard, early acute rejection episodes
occurring within the first 3 months post-transplantation have been shown to be less
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predictive ofCAN than those occurring at a later stage ' , and recurrent episodes
are more often associated with the development ofCAN than single episodes of
acute rejection189"191. The nature of the acute rejection episode may also be important
since severe episodes, those incompletely reversed with anti-rejection agents or
episodes with a predominant vascular component appear to be more predictive of
subsequent chronic changes188,192.
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The second line of evidence supporting an immunological role for the later
development of CAN comes from the observation that the length of transplant
survival is inversely related to the number of human leukocyte antigen (HLA)
mismatches carried by the graft, with a step-wise decrease in graft half-life as the
number ofHLA mismatches increases193"196. The best results are obtained with HLA-
identical siblings197'198 with some authors reporting the complete absence ofCAN in
the recipients ofHLA-identical donors199. Mismatches at the HLA-DR locus are
associated with a relatively poor prognosis compared to mismatches at the HLA-A
and B loci and it is for these reasons that HLA matching has formed the basis of the
kidney allocation process.
Nevertheless, that living donor allografts, irrespective ofHLA mismatching, do
better than cadaveric allografts emphasizes the importance of alloantigen-
independent factors in the aetiology of CAN170'200. Indeed, the early work of
Glassock et al201 demonstrated the failure of 40% of kidney transplants between
identical twins at 10 years, with the kidneys exhibiting histopathological changes in
the graft including arterial obliteration and glomerulosclerosis, consistent with the
changes of CAN. This is supported by experiments in rodent models suggesting that
isografts can develop changes consistent with CAN, albeit less rapidly than
allografts202. Many alloantigen-independent factors may contribute to the differences
observed in graft outcome. Indeed, cadaveric organs have been subjected to a
multitude of injurious effects all of which may play a role in the pathogenesis of
CAN190'203"205. Factors related to the donor such as donor hypertension and diabetes
probably play a role in the outcome of the graft and it has further been shown that
age, race and sex206 of the donor and donor-recipient size mismatching can impact on
the long term outcome of the transplanted kidney. Furthermore, that cadaveric donors
have almost invariably sustained a huge central nervous system (CNS) insult prior to
death renders their condition far from any physiological norm. There is evidence to
suggest that the upregulation of cytokines, chemokines and adhesion molecules
occurs following a brain injury with a rapid leukocyte infiltration and upregulation of
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their inflammatory products " . Furthermore, brain death includes a period of
autonomic storm and changes associated with early chaotic swings in vascular
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resistance and blood pressure with altered perfusion of peripheral tissue. Thus, there
is the potential for the donor organs to be subjected to severe ischaemic injury prior
to their removal. Indeed, possibly as a result of this severe ischaemic injury, the
incidence of acute tubular necrosis (ATN) with delayed graft function is frequently
increased in engrafted kidneys harvested from unstable brain-dead donors compared
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to those from living donors ' . Other factors that may contribute to the long-term
function of the cadaveric allograft include the inevitable effects of cold ischaemia i.e.
following donor nephrectomy, and ischaemia-reperfusion injury212. In the living
donor, the cold ischaemic time may be less than one hour; this is rarely the case for
recipients of cadaveric kidneys. In experimental models, Tullius and others have
demonstrated that prolonged ischaemia and delayed graft function result in
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functional and morphological changes consistent with CAN " . Specifically, some
authors have postulated that cold ischaemic time may contribute to 40-45% of the
vasculopathy present215. Others have suggested that cold ischaemia may play a
greater role in the development of tubulointerstitial damage, with allogenicity
proposed to play a greater role in the development of the vasculopathy seen in
CAN216. Infection in general but particularly, cytomegalovirus (CMV) infection may
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also play a role in the development of chronic graft failure .
Factors in the recipient may also impact prognostically on the allograft. These
include the effects of hypertension218 and lipid abnormalities, the latter, notably
elevated cholesterol and triglycerides, believed to play a role in the vascular changes
seen in CAN219,220. Whether this occurs through the upregulation of growth factor
receptors on smooth muscle and other cells as has been postulated by some
authors221, is not clear. A recent report has suggested that the oxidation ofLDL
lipids may stimulate fibrogenic cytokine formation and, in particular, TGF-P from
222
macrophages .
1.3.3 Histopathological Changes in CAN
CAN is characterised by a variety of histopathological changes which, once
established, are invariably associated with graft loss. The dominant underlying
pathological process appears to be fibrosis, with chronically failing allografts
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demonstrating an excess of extracellular matrix (ECM) proteins. Indeed, the degree
of fibrosis seems to provide the best morphological correlation with renal function
and prognosis ' . The hallmarks of chronic rejection first described by Hume in
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1955 still form the basis of the Banff classification for renal transplant pathology
used today. The Banff classification226'227 grades "chronic transplant nephropathy"
changes within the four structural compartments of the kidney, vascular, glomerular,
interstitial and tubular lesions and it is the severity of these changes that impacts
significantly on the prognosis of the graft.
The vascular lesion (also referred to as transplant vasculopathy) is common to all
forms of chronic allograft pathology, irrespective of the organ involved and is
illustrated in Figure 3.1e. It is characterised by perivascular inflammation,
arteriosclerosis and concentric intimal fibrosis affecting large parts of the arteries and
arterioles of the allograft. All arterial vessels may be affected including the small
pre-glomerular arterioles, the interlobular arteries and, occasionally, the renal artery
itself. The initial injury to the endothelium appears to be critical in the triggering of
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the cycle of events leading to CAN and is likely to be initiated by both immune
and alloantigen-independent factors as outlined above. Endothelial inflammation is
associated with vacuolisation of the endothelial cells and their detachment from the
basement membrane. Underlying adhesion molecules such as ICAM-1 and VCAM-1
are exposed229 and this, together with the exposure of antigens, may attract
inflammatory cells into the graft through the release of cytokines and growth
factors230. The inflammatory infiltrate consists mainly of T cells and macrophages all
ofwhich may contribute to the luminal occlusion231"234. Frank endothelial
inflammation, representing acute on chronic changes, may be seen in more than 50%
of acute rejection biopsy specimens and represents a highly significant adverse
prognostic feature compared to the features of a predominantly tubulointerstitial
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rejection ' , rendering episodes of acute rejection less responsive to steroids.
Endothelial inflammation encourages fibromuscular proliferation and the deposition
of extracellular matrix contributing to the formation of a neointima and narrowing of
the vessel lumen233'236. Eventually, obliteration of the allograft arteries occurs237.
Indeed, it is likely that many of the glomerular and tubular changes seen in CAN
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occur as a result of ischaemia secondary to the vascular injury, events correlating
well with deteriorating renal function.
The glomerular changes occurring in CAN are less well defined than the changes
seen in the vessels and are illustrated in Figure 3.If. Glomerular tuft collapse,
glomerular hypertrophy and atrophy may all occur238 and are associated with
expansion of the mesangium. There is often glomerular basement membrane
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duplication associated with scarring and adhesion . Focal glomerulosclerosis is
often seen240.
The tubular changes in CAN, including dilatation and atrophy, are often patchy with
affected tubules being interspersed with normal or hypertrophied tubules. The
interstitium, often oedematous early in the development of CAN, later becomes
fibrous with a patchy inflammatory cell infiltrate composed predominantly of
macrophages241, plasma cells, mast cells242 and lymphocytes243'244. The inflammatory
cell infiltrate is important in the development ofCAN as evidenced by studies
demonstrating that the onset and pace of CAN are slowed if the infiltration of
mononuclear cells is inhibited245.
1.3.4 Macrophages and macrophage products in CAN
Macrophages and T cells246 are the predominant cell types seen in the
tubulointerstitial inflammatory cell infiltrate and, indeed, recipient monocytes and
lymphocytes are the first cells to infiltrate the graft after transplantation. T
lymphocytes are consistently present in low numbers and may provide continuous
background immunological activity but the infiltration ofmonocytes into the graft
relatively early following transplantation may be critical to graft outcome237'247'248.
Acute rejection is accompanied by an increase in infiltrating monocytes and
macrophages in renal allografts249"251 and it has been suggested that macrophages
formed the largest components of infiltrating cells in acute as well as chronic
transplant pathology, with some authors suggesting that macrophage infiltration may
prove a useful marker of acute rejection252, perhaps more useful than markers of
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lymphocyte activity253. In the chronically failing allograft, macrophage infiltration
and activity correlates directly with graft survival241'247'248. In one study, the number
of infiltrating interstitial macrophages was markedly higher in the chronically failing
allograft compared to a control group having stable renal graft function for more than
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5 years . In the same study, numbers of infiltrated glomeruli were also significantly
higher254. By producing chemokines and cytokines such as IL-1, IL-6, TNFa,
RANTES, MCP-1 and iNOS255 and interacting with T cells, activated macrophages
are important mediators in the development and amplification of the inflammatory
response. Importantly, they are key mediators in fibrosis providing a large number of
profibrotic factors and ECM proteins256'257. Indeed, the use of gamma lactone, a
specific inhibitor ofmacrophage generation and effector activity in vitro258, results in
histologically normal glomeruli and arteries and the prevention of proteinuria.
In addition to cytokines, macrophages produce a number of growth factors, many of
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which are implicated in the development of CAN ' . These include platelet-
derived growth factor (PDGF), a potent growth factor for smooth muscle cells244'261.
That PDGF may play a significant role in the development ofCAN has been
highlighted recently by studies showing that the inhibition ofPDGF prevents the
development of CAN in a rat model262. Other macrophage-derived growth factor
products upregulated in CAN include insulin-like growth factor-1 (IGF-1), a weak
mitogen of smooth muscle cells which may enhance the mitogenic effects of PDGF,
and fibroblast growth factor (FGF) which appears to have a crucial role in the
regulation ofmedia smooth muscle cell proliferation263 and the glomerular lesions
associated with CAN264. The macrophage product, VEGF, is a potent endothelial cell
mitogen, angiogenic factor and enhancer of vascular permeability. It is also
chemotactic for monocytes. It is upregulated in the interstitium in chronic renal
allograft rejection and in the interstitium of kidneys with chronically reduced blood
flow, where its expression co-localises with CD68-positive macrophages265'266. It is
also upregulated in the glomeruli and vascular compartments of patients with chronic
rejection although overall VEGF protein and mRNA expression is decreased in the
chronically failing allograft as it is in other forms of chronic renal disease267.
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TGF-p is believed to be perhaps the single most important mediator of the fibrosis
seen in CAN, with its expression being shown to be a significant correlate of
268 270 • 271 177interstitial fibrosis " , glomeruloscerosis , vasculopathy and declining renal
function272. TGF-P is a multifunctional growth factor produced by a number of
different cell types in response to a range of different stimuli107. TGF-P has 3
isoforms whose biological properties are almost identical; TGF-P 1, 2 and 3. TGF-P 1
is a potent chemotactic agent for fibroblasts and, through the enhanced production of
acidic fibroblast growth factor stimulates fibroblast proliferation273, an effect
contributed to by other activated macrophage and lymphocyte products such as
TNFa and IL-ip. TGF- P enhances the synthesis of a number of extracellular matrix
proteins including collagen, fibronectin and proteoglycans274 and it inhibits the
degradation of newly formed matrix proteins275'276. TGF-P 1 is normally transiently
upregulated in response to tissue injury and is essential in driving normal wound
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healing ' . However, fibrosis represents a pathological excess of the normal
process of tissue repair and sustained or increased synthesis of TGF-P results in a
shift towards accumulation ofECM and inhibition of its degradation. The
administration of intravenous TGF-P induces serious systemic effects in rats
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including marked fibrosis in the kidneys and liver and at the injection site .
Furthermore, in mice given TGF-P 1 intraperitoneally for 10 days, severe cahexia and
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generalised tissue fibrosis develop . TGF-P 1 plays other roles of relevance to the
development ofCAN. For example, it regulates PDGF (in smooth muscle cells and
fibroblasts), FGF (in endothelial cells) and TNFa and IL-1 (in monocytes)280'281. It
also induces the transdifferentiation ofproximal convoluted tubule epithelial cells in
the kidney into myofibroblasts282, cells having properties of both smooth muscle
cells and fibroblasts. In addition, it inhibits lymphocyte proliferation and effector
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function and, furthermore, is capable of exhibiting positive autoregulation of its
own synthesis, thereby augmenting its fibrogenic actions284. The commonly





As discussed above, macrophages are an integral component in the inflammatory cell
infiltrate seen in CAN. Furthermore, they provide a critical link between the innate
and adaptive immune systems acting as a stimulus for T cell activation and effector
function. Macrophages have been shown to express the receptor for Shh, Ptc, and,
since both epithelium and CD4+ T cells express Shh, there is clearly the potential for
a number of interactions to occur at sites of epithelial damage and immune cell
infiltration through the Shh signalling pathway. Given that macrophages may be able
to respond to a Shh signal, an area that has been explored in Chapter 5 of this thesis,
this part of the introduction introduces the concept of macrophage activation. The
aim of this section of the introduction, like the following section on T cell activation,
however is not to comprehensively review these areas and the reader is directed to a
number of reviews covering the area287" 90. Rather, these sections will concentrate on
the areas ofmacrophage and T cell activation relevant to the experimental
procedures described later in this thesis.
1.4.2 The Innate Immune System
The innate immune system represents the first line of defence to attack by pathogens.
Pathogens that breach the epithelial barrier are intercepted by macrophages and
dendritic cells capable of binding to and phagocytosing a wide variety of pathogens.
Subsequent processing of the antigen allows presentation to lymphocytes, thus
instigating adaptive immunity in the form of specific T and B cell effector
mechanisms. The initial recognition ofpathogens is mediated by a number of
different pattern recognition receptors (PRRs) on the host phagocyte and these are
responsible for initiating acute inflammatory responses against invading
pathogens291. These receptors recognise pathogens by detecting highly conserved
repeating patterns (pathogen associated molecular patterns, PAMPs)292 which are
essential for survival of the pathogen. The PRRs represent a diverse group of
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receptors which includes scavenger receptors293'294, the type 3 complement receptor,
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CD36 , DC-SIGN and the mannose receptors . In addition to these receptors,
there is a further large group ofPRRs, the Toll-like receptors (TLRs), which have
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transformed our knowledge of innate immunity " and will be discussed in greater
detail below. PRRs instigate the uptake and processing of the pathogen by the
phagocyte, allowing pathogenic antigens to be presented on the surface of the host
antigen presenting cells (APCs) in conjunction with MHC molecules thus allowing
activation of specific T and B lymphocytes to occur and the triggering of the
adaptive immune response.
1.4.3 The Toll-Like Receptors
1
Since the discovery of the human homologue ofDrosophila Toll , there has been a
rapid expansion in the number ofTLRs identified291'299. To date, 10 TLRs have been
reported and these are differentially expressed in immune cells, including
macrophages, dendritic cells and T cells, and a number of non-immune cells
including endothelial cells and epithelial cells. Nearly all of the TLR agonists so far
identified are bacterial in origin reflecting the variety of bacterial components that
can be recognised by the innate immune system.
Of the TLRs, most attention has focused on TLR4, the main transducer of the
lipopolysaccharide (LPS) signal. LPS is an extremely potent stimulant of immune
responses and is the principal cause of septic shock in humans302. The potency of
LPS is highlighted by studies showing that as little as lOpg/ml LPS can induce
significant cytokine production303'304. Although TLR4 is the best characterised of the
TLRs and the main receptor responsible for the signal transduction of LPS, other
TLRs are recognised to play important roles in the recognition of bacterial
components299'305. For example, TLR2 recognises lipoproteins306, glycolipids,
peptidoglycans307, lipoteichoic acid308 and a variety of other Gram positive bacterial
products. TLR3 recognises double-stranded RNA309 and TLR5 and TLR9 recognise
flagellin310 and bacterial DNA respectively. Indeed, bacterial agonists have now been
identified for nearly all of the TLRs (Reviewed in 299'300'305)(See Figure 1.2)
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emphasizing the important role of these molecules in the recognition ofpathogens by
cells of the innate immune system. Interestingly, there have been a number of reports
in the literature proposing that, aside from exogenous agonists for the TLRs, a
number of endogenous agonists exist. Proposed endogenous agonists for the TLRs
are shown in Figure 1.2. The interest in these endogenous agonists for TLR4 has
been dramatic and unlike that seen for any other TLR. These structurally and
functionally unrelated endogenous agonists including the extracellular matrix
components fibronectin311, hyaluronic acid312, heparan sulphate313, fibrinogen314,
surfactant protein A315, fatty acids, P-defensins316 and members of the heat shock
protein (HSP) family; HSP60317"321 and HSP70322"324. These endogenous agonists are
purported to activate macrophages and dendritic cells in a similar way to the bacterial
TLR4 agonists, inducing the expression of proinflammatory cytokines and
costimulatory molecules discussed further below. Why endogenous agonists and,
indeed, so many structurally and functionally different agonists should induce similar
patterns of effector function in macrophages and dendritic cells is not clear. In the
case of the heat shock proteins, whose primary function is to chaperone proteins
(Reviewed in 325), it is proposed that the proteins are released from damaged or dying
cells326 thus providing a "danger signal" to the immune system327. Other
investigators have been more sceptical regarding the proposed endogenous TLR4
activators positing that some, if not all, of the effects seen in response to the
proposed TLR4 agonists may be attributable to bacterial components of the proteins
used to explore their effects in vitro. Indeed, some authors have reported on studies
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1.4.4 The Macrophage Effector Response
The TLRs show homology with the IL-1 receptor. Activation of the TLRs and the
IL-1 receptor results in the polymerisation of the TLRs or IL-1 receptor and the
interaction with an adaptor protein. Of the adaptor proteins, MyD88 was the first to
be associated with TLR signalling330 and is the best characterised. It appears to play a
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critical role in the response to TLR agonists and IL-1 . It is generally believed that,
following activation, MyD88 recruits a serine-threonine kinase - the IL-1 receptor
associated kinase (IRAK). This is activated by dephosphorylation and associates with
TRAF6 with the subsequent activation of the JNK and NF-kB pathways332"334. It has
been suggested that all TLR proteins may use MyD88330'332 and, indeed,
macrophages from mice deficient in MyD88 fail to generate a significant
inflammatory response to a variety ofTLR agonists
However, that TLR4 may also use other adaptor proteins was soon realised following
the observation that a TLR4 agonist induced downstream pathway activation in
MyD88-deficient mice331. Indeed, in these mice, LPS was also shown to induce
activation of the downstream targets NF-kB and JNK albeit with delayed kinetics.
Furthermore, this MyD88-independent activation pathway may have very distinct
biological roles (Reviewed in ). For example, the expression of IFN-y-inducible
genes, including IP-10 and IRG-1 by macrophages in response to LPS appears to be
TLR4-dependent but MyD88-independent305. It has also been posited that the LPS-
induced maturation of dendritic cells (DCs) may, at least in part, depend on MyD88-
independent pathways as evidenced by studies in which enhanced expression of
costimulatory molecules and increased T cell allo-stimulation was observed in DCs
from MyD88-deficient, but not TLR4 deficient mice335'336. One of the adaptor
proteins implicated in MyD88-independent signalling is the TIR domain-containing
adapter protein (TIRAP)337, a protein also known as MyD88 adapter-like (Mai)338. In
contrast to MyD88, TIRAP does not appear to participate in IL-1 signaling337. Other
adaptor proteins may also play a role in TLR signalling. For example, Toll-
interacting protein (TOLLIP), a protein first identified as a component of the IL-1
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receptor pathway339, may be important as a negative regulator of the TLR signalling
pathways320'340.
As a result ofTLR activation, a number of downstream pathways are activated. The
end result of activation of these pathways is the production of an effective
macrophage capable of both dealing effectively with elements recognised by the
body to be pathogenic or non-self and, also, activating T cells thus generating an
efficient adaptive immune response. The activation of T cells is discussed in greater
detail in Section 1.4.
Of the downstream pathways activated as a result of TLR activation, the highly
conserved and structurally related NF-kB proteins play a central role in several
immune and inflammatory processes341. In resting cells, NF-kB proteins are
sequestered in the cytoplasm by their inhibitors IkBoi, IkBP and IkBs. Activation of
the macrophage by LPS or other stimuli activates the IkB kinase complex (IKK)
which phosphorylates IkB. Phosphorylated IkB becomes degraded thus releasing
NF-kB and allowing the translocation ofNF-kb/Rel complexes such as p50/p65 to
the nucleus where they can activate the transcription of a number of genes playing
roles in the innate immune response. In addition to the activation ofNF-kB, TLR
signalling also initiates signalling through phosphoinositide-3-kinase (PI3K) and the
mitogen-activated protein kinases (MAPK) signalling cascades including the ERK,
JNK and p38 pathways with the subsequent direct or indirect activation of a series of
transcription factors including Elk-1, c-Jun, c-Fos, ATF-1 and 2, SRF and CREB342.
LPS induces a large number of genes that express inflammatory mediators and
enhance antigen presenting activity291'300'305. These include cytokines (e.g. IL-1, IL-2,
IL-6, IL-12, TNFa and GM-CSF), chemokines (e.g. IL-8, monocyte chemotactic
protein (MCP-1), Regulated on activation normal T cell expressed and secreted
(RANTES), Macrophage inflammatory protein (MlP)-la and-lp, melanoma growth
stimulatory activity (GRO), IFN-y-inducible protein-10 (IP-10)), adhesion
molecules, growth factors (e.g. VEGF) co-stimulatory molecules and inducible
enzymes (e.g. iNOS)341'342.
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It was once thought that LPS and other TLR agonists induced the same effector
response in responding cells. However, it is now increasingly being recognised that
activation via different TLR pathways can induce differential effector functions343"
347. The MyD88-dependent pathway, together with an apparently increasing group of
MyD88-independent pathways adds significant diversity to the TLR effector
response. Adding to this diversity are a number of other interesting reports in the
literature. For example, there are reports suggesting that synergy may occur between
TLRs348'349 and, furthermore, that TLR4 signalling may upregulate the expression of
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TLR2 . Together, these factors add a further dimension to the investigation ofTLR
mediated signalling suggesting that, far from serving a non-specific effector function
as previously thought, the innate immune system is potentially capable of
demonstrating both specificity and selectivity in its response.
A further element of specificity in the macrophage response is illustrated by the
recognition that different combinations of stimuli may also give rise to macrophages
with different effector functions. The phenotypes include the classically activated
macrophage, the alternatively activated macrophage, the type II activated
macrophage and other phenotypes generated following treatment with IL-10, steroids
or the uptake of apoptotic cells. These phenotypes have been reviewed
elsewhere ' ' and will only be discussed briefly here. Classical macrophage
activation involves 2 key signals, the first provided by TLR activation and the second
by IFN-y provided, in vivo, by T cells or natural killer cells. Proinflammatory
cytokines (including IL-ip, IL-6, IL-8, MCP-1, TNFa), nitric oxide and reactive
oxygen species are induced and costimulatory and MHC class II molecules are
upregulated. Classical activation plays a significant role in initiating the adaptive
immune response287. In contrast, alternative macrophage activation occurs typically
following exposure to IL-4 or IL-13353'354. Nitric oxide, TNFa and IL-6 production
are decreased on a background of increased mannose receptor and MHC class II
expression. These macrophages are proposed to play a role in tissue repair
processes355. The recently identified "type Il-activated macrophage"352 expresses
upregulated MHC class II, IL-10, IL-6 and TNFa but reduced IL-12 expression. The
phenotype was found to be induced by stimuli such as LPS or CD40 ligand together
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with IgG immune complexes356. Other macrophage phenotypes may be induced by
stimuli such as apoptotic cell uptake, IL-10 or steroid treatment351.
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1.5 T Cell Activation
1.5.1 Introduction
As highlighted in the previous section, macrophages are central to an efficiently
functioning innate immune response. In addition, as antigen presenting cells, they
present a critical link between the innate and adaptive immune responses.
Furthermore, the recent reports suggesting that macrophages express the receptor for
Shh, Ptc, and that Shh signalling is important in the generation of a CD4+ T cell
effector response highlight the potential role for Shh signalling in the link between
the innate and the adaptive immune responses. Thus, in the section of the
introduction that follows, areas ofT cell activation relevant to the context of this
thesis will be explored further.
Following development in the thymus, mature T cells circulate between the blood
and lymphoid tissue as nai've T cells. On encountering a specific antigen in
association with an antigen presenting cell (APC), a nai've T cell is activated. This
encounter halts the circulation of the T cell, inducing its proliferation and the
induction of an effector function that allows the T cell to deal appropriately with the
encountered antigen. The effector cells that result from this process re-enter the
blood and migrate to the sites of antigen invasion. Conversely, naive T cells which
do not recognise the specific antigen continue to recirculate between the blood and
lymphoid organs357'358. In addition to this primary immune response, immunological
memory is generated in the form of long-lived memory T cells which allow an
accelerated response to subsequent encounter with the same antigen.
1.5.2 Antigen presentation
For T cell activation to occur, the T cell recognises foreign antigen in association
with a major histocompatibility (MHC) complex present on APCs. Several cell types
can function as APCs including dendritic cells (DCs), macrophages and B cells.
Mature DCs are the most potent activators of nai've T cells, playing a role in the
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presentation of bacterial, viral and fungal antigens to T cells. Both immature
dendritic cells and resting macrophages originate from myeloid precursors which
lack high levels ofMHC and circulate in the blood to reach peripheral tissues. In the
periphery, these cells are capable of phagocytosing antigenic material, an action
effected through a range of receptors on the cell surface most ofwhich recognise
microbial products. Following phagocytosis, the antigenic material is processed.
Signalling triggered by the process of phagocytosis induces the upregulation ofMHC
molecules and it is this complex ofMHC and antigen that is recognised by the T cell
receptor (TCR) complex and will be discussed in more detail below.
In addition to a role in the T cell response to pathogenic antigens, T cell activation
also forms a vital component of the host response to alloantigen in the context of
transplantation. In this respect, donor organ alloantigens can be presented to recipient
naive T cells in 2 ways. In the first of these, termed direct allorecognition, donor
APCs (also termed passenger leukocytes) migrate from the donor organ and present
donor alloantigens to naive host T cells in the draining lymph nodes359. Passenger
leukocytes with the properties of immature dendritic cells360 migrate very rapidly out
of an organ following transplantation and quickly mature into APCs capable of
stimulating naive T cells361. Activated cytotoxic T cells return to the graft which can
then be attacked directly.
A further mechanism, termed indirect recognition, also plays a role in alloantigen
recognition. In this mode of alloantigen recognition, recipient APCs take up donor
alloantigens and present them to naive recipient T cells, a mechanism more in
keeping with the orthodox modes of antigen presentation observed during the
presentation of pathogenic antigens. Since the MHC class II pathway deals primarily
with exogenous proteins, it seems likely that most allo-MHC peptides might be
presented in the context ofMHC class II. However, some crossover between Class II
and I pathways may also exist362. The relevance of the indirect pathway to acute
rejection has not been completely established although it has been posited that this
pathway may play more of a role in chronic rejection processes where the ongoing
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presence of antigenic stimulus could continue to drive a background immune
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response .
1.5.3 T cell receptor mediated activation
For T cell activation to occur, only very small numbers of antigen-MHC complexes
are required. Indeed, as few as 1-400 complexes may be necessary to initiate
recognition by the TCR364"367. The TCR binding site comprises heterodimers of
variable TCR ap and y5 receptor chains368. The TCR associates with the CD3
complex, a structure consisting of invariant y, 5 and s chains and a homodimeric C,
chain. The TCR confers specificity ofMHC-antigen binding. Conversely, the C,
chains of the CD3 complex transduce activation signals to the T cell. Within the
chains of the CD3 complex exist amino acid sequences termed Immunoreceptor
Tyrosine-based Activation Motifs (ITAMs). Each CD3 chain contains one ITAM and
each C, chain contains three. Tyrosine phosphorylation of these motifs initiates TCR-
associated signal transduction and the downstream activation of intracellular
pathways369. CD8 and CD4 are accessory molecules to the TCR-mediated activation
process. They bind to MHC molecules at a different site to the TCR and form an
important part of the TCR complex, increasing the affinity of interaction between the
T cell and the APC. CD8 and CD4 also define the MHC restriction of the T cell
(recognising class I and class II MHC respectively) and have a role to play in the
optimisation ofT cell effector function. Although some similarities exist between
CD4 and CD8 T cell activation events, the following discussion regarding T cell
activation and T cell effector function will be directed at events occurring in the
CD4+ T cell since these bear direct relevance to the work presented in this thesis.
In the CD4+ T cell, TCR activation is not sufficient to generate optimal T cell
activation. A second co-stimulatory signal to the T cell is also required. Indeed TCR
activation in the absence of a second costimulatory signal results in T cell
unresponsiveness or anergy370. Several molecules are likely to contribute to
costimulatory signals and include the B7 family of molecules, B7-1 (CD80) and B7-
2 (CD86). CD80 is absent and CD86 is expressed only at low levels on resting
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APCs371 although both are upregulated alongside MHC molecules when APCs take
up and process antigen in the periphery.
The receptor for the B7 molecules on the T cell is CD28372'373, a glycoprotein
expressed as a homodimer and present on 95% CD4+ T cells and 50% CD8+ T
cells374"376. CD28 interacts with B7 ligands through a MYPPPY recognition motif in
its extracellular domain373. In contrast to the TCR signalling through ITAMs, CD28
signals are mediated through phosphorylated tyrosines and proline-rich motifs in its
41-residue cytoplasmic tail377. Costimulation through CD28 ligation synergises with
TCR engagement, lowering the threshold for activation to occur and resulting in a
• • • • • ^7R
rapid increase in the tyrosine phosphorylation of CD28 . The synergistic signal
provided by CD28 appears to be greatest in instances of low TCR occupancy. In
contrast, very strong TCR signals and T cells exposed to antigen appear to be less
CD28-dependent379.
Aside from CD28, other costimulatory molecules are likely to also contribute to T
cell signalling. Such molecules include Inducible co-stimulator (ICOS), a T cell
costimulatory protein related to CD28380 that is expressed on resting but not activated
T cells380, and members of the TNF receptor family including CD40 Ligand
(CD40L/CD154)381, OX-40 (CD134)382, a potent inducible costimulatory
molecule383, 4-1BB (CD137) and CD27384, a molecule implicated in T cell
activation, T cell development and T cell dependent antibody production by B cells.
Other co-stimulatory molecules on the T cell surface capable of upregulating TCR
signals include CD5, CD9385 and CD2386.
The initial interaction of the TCR with the MHC-antigen complex triggers a tyrosine
• • ... TR7 7RQ
phosphorylation cascade that triggers multiple branching signalling pathways " .
These early signals may be sufficient to trigger some effector functions such as killer
T cell activity but other functions such as T cell proliferation and cytokine effector
function appear to require a more prolonged TCR engagement in keeping with
minutes or hours of T cell-APC contact. In this regard, the formation of the
immunological synapse appears to be central to the T cell TCR-MHC interaction390.
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The mature T cell synapse is thought to comprise a central cluster of TCRs
surrounded by a ring of integrins, mainly LFA-1390'391. Although the TCR plays a key
role in the initiation and maintenance of an activated state, it may be that the
integrins and other T cell surface molecules such as the costimulatory molecules play
important roles in recognition. One commonly held view is that the T cell first probes
the APC through pseudopodial extensions and, following recognition, integrins allow
the T cell to flatten against the APC with the formation of the immunological
synapse. Although synapse formation does not appear to be necessary to trigger
signalling through the TCR, it may be needed to sustain the activated T cell response.
The combination of TCR/CD3 signalling, co-stimulation and integrin interactions
appear to initiate the active transport of TCR molecules from all over the T cell to the
immunological synapse allowing concentration of the signalling components and
optimal stimulation of the T cell by the antigen-MHC complex392'393. Studies
investigating the mechanisms underlying synapse fonnation have suggested that lipid
rafts may serve as a platform for T cell signalling394"396. Indeed, it would seem that,
following TCR engagement, the TCR C, chain and downstream transducers are
tyrosine phosphorylated and stabilised within lipid rafts allowing further rafts to be
recruited with the formation of larger rafts at the TCR contact point (cap). This raft
coalescence appears to be critical for the generation of a sustained TCR signal,
tq7 tqr •
effective signal transduction (reviewed in ' ) and the subsequent production of
IL-2399.
TCR ligation, in association with a second costimulatory signal, initiates a complex
series of intracellular activation events which culminate in the activation of at least
three central signalling pathways; nuclear factor of activated T cells (NFAT)400,401,
activator protein 1 (AP-1)402 and nuclear factor kB (NFkB)403. The activation of
phospholipase C-y (PLC-y) is central to the activation of the NFkB and NFAT
pathway. PLC-y activity results in the generation of inositol-3,4,5-triphosphate (IP3)
and diacylglycerol (DAG) from phosphatidylinositol-4,5-biphosphate (PIPi)- IP3
promotes calcium release from the endoplasmic reticulum. The elevation in
intracellular calcium activates calmodulin, a calcium binding protein and calcineurin,
a serine/threonine protein phosphatase404. Calcineurin is activated by the binding of
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calcium and calmodulin, and transmits signals to the nucleus through the
dephosphorylation and translocation ofNFAT transcription factors. NFAT is central
to lymphocyte development and proliferation as evidenced by studies in which
targeted disruption ofNFAT leads to defective development and proliferation405'406.
Ciclosporin and tacrolimus (FK506) inhibit the phosphatase activity of calcineurin
resulting in the relocalisation ofNFAT to the cytosol, loss of its DNA-binding
activity and consequent inhibition of T cell proliferation, differentiation and effector
function. It is for this reason that calcineurin inhibitors are often used in the
immunosuppressive regimen for recipients of solid organ transplants.
1.5.4 The CD4+ T cell effector response
Activation of the downstream pathways outlined above serves to control a number of
T cell events and effector processes. Specifically, T cell activation induces the clonal
expansion of T cells and promotes T cell differentiation into effector cells407'408. The
clonal expansion of T cells occurs primarily through an increase in IL-2
secretion409'410. Enhanced IL-2 production is accompanied by associated increases in
IL-2 receptor (IL-2R) expression411. The IL-2R comprises 3 chains: a, P and y and
the upregulated IL-2 production is associated with a concomitant increase in the
expression of the a chain of the IL-2 receptor. This, when associated with the P and y
chains, results in a receptor with high affinity for IL-2 allowing cells to rapidly
respond to low levels of IL-2 and clonally expand and differentiate into effector T
cells.
Following T cell activation, a range of different cytokines may be expressed and the
profile demonstrated determines the effector function of a given CD4+ T cell. In the
1980s, it was proposed that, based on the cytokine expression profile, 2 broad
populations of effector T cell were generated412'413. These were termed Thl and Th2
CD4+ T cells. Although this classification is simplistic and increasingly believed to
be inappropriate, indeed the given cytokine effector profile is likely to be a mixture
of cytokines reflecting the heterogeneity of immune responses induced, it is still used
to broadly describe the types of cytokine profile generated by different subsets of Th
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cells. Both Thl and Th2 cells appear to derive from a common ThO precursor.
Whether a Thl or Th2 cell develops depends on the cytokine milieu in which the Th
cell finds itself. The production of IL-12 by macrophages and dendritic cells will
direct the ThO cell towards a Thl phenotype. Such cells produce relatively large
quantities of cytokines important for cell-mediated immunity including IL-2, IFN-y
and TNF. As outlined above, IL-2 is rapidly induced by T cell activation. It is
primarily responsible for regulating T cell growth and clonal expansion414. It also
stimulates B cell and natural killer (NK) cell growth. IFN-y has a number of effector
functions. It activates macrophages, upregulates MHC class I and II expression and
enhances their phagocytic and microbicidal activity. Furthermore, it activates
neutrophils and NK cells and is also responsible for induction of antibody class
switching to the IgG2a isotype in B cells415'416. IFN-y is induced not only by TCR-
mediated activation414 but also by other cytokines including IL-2, IL-12, IL-15, TNF.
Together, the Thl cytokines promote the development of cytotoxic T cells and
facilitate antibody-dependent cellular cytotoxicity serving as effector mechanisms
against intracellular pathogens. In contrast to the inflammatory cytokines induced in
Thl T cells, Th2 T cells secrete effector molecules concerned with regulation of
Thl-mediated effects and the humoral immune response417. ThO cells are polarised
towards a Th2 phenotype when cultured in the presence of IL-4, the source ofwhich
may be a number of different cell types including naive T cells and a small
population ofNK T cells. Cytokines produced by Th2 cells include IL-3, IL-4, IL-5,
IL-6, IL-9, IL-10 and IL-13, cytokines important in mediating the B cell response.
These cytokines stimulate B cell proliferation and synthesis of antibodies, promote
the differentiation of B lymphocytes into antibody-secreting plasma cells and allow
antibody class switching. These cytokines also allow B lymphocytes to activate
eosinophils. Furthermore, IL-5 plays a role in enhancing IL-2-dependent T cell
proliferation and differentiation although, since T cells do not express a clear
receptor for IL-5, the mechanism by which this occurs is not clear. IL-10 is an
important cytokine originally incorporated into the Th2 subset but produced by a
number of cell types including macrophages, Thl and Th2 CD4+ T cells and CD8+
T cells, NK cells, mast cells and B cells418'419. IL-10 is important for a number of
reasons, not least because it functions as a significant down-regulator of
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inflammatory responses. IL-6 is important in inducing B cells to differentiate into




The Shh signalling pathway has a number of roles in a variety of developmental
processes. More recently, a growing body of evidence has evolved to suggest that
activation of the Shh signalling may play a role in the adult. Recent reports in the
literature have suggested that Shh signalling may play a role in inflammation and
fibrosis and, further, that it may be important in the maintenance of peripheral
immunity. Indeed, immune cells have been shown to express Shh signalling pathway
components and further work from our laboratory has shown that the proliferation
and cytokine effector function of CD4+ T cells is modulated by Shh signalling. The
work to date suggesting a role for Shh signalling in inflammation and fibrosis has
concentrated on human lung disease and a murine model of lung fibrosis. Other
conditions characterised by inflammation and fibrosis have not been investigated.
Chronic renal allograft nephropathy (CAN), as discussed earlier in this chapter, is
characterised by interstitial fibrosis, tubular atrophy, vasculopathy and a
mononuclear cell infiltration. The inflammatory cell infiltrate consists of mainly
macrophages and T cells. TGF-I3 and VEGF are among a number of factors produced
by activated macrophages and both growth factors have been demonstrated to be
upregulated in CAN. Both factors may also be downstream targets of Shh signalling.
Therefore, kidney and the kidney affected by CAN prove interesting areas for further
study. Thus, the first hypothesis central to this thesis was that Shh signalling
pathway components are expressed in and relevant to normal and CAN kidney.
The second hypothesis evolves from the findings that macrophages and T cells
express Shh signalling pathway components and that the addition of recombinant
Shh to cultures of activated CD4+ T cells modulated the proliferation and cytokine
effector function of these cells. Thus, the second hypothesis was that Shh
signalling may be important in peripheral immunity. Specifically, in this regard,
the work presented here has questioned the possible role for Shh signalling in
macrophages, an area which has, to date, not been explored. Furthermore, and
drawing on the recently published reports suggesting a role for Shh signalling in
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adult human and murine T cell effector function, this work has sought to further






All reagents were purchased from Sigma (Poole, Dorset, UK) unless stated
otherwise.
2.1.1 Media
The following media were used for the tissue culture experiments:
Serum-free IMDM culture medium for monocyte adherence
500 ml IMDM (Gibco, Paisley, UK) with 50IU/ml penicillin/50pg/ml streptomycin
(Gibco, Paisley, UK) and 2mM L-glutamine (Gibco, Paisley, UK). Stored at 4°C.
Complete IMDM culture medium with 5% fetal calf serum (IMDM-FCS) for
macrophage culture
500 ml IMDM (Gibco, Paisley, UK) with 50IU/ml penicillin/50pg/ml streptomycin
(Gibco, Paisley, UK), 2mM L-glutamine (Gibco, Paisley, UK) and 5% fetal calf
serum (FCS) (F-9665). Stored at 4°C.
Serum-free RPMI culture medium for monocyte adherence
500 ml RPMI 1640 (R-0883) with 50IU/ml penicillin/50pg/ml streptomycin (Gibco,
Paisley, UK) and 2mM L-glutamine (Gibco, Paisley, UK). Stored at 4°C.
Complete RPMI culture medium with 5% human AB serum for T cell culture
500 ml RPMI 1640 (R-0883) with 50IU/ml penicillin/5Opg/ml streptomycin (Gibco,
Paisley, UK), 2mM L-glutamine (Gibco, Paisley, UK) and 5% human AB (heat
inactivated) serum (H-1513). Stored at 4°C.
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Complete DMEM for ACHN cell culture
500ml DMEM with lOOIU/ml penicillin/lOOpg/ml streptomycin (Gibco, Paisley,
UK), 2mM L-glutamine (Gibco, Paisley, UK), 10% FCS and 1% Non-Essential
Amino Acids (Gibco, Paisley, UK). Stored at 4°C.
Complete DMEM for murine renal tubular epithelial cell culture
500ml DMEM/F12 (Gibco, Paisley, UK) with lOOIU/ml penicillin/lOOpg/ml
streptomycin (Gibco, Paisley, UK), 2mM L-glutamine (Gibco, Paisley, UK), 1%
ITS (insulin/transferring/sodium selenite) supplement (1-3146), 30ng/ml
dexamethasone (D-8893), 25ng/ml Epidermal Growth Factor (E-4127). Stored at
4°C.
Complete HBSS
500ml HBSS with 50IU/ml penicillin/50pg/ml streptomycin (Gibco, Paisley, UK).
Stored at 4°C.
2.1.2 Cell Separation and Stimulation Reagents
The following reagents were employed in the isolation of specific cell populations
from Buffy coats and for the cell stimulation experiments:
MACS Buffer
0.5% BSA (A-2153) in PBS (D-8537). Stored at 4°C.
Red Blood Cell Lysis Buffer
ImM NH4HCO3 and 114mM NH4C1. Stored at 4°C.
Collagenase Digestion Mixture
20ml complete HBSS with 0.05% collagenase (C-5138) and 20pl (0.1%) DNAse I
(Roche 1284932). Sterile filtered prior to use. Stored at 4°C.
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Freezing Mix
10% DMSO in FCS
2.1.3 Flow Cytometry Reagents
The following reagents were utilised for experiments involving flow cytometry:
FACS Wash Buffer
0.1% sodium azide, 0.2% bovine serum albumin (BSA) (A-2153) in PBS (D-8537).
Stored at 4°C.
FACS Fixing Reagent
2% paraformaldehyde (P-6148) in PBS (D-8537). Stored at 4°C.
2.1.4 Immunoassay Reagents
The following reagents were employed in Enzyme Linked Immunosorbent Assay
(ELISA) experiments:
ELISA Wash Buffer
PBS tablets (Oxoid BR14) diluted in distilled water (1 tablet/lOOml water) with
0.05% Tween-20 (P-7949). Stored at room temperature.
ELISA Block Buffer (VEGF and Shh ELISA)
1% BSA (A2153), 5% sucrose, 0.05% sodium azide in PBS. Stored at 4°C.
ELISA Block Buffer (TGF-P ELISA)
5% Tween-20 (P-7949), 5% sucrose, 0.05% sodium azide in PBS. Stored at 4°C.
ELISA Reagent Diluent (VEGF and Shh ELISA)
1% BSA in PBS, pH 7.2-7.4, 0.2pm sterile filtered. Stored at 4°C.
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ELISA Reagent Diluent (TGF-p ELISA)
1.4% delipidised bovine serum (R&D Systems, Abingdon, UK), 0.05% Tween-20
(P-7949) in PBS, pH 7.2-7.4, 0.2pm sterile filtered. Stored at 4°C.
ELISA Substrate Solution
1:1 mixture of colour reagent A (hydrogen peroxide) and colour reagent B




The following reagents were used in the immunohistochemistry experiments
employed to evaluate tissue and cellular protein expression:
Antigen Retrieval Solution
5mls Vector antigen retrieval solution (Vector Laboratories, Peterborough, England)
in 500mls deionised water. Freshly made for each experiment.
Endogenous Peroxidase Block
18mls 30% hydrogen peroxide (H-1009) in 375mls tap water. Freshly made for each
experiment.
Phosphate Buffered Saline (PBS)
PBS tablets (Oxoid BR14) diluted in distilled water (1 tablet/1 OOmls). Stored at room
temperature.
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2.1.6 Molecular Biology Reagents
The following reagents were used in the molecular biology experiments employed to
evaluate tissue and cellular mRNA expression:
6x PCR loading buffer
0.25% weight/volume bromophenol blue and 40% weight/volume of sucrose in
distilled water. Stored at 4°C.
TE Buffer
lOmM Tris-HCl (pH 8), ImM EDTA
2.1.7 Protein Analysis Reagents
The following reagents were used in Western blotting experiments employed to
determine tissue protein expression:
4 x Buffer pH 8.8
1.5M Tris HC1, 0.4% SDS in distilled water. Stored at room temperature.
4 x Buffer pH 6.8
0.5M Tris HC1, 0.4% SDS in distilled water. Stored at room temperature.
10% Separating Gel
10% Polyacrylamide, 25% 4x Buffer pH8.8, 0.05% APS (A-3678), 0.05% Temed
(T-9281) in distilled water. Freshly made for each experiment.
4% Stacking Gel
4% Polyacrylamide, 25% 4 x Buffer pH6.8, 0.05% APS (A-3678), 0.1% Temed (T-
9281) in distilled water. Freshly made for each experiment.
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Protein Loading Buffer
50mM Tris HC1 (pH6.8), lOOmM Dithiothreitol, 2% SDS, 0.1% bromophenol blue,
10% glycerol in distilled water. Stored at -20°C.
Protein Lysis Buffer
50mM Tris HC1 pH7.5, 320mM sucrose, ImM EDTA (pH8), 1% protease inhibitor
cocktail (P-2714), ImM PMSF (P-7626) in lOOmls distilled water. Stored at "20°.
5 x Running Buffer
72g glycine (G-7403), 15.lg Trizmabase (T-1503), 50mls 10% SDS, made up to
lOOOmls with distilled water. Diluted in distilled water to 1 x Running Buffer made
up fresh for each experiment.
Transfer Buffer
14.4g glycine (G-7403), 2.93g Trizma base (T-1503), 200ml methanol (M-1770),
made up to lOOOmls with distilled water. Made up fresh for each experiment.
Blocking Buffer




2.2.1 Macrophage experiments using human peripheral blood monocyte-
derived macrophages
2.2.1.1 Isolation of peripheral blood mononuclear cells (PBMCs) for monocyte
isolation
The method used for isolation ofmonocytes is based on methods previously
described20'420'421. Single donor Buffy coats from normal human donors were
obtained from Scottish National Blood Transfusion Service. Each Buffy coat was
made up to 200mls with phosphate buffered saline (PBS). Peripheral blood
mononuclear cells (PBMCs) were isolated by centrifugal separation over Histopaque
1077 (Sigma) for 25 minutes at lOOOg. Red cells and debris collected at the base of
the tube and the PBMCs appeared as a distinct creamy layer at the interface between
the Histopaque and serum. The PBMCs at the interface were removed and washed in
PBS, centrifuged for 10 minutes at 300g and then resuspended in PBS. In cases
where a distinct creamy layer failed to form and was clearly contaminated by red
blood cells, the cells at the interface were removed, washed with PBS, pelletted and
resuspended in lOOmls PBS. This was layered onto Histopaque for a second time.
PBMCs were removed from the interface and washed twice with PBS to remove
platelets.
2.2.1.2 Macrophage purification and culture
CD 14 positive monocytes were isolated from PBMCs by positive selection using
magnetic cell sorting. This technique involves the labelling ofPBMCs with magnetic
CD 14 microbeads, passing them through a column which is placed in the magnetic
field of a VarioMACS separator. The magnetically labelled CD14+ cells are retained
in the column and other cells pass through as the negative fraction. The CD 14+ cells
are then be eluted from the column. The procedure was performed according to the
manufacturer's instruction (Miltenyi Biotech) incorporating a red cell lysis step.
Briefly, 1ml of red cell lysis buffer and 4mls PBS were added to 108 PBMCs. The
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cells were incubated on ice for 2 minutes. This was followed by 3 washes with PBS.
The viable cells were counted using a haematocytometerwith 0.4% trypan blue
n
.
exclusion. Viability of the cells was always >95%. 20 x 10 viable cells were then
resuspended in 1600pl MACS buffer. 400pl CD 14 MicroBeads (Miltenyi Biotec)
were added and, following thorough mixing, the cells were incubated on ice for 15
minutes. The cells were then washed with MACS buffer, and the cell pellet
resuspended in 500pl MACS buffer. The MS+/RS+ columns (Miltenyi Biotec),
applicable for the separation ofup to 107 positive cells, were used. Prior to use, the
column was washed with 500pl MACS buffer and the cell suspension applied.
Negative cells were rinsed off the column using 3x 500pl buffer. The column was
withdrawn from the magnetic field and the positive cells flushed out with 1ml buffer
using the plunger provided. Purity checks were performed on the cells using flow
cytometry and the cells were found to be consistently >93% CD 14+.
Following isolation of the monocytes in this way, the cells were incubated for 1 hour
at 106 cells/ml (1ml per well in 24 well tissue culture plates) in serum-free IMDM at
37°C in a humidified 5% carbon dioxide incubator to allow the monocytes to adhere
to the plastic. At the end of this time, the monolayers were washed once with IMDM.
Fresh IMDM-FCS was applied and the cells returned to the incubator. The cells were
washed the following day and every second day thereafter. Adherence continued for
6 days.
2.2.1.3 Macrophage stimulation experiments
Day 6 macrophages seeded at 106 cells per well in 24 well tissue culture plates were
washed with IMDM-FCS. Where the cells were pre-incubated either with
cyclopamine (Toronto Research Chemicals, Toronto, Canada), polymyxin B (PMB)
or the purified CD14 functional blocking antibody 61D3 (eBioscience, San Diego,
USA) or its isotype control (functional grade purified mouse IgGl isotype
(eBioscience)), this was performed for 45 minutes at 37°C prior to the addition of
rShh. Recombinant murine Shh peptide was purchased from R&D Systems
(Abingdon, UK) and reconstituted in IMDM-FCS to allow a final concentration
range of rShh 10-1000ng/ml. Macrophages were cultured in this way for 24 hours at
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37°C. At the end of this incubation period, the medium from each culture well was
removed and set aside for later cytokine analysis. The cells were washed using PBS
and RNA extracted where required as described in Section 2.2.5.1.
2.2.2 T cell experiments using human peripheral blood-derived T cells
2.2.2.1 Isolation ofperipheral blood mononuclear cells fPBMCs! for CD4+ T cell
isolation
As above, PBMCs were isolated from normal, single donor Buffy coats obtained
from the Scottish National Blood Transfusion Service, Edinburgh. Each
Buffy coat was made up to 200mls using PBS and PBMCs were obtained by
centrifugation over Lymphoprep (Gibco) for 25 minutes at lOOOg. The PBMCs,
appearing at the interface between the Lymphoprep and serum, were removed and
washed twice in PBS to remove platelets. The PBMCs were reconstituted in serum-
free RPMI and plated into culture flasks at 5 x 106/ml. The cells were incubated for 1
hour at 37°C in a humidified 5% carbon dioxide incubator to allow adherent
monocytes to be depleted from the PBMCs, by adherence to the plastic culture flask.
Non-adherent cells were removed, counted and washed in PBS prior to proceeding to
cell separation.
2.2.2.2 CD4+ T cell purification and culture
3 methods were used to purify CD4+ T cells:
2.2.2.2.1 Preparation ofCD4+ T cells using depletion columns
PBMCs derived from centrifugation over Lymphoprep were prepared as described
above. Red blood cell lysis was performed and the cells counted using a
haematocytometer with 0.4% trypan blue exclusion prior to CD4 T cell separation.
The Human T cell CD4 subset depletion column kit (R&D Systems) was used to
isolate CD4+ cells by negative selection according to the manufacturer's instructions.
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Briefly, 2 x 108 PBMCs suspended in 1ml of column buffer (R&D Systems) were
incubated with a monoclonal antibody cocktail at room temperature for 15 minutes.
The cocktail binds B cells, monocytes and non-selected T cells. The cells were
washed to remove any unbound antibodies and the pellet resuspended in 2mls
column buffer. The column was washed with lOmls column buffer and the cell
suspension applied to the column. The cells were incubated on the column for 10
minutes at room temperature and the negative fraction containing the unbound cells
eluted from the column using 12mls column buffer. The cells were washed and
counted. Yields of cells in the negative fraction were typically in the order of 1.5 - 3
x 107 cells from a starting population of 2 x 108 PBMCs. The purity of the CD4+ T
cells was checked using flow cytometry and the cells were found to be consistently
82-88% CD3+ CD4+.
2.2.2.2.2 Preparation ofCD4+ T cells bypositive selection
PBMCs derived from centrifugation over Lymphoprep were prepared as described
above. Red blood cell lysis was performed and the viable cells counted using a
haematocytometer with 0.4% trypan blue exclusion prior to CD4 T cell separation.
CD4 positive cells were isolated from the PBMCs by positive selection using
magnetic cell sorting. The PBMCs were labelled with magnetic CD4 microbeads
(Miltenyi) and passed over a column in the magnetic field of the VarioMACS
separator. The CD4+ cells are retained in the column and other cells pass through as
the negative fraction. The CD4+ cells are then be eluted from the column. The
procedure was performed according to the manufacturer's instruction (Miltenyi
Biotech). 20 x 107 cells were resuspended in 1600pl MACS buffer. 400pl CD14
MicroBeads were added and, following thorough mixing, the cells were incubated on
ice for 15 minutes. The cells were then washed with MACS buffer, and the cell pellet
resuspended in 500pl MACS buffer. The MS+/RS+ columns (Miltenyi Biotec),
applicable for the separation of up to 107 positive cells, were used. Prior to use, the
column was washed with 500pl MACS buffer and the cell suspension applied.
Negative cells were rinsed off the column using 3x 500pl buffer. The column was
withdrawn from the magnetic field and the positive cells flushed out with 1ml buffer
using the plunger provided. Yields of cells in the positive fraction were typically in
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the order of 2.5 - 3.8 x 107 cells from a starting population of 2 x 108PBMCs. Purity
checks were performed on the cells using flow cytometry and the cells were found to
be consistently >95% CD3+ CD4+.
2.2.2.2.3 Preparation ofCD4+ T cells by FACS cell sorting
PBMCs derived from centrifugation over Lymphoprep were prepared as described
above. Red blood cell lysis was performed and the cells counted using a
haematocytometer with 0.4% trypan blue exclusion prior to CD4 T cell separation.
The Human T cell CD4 subset column kit (R&D Systems) was used to isolate CD4+
cells by negative selection as described in 2.2.2.2.1 above. The cells produced were
then incubated with an excess (lpg/106 cells) ofAPC-labelled mouse anti-human
CD4+ and PE-labelled mouse anti-human CD3+ antibodies and incubated at 4°C for
25 minutes to allow labelling of the cells to occur. The cells were then washed in
FACS buffer for 5 minutes at lOOg and the cell pellet was reconstituted in 1% serum-
containing RPMI at a concentration of 107 cell/ml. FACS cell sorting was performed
by Shonna McCall (flow cytometry technician, University of Edinburgh) using a
FACSVantage (BD Biosciences, San Jose, CA, USA) sorter. CD3+ CD4+ T cells
were sorted into medium containing 5% AB serum and the cells were used for
culture as above. From a starting population of negatively selected cells, yields of
CD3+ CD4+ T cells were typically in the order of 20-25%. Cells purified in this way
were typically >98.8% pure.
2.2.2.3 CD4+ T cell stimulations using anti-CD3s and anti-CD28 antibodies
CD4+ T cell stimulations were performed using plate-bound anti-CD3s and soluble
anti-CD28 antibodies (BD Pharmingen, San Diego, CA, USA) as described
previously20'21. Briefly, the anti-CD3s antibody was first immobilised onto the wells
of 96 well round bottomed plates by diluting the antibody in PBS to final
concentrations of either 0.2pg/ml or lpg/ml. The plates were incubated for 2 hours at
37°C and then washed 3 times with PBS to remove unbound antibody. The plates
were air-dried for 30 minutes at 37°C prior to use. Anti-CD28 antibody was
reconstituted in medium to final concentrations of lpg/ml and 5pg/ml. Thus, anti-
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CD3e at 0.2pg/ml with anti-CD28 at lpg/ml constituted a "suboptimal" stimulus and
anti-CD3s at lpg/ml with anti-CD28 at 5pg/ml constituted an "optimal" stimulus in
keeping with previous studies20'21. Each condition was replicated in quadruplicate on
the 96-well plate. The T cells were cultured in these conditions for 72 hours.
2.2.2.4 Mixed leukocyte reactions (MLRs)
Macrophages were prepared by maturing CD14+ PBMC-derived monocytes as
described in Section 2.2.1.2 for 6 days in 162cm tissue culture flasks (Costar, Fisher
Scientific, Loughborough, Leicestershire, UK). Following this incubation, the cells
were removed from the culture flasks using cell lifters (Costar). The macrophages
were treated with Mitomycin-C (MMC)(Sigma), an antibiotic that inhibits nucleic
acid synthesis. The cells were mixed with 50pg/ml MMC and incubated for 30
minutes at 37°C. The cells were then thoroughly washed 4 times with ice-cold
medium to remove any residual MMC. Cells prepared in this way were counted and
plated out into round-bottomed 96 well culture plates at a range of concentrations
from 104 - 5 x 105 cells per well. These cells were used to stimulate CD4+ T cells
from a different donor in the mixed leukocyte reactions. The MLRs were incubated
for 72 hours.
2.2.2.5 Proliferation assay
After 72 hours in culture, proliferation was evaluated by pulsing the cells with
tritiated methyl thymidine (3H-TdR-Amersham Pharmacia Biotech, Amersham, UK)
at a concentration of lpCi/well and incubating for a further 18 hours. 3H-TdR
incorporation was evaluated using a Betaplate 1205 liquid scintillation counter
(Wallac, Milton Keynes, UK).
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2.2.3 Renal Epithelial Experiments
2.2.3.1 ACHN Cell Line Management
An aliquot of the ACHN human renal adenocarcinoma cell line (ECACC No.
88100508) was a gift from Dr Ewan Harrison (Centre for Inflammation Research,
University ofEdinburgh). Cells were grown in complete DMEM. The ACHN cells
were grown in culture flasks and incubated in 5% CCb at 37°C. When the cells
reached -75% confluence, the cells were incubated in 0.5g/L trypsin/0.2g/L EDTA
(Invitrogen, Paisley, UK) for 10 minutes at 37°C to lift the cells from the base of the
flask. The cells were washed in complete DMEM and centrifuged at 300g for 5
minutes. The cell pellet was reconstituted in complete DMEM and the cells split 1:5.
Where cells were to be set aside for storage, 5 x 106 cells were resuspended rapidly
in 1ml of freezing mix and stored at -70°C for 2 days. The cells were subsequently
transferred to liquid nitrogen for long-term storage.
2.2.3.2 Murine primary renal epithelial cell (REC) culture
Normal kidneys were removed from C57BL/6 mice and placed whole into complete
HBSS. The kidneys were rinsed in HBSS and the capsule and pelvis removed by
sharp dissection. The kidneys were placed in a petri dish, chopped into small pieces
-lmm3 in size and transferred to a universal container. lOmls of collagenase mixture
were added, mixed with the kidney pieces and incubated at 37°C for 30 minutes. The
mixture was agitated every 10 minutes to aid digestion. After 30 minutes, the mixture
was agitated and the pieces allowed to settle. A sample of supernatant was taken at
this time and observed under the microscope. If short tubules were present, the
supernatant was removed and placed in a clean universal container with fresh HBSS.
The tubules were settled out by placing the mixture on ice for 20 minutes. After 20
minutes, the supernatant was removed and replaced with fresh HBSS. After a further
20 minute incubation on ice, the tubules were resuspended in complete DMEM F12
culture medium and plated out into flasks. The medium was changed every 2-3 days




Flow cytometry was used to analyse the expression of cell surface molecules.
Briefly, 2-3 x 105 cells were washed with 500pl FACS wash and centrifuged at 4°C
for 5 minutes at 300g. The cells were then incubated in 50pl FACS wash buffer and
200ng of the relevant directly conjugated monoclonal antibody (BD Pharmingen, San
Diego, CA, USA) in the dark at 4°C for 25 minutes. The antibodies used for flow
cytometry were Phycoerythrin (PE) - Cy5 mouse anti-human CD 14 antibody and
mouse IgG2a isotype control (Serotec, Kidlington, Oxford, UK), PE mouse anti-
human CD3 and mouse IgGjK (BD Pharmingen, San Diego, CA, USA),
Allophycocyanin (APC) mouse anti-human CD4 and mouse IgGjK isotype (both BD
Pharmingen, San Diego, CA, USA). The cells were washed with 500pl FACS wash.
Where immediate analysis of the samples took place, the cell pellet was resuspended
in 300pl FACS buffer and analysed. Where sample analysis was delayed, the cell
pellet was instead reconstituted in 300pl FACS wash buffer together with 200pl
FACS fixing reagent. Fixed samples were stored for no longer than 1 week in the
dark at 4°C. Sample acquisition was performed using a Becton Dickinson
FACSCalibur (BD Immunocytometry Systems, San Jose, CA, USA) and analysed
using BD CellQuest Software with help from Shonna McCall (flow cytometry
technician, University of Edinburgh).
2.2.4.2 Enzyme Linked Immunosorbent Assay (ELISA)
Duoset ELISAs were used to quantify human TGF-pi and VEGF and murine Shh
protein in cell culture supernatants, according to the manufacturer's instructions
(R&D Systems, Abingdon, Oxfordshire, UK). Both latent and active TGF-pi were
assayed using the Duoset TGF-pi ELISA. To evaluate latent TGF-pi, activation was
performed using IN HC1 followed by 1.2N NaOH/0.5M HEPES according to the
manufacturer's instructions. The resulting product was then analysed in parallel with
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the untreated samples on the TGF-|3 ELISA. Briefly, for all ELISAs, the appropriate
capture antibody was diluted in PBS and used to coat the wells of 96 well
immunoassay plates (Corning, NY, USA). The plates were sealed and incubated
overnight at room temperature. The capture antibody was removed and the wells
washed 3 times using ELISA wash buffer. 300pl of the appropriate block buffer was
applied to each well for at least 1 hour at room temperature. The block buffer was
removed and the wells washed 3 times with ELISA wash buffer. 50pl of either
standard or sample was applied to well. Both standards and samples were run in
duplicate. The plates were sealed and incubated at room temperature for 2 hours.
Wells were washed 3 times with ELISA wash buffer and the detection antibody
diluted in ELISA reagent diluent, applied in a volume of 50pl per well. Following a 2
hour incubation, the detection antibody was removed and the wells again washed
with ELISA wash buffer. 50pl streptavidin-HRP was applied to each well. The plate
was covered and incubated for 20 minutes at room temperature. Further washing
with ELISA wash buffer was followed by the addition of 50pl substrate solution and,
once again, the plates were protected from light. After 20 minutes, the reaction was
stopped using 25pl stop solution. The optical density of each well was evaluated
using a microplate reader (Dynatech Laboratories, USA) set to a wavelength of
450nm with wavelength correction set to 570nm.
2.2.4.3 Cytometric Bead Arrays (CBAf
The Cytometric Bead Array (CBA) (BD Biosciences, San Diego, USA) allows the
simultaneous flow cytometric evaluation of several cytokines in a single small
sample (50pl) of supernatant. The assay utilises bead populations and each
population is coated with antibodies specific for a cytokine. The bead populations
each have distinct fluorescence intensities resolved in the FL3 channel of the flow
cytometer. The CBAs were performed according to the manufacturer's instructions.
The CBAs used in this thesis and the cytokines analysed by each CBA are shown in
Table 1. The standard cocktail was reconstituted in 200pl reagent diluent and then a
standard curve was generated by serial dilutions of the top standard in reagent diluent
(BD Biosciences). 50pl of either standard or vortexed sample was placed in 75mm
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tubes (BD Falcon). 5pl of each cytokine bead suspension were mixed together by
gentle vortexing and 25pl of the bead mix was added to the 50pl of standard or
sample already present. To each tube, 25pl PE detection reagent (BD Biosciences)
was added and the contents of each tube were mixed by brief vortexing. The samples
were protected from light and incubated for 3 hours at room temperature to allow
sandwich complexes to form. At the end of this incubation, the beads were washed
with 500pl wash buffer (BD Biosciences) and centrifuged for 5 minutes at 300g. The
supernatant was discarded and, following resuspension of the beads in 200pl wash
buffer, the data was acquired using a Becton Dickinson FACSCalibur (BD
Immunocytometry Systems) flow cytometer. The analysis was performed using the
BD CBA analysis software. The assays were sensitive within the range 20-
5000pg/ml. Where values over 5000pg/ml were obtained, the assay was repeated
following further dilution of the samples.
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TABLE 1: Cytometric Bead Arrays (CBAs)
Table lists CBAs used in thesis and the cytokines or chemokines analysed by each kit.
Cytometric Bead Array Cytokines analysed
Human Inflammation IL-ip, TNF-a, IL-10, IL-6, IL-12p70, IL-8
Human Chemokine IP-10, MCP-1, MIG, RANTES, IL-8




Ethical approval was obtained from Lothian Research Ethics Committee. Normal
human renal tissue was obtained from 3 cadaveric transplant donors whose kidneys
were not placed for transplantation. Prior consent to the use of these kidneys for
research purposes was obtained from the donors' relatives. Further fresh tissue was
obtained from 3 patients undergoing transplant nephrectomy for CAN. A further 10
specimens of normal and CAN kidney were obtained from the pathology archives.
2.2.4.4.2 Immunohistochemistry usingformalin-fixed, paraffin-embedded
(FFPE) tissue sections
Immunohistochemistry was used to determine the tissue expression of proteins.
Three pm sections were cut from archival formalin-fixed, paraffin-embedded (FFPE)
tissue and mounted on Vectabond treated slides (Vector Laboratories, Peterborough,
England). The paraffin sections were de-waxed in xylene and rehydrated through
descending alcohols. Antigen retrieval was performed using Vector antigen retrieval
solution (Vector Laboratories) according to the manufacturer's instructions.
Following a wash in PBS, endogenous peroxide in the tissue sections was blocked
using 3% hydrogen peroxide for 10 mins and the slides were loaded onto Sequenza
clips (Shandon Scientific Ltd, Cheshire, UK). Avidin/biotin blocking (Avidin/Biotin
blocking kit, Vector Laboratories) was performed on all slides according to the
manufacturer's instructions and non-specific binding was blocked using Dako serum-
free protein block (Dako Ltd, Ely, UK). The sections were probed with the
appropriate primary antibody for either 1-2 hours at room temperature or overnight at
4°C depending on the antibody used. The primary antibodies used included: goat
polyclonal antibodies to N-terminus of Shh and C-terminus of Ptc (at 1:40 and 1:30
dilution respectively)(Santa Cruz, Biotechnology), mouse monoclonal anti-CD68 (at
1:20 dilution)(Dako Ltd), mouse monoclonal anti-CD3 (at 1:30 dilution), chicken
polyclonal anti-TGF-P (1:50 dilution) (R&D Systems, Abingdon, UK) and rabbit
polyclonal anti-VEGF (1:40 dilution) (Santa Cruz Biotechnology). To check
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specificity, the polyclonal Santa Cruz antibodies were preincubated overnight with
the appropriate specific blocking peptide, where available, according to the
manufacturer's instructions (Santa Cruz Biotechnology). These blocking peptides are
designed to bind to the epitope of the antibody responsible for binding to the protein
of interest and, thus, when used in excess, should not allow binding of the antibody
to the specific protein to occur. In accordance with the manufacturer's instructions
(Santa Cruz Biotechnology), the antibodies were each pre-incubated with a five-fold
excess (by weight) ofblocking peptide and then applied to the sections in
experiments performed in parallel with experiments in which primary antibodies
were applied to the slides. Following the overnight incubation, the slides were
washed with PBS and the appropriate biotinylated secondary antibody applied (Dako
Ltd, Ely, UK) at 1:400 dilution for 30 mins. Further washing was followed by the
application ofVector RTU ABC (Vector Laboratories, Peterborough, UK) and
positive signalling identified using diaminobenzidine (Dako Ltd). The slides were
finally counterstained with haematoxylin.
2.2.4.4.3 Picrosirius red staining
Picrosirius red is a collagen stain that appears as a red stain, but under polarised light
422
appears green . Dewaxing of the paraffin sections and rehydration through
descending alcohols was followed by antigen retrieval using Vector antigen retrieval
solution (Vector Laboratories) according to the manufacturer's instructions.
Following a wash in PBS, the sections were stained for 10 minutes in Picrosirius red
(0.1% Sirius red F3BA in picric acid) (Sigma) and then washed again in PBS prior to
rehydration through alcohol and mounting.
2.2.4.4.4 Macrophage Immunohistochemistry
CD 14 positive monocytes were isolated from human PBMCs by positive selection
using magnetic cell sorting as outlined in section 2.2.1.2 above. The cells were
counted using a haematocytometer with 0.4% trypan blue exclusion. Glass coverslips
were rinsed in alcohol and allowed to air dry. Once dry, the coverslips were placed at
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the base of 6 well tissue culture plates. Monocytes were plated into each well at a
concentration of 106/ml with 2mls per well in serum-free medium (IMDM).
Following a 1 hour adherence step, the medium was then replaced with IMDM-FCS
and the macrophages were allowed to mature over the course of 6 days with a change
ofmedium every 2 days. After 6 days, the medium was removed and the
macrophages were washed thoroughly 3 times with PBS. The cells were fixed using
a 10% dry acetone/90% methanol mix for 5 minutes. The coverslips were then
allowed to air dry. A further PBS wash was followed by blockade of the endogenous
peroxidase for 10 minutes using hydrogen peroxide as above. The primary antibodies
were then applied to the coverslips in a final volume of 300pl and left overnight at
4°C. The primary antibodies used for the macrophage experiments were goat
polyclonal antibodies to the N-terminus of Shh (1:40 dilution), C-terminus ofPtc
(1:30 dilution), Smo (1:30 dilution) and Gli-1 (1:30 dilution) (Santa Cruz
Biotechnology, Insight Biotechnology Ltd, Wembley, Middlesex, UK). All
antibodies were diluted in Dako diluent immediately prior to use. To check antibody
specificity, a further aliquot of each antibody was preincubated overnight with its
specific blocking peptide. Cells treated in this way served as negative controls to the
experiments. Following overnight incubation, three 5 minute PBS washes were
performed and then biotinylated anti-goat IgG secondary antibody (Dako Ltd, Ely,
UK) diluted 1:400 in Dako diluent was applied to the coverslips for 1 hour. This was
followed by 3 further PBS washes and the application ofVector RTU ABC (Vector
Laboratories, Peterborough, UK) for 30 minutes. Positive signalling was identified
using diaminobenzidine (Dako Ltd). The coverslips were counterstained with
haematoxylin prior to mounting.
2.2.4.4.5 ACHN and REC Immunohistochemistry
ACHN or REC cells were grown to approximately 75% confluence on glass
coverslips placed at the bases of 6 well culture plates. The medium was removed and
the cells washed thoroughly 3 times with PBS taking care not to lift the cells from
the coverslips during washing. The cells were fixed using a 10% dry acetone/90%
methanol mix for 5 minutes. The coverslips were allowed to air dry. The primary
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antibodies were then applied to the coverslips in a final volume of 300pl and left
overnight at 4°C. The primary antibodies used for the ACHN cells were goat
polyclonal antibodies to the N-terminus of Shh (1:40 dilution) and C-terminus of Ptc
(1:30 dilution) (Santa Cruz Biotechnology, Insight Biotechnology Ltd, Wembley,
Middlesex, UK). The same antibodies were used with the RECs together with
monoclonal anti-pancytokeratin and -vimentin antibodies (Sigma) used at 1:100
dilution. All antibodies were diluted in Dako diluent immediately prior to use. To
check the antibody specificity of the anti-Shh and anti-Ptc antibodies, a further
aliquot of each antibody was preincubated overnight with its specific blocking
peptide where available. This was then applied to the coverslips in experiments
performed in parallel with experiments in which primary antibodies were applied to
the coverslips. The cells were incubated for 2 hours at room temperature with the
anti-pancytokeratin and anti-vimentin antibodies and overnight at 4°C with the anti-
Shh and anti-Ptc antibodies. For the anti-pancytokeratin and anti-vimentin
antibodies, omission of the primary antibody served as the negative control. The
primary antibody incubations were followed by three 5 minute PBS washes and the
appropriate biotinylated secondary antibody, either rabbit anti-goat or rabbit anti-
mouse antibodies (Dako Ltd, Ely, UK) diluted 1:400 in Dako diluent was applied to
the coverslips for 1 hour. This was followed by 3 further PBS washes and the
application ofVector RTU ABC (Vector Laboratories, Peterborough, UK) for 30
minutes. Positive signalling was identified using diaminobenzidine (Dako Ltd). The




Adherent cells were removed from the bases of tissue culture wells using a cell
scraper and immediately centrifuged with ice cold PBS at 300g for 5 minutes at 4°C.
The supernatant was removed and protein lysis buffer applied to the cell pellet. For
the renal epithelial cell experiments, 200pl protein lysis buffer for the 75% confluent
cells in 3 wells of a 6 well culture plate was used. The lysates were mixed thoroughly
on ice and sonicated for 30 seconds in 5 minute bursts prior to protein quantification.
2.2.4.5.2 Protein Quantification
Protein was quantified using the Bio-Rad (Bradford) protein assay (Bio-Rad
Laboratories, Hemel Hempstead, Hertfordshire, UK) according to the manufacturer's
instructions. Briefly, the Bio-Rad reagent was diluted 1:5 with distilled water and
filtered into a foil-covered storage vessel through Whatman Grade No. 1 filter paper.
A lOmg/ml bovine serum albumin (BSA) stock solution was prepared using distilled
water and this was used to generate a standard curve of protein concentrations diluted
to the appropriate concentration using protein lysis buffer. 2 mis of freshly prepared
Bio-Rad reagent were added to a cuvette. 50pl of standard or sample was added to
the cuvette, mixed with the Bio-Rad reagent and incubated at room temperature for
15-20 minutes. After this incubation, the samples were read on the
spectrophotometer at 595nm (OD595). All samples were run in triplicate and the
values were normalised back to the negative control (Bio-Rad reagent and 50pl
distilled water). The values for the standards were used to generate a standard curve
from which the sample values were extrapolated.
2.2.4.5.3 Western Blot Protocol
Western blots were perfomed using cellular protein, lysed and quantified as
described above. The technique was also used in an attempt to detect protein in cell
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culture supernatants from cells grown in lOmls medium in 162cm2 culture flasks. In
this instance, each supernatant was transferred to dialysis tubing and placed on
polyethylene glycol (PEG) (Fisher Scientific UK, Loughborough, Leics, UK), the
latter binding water and thus concentrating the protein to a volume of less than
2.5mls. The protein content was quantified, as previously, using the Bradford protein
assay, performed on each sample in triplicate. lOOpg of protein was then used for the
Western blot experiments.
10% polyacrylamide electrophoresis gels were cast and overlayed with 4% stacking
gels. lOOpg protein samples were added to 2x protein loading buffer, heated at 100°C
for 10 minutes, and electrophoresed at 100V for 2 hours in lx running buffer
alongside pre-stained molecular weight markers (Invitrogen, Paisley, UK). The
electrophoresed samples were then transferred to nitrocellulose in transfer buffer at
150V for 30 minutes. The membranes were washed in ELISA wash buffer and then
incubated overnight in blocking buffer to block non-specific binding. The
membranes were washed 3 times using ELISA wash buffer and then probed for 2
hours with the appropriate antibody diluted in 2.5% Marvel in PBS with 0.05%
Tween-20. In parallel experiments, to confirm antibody specificity, an aliquot of the
antibody was pre-incubated with the specific blocking peptide (Santa Cruz
Biotechnology), where available, prior to application to the membrane. Following
incubation with the primary antibody, the membranes were washed 3 times with
ELISA wash buffer. The secondary antibodies were made up to the appropriate
dilution in ELISA wash buffer and were applied for 2 hours. The membranes were
washed a further 3 times. Detection was effected using the ECL plus system
(Amersham Pharmacia Biotech, Amersham, UK) according to the manufacturer's
instructions. Briefly, 2000pls solution A was added to 50pl solution B, mixed and
applied to the membrane for 5 minutes. Excess reagent was removed and the
membrane placed under X-ray sensitive film for various lengths of exposure time.





Where RNA was required from fresh renal tissue, 1mm3 cubes of tissue were
prepared using sharp dissection. The tissue was homogenised in Trizol (Gibco) such
that the tissue volume did not exceed 10% of the volume of Trizol. Where RNA was
required from cells grown in tissue culture wells, 1ml Trizol was applied to 5-10 x
106 cells. The samples were incubated in Trizol for 5 minutes at room temperature.
Where immediate RNA extraction was not performed, the samples in Trizol were
transferred to storage at -70°C for no longer than 4 weeks. Following the
homogenisation step, per 1 ml Trizol, 200pl chloroform was added and the mixture
vigorously shaken for 15 seconds. Following a 5 minute room temperature
incubation, the mixture was centrifuged at 12,000g for 15 minutes at 4°C. The upper
aqueous phase was carefully removed and transferred to a 1.5ml RNAse-free
eppendorf. To this was added 500pl of isopropyl alcohol. The mixture was inverted a
few times, incubated for 10 minutes at room temperature and centrifuged at 12,000g
for 10 minutes at 4°C. The supernatant was removed, washed with 75% ethanol and
vortexed. The sample was centrifuged at 9500g for 5 minutes at 4°C and the
supernatant removed. The RNA pellet was then air-dried by inverting the open
eppendorf onto clean tissue paper and leaving for 30 minutes at room temperature.
At the end of this time, the RNA pellet was dissolved in 10pl RNAse-free water.
2.2.5.1.1 DNase Treament ofRNA
Contaminating DNA was removed from the RNA using the RNase-free DNase set
(Gibco) according to the manufacturer's instructions, lpg ofRNA was added to 1 pi
of lOx DNase buffer 1 and DEPC water added to a final volume of lOpl. The mixture
was incubated for 15 minutes at room temperature. To this mixture, lpl of 25mM
EDTA was added and incubated for 10 minutes at 65°C.
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2.2.5.1.2 Quantification ofRNA
The RNA was quantified by measuring absorbance at 260 and 280nm in a
spectrophotometer (Ultrospec, Pharmacia Biotech). The purity was evaluated by
determining the ratio of absorbance at 260nm and 280nm (OD260/280). For pure
RNA, this should be around 2.0.
2.2.5.1.3 Testing RNA Quality
RNA quality was evaluated by reconstituting lpg ofRNA into a total volume of lOpl
in RNase free water. This was mixed with 2pl 6x PCR loading buffer which was
heated at 65°C for 5 minutes and cooled on ice for 3 minutes. The sample was run on
a 1 % agarose gel at 60 volts for 40 minutes. When viewed under a white/ultraviolet
transilluminator, good quality RNA should appear as 2 discrete bands. Conversely, a
smear indicates degraded or poor quality RNA.
2.2.5.2 Reverse Transcription ofRNA to cDNA
Reverse transcription of 400ng RNA was performed using the Taqman Reverse
Transcription Reagent Kit (Applied Biosystems, Warrington, Cheshire, UK). Briefly,
400ng RNA in a maximum volume of 4pl was mixed with 2pl lOx Taqman buffer,
4.4pl MgCb, 4pl dNTP, lpl random hexamers, 0.4pl RNase inhibitor, 0.5pl
Multiscribe reverse transcriptase and 3.7pl nuclease free water to give a final
reaction volume of 20pl. Each reaction in a 200pl RNase-free tube was amplified in
a PTC 200 Peltier Thermal Cycler in a programme with the following conditions: 10
minutes at 25°C, 40 minutes at 48°C and 5 minutes at 95°C. The cDNA produced
was stored at -20°C.
2.2.5.3 Standard PCR
500ng cDNA was amplified in each 20pl reaction. A typical PCR reaction contained
1,8pl reaction buffer (BioGene, Kimbolton, Cambridegeshire, UK), 1,5mM MgCh or
1,2mM Mg Cf depending on the primer, lpl of each primer, 2pl cDNA, lOOpM
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dNTPs, 0.1% bovine serum albumin, 0.25 units Taq polymerase (Biogene). The PCR
cycle programme was 94°C for 3 minutes, 40 cycles of 94°C for 1 minute, annealing
temperature ™ specific for each gene for 1 minute (See Table 2) and, finally, 72°C
for 1 minute 30 seconds. PCR products were analysed by electrophoresis using a 1%
agarose gel, stained with ethidium bromide.
The primers and annealing temperatures used for each gene are shown in Table 2.
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TABLE 2: RT-PCR Primers
Table lists primer sets used for the evaluation of Shh signalling pathway components
using RT-PCR.




Human Shh Forward: act ggg tgt act acg agt cca agg
Reverse: aaa gtg agg aag teg ctg tag age
211 60
Human Ptc Forward: tec teg tgt gcg ctg tct tec ttc
Reverse: cgt cag aaa ggc caa age aac gtg a
462 60
Human Smo Forward: ctg gta cga gga cgt gga gg
Reverse: agg gtg aag age gtg cag ag
140 62
Human Glil Forward: act gaa gac etc tcc age
Reverse: get gac agt ata ggc aga
244 62
Human Gli2 Forward: tgg ccg ctt cag atg aca gat gtt g
Reverse: cgt tag ccg aat gtc age cgt gaa g
200 62
Murine Shh (1) Forward: agg ggg ttt gga aag agg
Reverse: gga ttc ata gta gac cca gtc g
450 60
Murine Shh (2) Forward: tta aat gcc ttg gcc ate tc
Reverse: cca egg agt tct ctg ctt tc
200 60
Murine Shh (3) Forward: atg tea gtg tea tcc gag tgg c
Reverse: tga ata cca cca cca cag cag c
250 65
P-Actin Forward: cca cca act ggg acg aca tg
Reverse: gta tea aac atg ate tgg gtc ate
151 58
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2.2.5.4 Real Time PCR
Real time PCR is a method of quantifying PCR products as they are produced, hence
the term 'real time'. The technique employs the 3'-5' exonuclease activity of Taq
polymerase to cleave a fluorescent probe which is then detected and quantified. The
probe is 20-30 oligonucleotides long and contains the reporter fluorescent dye
('fam') and a quencher dye at the 5' and 3' end respectively. Such close proximity of
the reporter fluorescent dye and the quencher dye prevents fluorescent emission
while the probe is intact. However, when the probe is cleaved, the quencher and
reporter are separated and the fluorescent signal increases proportionally to the
amount ofPCR product generated. The amount of fluorescent signal generated at
each cycle produces a sigmoid waveform from which it is possible to detect the first
significant increase in the amount ofPCR product. This correlates with the initial
quantity of target template. The threshold cycle (Ct) value is the cycle when a
significant increase in reaction product is first detected. The higher the initial amount
of genomic DNA, the earlier the product accumulates and the sooner it is detected by
the system, giving a lower Ct value. A Ct value of 40 suggests no amplification and
no significant PCR product. The fam values generated are then normalised to 18S
rRNA which serves as the endogenous internal control and is labelled with the
fluorescent dye 'vie'.
Primers and probes were designed using Primer Express software and the
combinations used are shown in Table 3. The conditions employed for all reactions
were: 2 minutes at 50°C, 10 minutes at 95°C, 15 seconds at 95°C and 1 minute at
60°C and this cycled 40 times. Each sample was run in triplicate and each set of
samples was run against its own control i.e. treated versus untreated where the
untreated samples were always given a value of 1. Results were expressed relative to
the untreated sample value.
101
TABLE 3: Real-Time Primer and Probe Sequences
Table lists primer and probe sets used for evaluation of the Shh signalling pathway
components using Real-Time PCR
Gene Primer Sequence (5'-3')
Human Shh Forward: taa gga caa gtt gaa cgc ttt gg
Reverse: teg gtc acc cgc agt ttc
Probe: cat etc ggt gat gaa cca gtg gcc a
Human Ptc Forward: egg cag ccg cga taa g
Reverse: tta atg atg cca tct gca tcc a
Probe: ate gac ate age cag ttg act aaa cag cgt c
Murine Shh (1) Forward: tga ccc ctt tag cct aca age a
Reverse: ttc ttg tga tct tcc ctt cat ata tct g
Probe: ttt att ccc aac gta gcc gag aag acc c
Murine Shh (2) Forward: tga ccc ctt tag cct aca age a
Reverse: ttt ttg tga tct tcc ctt cat ate tg
Probe: ttt att ccc aac gta gcc gag aag acc c
Murine Shh (3) Forward: gag cag acc ggc tga tga ct
Reverse: aga gat ggc caa ggc att taa ct
Probe: tgt ctt tgc acc tct g
Murine Ptc Forward: etc caa gtg teg tcc ggt tt
Reverse: tgt act ccg agt egg agg aat c
Probe: cgt gcc tcc tgg tea cac gaa caa
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2.2.6 Endotoxin Assay
The Limulus Amebocyte Lysate (LAL) assay was used to evaluate the LPS content
of reagents used in the in vitro experiments. The system used was a LAL endpoint
chromogenic assay (Associates ofCape Cod, Falmouth, Massachusetts, USA). This
chromogenic assay uses a modified LAL reagent (Pyrochrome) incorporating an
aqueous extract of the amebocytes of Limulus polyphemus and a chromogenic
substrate423, cleavage of which releases the yellow substance p-nitroaniline which
absorbs at 405nm. The amount ofp-nitroaniline released is assayed after a fixed
incubation time. The assay was performed according to the manufacturer's
instructions. Briefly, the control standard endotoxin (CSE) was reconstituted in LAL
reagent water and a serial dilution was prepared to generate a set of standards. 50pl
sample or standard was then added to 50pl Pyrochrome in the wells of a sterile 96
well plate and mixed thoroughly for 30 seconds on a plate-shaker. The plate was
transferred to an incubator block set at 37°C. After 20 minutes, the plate was
removed from the incubator block and the reaction stopped using 20pl of 50% acetic
acid. The optical density was then read in a plate reader set at 405nm. All samples
were prepared in quadruplicate and the mean optical density of the negative control
(LAL water alone) was subtracted from all other readings. The results obtained from
the samples were plotted against a standard curve consisting ofmeasured optical
density plotted against the standard endotoxin concentrations.
2.2.7 MTT Assay
MTT is a water soluble tetrazolium salt. When the tetrazolium ring is cleaved by
dehydrogenase enzymes424, dissolved MTT is converted to an insoluble purple
formazan. This can be solubilised and then measured spectrophotometrically to yield
absorbance as function of concentration of converted dye. Only active mitochondrial
dehydrogenases of living, and not dead, cells cause the conversion. The MTT assay
was performed according to the manufacturer's instructions (Sigma M-5655).
The MTT was reconstituted to 5mg/ml in PBS. A maximum of 3 hours before the
end of the incubation, '/ioth of the culture medium volume was removed and replaced
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with the same volume ofMTT stock solution. The cells were returned to the
incubator and, at the end of the incubation period, the medium was removed and the
converted dye solubilised using DMSO. lOOpl aliquots of each well were transferred
to a 96 well plate and the absorbance read at a wavelength of 570nm.
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Chapter 3
Sonic hedgehog is differentially expressed in normal
kidney and chronic renal allograft nephropathy
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3.1 Introduction
As discussed in Chapter 1, the highly conserved hedgehog family of proteins has an
important role in determining both cell fate and proliferation during development.
Sonic hedgehog (Shh) acts as a mitogen, inducing proliferation in keratinocytes425,
neuronal precursor cells426 and haematopoietic precursors19. Expression of pathway
components is widespread in the embryo and Shh is required for developmental
patterning and cell fate induction in various organ systems3. In particular, Shh
signalling has roles in the development of the gut4'5'7,427 lungs4'5'16 and central
nervous system5.
Less, however, is known about the role of Shh signalling in the development of the
kidneys. Shh mutants have a single fused midline kidney, and Gli2-/-;Gli3+/-
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mutants have paired horseshoe-shaped kidneys . In the metanephric kidney, Shh
expression has been reported in the urogenital sinus, the tip of the urethral
epithelium428 and in the uroepithelium of collecting ducts and the ureter2'4'138'139.
There have been no previous reports of Shh expression in the adult human kidney
although expression of another vertebrate Hh family member, Ihh, has been
reported2'146.
Chronic renal allograft nephropathy (CAN) is the major cause of long-term renal
failure in kidney allograft recipients. It is characterised by a mononuclear cell
infiltration (consisting predominantly of macrophages and T cells), interstitial
776* 777
fibrosis, tubular atrophy and dilatation, and vascular wall thickening ' . The
progressive fibrosis that occurs is considered to be the main cause for the gradual
deterioration in renal function and graft failure.
That the Shh pathway may play a role in the aetiology ofCAN is suggested by
several lines of evidence. Specifically, Stewart et al149 demonstrated recently the
upregulation of Shh in epithelial cells at sites of fibrotic disease in both human
fibrotic lung disease (crytpogenic fibrosing alveolitis and bronchiectasis) and in
murine models of fibrotic lung disease, suggesting that the pathway may play a role
106
in the development of fibrosis. Furthermore, components of the Shh pathway have
been demonstrated in immune cells recognised to play a role in the pathogenesis of
CAN. Both T cells and macrophages246 are present in the inflammatory cell infiltrate
in CAN with macrophage infiltration and activity correlating directly with graft
survival241. Shh, Ptc and Glil expression have been demonstrated in T cells, and Ptc
expression has also been reported in macrophages14 . Furthermore, other factors
known to be upregulated in CAN may also be upregulated by Shh. These include the
growth factors, Transforming Growth Factor-P (TGF-P) and Vascular Endothelial
Growth Factor (VEGF).
TGF-P stimulates fibroblasts to synthesise matrix proteins, including collagen,
fibronectin and proteoglycans274 and inhibits the degradation ofnewly formed matrix
proteins275'429'430. Persistent or upregulated TGF-P production in CAN, however,
contributes to fibrogenesis, with an accumulation of extracellular matrix and
inhibition of its degradation. In CAN, TGF-P is expressed in the glomerular
mesangium, Bowman's capsule, renal tubule and interstitium, the level of mRNA
expression correlating well with interstitial fibrosis and progressing allograft
nephropathy259'269'431"436. Although a direct upregulation of TGF-P by Shh has not
been demonstrated, members of the TGF-P superfamily members including the bone
morphogenetic proteins (BMPs)4'119'427 and, in Drosophila, the morphogen
Decapentaplegic (Dpp) are downstream targets ofHh signalling. The segment
polarity gene Wingless (wg) pathway437 is also downstream of Hh signalling437'438
and interactions between the wg and TGF-p signalling pathways have been
described117'120. Furthermore, at sites of fibrosis in the lung, both TGF-P and Shh
expression were apparent in the epithelium149 suggesting that the two pathways may
communicate during fibrogenesis.
VEGF is an endothelial mitogen produced by a number of cell types including
epithelial cells and macrophages439"441. In addition to its mitogenic and angiogenic
properties, it also causes an increase in vascular permeability442 and acts as a
chemoattractant for monocytes443'444. VEGF is expressed constitutively in the normal
kidney where mRNA and protein are co-localised to the podocytes and ductal
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epithelial cells445"449. In chronically, but not acutely, rejecting human renal allografts
VEGF expression has also been demonstrated in the macrophages of the
tubulointerstitial cell infiltrate and in viable podocytes265'2 '5 . A direct association
between Shh signalling and VEGF has been shown with recent reports suggesting
109 •
that administration of Shh upregulates VEGF in myofibroblasts and induces
capillary morphogenesis in cultured endothelial cells65. Furthermore, in the zebrafish
embryo, the injection of Shh mRNA induced VEGF expression in the somites163.
Thus, the initial aims of the work described in this chapter were 2-fold. The first aim
was to evaluate the histology, cellular infiltration and growth factor expression in a
population of normal human kidney samples and samples of CAN to establish
whether the sample set used here demonstrated similar patterns of expression and
histological phenotypes to those published previously. The second aim of this work
was to evaluate the expression of the Shh signalling pathway components, Shh and
Ptc in the same samples of both normal kidney and CAN kidney.
108
3.2 The hallmarks of CAN
It has been shown previously that chronic renal allograft nephropathy (CAN) is
characterised histologically by interstitial fibrosis, tubular atrophy, an inflammatory
cell infiltrate consisting mainly ofmacrophages and T cells, glomerulopathy and
vasculopathy226'227'246. This section ofwork aimed to establish whether, in a selected
population of CAN specimens, the same histopathological features are evident.
CAN samples were obtained from 3 patients undergoing transplant nephrectomy for
chronically failing allografts. Written and verbal consent to the use of the renal tissue
for the purposes of these experiments was obtained from each patient. A further 10
FFPE CAN specimens were obtained from archival transplant nephrectomy material.
As previously, ethical approval for these studies was obtained from the Lothian
Research Ethics Committee.
Immunohistochemistry was performed on 3 pm sections of FFPE tissue as described
in Chapter 2. Haematoxylin-eosin staining was performed to allow the gross
morphological features of CAN to be identified. Picrosirius red was used to visualise
collagen present in the sections, as described previously422 and as outlined in Chapter
2. Viewed with non-polarised light, the fibres appear red. Mouse monoclonal anti-
human antibodies to CD68 (1:20 dilution) and CD3 (1:30 dilution) (Dako Ltd) were
employed to detect macrophages and T cells respectively. For the
immunohistochemical detection ofCD68 and CD3, tissue sections were subjected to
antigen retrieval using Vector antigen retrieval solution (Vector Laboratories,
Peterborough, England) and avidin/biotin blockade (Avidin/Biotin blocking kit,
Vector Laboratories). Non-specific binding was blocked using Dako serum-free
protein block (Dako Ltd, Ely, UK). The sections were incubated for 1 hour at room
temperature with the appropriate primary antibody. Following washing, the
secondary antibody was applied for 1 hour. The secondary antibody for both primary
antibodies was a biotinylated anti-mouse IgG antibody (Dako Ltd) used at 1:400
dilution. Positive signalling was identified using diaminobenzidine (Dako Ltd).
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Representative results are shown in Figures 3.1 and 3.2. Figure 3.1 demonstrates
some of the hallmarks of CAN (Figure 3.1a), notably an inflammatory cell infiltrate
(Figure 3.1b), consisting of macrophages (Figure 3.1c) and T cells (Figure 3.Id),
allograft vasculopathy (Figure 3.1e) and glomerulopathy (Figure 3.If). Picrosirius
red staining, demonstrating marked fibrosis in CAN, is shown in Figure 3.2a. A
section of normal kidney, also stained with picrosirius red, is shown for comparison
(Figure 3.2b).
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FIGURE 3.1
CAN is characterised by an inflammatory cell infiltrate, tubular atrophy, allograft
vasculopathy and glomerular sclerosis
Immunohistochemistry was performed on 13 sections ofCAN derived from allograft
nephrectomy material. Haematoxylin-eosin (H&E) staining was performed to allow the
gross morphological features ofCAN (Figure 3.1a, Mag x 200) to be identified. H&E
staining confirmed the presence of tubulointerstitial inflammatory cell infiltration (3.1b,
Mag x 400), and anti-CD68 (Figure 3.1c, Mag x 400) and anti-CD3 (Figure 3.Id, Mag x
400) staining confirmed the presence ofmacrophages and T cells respectively in the
inflammatory cell infiltrate. H&E staining was also used to demonstrate the presence of







CAN is characterised by fibrosis
Fibrosis was evaluated using picrosirius red staining on sections ofCAN derived from
allograft nephrectomy material. Collagen fibres appear red when stained with picrosirius
red and Figure 3.2a (Mag x 200) illustrates the marked collagen deposition seen in CAN.
A section of normal kidney stained with the picrosirius red is shown for comparison in
Figure 3.2b (Mag x200)
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3.3 TGF-p and VEGF are expressed in CAN
In addition to the histological hallmarks of CAN, a number of growth factors are also
believed to be expressed and play a role in CAN. These factors include TGF-
p269,432,434-436^ ygQp265,266,450^ piatelet-derived growth factors (PDGF)262 and basic
fibroblast growth factor (bFGF)451. Of these, TGF-P and VEGF warrant further
consideration given their possible relationship with, and regulation by, the Shh
signalling pathway. Thus, in this section ofwork, the expression of TGF-P and
VEGF was evaluated in a series ofCAN specimens.
As above, CAN samples were obtained from 3 patients undergoing transplant
nephrectomy for chronically failing allografts. A further 10 FFPE CAN specimens
were obtained from archival transplant nephrectomy material. The sections were
evaluated immunohistochemically using a chicken polyclonal anti-human TGF-P 1
(1:50 dilution) (R&D Systems, Abingdon, UK) and a goat polyclonal anti-human
VEGF (1:40 dilution) (Santa Cruz Biotechnology) to detect TGF-P 1 and VEGF
respectively. Sections were incubated in the appropriate primary antibody overnight
at 4°C. Following washing, the secondary antibody was applied for 1 hour. The
secondary antibodies were a biotinylated anti-chicken IgG antibody (Vector) used at
1 GOO and a biotinylated anti-goat IgG antibody (Dako Ltd) used at 1:400. Positive
signalling was identified using diaminobenzidine (Dako Ltd).
In keeping with previous reports in the literature, TGF-P was found to be expressed
in the glomeruli and tubulointerstitium (Figure 3.3a) and VEGF was expressed in the
tubulointerstitial cell infiltrate and in viable podocytes (Figure 3.3b) in CAN.
Thus, taken together with the results presented in Section 3.2, these results confirm
that the population of CAN specimens utilised here exhibits similar features in terms
of histopatholgy, cellular infiltration and TGF-P and VEGF expression to those
described in earlier studies259'265'266'431-432'434"436.
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FIGURE 3.3
TGF-P and VEGF expression are evident in CAN
Polyclonal chicken and goat antibodies were used to detect TGF-P and VEGF
respectively. TGF-p (Figure 3.3a, Mag x 400) and VEGF (Figure 3.3b, Mag x 400) are
both expressed in CAN in the glomeruli and tubulointerestitium in keeping with
previous reports in the literature.
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3.4 Shh is expressed in normal adult human kidney
Although Shh expression has been reported in the metanephric kidney ,4,138,139'428,
there have been no previous reports of Shh expression in the normal adult human
kidney. Therefore, the aim of these studies was to determine whether Shh and its
receptor Ptc are expressed in normal adult human kidney.
Normal human renal tissue was obtained from 3 cadaveric transplant donors whose
kidneys were not placed for transplantation. Fresh tissue from these kidneys was
fixed in formalin prior to paraffin embedding. A further 7 formalin-fixed, paraffin
embedded (FFPE) archival samples from non-diseased parts of kidneys
nephrectomised for renal tumours were also available for analysis. Ethical approval
for these studies was obtained from the Lothian Research Ethics Committee.
Immunohistochemistry was performed on 3pm sections of FFPE tissue as described
in Chapter 2. All tissue sections were subjected to antigen retrieval using Vector
antigen retrieval solution (Vector Laboratories, Peterborough, England) and
avidin/biotin blockade (Avidin/Biotin blocking kit, Vector Laboratories). Non¬
specific binding was blocked using Dako serum-free protein block (Dako Ltd, Ely,
UK). The sections were incubated overnight at 4°C with antibodies to Shh and Ptc.
These were goat polyclonal antibodies to the N-terminus of Shh and C-terminus of
Ptc (Santa Cruz Biotechnology, Insight Biotechnology Ltd, Wembley, Middlesex,
UK) and were used at 1:40 and 1:30 dilution respectively, as described previously149.
To check antibody specificity, a further aliquot of each antibody was preincubated
overnight with its specific blocking peptide. These blocking peptides are designed to
bind to the epitope of the antibody responsible for binding to the protein of interest
and, thus, when used in excess, should not allow binding of the antibody to the
specific protein to occur. In accordance with the manufacturer's instructions (Santa
Cruz Biotechnology), the antibodies were each pre-incubated with a five-fold excess
(by weight) of blocking peptide and then applied to the sections in parallel with
slides in which primary antibodies alone were applied. Tissue sections treated in this
way served as negative controls. The secondary antibody for both primary antibodies
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was a biotinylated anti-goat IgG antibody (Dako Ltd) used at 1:400. Positive
signalling was identified using diaminobenzidine (Dako Ltd).
Figure 3.4 illustrates the results from these experiments. Shh (Figure 3.4a), but not
Ptc (Figure 3.4b), expression was apparent in all 10 sections of normal adult human
kidney. In all sections, there was focal staining for Shh in the brush border of the
proximal convoluted tubules (PCT) (Figure 3.4c). In 6 of the 10 samples, this was in
association with isolated diffuse cytoplasmic staining of the epithelium of the PCT
(Figure 3.4d). All staining was significantly abrogated using the specific blocking
peptide for Shh (Figures 3.4e and 3.4f).
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FIGURE 3.4
Shh, but not Ptc, is expressed in normal adult human kidney
Immunohistochemistry was performed on 10 sections of normal adult human kidney using
goat polyclonal antibodies to the N-terminus of Shh and the C-terminus of Ptc at dilutions of
1:40 and 1:30 respectively. Although all 10 sections demonstrated focal expression of Shh
(Figure 3.4a, Mag x 200), Ptc was not expressed in any of the sections (Figure 3.4b, Mag x
200). In all 10 sections, focal expression of Shh on the brush border of the proximal
convoluted tubule was apparent (Figure 3.4c, Mag x 1000). In 6 of the samples, this was in
association with isolated diffuse cytoplasmic staining of the epithelium of the proximal
convoluted tubule (Figure 3.4d, Mag x 1000). This brush border (Figure 3.4e, Mag xlOOO)
and cytoplasmic staining (Figure 3.4f, Mag x 1000) could be blocked using the specific Shh
blocking peptide.
3.5 Ptc, but not Shh, is expressed in CAN
Given that upregulated Shh expression has been demonstrated in human idiopathic
pulmonary fibrosis and murine models ofpulmonary fibrotic disease149, the
following experiments were performed to determine whether Shh and Ptc expression
were evident in CAN.
3.5.1 Immunohistochemistry
Using the same CAN specimens as those used in Sections 3.3,
immunohistochemistry was performed to determine the expression of Shh and its
receptor, Ptc. Goat polyclonal antibodies to the N-terminus of Shh and C-terminus of
Ptc (Santa Cruz Biotechnology) were used at 1:40 and 1:30 respectively and
specificity was confirmed using the appropriate specific blocking antibodies.
The results from the immunohistochemical studies are shown in Figure 3.5. There
was a complete absence of Shh staining across all specimens examined (Figure 3.5a
and c). In contrast, Ptc was detected on infiltrating inflammatory cells (Figure 3.5b
and d) in all CAN sections.
3.5.2 Real-time PCR
In addition to the immunolocalisation studies described above, RNA was extracted
using Trizol extraction from the normal kidneys not used for transplantation (n=3)
and from the kidneys nephrectomised for chronically deteriorating graft function
(n=3). RNA was reverse transcribed to cDNA. Real-time PCR was then performed
on each sample in duplicate using 18S RNA as an internal control to compare the
relative expression of Shh and Ptc in normal and CAN kidney. Values are expressed
as a ratio of the concentration of Shh and Ptc mRNA in CAN relative to normal
kidney, where normal kidney is given a value of 1.
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The results are shown in Figure 3.6. While Ptc expression is upregulated in CAN
(1.6-fold), Shh expression is lower (5-fold) than that seen in normal kidney. Thus,
these results corroborate the protein results obtained using the immunohistochemistry
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Ptc, but not Shh is expressed in CAN
Immunohistochemistry was performed on 13 sections ofCAN derived from allograft
nephrectomy material using polyclonal antibodies to Shh and Ptc as previously. There
was a complete absence of Shh staining across all specimens examined (Figure 3.5a,
Mag x 200 and Figure 3.5c, Mag x 400). In contrast, Ptc was detected on the infiltrating




Shh and Ptc mRNA expression in normal kidney and CAN
Real-time PCR was performed to determine the relative expression ofShh and
Ptc mRNA in normal kidneys (n=3) and in kidneys nephrectomised for
chronically deteriorating graft function (n=3). RNA was reverse transcribed to
cDNA. Real-time PCR was then performed on each sample in duplicate using
18s as an internal control to compare the relative expression of Shh and Ptc in the
normal and CAN kidneys. Values are expressed as a ratio of the concentration of
Shh and Ptc mRNA in CAN relative to normal kidney, where normal kidney is
given a value of 1. The results presented are representative of 3 independent
experiments.
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3.6 Shh and Ptc expression are not apparent in renal
biopsy specimens
That Shh is expressed in normal kidney but that this expression is lost in CAN is
interesting and contrasts with the upregulated Shh expression seen in human fibrotic
lung disease and murine models of fibrotic lung disease149. The work of Stewart et al
exploring the expression of Shh and Ptc in fibrotic pulmonary disease demonstrated
that Shh is upregulated at sites of active epithelial inflammation overlying areas of
fibrosis. Thus, it may be that Shh upregulation occurs in response to injury and,
indeed, it has been postulated that Shh may play a role in either repair and/or
remodelling processes149'161. Other reports in the literature would lend support for
such a role. For example, the application of recombinant Shh to endothelial cells has
been shown to induce capillary morphogenesis65 and, in the hindlimb ischaemia
model, Shh was shown to induce angiogenesis, improving the blood flow to the
ischaemic limb102'103. Furthermore, Hh signalling may be involved in fracture repair
as evidenced by studies reporting the activation ofHh signalling under these
conditions152'153.
In light of these reports implicating an early role for Hh signalling in inflammatory
process and/or repair, it is perhaps not then surprising that, in CAN, characterised by
end-stage epithelial damage and tubular loss, Shh expression is lost. If indeed Shh
signalling is more relevant in the acute stages of renal disease, investigating the
effects of earlier insults to the allograft may be more relevant and informative. In this
regard, 2 other renal pathologies, acute rejection (AR) and acute tubular necrosis
(ATN) were chosen for further investigation.
During the early course following allograft implantation, a deterioration in graft
function most commonly reflects either AR or ATN. Both pathologies effect changes
in the tubule. AR is characterised by tubulitis, i.e. mononuclear cell infiltration
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between or beneath tubular cells and arteritis. ATN is characterised by loss of the
brush border, interstitial oedema and an interstitial inflammatory cell infiltrate. Thus,
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both pathologies represent instances in which, if Shh is involved in tubular
inflammation or repair, altered expression of Shh may be exhibited.
Therefore, the aim of the following experiments was to evaluate Shh and Ptc
expression in both AR and ATN. Archival material in the form of 20 diagnostic
biopsies, taken 7 days post-transplantation, was available for immunohistochemical
analysis. Ten biopsies had been reported as ATN and a further 10 as AR. Of the
latter 4, 2, 3 and 1 were graded as Grades la, lb, 2a and 2b acute cellular rejection
respectively. As in the earlier sections of this chapter, the biopsies were investigated
for Shh and Ptc expression using goat polyclonal antibodies (Santa Cruz) to Shh and
Ptc at 1:40 and 1:30 respectively. In each run of immunohistochemistry, a sample of
normal kidney was run in parallel as a positive control. As previously, antibodies
pre-incubated with the respective blocking antibody acted as the negative controls.
Representative results are shown in Figure 3.7. Neither Shh (Figure 3.7a) nor Ptc
were apparently expressed in any of the biopsy sections (Figure 3.7b). There was,
however, a marked edge effect around many of the sections examined. This could not
be eliminated despite further optimisation of the immunohistochemistry protocol. In
contrast, staining of the biopsy samples using monoclonal anti-CD3 (Figure 3.7c) or
anti-68 (Figure 3.7d) antibodies in the same specimens revealed good quality
staining in the absence of non-specific staining or artefacts. Therefore, from these
results, it is not clear whether the absence of Shh expression reflects a true lack of




Shh and Ptc expression are not apparent in renal biopsy specimens
Immunohistochemistry was employed to determine Shh and Ptc expression in 10 acute
rejection and 10 acute tubular necrosis biopsy specimens. Neither Shh (Figure 3.7a, Mag
x 200) nor Ptc (Figure 3.7b, Mag x 200) were apparently expressed in any of the biopsy
specimens and, indeed, a marked edge effect was noted around some of the biopsies
(Figure 3.7b, circled). In contrast, staining of the biopsy samples using monoclonal anti-
CD3 (Figure 3.7c, Mag x 200) or anti-68 (Figure 3.7d, Mag x 200) antibodies in the




The work presented in the first part of this chapter has used immunohistochemistry
on samples of adult human kidney, removed after transplant failure due to CAN in
order to investigate the histopathology, cellular infiltration and growth factor
expression in CAN. Indeed, this work has confirmed, in this sample, the presence of
the hallmarks ofCAN including interstitial fibrosis,vasculopathy, glomerulopathy
and a mononuclear cell infiltration. In addition, concentrating on the cell types and
growth factors specifically relevant to this thesis, this work has confirmed that both
macrophages and T cells are present in the CAN kidney and that TGF-P and VEGF
are expressed. These results show that, not only do the samples used in this study
exhibit the histopathological hallmarks ofCAN, but, also, that similar patterns of
growth factor expression to those reported previously can be demonstrated.
In the second part of the chapter, immunohistochemistry has been used further in
association with real-time PCR, to investigate the expression of the Shh signalling
pathway components Shh and Ptc in samples of both normal adult human kidney and
CAN. The findings from this investigation are discussed below:
3.7.1 Shh is expressed in normal adult human kidney but not CAN
Although Shh expression has been described previously in the embryonic kidney, the
results presented in this chapter are the first to indicate that Shh is expressed in the
normal adult human kidney. In all sections of normal kidney tested, Shh expression
was detected on the brush border of the proximal convoluted tubule (PCT). In 6 of
the 10 samples, this was in association with isolated diffuse cytoplasmic staining of
the epithelium of the PCT. All staining was significantly abrogated using the specific
blocking peptide for Shh. In contrast, Ptc protein expression was not detected in
normal kidney. Conversely, although Shh expression is lost in CAN, Ptc is
expressed on cells within the inflammatory cell infiltrate. Although the precise
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inflammatory cell type responsible for Ptc expression is not clear, both T cells '
and macrophages149 are known to express Ptc and both cell types are present within
125
the inflammatory cell infiltrate seen in CAN. The differential expression of Shh and
Ptc in the CAN versus normal kidney is further confirmed by the results of the real¬
time PCR experiments.
The reasons for these patterns of expression are not immediately apparent. Given that
Shh expression upregulation has been reported in epithelium overlying areas of
fibrosis in murine models of fibrotic lung disease and in idiopathic pulmonary
disease in humans149, it is perhaps surprising that Shh expression is lost in CAN, a
disease characterised by extensive fibrosis. However, that Shh expression is localised
to the proximal tubular cells in normal kidney may help, at least in part, to explain
this absence of expression in CAN since tubular atrophy is one of the earliest
changes observed in diagnosing CAN and is a feature of all but the mildest forms of
227CAN . Thus, although occasional tubules did appear macroscopically intact in the
CAN kidneys and these were negative for Shh expression, it is extremely likely that
the loss of tubular expression may reflect an absence of viable or healthy tubules.
Indeed, even tubules with apparently normal appearance by light microscopy can be
markedly dysfunctional452.
Although Shh expression has been reported previously in the developing
kidney2'4'139, the pattern of expression in the adult is not in keeping with the pattern
seen in the embryo. In the embryonic metanephric kidney, the uroepithelium of the
collecting ducts and the ureter express Shh2'4'138'139. In contrast, neither proximal
tubular cytoplasmic nor brush border Shh expression have been previously reported
in the developing kidney. Thus, the tubular and brush border expression reported
here in normal kidney represent particularly interesting findings, although one can
only speculate on the reason for this pattern of expression. Although Shh expression
has not been detected in the adult human kidney, another of the Hedgehog
homologues, Ihh, has been reportedly expressed in the adult kidney2'146. Notably,
studies by Valentini et al146 reported on Ihh mRNA expression in proximal
convoluted tubule of the murine kidney. Thus, there is the possibility that the
antibody directed against the N-terminus of Shh may also be capable of detecting
Ihh. Indeed, murine Ihh has been demonstrated to show 89% identity and 96%
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similarity to murine Shh over the N-terminal region. In addition, all Hh proteins have
been shown to bind Ptc with equal affinity453 and proteolysis of Ihh gives rise to a
19kDa active peptide in a similar proteolytic cleavage process to that occurring for
Shh146. Therefore, given these similarities, one possibility is that the Shh antibody is
recognising Ihh rather than Shh. However, that the antibody is reported by the
manufacturer (Santa Cruz Biotechnology) to be non-cross-reactive with Ihh or Desert
hedgehog (Dhh) would not lend support to this idea. A further possibility also exists;
that the brush border binding of antibody and indeed PCT binding represent artefacts
of immunohistochemical staining. However, 2 lines of evidence would lend support
for this staining being neither artefactual nor non-specific. Firstly, the staining was
significantly abrogated using the specific Shh blocking peptide, a peptide specifically
designed to bind to the epitope of the antibody responsible for binding to the protein
of interest. Secondly, the immunohistochemistry data is corroborated by the real-time
PCR results. These demonstrated a 5-fold difference in Shh mRNA expression
between normal and CAN kidney which is in keeping with the respective presence
and absence of Shh protein in the normal kidney and CAN sections.
3.7.2 Possible roles for Shh in normal kidney
Taken together, the findings prompt speculation regarding a possible role for Shh in
the epithelium of the normal adult kidney. Shh typically effects its action on target
cells through binding to its receptor Ptc40,100. It is therefore of particular interest that
Ptc protein expression was not apparent in any of the sections of normal kidney. That
this is the case did not appear to represent inadequate optimisation of the Ptc
antibody for this purpose since Ptc expression was clearly detected on the infiltrating
inflammatory cells in the sections of CAN, which, for practical purposes, were run in
parallel experiments with the immunohistochemistry on the normal kidney sections.
During development of the metanephric kidney, upregulation ofPtc in the
mesenchyme surrounding the distal collecting ducts and the ureter suggests that Shh
functions via Ptc in a paracrine manner. Indeed, in vivo and in vitro analyses
demonstrate that Shh signalling through Ptc promotes mesenchymal cell
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proliferation, regulates the timing of differentiation of smooth muscle progenitor
cells, and sets the pattern ofmesenchymal differentiation138. However, the absence of
Ptc protein expression in the adult kidney would suggest that either protein
expression is absent or that its expression is so low as to evade detection by the Ptc
antibody. That Ptc mRNA could be detected by real-time PCR lends support to the
latter although it is possible that, under certain circumstances, Ptc mRNA expression
is upregulated, and translated into upregulated protein expression, allowing Shh
signalling through the Shh-Ptc axis to occur. Alternatively, Shh may signal via a
different receptor. For example, Shh can bind to the less well characterised Ptc
receptor, Ptc212 '13° or the membrane glycoprotein Hedgehog interacting protein
(Hip). Hip, like Ptc, is a transcriptional target ofHh124 although it remains to be
determined whether either Ptc2 or Hip are expressed in the kidney. Alternatively, it
may be that Shh, if functional in the kidney, acts independently of the Ptc-Smo-Gli
axis altogether. Such pathway independence has been demonstrated recently in
investigations into the effect of Shh on cell adhesion and migration of neural crest
cells121. Testaz et al121 posited that the effect of Shh on neural crest cells may be
mediated, at least in part, through interactions with members of the integrin family
since Shh failed to exert its effect in pi-integrin-deficient mice. Indeed, it is
interesting to note that interactions between Shh and the extracellular matrix protein,
vitronectin, have also been described454.
A further possibility arises out of a recent discovery suggesting that Shh can bind to
megalin126. Megalin, originally recognised as the Heymann nephritis autoantigen,
gp330455'456, and then, subsequently, as a member of the LDL receptor family2 3'457,
is one of the most abundant proteins in the renal proximal tubule (PCT)135'458. Indeed,
expression ofmegalin on the apical surface ofproximal tubular cells has been
demonstrated in preliminary experiments in 2 samples ofnormal kidney (See
Appendix 1), a finding in keeping with previous reports459.
Megalin functions as a receptor for numerous ligands460. These include
apolipoprotein E-enriched lipoprotein particles, complexes composed of urokinase
and tissue-type plasminogen activator in complex with type-1 inhibitor (PAI-1)461,
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receptor-associated protein (RAP)462, vitamin D463 and calcium, as well as vitamin
B12464'465, albumin and polypeptide hormones. One of the key functions ofmegalin
is to mediate endocytosis and transepithelial transport of ligands in the kidney,
targeting them for either lysosomal degradation or transcytosis459'466.
In this chapter, it has been shown that Shh, like megalin, is expressed on the apical
surface of the PCT, this close proximity suggesting the possibility of a Shh-megalin
interaction. It is also notable that both Shh and megalin are expressed in the
lung135'149. In the adult lung, megalin expression has been localised to the type II
pneumocytes135 and, indeed, these same cells exhibited upregulated Shh expression
in fibrotic pulmonary disease in the human and a mouse model149. It remains to be
seen whether this interesting association in the lung and kidney represents an
underlying functional mechanism or merely an irrelevant coincidence. If, indeed, the
Shh and megalin interaction is important in the kidney, it is tempting to speculate as
to its possible role. One possibility is that Shh protein is present in the glomerular
filtrate and is endocytosed by megalin binding it to the apical surface of the PCT. If
this is the case, it is not clear why this would occur. Urine is not known to contain
Shh, although this could be readily evaluated, at least in mice, using the
commercially available murine Shh ELISA. It is also conceivable that the Shh
antibody is detecting Shh protein bound to megalin on the surface of the cells and
either free Shh, or Shh in association with megalin in the cytoplasm of the PCT.
Although an interesting possibility, this is unlikely to represent the whole picture
since this mechanism would not explain the relatively high levels of Shh mRNA
expression in normal kidney relative to CAN kidney. Thus, it seems possible that at
least some contribution to the epithelial Shh arises from de novo synthesis of Shh
mRNA.
Another issue of interest here relates to the possible implications of an interaction
between Shh and megalin. It has been postulated that megalin may modulate Ptc and
Smo trafficking127. Indeed a number of studies report low levels ofPtc on the
surfaces of cells and that the majority ofPtc protein is present in the intracellular
endosomal compartments57'58. It is possible that low levels of surface Ptc and
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increased endosomal accumulation may result from megalin-mediated endocytosis, a
scenario analogous to the roles of other members of the LDL receptor family467. It is
of further interest then that studies investigating the interaction ofPtc and Smo in
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endosomes used a renal epithelial cell line for this investigation . Indeed, Incardona
et al52 demonstrated Ptc-Smo complex internalisation following binding of Shh
ligand in this model. The failure of Ptc protein to be detected in the kidney by
immunohistochemistry, despite the presence ofPtc mRNA would be in keeping
either with low levels of expression or masking of the Ptc, by megalin, Smo or Shh,
to the detection antibody.
Although megalin appears to play a role in mediating endocytosis, it is not entirely
clear whether megalin binding is capable of directly inducing signal transduction
pathways. However, other members of the LDL receptor family do appear to mediate
signalling467. Interestingly, some mediate signalling through the phosphoinositide 3-
kinase pathway468, a pathway also previously shown to be activated by Shh's
interaction with Ptc in endothelial cells65. Thus, these interesting reports point to a
possible role for Shh's interaction with megalin in the kidney. A final point of
interest relates to the recent findings of Gekle et al469 illustrating that enhanced levels
of TGF-P 1 lead to reduced megalin-cubilin-mediated endocytosis469. If Shh does
bind to megalin in the epithelium of the PCT, it is possible that further effects
stemming from this interaction may also be inhibited by TGF-p. Indeed, given the
upregulated TGF-P in association with the extensive fibrosis seen in CAN, it is quite
possible that this TGF-P upregulation could have profound effects on Shh expression
and possible Shh-megalin interactions. Interestingly, findings from preliminary
experiments in which megalin protein expression was evaluated in CAN, suggested
that megalin expression is lost in CAN (See Appendix 2). Whether this observation
reflects the loss of the brush border and proximal convoluted tubule integrity seen
early in CAN or, instead, parallels the loss of Shh as a ligand for megalin, is not
known.
One can only speculate further as to the function of Shh in renal epithelium. Perhaps
it has a role in maintaining cell viability, acting as a survival factor. Several reports
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in the literature would lend support to such a role425'470"472. Indeed, Shh has been
shown to induce the survival factor bcl-2425,471 in keratinocytes and lymphocytes21.
Both bcl-2 and bcl-xl are expressed in proximal tubular epithelial cells and,
interestingly, recent reports have suggested that the balance of survival to
proapoptotic factors following cadaveric renal transplantation may be critical to
determining the early outcome of the graft473"475. For example, upregulated bcl-2
expression has been demonstrated in the tubular cells of renal transplant recipients
without post-ischaemic renal failure following cadaveric renal transplantation
compared to those with acute renal failure473. In contrast, acute allograft rejection has
been associated with a shift in the ratio ofbcl-2 to bax (a pro-apoptotic) factor in
tubular epithelium and increased expression ofp53 in tubular nuclei474. Furthermore,
in cadaveric renal allografts, bax expression is more prevalent than in living donors,
a finding which may contribute to the poorer graft survival seen in cadaveric
compared to living donor kidneys475. If Shh is involved in the upregulation of bcl-2
in renal tubular epithelium, it is conceivable that it may help to maintain cell viability
in these cells, possibly influencing the early outcome of renal damage. Such an
immediate early function for Shh would perhaps help to further explain the loss of
Shh expression in CAN. It is interesting to speculate further on the significance of
this. For example, given the epithelial expression of Shh and its possible action on
immune cells, perhaps Shh is functioning as an endogenous danger signal in keeping
with the danger theory proposed by Matzinger in the 1990s47 '477. Proposed
candidates for this role already include the heat shock proteins (HSPs). Increased
expression of the heat shock proteins and molecular chaperones is a ubiquitous
feature of cells exposed to acute but typically transient, stress conditions. In a
number of organisms, induced expression of HSPs can be a marker for the adaptation
to cyclical environmental changes478. In contrast, constitutively high levels of
inducible HSPs such as HSP70 are not commonly seen in mammals. However, in
response to injuries such as ischaemia and/or reperfusion heat shock protein
expression is induced479. Furthermore, the induction of heat shock proteins has been
shown to protect against ischaemia/reperfusion injury480"4 3, at least some of this
effect attributable to the induction of bcl-2 as well as that of HSP 70 and 90 and
heme-oxygenase i480>484. Whether Shh signalling has the potential to be involved in
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cell viability and/or preconditioning responses in the kidney is not clear. Interestingly
in this regard, several groups have suggested that the antiapoptotic role of certain
types ofpreconditioning may be, in part, mediated by AKT signalling leading to the
prevention of caspase activation485'486. AKT has been shown to promote cellular
survival in vivo487 and it is notable that recent work by Kanda et al65 has suggested
that, in endothelial cells, Shh induces AKT signalling. Thus, it can be seen that
tissue-derived Shh has the potential to function as a survival factor through the
activation of a number of different downstream pathways including the bcl family of
proteins and AKT signalling. In light of some of the similarities Shh may share with
the heat shock proteins (ie upregulated at sites of damage, capable of activating cells
of the immune system and survival effector function), further investigation along
such lines would provide interesting avenues for further enquiry.
Other feasible roles for Shh in the kidney include a role in the maintenance of a
healthy differentiated phenotype in tubular cells. A similar such role for Shh
signalling has been proposed in the gut67 and it is conceivable that it may assume a
similar role in the kidney. Renal injury results in morphological and functional
changes in epithelial cells ' . Tubular epithelial cells are particularly susceptible
and appear to dedifferentiate during renal ischaemia. It would be interesting to
determine whether such dedifferentiation is associated with a loss of tubular Shh
expression. It is of note that members of the bone morphogenetic proteins (BMPs),
recognised downstream targets ofHh signalling, are expressed during renal
development489 and in the adult kidney490 and several lines of evidence suggest that,
at least some of the BMPs, most notably BMP7, may be important in stimulating and
maintaining a healthy differentiated epithelial cell phenotype in the kidney. Firstly,
severe renal dysorganogenesis occurs in the BMP7-deficient mouse with an absence
of nephron formation491. Secondly, recombinant BMP7 protein is capable of
inducing epithelial differentiation with subsequent nephron formation in metanephric
organ culture492 and in metanephric mesenchymal cell cultures490. Furthermore,
BMP7 mRNA was shown to be downregulated in ischaemic kidneys compared to
normal kidneys490 and the administration of recombinant BMP7 prevents the tubular
interstitial nephritis caused by obstructive uropathy493, abrogates glomerular sclerosis
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in diabetic nephropathy494, blunts renal fibrosis493 and leads to the repair of severely
damaged renal tubular epithelial cells in a mouse model of chronic renal injury273.
The mechanism ofBMP7's action appears to be preservation of epithelial cell
phenotype, inhibition of epithelial-mesenchymal transdifferentiation and inhibition
of injury-induced apoptosis494.
Aside from possible maintenance of cell viability and/or maintenance of the healthy
epithelial phenotype, other roles for Shh may be relevant. For example, Shh may
have key roles in both embryonic163 and postnatal angiogenesis65'102'103. Indeed,
endothelial cells appear to be able to respond to Shh signalling as evidenced by work
in which Shh induced capillary morphogenesis in both murine brain capillary
endothelial cells and human umbilical endothelial cells150. Thus, it is possible that
Shh may play some role in maintaining the microvasculature of the kidney.
Although it is interesting to speculate on possible roles for Shh in the normal kidney,
a further possibility has yet to be considered - namely that the kidneys used in this
study may not represent the expression seen in normal kidney. Indeed, none of the
samples were truly "normal". Three of the samples were derived from kidneys not
used for transplantation and 7 from the normal parts of kidneys nephrectomised for
tumours. Of those kidneys not used for transplantation, 2 kidneys were from donors
with significant vascular disease. All 3 had further been subjected to the trauma
associated with death of the cadaveric organ donor, an invariably lengthy multi-
organ retrieval process, perfusion with preservation fluids and cold and warm
ischaemia. Given that Shh may be upregulated early in inflammation and/or injury, it
may be that Shh is released from renal epithelium in response to these insults.
Indeed, the proposed danger signals, the heat shock proteins are induced very early in
response to damage both in vivo and in vitro495'498. Thus, the normal kidneys from
these unused kidneys may well reflect a somewhat altered expression of Shh and Ptc.
Furthermore, the other 7 kidney specimens had been derived from kidneys
containing tumours and whether these may be considered to be representative of
truly normal renal tissue is also not clear.
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3.7.3 Summary
The work presented in this chapter has used immunohistochemistry to demonstrate
the established features of CAN in a sample population of kidneys nephrectomised
for CAN. The work has further demonstrated that, in keeping with other reports in
the literature, the growth factors TGF-P and VEGF are expressed in CAN. In the
latter part of the chapter, immunohistochemistry has further been employed to
evaluate the expression of components of the Shh signalling pathway in normal and
CAN kidney. The results demonstrate that Shh, but not Ptc, is expressed in normal
adult human kidney. The results also indicate that, contrary to the enhanced
expression of Shh seen in other models of fibrosis and human pulmonary fibrotic
disease149, Shh is not expressed in CAN. Conversely, Ptc expression is evident in
CAN, with expression being limited to cells of the inflammatory cell infiltrate.
Possible reasons for this pattern of expression are discussed, as are possible roles for
Shh in the normal adult kidney.
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Chapter 4
The effect of immunosuppressive agents and cell




The results from Chapter 3 have raised a number of interesting questions with
regards the possible role for Shh signalling in the adult kidney. Expression at the
mRNA or protein level clearly does not provide sufficient evidence for an active role
for Shh signalling in the kidney but it does tempt speculation regarding the possible
roles Shh could play in the normal kidney and possible reasons for its loss in the
kidney affected by CAN. Indeed, for Shh expression to be absent in the transplanted
kidney affected by CAN could reflect the result of one or many different disease
processes or idiopathic interventions that an allograft is subjected to during its
lifespan. All transplanted kidneys used in this work were originally from cadaveric
donors and had been subjected to treatment with immunosuppressive agents; they
had undergone one or more episodes of acute allograft rejection and had progressed
to chronic allograft nephropathy. Furthermore, by the time of transplant
nephrectomy, all immunosuppressive agents had been discontinued with the
invariable result that acute rejection changes superimpose on the underlying
nephropathy. Thus, it can be seen that the Shh expression seen in normal kidney may
well have been lost at any stage during the lifespan of the allograft. That the kidney
affected by CAN has been subjected to a large range of potential insults, all ofwhich
may have led to the loss of Shh expression in the setting of allograft nephropathy,
opens up several lines of enquiry. In Chapter 3, an attempt was made to investigate
the expression of Shh in sections of kidney affected by ATN or ACR. Whether the
apparent absence of Shh expression demonstrated in these immunohistochemistry
experiments truly reflects the failure of Shh to be expressed in these conditions or
whether it reflects an artefact of the immunohistochemistry in these biopsy samples
remains to be established. If the apparent absence of expression seen in ATN and
ACR accurately represents the Shh expression in these conditions in vivo, these
results would suggest that Shh expression is lost early in the allograft's life, prior to,
or as a result of, injury sustained as a result ofATN or ACR. For this reason, 2
avenues were chosen for further study in this chapter, both ofwhich represent
possible insults sustained by the transplanted kidney early in its lifespan. Firstly, and
as outlined in the first part of this chapter, the effect of immunosuppressive agents on
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renal epithelial Shh expression has been evaluated since the immunosuppressive
agents are employed very early in the course of the allograft's life. In the second part
of the chapter the effect of damaging agents on renal Shh expression has been
explored. This is ofparticular relevance since, not only has the expression ofHh
signalling components been associated previously with epithelial damage,
inflammation149 and repair152 processes, but also epithelial damage is invariably seen
in transplant nephropathy.
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4.2 The effect of the immunosuppressive agents
ciclosporin and dexamethasone on Shh
expression in ACHN cells
Of the factors that might influence Shh expression, the effect of immunosuppressive
agents presented an avenue of inquiry that could be readily explored. All of the
transplant nephrectomy samples used in the immunohistochemistry experiments
described in Chapter 3 had been subjected to an immunosuppressive treatment
consisting of a ciclosporin and steroid-based regimen. Thus, the aim of this section
ofwork was to determine whether ciclosporin and the steroid, dexamethasone, could
influence the Shh expression of human renal epithelium. For these experiments, the
human renal adenocarcinoma (ACHN) (European Collection of Cell Cultures,
ECACC No: 88100508) cell line was used. This cell line has been used previously499
as an in vitro model of renal tubular cells. The management of this cell line, together
with the medium used for cell cultures, is described further in Chapter 2.
4.2.1 Ciclosporin upregulates Shh expression in ACHN renal epithelial cells
ACHN cells were seeded at a density of 50,000 cells per well in 6 well plates. After 2
days, when the cells were 75% confluent, the cells were washed with fresh medium
(complete DMEM) and treated with 10-1000ng/ml ciclosporin (Sigma) or 10-
lOOOng/ml dexamethasone (Sigma) reconstituted in complete DMEM. These
concentrations of the immunosuppressive agents were chosen since they have been
used by other authors to broadly reflect the concentrations that may be present at the
tissue level in vivo following transplantation500"506 and without evidence of toxicity.
Cells in fresh medium alone constituted the negative controls. The cells were
cultured under these conditions for 2-48 hours. At the end of this time in culture, the
supernatants were set aside for later experiments (described in Section 4.3) and the
RNA was extracted from the cells using Trizol extraction as described in Chapter 2.
cDNA was prepared from the RNA and real-time PCR was used to evaluate Shh and
Ptc expression. Values are expressed as a ratio of the concentration of Shh and Ptc
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mRNA in treated cells relative to untreated (control) cells, where control cells are
given a value of 1.
To determine Shh and Ptc protein expression in the ACHN cells, parallel
experiments were set up in which glass coverslips, rinsed in alcohol and air-dried,
were placed in each well of 6 well culture plates, prior to the addition ofACHN
cells. The cells on the coverslips were treated with ciclosporin and dexamethasone
and cultured under these conditions for 2-48 hours, as described above. Following
this incubation period, the cells were washed with PBS and immunohistochemistry
performed on them using polyclonal antibodies to Shh and Ptc (Santa Cruz
Biotechnology) to evaluate the expression of these proteins as described in Chapter
2. To check specificity, the same antibodies were pre-incubated with the appropriate
specific blocking peptides (Santa Cruz Biotechnology) as outlined in Chapter 2 and
applied to coverslips in parallel with experiments in which primary antibodies were
applied to the cells. Cells treated in this way served as negative controls for the
immunohistochemistry.
The results from these experiments are shown in Figures 4.1 and 4.2. As shown in
Figure 4.1, resting ACHN cells express Shh (Figure 4.1a), but not Ptc (Figure 4.1b),
protein. In response to ciclosporin, this staining appears to increase in intensity,
reaching a maximum at 12 hours (Figure 4.Id) and then declining thereafter. By 48
hours (Figure 4.1e), the Shh expression appeared less intense than in the untreated
cells. In contrast, in response to dexamethasone, Shh protein expression did not
appear to be modulated (n=3, data not shown).
The results from real-time PCR experiments corroborate these findings. As shown in
Figure 4.2, ciclosporin induced an early upregulation in Shh expression, preceding
the upregulation in protein expression. This effect was maximal at the highest
concentration of ciclosporin used (lOOOng/ml) and reached a peak at 6 hours.
Conversely, although dexamethasone appeared to upregulate Shh expression, the
maximum upregulation seen was 1.7 fold, a peak also occurring at 6 hours. The
effect induced by dexamethasone, however, did not bear any correlation to the dose
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of dexamethasone used. Although it is difficult to determine what constitutes a
biologically significant upregulation ofmRNA expression, it is generally accepted
that a 2-fold or greater increase in gene expression is significant when using real¬
time PCR507'508. This, together with the absence of a dose-dependent effect of
dexamethasone, would suggest that the effect of dexamethasone on the ACHN cells
may not be significant.
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Figure 4.1
Shh expression is upregulated by ciclosporin in ACHN cells
ACHN cells were cultured in medium alone or in the presence of ciclosporin or dexamethasone
10-1000ng/ml for 2-48 hours. Immunohistochemistry was performed using polyclonal
antibodies to Shh and Ptc, as previously. Untreated ACHN cells expressed Shh (Figure 4.1a,
Mag x 1000), but not Ptc (Figure 4.1b, Mag x 1000). In response to ciclosporin lOOOng/ml,
intensity of staining increased at 6 hours (Figure 4.1c, Mag xlOOO), reaching a maximum at 12
hours (Figure 4.Id, Mag x 1000) and, by 48 hours, had decreased dramatically (Figure 4.1e,
Mag x 1000). All positive staining could be blocked using the specific blocking peptide (Figure
4.If, Mag x 1000). Results are representative of 3 individual experiments and data for
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Figure 4.2
Shh expression is differentially modulated by ciclosporin and
dexamethasone in ACHN cells
ACHN cells were cultured either in medium alone or in the presence of
ciclosporin (CsA) (Figure 4.2a) or dexamethasone (Figure 4.2b) 10-
lOOOng/ml for 2-48 hours. Real-time PCR was then performed on
each sample in duplicate using 18s as an internal control to compare the
relative expression of Shh mRNA in untreated (medium alone) and
treated ACHN cells. Values are expressed as a ratio of the
concentration of Shh mRNA in treated cells relative to untreated cells,
where the latter are given a value of 1. The results presented are
representative of 3 independent experiments.
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4.2.2 Evaluating the toxicity of ciclosporin and dexamethasone to ACHN renal
epithelial cells
Although ciclosporin and dexamethasone have been used in in vitro experiments
previously at the concentrations used here without evidence of toxicity, it was
important to evaluate whether these agents were toxic to the ACHN cells used in
these experiments. Thus, to confirm that neither agent was toxic to the cells used in
my system, 3 methods were used to assess cell viability. Firstly, the cells were
inspected by light microscopy to determine the presence of any gross changes in cell
morphology. Secondly, cell viability was assessed by exclusion of trypan blue
entry501. Finally MTT assays were performed, as described in Chapter 2, to
determine whether ciclosporin and dexamethasone in the concentration ranges used
were toxic to the ACHN cells. The MTT assay allows an assessment of cell viability
since only metabolically active cells are capable of reducing the MTT tetrazolium
compound into a coloured formazan product509. The quantity of formazan product is
then measured by the amount of absorbance at 570nm which is proportional to the
number of living cells in culture.
Figure 4.3 illustrates the results from the MTT assay. Consistent with previous
reports in the literature, the results from the assay demonstrated that neither
ciclosporin (Figure 4.3a) nor dexamethasone (Figure 4.3b) were toxic to the ACHN
cell line at any of the concentrations used. Representative results at the highest
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FIGURE 4.3
Evaluation of ciclosporin and dexamethasone cytotoxicity on
ACHN cells using MTT
ACHN cells were incubated with either ciclosporin or dexamethasone
in the concentration range 10-1000ng/ml for 2-48 hours. Viability was
evaluated using the MTT assay. Data for lOOOng/ml ciclosporin
(Figure 4.3a) and dexamethasone (Figure 4.3b) are shown. Results are
presented as the ratio of treated to untreated cells as a percentage where
untreated cells are given a value of 100%. Experiments were performed
in triplicate and means and standard deviations are shown.
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4.3 Shh release from ACHN cells
Given that ciclsporin induced a marked and early upregulation in Shh mRNA
expression and that this appeared to be mirrored by changes in protein expression
resulting in the apparent loss ofprotein expression detected by
immunohistochemistry at later time points, it was tempting to speculate that Shh may
be released from the ACHN cells in response to ciclosporin treatment. Few
antibodies and reagents are available for investigation of the Shh signalling pathway
and this ensures that attempts to detect Shh release are difficult. It is only relatively
recently that a murine Shh ELISA has become commercially available. However, to
address the possibility that ciclosporin might induce Shh release from ACHN cells, 2
approaches were employed, ELISA and Western blotting techniques.
4.3.1 ELISA
Although a human Shh ELISA is not yet commercially available, an attempt was
made to use the commercially available murine Shh ELISA (R&D Systems) for the
• • • • • 2detection of human Shh. Human and murine Shh differ in only one amino acid and
most of the commercially available antibodies are capable of recognising Shh from
more than one species. Furthermore, recombinant murine Shh has been used in the
literature for the investigation of human cell responses20,65,510. Thus, it was possible
that the murine Shh ELISA available may also recognise human Shh. The murine
sandwich ELISA utilises a rat anti-mouse capture antibody for primary Shh detection
and a biotinylated rat anti-mouse secondary antibody and is calibrated against the
same recombinant murine Shh utilised in this work and other human studies in the
literature20,510,511. The ELISA was therefore used initially to determine whether Shh
could be detected in the cell culture supernatant of cells treated with the
immunosuppressive agents ciclosporin and dexamethasone. The ELISA was
performed according to the manufacturer's instructions and supernatants from the
experiments described in Section 4.2.1 were used.
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Although the recombinant Shh standards produced a robust standard curve, Shh
failed to be detected in supernatants from either the control cells or the ciclosporin-
or dexamethasone-treated cells. These results suggest that either the ELISA is failing
to detect human tissue-derived Shh, that Shh is not released into the supernatant in
response to treatment with the immunosuppressive agents or that Shh is released but
in a form not recognised by the ELISA.
4.3.2 Western blotting
That Shh was not detected in the cell culture supernatants may well reflect the
inability of the murine ELISA to detect human Shh and, indeed, the reported cross-
reactivity of the ELISA for human Shh is in the order of 11.8%. Thus, a different
approach was required. To explore possible release of Shh by the ACHN cells,
Western blotting techniques were employed. The aim was to determine whether Shh
protein expression in untreated cells could be detected by Western blotting; whether
this expression was modulated by treatment with ciclosporin or dexamethasone and
finally, if expression in the cells was modulated, whether this was associated with the
appearance of Shh protein in the supernatant.
4.3.2.1 Shh protein is detected in ACHN cells by Western blotting
To determine whether Shh protein could be detected by Western blotting techniques,
ACHN cells were sonicated in protein lysis buffer as described in Chapter 2. Protein
quantification was undertaken using the Bradford protein assay (Bio-Rad, Hemel
Hempstead, Hertfordshire, UK) and each sample was assayed in triplicate. lOOpg of
each protein sample was used in the Western blotting experiments. Western blot
protocols have been described in more detail in Chapter 2. Briefly, protein samples
were added to 2x protein loading buffer, heated at 100°C for 10 minutes, and
electrophoresed at 100V for 2 hours alongside pre-stained molecular weight markers
(Invitrogen, Paisley, UK). Lysates from untreated ACHN cells and cells treated with
10-1000ng/ml ciclosporin or dexamethasone were evaluated alongside lOOng/ml
rShh which served as the positive control. Following transfer to nitrocellulose at
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150V for 30 minutes, the membranes were incubated overnight in blocking buffer to
block non-specific binding. The membranes were then probed for 2 hours with either
a goat polyclonal antibody to the N-terminus of Shh (Santa Cruz Biotechnology) or a
mouse monoclonal antibody to Shh, 5E1 (Developmental Studies Hybridoma Bank).
In a parallel experiment, to confirm the antibody specificity of the goat polyclonal
antibody, an aliquot of the antibody was pre-incubated with the specific blocking
peptide (Santa Cruz Biotechnology) prior to application to the membrane. The
secondary antibodies used were HRP-rabbit anti-goat and HRP-rabbit anti-mouse
and were applied for 2 hours at 1:2000 dilution. Detection was effected using the
ECL plus system (Amersham Pharmacia Biotech, Amersham, UK). Excess reagent
was removed and the membrane placed under X-ray sensitive film for various
lengths of exposure time (30 seconds - 10 minutes).
Representative results are shown in Figure 4.4. Although both the goat polyclonal
antibody (Figure 4.4a) and the 5E1 mouse monoclonal antibody (Figure 4.4b) clearly
detected the rShh used as a positive control, only the goat polyclonal antibody was
able to detect Shh in the ACHN lysate (Figure 4.4c), despite numerous protocol
optimisation strategies. Two relevant bands were detected in the ACHN cell line, one
at 45kDa and one at 19kDa consistent with the presence of full-length precursor Shh
and its active cleaved form respectively (Figure 4.4c). These bands could be blocked
when the membranes were incubated with an antibody/blocking peptide cocktail,
thus suggesting that the bands were specific in nature. However, in response to
ciclosporin or dexamethasone, there was no apparent change in Shh expression in the






Western blots of ACHN cell lysates
Lysates from untreated cells (medium alone) and cells treated with
either 10-1000ng/ml ciclosporin or dexamethasone were evaluated
using Western blotting. Both a goat polyclonal and mouse
monoclonal antibody to Shh were used. Although both the goat
polyclonal (Figure 4.4a) and the mouse monoclonal (5E1) (Figure
4.4b) antibodies detected lOOng rShh used as the positive control,
only the goat polyclonal antibody detected Shh in the ACHN
(untreated, control) lysate (Figure 4.4c). However, in response to
ciclosporin or dexamethasone, there was no apparent change in Shh
expression in the treated cells. Figures 4.4d and 4.4e represent the
effect of treatment with 1 OOOng/ml ciclosporin and dexamethasone
respectively.
148
4.3.2.2 Shh is not detected in the supernatant ofcells treated with ciclosporin or
dexamethasone
Despite the difficulties associated with optimisation of the Western blot experiments,
attempts were also made to detect Shh protein in the supernatant of untreated and
ciclosporin or dexamethasone-treated cells. ACHN cells were seeded into 162cm2
flasks and grown to 75% confluence as in the previous experiments. The cells were
treated with either medium alone, ciclosporin or dexamethasone in the concentration
range 10-1000ng/ml in a volume of lOmls. The supernatants were harvested
following 2-48 hour incubations. Each supernatant was transferred to dialysis tubing
and placed on polyethylene glycol (PEG) (Fisher Scientific UK, Loughborough,
Leics, UK), the latter binding water and thus concentrating the protein to a volume of
less than 2.5mls. The protein content was quantified, as previously, using the
Bradford protein assay, performed on each sample in triplicate. 1 OOpg of protein was
analysed by Western blot as described above using the goat polyclonal antibody to
the N-terminus of Shh as the primary antibody (Santa Cruz Biotechnology).
Using this technique, although the positive control rShh was readily detected, the
presence of Shh in the cell supernatants could not be demonstrated.
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4.4 Primary murine renal epithelial cell cultures
From the results so far presented, it would appear that ciclosporin is capable of
upregulating Shh mRNA in the ACHN cell line and that this may be mirrored at the
protein level as reflected by the immunohistochemistry results. Conversely,
dexamethasone did not significantly modulate either Shh mRNA or Shh protein
expression. The peak in Shh protein expression induced by ciclosporin is followed by
an apparent decline in expression. This observation would be consistent with either a
release of Shh protein from the ACHN cells or intracellular modification resulting in
the masking of Shh protein to the detection antibody. Given that the recently
proposed targets for Shh include immune cells20'21'149 and fibroblasts102, it is tempting
to speculate that Shh may be released from epithelium whereupon it can act on these
cells. However, the methods used above to investigate the possibility of Shh release
were largely unsuccessful and are hampered by the scarcity of commercially
available reagents. Thus, it remains unclear whether these agents induce the release
of Shh from epithelium. Furthermore, although the results from the ACHN cell line
are interesting, it is not clear whether these findings adequately represent the
situation in normal renal tissue or in vivo. Although the ACHN cell line has been
previously used to represent normal proximal tubular epithelium, this is probably not
appropriate. The ACFIN cell line is derived from a renal adenocarcinoma and, as
such, does not therefore represent normal renal epithelium. This may be of particular
importance in the context of Shh signalling. Although significant Hh expression is
not detected in many adult tissues, recent reports have suggested that active Hh
signalling may be critical to the growth of a number of tumour cell lines66. For
example, although Hh signalling appears to be important in the growth of
oesophageal tumours, as indicated by cell line studies, there have been no reports of
Shh expression in the adult oesophagus66. Thus, results suggesting an effect on Shh
expression in a tumour cell line require to be interpreted with caution. Therefore, a
new approach was required to fulfil 2 roles. Firstly, the approach must satisfy the
need to investigate normal renal epithelium, rather than extrapolating results from a
cell line, and secondly, in view of the difficulties encountered in the investigation of
Shh release from human epithelium, it was necessary to employ a murine model
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since there is, at least, a commercially available Shh ELISA available to allow Shh
protein quantification. In this regard, primary cultures ofmurine renal epithelium
were prepared and investigated for both the expression of Shh and the possible
release of Shh protein in response to treatment with ciclsporin.
4.4.1 Primary renal epithelial cell (REC) cultures
Primary epithelial cultures were prepared from C57BL/6 (B6) mice by collagenase
digestion of renal cortex based on methods described previously512'513 and outlined in
Chapter 2. Following digestion and precipitation on ice, the tubules were
resuspended in complete DMEM F12 culture medium and plated into 6 well culture
plates. To minimise the outgrowth of fibroblasts, the primary cultures were
maintained in serum-free conditions. The tubules from one pair of kidneys were
distributed between four 6-well plates, with 2mls ofmedium in each well. The cells
were cultured for 10 days and the medium was replaced with fresh DMEM F12
medium every 2 days.
By the end of this incubation period, large islands of confluent cells were apparent
with defined advancing edges. Although the culture conditions promote the growth
ofproximal tubular epithelial cells512'514'515, the islands were observed to consist of
markedly heterogenous populations of cells. In order to define the phenotype of the
cells prior to investigating Shh expression and the effect of immunosuppressive
agents on the cells, experiments were set up in which glass coverslips were placed at
the bases of the wells in 6 well plates. Cells cultured on these glass coverslips were
employed to immunohistochemically investigate the phenotype of the cells cultured.
Following washes to remove culture medium, the cells were probed with monoclonal
anti-pancytokeratin and -vimentin antibodies (Sigma) to broadly identify epithelial
and fibroblastic phenotypes within the cell culture islands as described previously501.
The antibodies were incubated at 1:100 dilution for 2 hours and secondary detection
performed using a biotinylated rabbit anti-mouse antibody for 1 hour. As previously,
positive signalling was identified using diaminobenzidine (Dako Ltd).
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As shown in Figure 4.5a, most cells present in the cell culture islands were
pancytokeratin positive suggesting that the primary culture was of renal epithelial
phenotype. However, there were present smaller collections of cells which were
vimentin positive (Figure 4.5b) suggesting that a few non-epithelial, probably
fibroblastic, components were present.
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FIGURE 4.5
Immunohistochemical phentoyping of Renal Epithelial
Cell (REC) cultures
RECs were prepared from C57BL/6 murine kidneys by
collagenase digestion. Immunohistochemistry was
performed using antibodies to pancytokeratin (Figure 4.5a,
Mag x 200) and vimentin (Figure 4.5b, Mag x 200). As
shown, most cells present were pancytokeratin positive.
Smaller clusters of vimentin-positive cells (circled) were
also evident.
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4.4.2 Shh and Ptc expression in REC cultures
Having determined that most cells present in the cell cultures were of epithelial
phenotype, immunohistochemistry was performed to determine whether the RECs
express Shh and Ptc. Representative results are illustrated in Figure 4.6. It can be
seen that, using the goat polyclonal antibody to the N-terminus of Shh at the same
dilution as that used previously in this work (1:40), the epithelial cells stained weakly
for Shh. This staining could be blocked effectively using the specific blocking
peptide for the Shh antibody. Conversely, small clusters of cells, in keeping with
those staining positively for vimentin, expressed Shh relatively strongly at 1:40
(Figure 4.6a). When investigated for the expression ofPtc, the pancytokeratin
positive cells were negative for Ptc (Figure 4.6b). In contrast, the vimentin-positive
cells were also Ptc-positive (Figure 4.6b). That fibroblasts are positive for Ptc in this
work is consistent with previous reports in which fibroblasts were found to express
i r\j
Ptc and were capable of responding to a Shh signal .
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FIGURE 4.6
Renal Epithelial Cells express Shh, but not Ptc
RECs were investigated for the expression of Shh and Ptc
using immunohistochemistry. RECs were observed to
stain weakly for Shh with the most marked expression in
those cells previously observed to be vimentin-positive
(Figure 4.6a, Mag x 200). Conversely, Ptc expression
was absent in all but these clusters of cells (Figure 4.6b,
Mag x 200) consistent with the expression ofPtc by
fibroblast-type rather than epithelial cells.
155
4.5 Shh expression by and release from REC
cultures in response to ciclosporin and
dexamethasone
Using RECs prepared as outlined above, the cells were treated with ciclosporin and
dexamethasone in similar experiments to those described above in Section 4.1.
Briefly, RECs were cultured in the presence of 10-1000ng/ml of either ciclosporin or
dexamethasone for 2-48 hours. At the end of this period in culture, the supernatants
were harvested and the murine Shh ELISA (R&D Systems) was employed to detect
any Shh in the supernatant, according to the manufacturer's instructions. RNA was
also extracted from the cells using the Trizol extraction techniques described in
Chapter 2. Following reverse transcription of the RNA to cDNA, standard RT-PCR
and real-time PCR were employed using the primers outlined in Tables 2 and 3 in an
attempt to determine whether Shh expression is upregulated in response to treatment
with ciclosporin or dexamethasone.
To determine Shh and Ptc protein expression in the RECs, parallel experiments were
performed in which glass coverslips, rinsed in alcohol and air-dried, were placed in
each well of 6 well culture plates, prior to the addition of cells. The cells were treated
with 10-1000ng/ml ciclosporin and dexamethasone and cultured under these
conditions for 2-48 hours as described above. Following this incubation period, the
cells were washed with PBS and immunohistochemistry performed on the cells using
polyclonal antibodies to Shh and Ptc (Santa Cruz Biotechnology) to evaluate the
expression of these proteins.
Further parallel experiments were set up to allow analysis of possible toxic effects of
the immunosuppressive agents on the RECs using the MTT assay, as performed for
the ACE1N cells above. As in the ACHN cell culture system, the MTT assay
confirmed that neither ciclosporin nor dexamethasone in the dose range 10-
1 OOOng/ml were toxic to the RECs.
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Although rShh, used as a positive control, was detected by the Shh ELISA, the
ELISA failed to detect any Shh in the cell culture supernatants. Furthermore, in
contrast to the results seen using the ACHN cell line, neither ciclosporin nor
dexamethasone treatment modulated the Shh protein expression ofRECs detected
using immunohistochemistry (Figure 4.7).
Furthermore, despite obtaining good quality RNA, Shh expression could not be
detected in any of the REC samples, irrespective ofwhich primers were used and
whether RT-PCR or real-time PCR techniques were employed. The primers used
included sequences previously employed by our group to detect Shh using RT-PCR
and real-time PCR and are documented in Chapter 2. Despite considerable
optimisation (altering magnesium concentrations, dNTPs and the annealing
temperatures for the RT-PCR primers), Shh expression was detected neither in the
REC samples nor indeed in both archival and freshly prepared murine thymus




♦ Jh » * 1* * •'* * %■ flp * m 'Wr
# ^0 * % m
0 0- jA
m mm. m , w- m. ^ *0 ^
m #* * \t *'
# # # * 0 m if"
■ * 1
•
/ * ** ^ ' a *
a . »" • _« «
*4 • * * •
_
• *
*... * " • * * ^ %
k % # *
M ' m





Con.ro! | 12 hour
s- «(►Jte H11
48 hour MSB ■B
FIGURE 4.7b
FIGURE 4.7
The expression of Shh in Renal Epithelial Cells is not modulated by ciclosporin or
dexamethasone
Following treatment ofRECs with 10-1000ng/ml ciclosporin or dexamethasone,
immunohistochemistry was used to evaluate Shh expression as previously. Neither
ciclosporin nor dexamethasone modulated the expression of Shh in RECs. Illustrated are
untreated controls together with the expression pattern seen in response to 1 OOOng/ml
ciclosporin (Figure 4.7a) and 1 OOOng/ml dexamethasone (Figure 4.7b) following 12 and 48
hours in culture.
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4.6 Damage fails to modulate Shh release from
RECs
It has been hypothesised that Hh signalling may be important in the adult during
inflammation, repair and/or remodelling processes149'153'161. Shh is expressed in a
variety of epithelia including pulmonary, gut and thymus67'147"149'516 and may be
upregulated at sites of inflammation149'161. It is conceivable then that Shh may be
released at sites of epithelial damage whereupon it has the potential to act in a
paracrine fashion on other cells types including cells of the immune system20'21,
fibroblasts102 and endothelial cells65, thus perpetuating the inflammatory response.
Indeed both T cells and macrophages express Ptc and may be able to respond to a
Shh signal20'21'149. Given that ciclosporin upregulated Shh mRNA expression in
ACHN cells, it was tempting to speculate that ciclosporin may induce Shh release
from epithelium. From the limited data available, ciclosporin did not appear to
induce the release of Shh from epithelium. In light of these results, the aim of the
following section ofwork was to perform preliminary experiments to determine
whether established methods of inducing cellular damage could induce Shh
expression or release from tubular epithelium. In order to pursue this line of enquiry,
2 damaging methods were employed: oxidative cell damage and ultraviolet B
irradiation-induced damage.
4.6.1 Oxidative cell damage
Hydrogen peroxide may be used in in vitro cultures to induce oxidative cell damage.
It has been shown to cause a rapid increase in intracellular free calcium concentration
C17 CIO
in several cell types including renal tubular cells ' , enhanced calcium influx into
mitochondria and the disruption ofmitochondrial metabolism leading to cell
death519'520. Previous reports in the literature using hydrogen peroxide to induce
oxidative cell damage have used a range of concentrations in tubular epithelial
cultures, from 0-2mM521"523 for incubation periods of 2-48 hours.
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Therefore, in this series of experiments, RECs were prepared, as previously, and
plated into 6 well culture plates. After 10 days in culture, when large confluent
islands of cells were apparent, the medium was replaced with hydrogen peroxide
(Sigma) in the concentration range 0-5mM and the cells were incubated for 1-24
hours. After this incubation period, the cells were washed and the medium was
replaced with fresh medium. At the higher end of the concentration range of
hydrogen peroxide used, notably 5pM - 5mM, the cells had become detached by the
end of the 24 hour period in culture and required to be centrifuged for 5 minutes at
lOOg prior to re-suspension in fresh medium. The cells were incubated at the end of a
further hour in culture with fresh medium to allow any Shh present in the damaged
cells to be released into the culture medium. The supernatants were harvested and set
aside for later analysis using the murine Shh ELISA (R&D Systems). In a parallel
series of experiments, following incubation with the hydrogen peroxide, the
supernatants were drawn directly from the culture wells without prior cell washing
and replacement of the cell medium. This was performed in order to avoid missing
any Shh released early into the culture medium that would have been removed by the
subsequent washes. Supematants harvested from both experiments were analysed
using the murine Shh ELISA (R&D Systems) according to the manufacturer's
instructions.
In a further set of parallel experiments, the MTT assay was used, as described in
Chapter 2, to assess cell viability at the end of the incubation period. As described
above, when cell detachment was apparent in the cultures, the cells were first
centrifuged for 5 minutes at lOOg prior to removal of the medium and replacement
with fresh medium and MTT reagent. An example of the results obtained following a
2 hour incubation with varying concentrations of hydrogen peroxide is demonstrated
in Figure 4.8. As shown, increasing concentrations of hydrogen peroxide are
associated with decreasing cell viability in the REC cultures.
Although a reduction in cell viability was clearly seen in response to treatment with
hydrogen peroxide, Shh failed to be detected by ELISA in any of the cell culture
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supernatants examined, irrespective ofwhether supernatants were harvested
following a wash with medium following removal of the hydrogen peroxide or
whether the supernatants were harvested directly from the hydrogen peroxide
incubation. The rShh used as a positive control was however detected by the Shh
ELISA in all experiments.
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FIGURE 4.8
Concentration of hydrogen peroxide
FIGURE 4.8
Evaluation of hydrogen peroxide cytotoxicity on RECs using MTT
Renal epithelial cells were incubated with hydrogen peroxide in the concentration range
lnM-5mM for 1-24 hours. Viability was evaluated using the MTT assay. Representative
data for the 2 hour incubation period are shown. Results are presented as the ratio of treated
to untreated cells as a percentage where untreated cells are given a value of 100%.
Experiments were performed in triplicate and means and standard deviations are shown.
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4.6.2 Ultraviolet B irradiation-induced damage
The results outlined above in Section 4.4.1 were unexpected. If indeed Shh is
released from any damaged epithelium, it might have been anticipated that oxidative
cell damage would have resulted in Shh being released into the culture medium.
Indeed, a wide concentration range of hydrogen peroxide was employed and
cytotoxicity clearly demonstrated using the MTT assay. That early peaks in Shh
release may have been overlooked on account of the subsequent washing was
circumvented by separate experiments in which washing was omitted. In neither
series of experiments was Shh detected. There are a number of reasons why this
might have been the case, outwith the possibility that Shh may not be released in
response to oxidative cell damage. Notably, either the overt introduction of hydrogen
peroxide into the ELISA system, or indeed any carryover that may have resulted
following cell washing, carries with it the strong possibility of interference with the
performance of the ELISA, a point of particular relevance given that the ELISA
employs a streptavidin-horseradish-peroxidase (HRP) conjugate. Indeed, such an
effect is likely to result in any system in which a cytotoxic agent is utilised to induce
damage. This situation cannot be readily circumvented since thorough washing to
exclude possible carryover effects inevitably will remove protein released in the
early phases of cell damage, thus preventing its detection by the ELISA. Therefore,
in the following series of experiments, a different method of cell damage was
employed which avoided the use of cytotoxic agents.
Ultraviolet B (UVB) irradiation has been shown to induce apoptosis in a range of cell
types. These include mast cells524, epithelial cells525"527, macrophages528 and
fibroblasts529 and protocols used previously have included treatments of 10mJ/cm2-
500mJ/cm2 for durations of 30 minutes to 4 hours to induce apoptotic changes.
In 3 preliminary experiments, RECs were prepared as previously and subjected to
high levels ofUVB (100mJ/cm2 - 500mJ/cm2) for 1 hour. Supernatants were
removed from the cells both to treatment, at the termination of treatment and 1,6, 12
and 24 hours after the termination of treatment. Twelve hours following the
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termination of treatment, the cells were only weakly adherent and macroscopically
unhealthy with condensed nuclei. By 24 hours, all cells had become detached from
the base of the culture wells and Trypan blue exclusion revealed >95% cell death.
The culture supematants removed were analysed as previously by murine Shh
ELISA (R&D Systems). As in section 4.6.1 above, although the rShh used as a
positive control was detected by the Shh ELISA, Shh was not detected in any of the
cell culture supematants tested.
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4.7 Discussion
The work in this chapter has investigated, using both a human tubular cell line
(ACHN) and primary cultures ofmurine renal epithelial cells, factors that may
influence whether Shh is expressed and/or released from renal tubular epithelium.
These are interesting areas for a number of reasons. Firstly, Shh expression is
upregulated at sites of epithelial damage suggesting that Hh signalling may be
important in repair and/or remodelling responses149. Secondly, several reports in the
literature have identified peripheral cellular targets of Shh signalling including cells
of the peripheral immune system20'21, endothelial cells65 and fibroblasts102. Taken
together, these reports indicate that the epithelium and these responder cells have the
potential to interact at sites of renal epithelial injury or disease. Thus, further
delineation of factors influencing Shh expression and identifying whether Shh
release occurs in Shh-expressing cells in the kidney may help determine a role for
Shh, either in the normal kidney, or in the kidney damaged by disease.
It is important to note at this stage that one of the key factors hampering the
experiments described in this chapter was the lack of robust reagents for
investigation of the Shh signalling pathway. As described, although it was possible to
detect human Shh mRNA, it was not possible to directly measure human Shh protein
except through the use of immunohistochemistry. In the murine studies, evaluation of
Shh protein was possible, albeit that Shh failed to be detected, through the use of the
commercially available murine Shh ELISA. However, attempts to quantify murine
Shh mRNA expression were hampered by the inability to optimise the RT-PCR
primers and real-time primers and probes to allow qualitative and quantitative studies
to be performed. Together, these difficulties ensured that attempts to link together
changes in mRNA expression quantitatively with changes in protein release or
expression were made very difficult. Given these methodological difficulties, it is
important to interpret any findings presented with caution since their relevance can
not be fully delineated in the absence of good reagents to fully evaluate Shh
expression at both the protein and mRNA level.
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4.7.1 The effect of immunosuppressive agents on Shh expression in renal
tubular epithelium
The experiments in the first part of this chapter were designed to evaluate whether
the immunosuppressive agents ciclosporin and dexamethasone altered the expression
of Shh in the renal epithelial cells. Given the findings from Chapter 3 suggesting that
proximal tubular epithelial cells were the sites of Shh expression in normal adult
human kidney, the renal adenocarcinoma cell line, ACHN, an in vitro model of
tubular epithelium, was initially used to evaluate the effect of the ciclosporin and
dexamethasone on Shh expression in these cells. The experiments were also
performed using primary cultures ofmurine renal epithelial cells. The effects of these
agents on both mRNA and protein expression were examined. Furthermore, the
possibility that Shh release may be induced by treatment with these agents was
explored in both systems.
Taken together, the results showed a marked upregulation of Shh mRNA and protein
expression in response to ciclosporin, but not dexamethasone, in ACHN cells.
Conversely, in RECs, such upregulation of Shh protein expression in response to
ciclosporin was not apparent. It is unfortunate that real-time PCR could not be
utilised to investigate the expression of Shh mRNA in response to ciclosporin and
dexamethasone in the RECs as utilised previously during investigation of the ACHN
cell line. Indeed, neither real-time PCR nor standard RT-PCR detected Shh
expression in the REC samples. The reasons for this inability to evaluate mRNA
expression are not readily apparent. The RNA derived from the cells was of good
quality as determined using the RNA quality check gels described in Chapter 2.
Furthermore, P-actin could be readily detected in the samples suggesting that the
problem lay in the nature of the primers. Indeed, the murine thymus cDNA
previously utilised as a positive control21 failed to demonstrate Shh mRNA
expression on repeated evaluation using various primer sets. This remained true
irrespective of the method ofRNA extraction employed, the age of the primers
employed, the concentrations ofmagnesium and dNTPs used, the temperature of the
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reactions and the investigator performing the experiment. Thus, further evaluation of
the effect of ciclosporin and dexamethasone relies purely on results obtained using
immunohistochemical detection ofprotein expression. Using this technique and
accepting that it is a qualitative rather than a quantitative method of evaluating
protein expression, it is interesting that, in contrast to the apparently upregulated
expression of Shh protein seen in ACHN cells in response to ciclosporin, the same
effect was not observed in the RECs. Rather, neither ciclosporin nor dexamethasone
induced a change in the apparent intensity of staining. Thus, there is the possibility
that the ACHN cells and the RECs do not behave similarly in response to ciclosporin
treatment.
If indeed the RECs do not respond to ciclosporin in the same way as the ACHN cell
line, it is interesting to speculate why not. The primary murine renal epithelial cell
cultures described here were cultured under conditions reported to promote a
proximal tubular cell phenotype512'514'515. Nevertheless, cultures produced very
heterogeneous populations of cells, which were phenotypically either pancytokeratin
positive or vimentin positive i.e. broadly epithelial or fibroblastic in nature. What
cannot be verified is whether all the epithelial cells were proximal tubular cells.
Tubular epithelial cells are characterised as being keratin positive, smooth muscle
actin negative, desmin negative, and vimentin negative. However, differentiating
proximal from distal tubular cells can be difficult. Several phenotypic and functional
characteristics of proximal tubular cells have been described530 and used to
differentiate these cells from other renal epithelial cells. These include the cell
531 •surface markers alkaline phosphatase , dipeptidyl peptidase IV and gamma-
glutamyl transpeptidase, an apical brush border enzyme , and also functional
markers such as sodium-dependent glucose transport and cAMP production induced
by parathyroid hormone, but not vasopression and gluconeogenesis530.
In the experiments described in this chapter, extensive phenotyping has not been
performed to confirm that all epithelial cells are derived from the PCT. Indeed, it is
possible that, although the cells were cultured under conditions believed to promote
the growth of proximal tubular cells, the cultures may not be cultures of pure PCT
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cells. Nevertheless, given that Shh was expressed by the RECs albeit with less
intense staining than in the tissue sections, together with the pancytokeratin and
vimentin positive and negative expression respectively, suggests that at least the
majority were likely to be proximal tubular cells. Nevertheless, the RECs failed to
respond to ciclosporin in the same way as the ACHN cells. This may reflect a
disadvantage ofprimary cultures ofPCT cells, since both the loss of PCT markers
and acquisition of new markers has been described in these cells under culture
CIA
conditions . Alternatively, the ACHN cells might respond in a manner not typical
of the RECs.
In the context of Shh signalling, this latter issue may be important - Hh signalling
has been shown to be important in the initiation, growth and survival of
medulloblastomas, small cell lung cancer and pancreatic adenocarcinoma533'534. More
recently Shh expression has also been demonstrated in a large number of cell lines
many ofwhich are derived from tissues not known to be associated with active Shh
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signalling in vivo ' ' . Furthermore, that the ACHN cell line differs from normal
renal epithelium in terms of cytokine or receptor profdes and antigen expression has
been reported536"539. Thus, employing a cancer cell line for investigating Shh pathway
components is probably not the most ideal system to employ, particularly when
active cell signalling can contribute to cell growth66. Other cell lines which might
have been better to use include those derived from normal (Madin-Darby canine
kidney cells) or embryonic (HK293 cells), although use of the former is complicated
by the lack of canine reagents for investigation of the Shh pathway. HK293 cells
derived from human embryonic cortex or, indeed, pre-plated human renal cortical
cells or cryopreserved human renal proximal tubules which are now available
commercially (In Vitro Technologies, Baltimore, Maryland, USA) may have been
better alternatives.
Even if the effect of ciclosporin on Shh expression is limited to an effect on the
ACHN cell line, this result is interesting and appears to a specific response to
ciclosporin since it was not demonstrated when cells were treated with
dexamethasone. Ciclosporin is a cyclic decapeptide derived from the soil fungus
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Tolypocladium inflatum. In the peripheral T cell, ciclosporin blocks proliferation by
inhibiting the phosphatase activity of the calcium activated enzyme, calcineurin.
Inhibition of this phosphatase activity has a number of effects540. It prevents the
intracellular signalling which would normally occur in response to TCR stimulation
and result in T cell activation and proliferation540. Notably, dephosphorylation of the
nuclear factor of activated T cells (NFAT) is inhibited thereby preventing the
translocation ofNFAT to the nucleus, binding to its recognition sequence in the IL2
promotor and subsequent promotion of IL2 gene transcription540'541. Similarly,
ciclosporin also inhibits the transcription of a number of other genes, including c-
myc, cytokines such as IL-3, IL-4, IL-5 and IFNg and cytokine receptors such as the
IL2 receptor. Conversely, ciclosporin upregulates transcription of TGF-pi which
may contribute to both the immunosuppressive properties of ciclosporin and
fibrogenesis seen with long term ciclosporin use542.
Given these actions and the downstream pathways modulated by ciclosporin, it is not
readily apparent how ciclosporin impacts on Shh gene expression and what the
significance of this upregulation might be. That ciclosporin can act on targets other
than calcineurin and that this may be responsible for some of its side effects
including tumour formation and nephrotoxicity has been proposed previously543.
Another possibility is that ciclosporin is having a cytotoxic effect on the tubular cells
and, indeed, one of the significant side effects of ciclosporin is nephrotoxicity544.
Thus, the upregulated Shh expression may represent a response to a cytotoxic effect.
The data presented here, however, would not lend support to frank cytotoxicity at the
concentrations of ciclosporin employed. Ciclosporin is used here at concentrations
below those considered to be cytotoxic in other studies501"503,505. Indeed, the results
from the MTT assay would also lend support to the absence of frank cytotoxicity. It
is entirely possible, however, that ciclosporin is having a damaging effect that is not
readily detected by the MTT assay. The assay relies on the conversion of a colourless
substrate to a coloured compound, conversion being proportional to the number of
metabolically active cells present. Although there were no macroscopic differences
between the wells or frank changes detected using trypan blue exclusion, it may be
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that small differences in cell viability may not be detected by the assay. Whilst the
MTT assay gives a crude estimate of cell death, it does not give an indication of
injured cells which may be more relevant in this system. Other methodologies may
be more useful. For example, the lactate dehydrogenase assay (LDH) may be more
appropriate545. Alternatively, it may be possible to assess cell damage by evaluating
markers of function such as sodium-dependent glucose transport and cAMP
production induced by parathyroid hormone530.
It is interesting to speculate why ciclosporin might upregulate Shh expression and
what the consequences of this upregulation might be. As discussed earlier in Chapter
3, one of the possible roles for Shh is that it may be acting as a danger signal, an
endogenous factor released from damaged tissues in response to stress and capable of
activating the immune system327'477. Like the proposed danger signals, the heat shock
proteins, Shh is upregulated at sites of epithelial cell damage149 and has the ability to
activate cells of the peripheral immune system20'21. It is of particular interest then that
ciclosporin has been shown to upregulate the expression and phosphorylation of the
heat shock protein, HSP27, in the monkey renal proximal tubular cell line BSC-1543
and, furthermore, that ciclosporin is reported to potentiate the synthesis of heat shock
proteins induced by a heat shock546.
In this chapter, attempts were made to investigate whether the upregulation in Shh
mRNA expression seen in ACHN cells was accompanied by release of Shh from the
cells. This relied on the use of the murine Shh ELISA and Western blotting
techniques to see whether loss of tissue Shh expression occurred in response to
treatment and whether this was associated with the appearance of Shh protein in the
supernatant. Attempts to delineate this were largely unsuccessful. Shh expression did
not appear to vary greatly in the treated versus the untreated cells, and Shh was not
detected using these techniques in the supernatants. Thus, these results may provide
preliminary evidence to suggest that Shh is not released from the cells in response to
ciclosporin treatment. With the availability ofmore robust Shh reagents, this could
be further explored. For example, it is not entirely surprising that human Shh was not
detected by the murine Shh ELISA, given the low reported cross-reactivity of the
170
ELISA for human Shh. Furthermore, determining Shh release into the supernatant by
using the supernatants in Western blot experiments is not entirely satisfactory, not
least because 1 OOpg supernatant protein taken from the concentrated supernatant may
only contain a very small quantity of Shh protein. Instead, the procedure could be
further optimised using immunoprecipitation of the Shh from the supernatant prior to
blotting. This involves the removal of Shh from the supernatant using an anti-Shh
antibody. When mixed with Protein A/G resin, the antibody associates with the resin
so that, with boiling, the antibody-protein complex dissociates and the antibody can
be precipitated out with the resin, leaving the Shh protein in solution. This can then
be used in a subsequent Western blotting experiment to detect for Shh. Ideally, the
antibody used to probe for Shh in the blotting is a different antibody to that used
previously for the immunoprecipitation. Attempts were made to perform this
technique using combinations of the goat polyclonal antibody and the mouse
monoclonal antibody, 5E1. However, 5E1, although able to detect rShh used as a
positive control, failed to detect tissue-derived Shh. Similarly, attempts to use the
goat polyclonal antibody failed to detect Shh in the supernatant although
immunoprecipitation with rShh could be readily detected.
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4.7.2 Epithelial damage and Shh release
In the second part of this chapter, the effects of damaging agents on Shh release from
REC cultures in 2 models of cell injury have been explored. Hydrogen peroxide and
UVB have both been used previously to induce oxidative cell damage and apoptosis
respectively in cell culture systems517"523'525"527'547. The results from this work would
suggest that, in both forms of damage, however, Shh was not released from the cells.
This could reflect 2 possibilities. Firstly, it may be that Shh is not released from these
cells in response to damage. Indeed, it is tempting to speculate that such release
occurs since Shh expression is upregulated at sites of epithelial damage149 and
numerous peripheral targets for Shh have been identified65'1 2'149. However, the
results from this section ofwork would not support this occurrence. What is evident
however is that protein expression is upregulated at sites of damage149. It has yet to
be shown whether this results in the release of Shh. A further possible reason for the
apparent lack of Shh release is that it failed to be detected by the systems employed
for Shh detection as outlined earlier in this discussion. Indeed, the only method
currently commercially available for detection of Shh release is the murine Shh
ELISA used in this work. It is perhaps of interest that this ELISA has only been
validated against recombinant Shh and Shh derived from cell lines overexpressing
the cDNA vector. It has not been validated against tissue-derived Shh. It is entirely
possible that the tissue-derived Shh is of a form not recognised by the ELISA. Indeed
attempts to run through supernatants derived from centrifuged protein cell lysates of
normal murine kidney were not detected by the ELISA suggesting that either cell-
derived Shh is not detected by the ELISA; that the lysis solution interfered with the
detection of Shh by the ELISA or that the amount of Shh present in the kidney was
below the detection of the ELISA. Regarding this latter point, immunohistochemistry
has been used by a number of groups to detect Hh proteins in a wide variety of cell
systems. Although the same antibodies are often used in different studies, the results
can vary dramatically with regards to the proposed expression reflecting the
concentrations of antibodies used by different groups ofworkers. That Shh was
detected in Chapter 3 using an antibody solution diluted to no more than 1:40
suggests that the level of expression may be quite low. This dilution was chosen to
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be in keeping with previous studies from our group149 and those of other authors160.
However, in other studies of Shh expression, dilutions of antibody in the order of
1:250 have been used with good effect516. That renal epithelial Shh was only detected
at 1:40 and not lower concentrations of antibody suggests that only very low levels
of Shh protein may be expressed, perhaps too low to be detected by the ELISA.
Other possibilities also exist. For example, Shh may be released from tissue in a form
which precludes detection by the Shh ELISA. Alternatively, it may be released in
association with other known binding proteins such as the Shh receptor Ptc, Hip or
dispatched37. Indeed Shh binds to Ptc at a region significantly overlapping with the
binding region for the Shh antibody and, therefore, could readily mask Shh from
detection. Furthermore, factors affecting ligand stability may also modulate the
ability of soluble Shh to be detected by an ELISA. Indeed, recent reports by
Bornemann et al548 would suggest that the stability of Shh ligand may be
significantly altered by heparan sulphate proteoglycans (HSPGs), thus potentially
affecting the ability of the ELISA to detect Shh in the culture medium.
In light of the few systems available for detecting Shh release, it may be some time
before this situation can be further clarified. A bioassay consisting of Shh-responsive
cells has been developed by Beachy et al64 and used previously to investigate
activation of the Hh pathway. A clonal NIH3T3 cell line, Shh-LIGHT2, stably
incorporating Gli-dependent firefly luciferase and constitutive Renilla luciferase
reporters forms the basis of this assay, such that active Shh signalling induces
luciferase activity. Another alternative would be to use another cell-based bioassay
for Shh, the differentiation of C3H10T1/2 cells549 whose read-out is alkaline
phosphatase activity, as has been used elsewhere in the literature550. Use of such
assays for the further evaluation of cell culture supernatants would aid greatly in
determining whether Shh is released from epithelium in response to damage.
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4.7.3 Summary
This chapter has explored factors that might influence the expression of Shh by renal
epithelium. Two cell culture systems have been employed, the renal adenocarcinoma
cell line, ACHN, and primary cultures ofmurine renal epithelial cells. These systems
have been used to investigate the effect of the immunosuppressive agents,
ciclosporin and dexamethasone, on Shh expression. In addition, and in light of
previous reports in the literature of relevance to this work, the effects of damage on
Shh expression in renal epithelial cells has been investigated. The results suggest
that, in the ACHN cultures, Shh expression is upregulated in response to ciclosporin.
Conversely, little effect is observed in response to dexamethasone and, in primary
murine epithelial cells, Shh expression is not grossly modulated in response to either
ciclosporin or dexamethasone. Release of Shh from epithelium does not appear to
occur in response to either the immunosuppressive agents or, indeed, in response to 2
commonly used damaging modalities. However, the experiments outlined in this
chapter have been largely hampered by the notably few reagents available for Shh
detection and investigation of the Shh pathway. Thus, until further reagents for the
Shh pathway are available, determining the importance and relevance of the findings
presented here will remain difficult.
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Chapter 5




Recent evidence has suggested that Sonic hedgehog (Shh) signalling may play a role
in peripheral immunity20'21. Murine and human CD4+ T cells express Shh and its
receptor, Ptc, and activated CD4+ T cells may respond to Shh through enhanced
proliferation and modulation of cytokine production20'21. Much less, however, is
known regarding a possible role for Shh signalling in the macrophage. Ptc, Smo and
Glil-3 expression have been reported in primitive human pluripotent haematopoietic
stem cells using RT-PCR19 and the same group observed Ptc and Smo expression in
mature myeloid (CD33+) cells19. More recently, murine alveolar macrophages have
also been shown to express Ptc149.
The aim of these experiments was to determine whether adult human macrophages
express components of the Shh signalling pathway and, furthermore, whether they
are capable of responding to a Shh signal.
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5.2 Shh signalling in human macrophages
5.2.1 Shh signalling pathway components are expressed in human
macrophages
As described in Chapter 1, Shh signalling occurs through the interaction of Shh with
its receptor Ptc40,49'551. In the absence of Shh binding, Ptc blocks the intrinsic activity
of a further signal transduction protein, Smoothened (Smo). Shh binding relieves this
blockade allowing pathway activation to occur •47>552'553 and, subsequently, members
of the Gli family of zinc finger transcription factors are activated3'78'554.
In these initial experiments, the expression of Shh, Ptc, Smo and members of the Gli
family were evaluated.
Peripheral blood mononuclear cells (PBMCs) were prepared from normal human
donor Buffy coats by centrifugation over Histopaque 1077 (Sigma) as described
previously20'420'421 and outlined in Chapter 2. Monocytes were isolated from the
PBMCs by positive selection using CD14-labelled magnetic beads (Miltenyi
Biotech, Bisley, Surrey UK). Following this isolation, purities of >93% were
consistently obtained as determined by flow cytometry using a Phycoerythrin (PE) -
Cy5 mouse anti-human CD14 antibody (Serotec, Kidlington, Oxford, UK) (Figure
5.1a and c). The isolated monocytes were matured into macrophages by plastic
adherence for 6 days as described in Chapter 2. During this adherence step, the cells
were washed and the medium replaced every 2 days such that, by the end of this
time, the cells were consistently >96% CD14+ (Figure 5.1b and d). RNA was
extracted from the macrophages using Trizol extraction and RT-PCR performed to
determine the expression of the Shh signalling pathway components Shh, Ptc, Smo,
Gli 1 and Gli 2. As shown in Figure 5.2a, macrophages express the signalling
pathway components Ptc, Smo, Gli-1 and Gli-2. However, although specific
transcripts for Shh have been identified in CD4+ T cells20'21 and were present in the
PBMCs that served as a positive control, transcripts for Shh mRNA were not
identified in macrophages from any of the 5 donors studied.
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To determine protein expression, immunohistochemistry was performed using
macrophages plated onto glass coverslips as described in Chapter 2. Polyclonal
antibodies to Shh, Ptc, Smo and Gli 1 (Santa Cruz Biotechnology, Insight
Biotechnology Ltd, Wembley, UK) were used to evaluate the macrophage expression
of these proteins. It was not possible to determine the expression ofGli 2 in these
experiments, as antibodies to Gli 2 are not currently commercially available. To
check specificity, the same antibodies were pre-incubated with the appropriate
specific blocking peptides (Santa Cruz Biotechnology). The blocking peptides are
designed to bind to the epitope of the antibody responsible for binding to the protein
of interest and thus, when used in excess, should not allow binding of the antibody to
the specific protein to occur. In accordance with the manufacturer's instructions, the
antibodies were each pre-incubated with a five-fold excess (by weight) of blocking
peptide and then applied to the cells in experiments performed in parallel with
experiments in which primary antibodies were applied to the cells. Cells treated in
this way served as negative controls to the experiments.
As demonstrated in Figure 5.2b, Ptc was expressed predominantly on the
macrophage cell surface and this staining could be blocked using the specific Ptc-
blocking peptide. Conversely, although Shh, Smo and Gli 1 appeared to be expressed
in the macrophage, this staining could not be abrogated using the appropriate specific
blocking peptides suggesting that the positive staining may be non-specific in nature.
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Representative flow cytometry data demonstrating purities of macrophages used for
macrophage experiments.
Following centrifugation over Histopaque, monocytes were isolated from PBMCs by
magnetic bead separation using CD 14 positive selection beads. The monocytes were
adhered for a period of 6 days. Representative flow cytometry scatter plots for unstained
monocytes (Figure 5.1a) and Day 6 macrophages (Figure 5.1b) are shown. Purities of
monocytes (Figure 5.1c) and macrophages (Figure 5.Id) were confirmed using a PE-Cy5
mouse anti-human antibody (shaded histograms) and percentages represent the purity of
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The Shh signalling components Ptc, Smo, Gli 1 and Gli 2 are expressed in
human PBMC-derived macrophages.
5.2a RT-PCR was used to demonstrate the expression ofPtc (Lane 1, 200bps), Smo
(Lane 2, 140bps), Gli 1 (Lane 3, 244bps) and Gli 2 (Lane 4, 200bps). Shh was
expressed in the PBMCs that served as a positive control (Lane 5,211bps) but not in
macrophages (Lane 6).
5.2b Immunohistochemistry was used to demonstrate protein expression of Ptc (i),
Smo (ii), Gli 1 (iii) and Shh (iv) in human macrophages. Specificity of staining was
tested using the appropriate specific blocking peptides for Ptc (v), Smo (vi), Gli 1
(vii) and Shh (viii). Staining for Ptc, but not Smo, Glil and Shh, could be blocked
using the appropriate blocking peptide.
180
5.2.2 Ptc expression is upregulated in response to recombinant Shh (rShh)
Given that human macrophages express Ptc and other components of the Shh
signalling pathway, at least at the mRNA level, the aim of these experiments was to
determine whether active Shh signalling occurs in these cells. In addition to its role
as a receptor for the Shh signal, Ptc also acts as a transcriptional target of
Shh16'20'21'32'44'99'100'102. Thus, upregulation ofPtc expression is widely considered to
reflect active signalling through the Shh pathway. The aim of these experiments was
to determine whether Ptc upregulation occurs in macrophages in response to Shh
stimulation.
For these and subsequent experiments, a recombinant mouse Sonic hedgehog peptide
(rShh) (R&D Systems, Abingdon, UK) was used to stimulate the macrophages. This
was the only peptide commercially available at the start ofmy PhD. It differs from
human Shh in only one amino acid and has been used elsewhere for human
studies20'65'510. Midway through my PhD, a recombinant human peptide (Peprotech
EC Ltd, London, UK) became available. This was shown to induce the same effector
function changes in the macrophages as those which will be discussed in this chapter.
However, to maintain consistency, the recombinant murine form of the peptide was
used for all experiments described herein.
PBMC-derived macrophages were stimulated with rShh in the dose range 250ng/ml
- 2000ng/ml, as described in Chapter 2. This dose range has been shown previously
20 21
to modulate the effector of human and murine CD4+ T cells ' . In keeping with
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previous in vitro studies , following a 24 hour incubation with rShh, RNA was
extracted from untreated (control) cells and rShh-treated cells. Ptc expression was
evaluated using real-time PCR using 18S as an internal control. Each sample was run
on a real-time plate in duplicate and the experiment was performed using RNA from
5 different donors.
As demonstrated in Figure 5.3, Ptc expression was upregulated in a dose-dependent
manner in response to rShh in the 5 donors studied.
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FIGURE 5.3
Ptc expression is upregulated in macrophages in response to rShh
Real-time PCR was performed to determine the expression ofPtc mRNA in
macrophages in response to rShh. Values are expressed as a ratio of the
concentration ofPtc mRNA relative to untreated macrophages grown in medium
alone. The untreated (Ong/ml rShh) macrophages are given a value of 1. Results
represent experiments performed on 5 individual donors and means and standard
deviations are shown.
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Collectively, these results show that macrophages express components of the Shh
signalling pathway and that, in response to rShh, Ptc mRNA expression is
upregulated. Taken together, these results suggest that active signalling occurs
through the Shh signalling pathway in response to rShh.
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5.3 rShh modulates the effector function of
macrophages
Although there have been previous reports describing the expression of Shh
signalling pathway components in cells ofmyeloid lineage1 '149, there have been no
reports in the literature describing possible roles for activation of the signalling
pathway in these cells. Therefore, the aim of this series of experiments was to
determine whether activation of the Shh signalling pathway was capable of inducing
a change in the effector function ofmacrophages.
5.3.1 rShh differentially modulates the Vascular Endothelial Growth Factor
and Transforming Growth Factor-p expression by macrophages
Although the role of Shh signalling in the macrophage has not been investigated to
date, there has been evidence suggesting a link between the Shh signalling pathway
and two recognised macrophage products, Vascular Endothelial Growth Factor
(VEGF) and Transforming Growth Factor Beta (TGF-P).
As discussed in Chapter 1, VEGF is a potent endothelial cell mitogen, angiogenic
factor, vasodilator and enhancer ofmicrovascular permeability442'555"557. That Shh
may be involved in VEGF signalling and angiogenesis is suggested by several recent
reports in the literature65'102'103'163. In 2001, Pola et al demonstrated VEGF
upregulation in myofibroblasts in response to Shh signalling and, in vivo, Shh
signalling was shown to induce neovascularisation in hindlimbs damaged by
ischaemia102. More recently, studies in the zebrafish embryo have supported these
findings163 with the injection of Shh mRNA inducing VEGFmRNA expression in
this model. Furthermore, Kanda et al65 demonstrated capillary morphogenesis in
cultured endothelial cells in response to rShh.
The TGF-P superfamily consists of a large number of growth factors all sharing
conserved cysteine residues in their C-terminal region118. Several members of the
TGF-P superfamily are involved with and regulated by the Hh signalling pathway.
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For example, the bone morphogenetic proteins (BMPs)4'119'427 and, in Drosophila, the
morphogen Decapentaplegic (Dpp) are both members of the TGF-p superfamily and
downstream targets ofHh signalling110. Furthermore the segment polarity gene
Wingless fwg)437 is a downstream target ofHh signalling437'438 and interactions
between this pathway and TGF-P signalling have been described117'120.
The aim of these initial experiments was to determine whether Shh signalling
modulates the production of TGF-P and VEGF from macrophages.
Adherence-matured macrophages were stimulated with rShh (500-2000ng/ml) over
the time course 3-72 hours and the supematants harvested for VEGF and TGF-P 1
analysis using ELISAs as described in Chapter 2. The TGF-P 1 Duoset ELISA (R&D
Systems) allows for the quantification of both active and latent TGF-P 1. In
accordance with the manufacturer's instructions, to detect latent TGF-P 1, each
sample was acidified using IN hydrochloric acid and then neutralised using 2.7N
Sodium hydroxide/0.5M HEPES. These treated samples were then run in parallel
with the untreated samples on a 96 well ELISA plate, thus allowing latent and
activated TGF-P 1 to be assayed for each sample. To circumvent the well-recognised
concern that serum can contain significant amounts of latent TGF-p l558'559,
macrophages were cultured for 6 days either in the presence (Iscoves Modified
Dulbeccos medium supplemented with 5% fetal calf serum; IMDM-FCS, Gibco) or
absence of serum (X-Vivo 10 serum-free medium, Cambrex Bioscience,
Wokingham, Berkshire, UK) prior to stimulation with rShh.
The results illustrated in Figures 5.4 and 5.5 reflect the response ofmacrophages
derived from 5 individual donors to rShh. As shown in Figure 5.4, the addition of
rShh induced a slight upregulation in the production of VEGF protein in
macrophages cultured in IMDM-FCS which was, at the highest concentration of
rShh used, at levels just above the level of sensitivity of the ELISA (15pg/ml). RNA
extracted from these macrophages revealed a dose-dependent upregulation of VEGF
mRNA expression. Conversely, in macrophages cultured in serum-free conditions,
significant modulation by rShh ofVEGF protein or mRNA was not observed in any
185
of the 5 donors studied (Figures 5.4c and d) irrespective of the time point studied
(data for 24 hours illustrated in Figure 5.4).
Figure 5.5 illustrates the effect of rShh on the TGF-pi production by macrophages at
24 hours. As shown, neither latent nor active TGF-(3 was modulated by rShh in any
of the donors studied and this was observed irrespective ofwhether serum-containing
or serum-free medium was used and irrespective of the time point studied (data for
24 hours illustrated in Figure 5.5).
Thus, the findings from this series of experiments would broadly support the
previous observations by Pola et al102 suggesting that rShh upregulates VEGF
expression. However, in the present series of experiments, the upregulation ofVEGF
appeared to be dependent on the presence of serum in the culture conditions and an
upregulation in VEGF expression was not observed under serum-free conditions.
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FIGURE 5.4
rShh differentially modulates macrophage VEGF expression
Macrophages were stimulated with rShh (500ng/ml-2000ng/ml) and supernatants and RNA
harvested to determine VEGF protein and mRNA expression using ELISA and real-time PCR
respectively. Results from 24 hour cultures with rShh are shown. Macrophages cultured in
IMDM-FCS responded to rShh by upregulating VEGF mRNA (a) and protein (b) expression in a
dose-dependent manner. Conversely, macrophages incubated in serum-free medium failed to
demonstrate upregulated VEGF mRNA (c) or protein (d) expression. Results represent
experiments performed on 5 individual donors and means and standard deviations are shown.
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rShh fails to modulate TGF-P production by macrophages
PBMC-derived macrophages were stimulated with rShh (500ng/ml-
2000ng/ml) and supernatants harvested to determine TGF-P 1
production using ELISA. Results from supernatants harvested after a
24 hour incubation with rShh are shown. Irrespective of whether FCS-
containing medium (a) or X-Vivo 10 serum-free medium (b) was used
to culture the macrophages, rShh failed to modulate either the active or
latent TGF-P 1 production. Results represent experiments performed on
5 individual donors and means and standard deviations are shown. The
limit of detection for the TGF-P ELISA is 15pg/ml.
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5.3.2 rShh differentially modulates the cytokine and chemokine expression by
macrophages
Given the upregulation ofVEGF by rShh, this prompted the question as to whether
rShh may also modulate the expression of other inflammatory cytokine and
chemokines by macrophages. Recent evidence suggests that active Shh signalling
may be important at sites of inflammation. Upregulated Shh expression has been
reported at sites of epithelial inflammation in the lung, both in human cryptogenic
fibrosing alveolitis and murine models of fibrotic lung disease149 and, in these same
sites, Ptc is expressed on the infiltrating mononuclear cells and alveolar
macrophages149. Furthermore, Shh has been reported to enhance the proliferation of
20 21 • • • •CD4+ T cells ' , an effect accompanied by a modulation in the cytokines produced
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by these cells . Notably, IF-2 and IFN-y appear to be at least partly dependent on the
Shh pathway as evidenced by some inhibition of this release when Shh signalling is
blocked. Together, these results would suggest that Shh signalling may be important
at sites of inflammation and the following experiments were performed to determine
whether Shh plays a role in modulating the cytokine and chemokine effector function
ofmacrophages.
Macrophages were prepared under serum-containing and serum-free conditions as in
Section 5.3.1 and stimulated with rShh (500-2000ng/ml) for 1-72 hours. Supernatants
were harvested for cytokine and chemokine analysis using the Inflammatory and
Chemokine Cytometric Bead Arrays (CBAs) (BD Biosciences, Cowley, Oxford,
UK) as outlined in Chapter 2. Using the Inflammatory and Chemokine CBAs the
following cytokines and chemokines can be detected: Interleukins -1 beta (IF-1(3), -
12p70, -6 and -8, Tumour necrosis factor alpha (TNFa), Monocyte chemoattractant
protein - 1 (MCP-1), Interferon gamma-inducible protein (IP-10), Monokine induced
by interferon gamma (MIG) and Regulated on activation, normal T cell expressed
and secreted (RANTES).
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Figures 5.6 and 5.7 demonstrate the effect of rShh on cytokine and chemokine
release at 24 hours in the presence of serum. For the purposes of statistical analysis,
treated macrophages were compared to untreated controls using a two-tailed t-test for
paired samples. A p value of <0.05 was considered significant (* p<0.05, ** p<0.01,
*** p<0.001).
rShh upregulated the production of IL-6, IL-8, IP-10, MCP-1, MIG and RANTES in
a dose-dependent manner when macrophages were cultured in the presence of serum,
this reaching significance at all concentrations of rShh used (Figure 5.6 (a-f)).
Conversely, under the same conditions, rShh failed to modulate the production of IL-
1 (3, IL-12p70 (Figure 5.7 a and b). TNFa and IL-10 were upregulated in only some
donors (8 of 20, and 7 of 20 respectively) but following statistical analysis, this
upregulation was not statistically significant (Figure 5.7 c and d).
When macrophages were cultured in the absence of serum (Figure 5.8), rShh also
induced an upregulation in IL-6, IL-8, MCP-1, IP-10, MIG and RANTES, albeit that
the magnitude of the response was less marked. IL-lp, IL-12p70, TNFa and IL-10
failed to be upregulated by rShh under serum-free conditions (Figure 5.9) in keeping
with the results obtained when cells were cultured in the presence of serum.
Furthermore, rShh failed to modulate these cytokines irrespective of the time point
studied (1-72 hours, data not shown). This is important given that temporal
differences in expression profiles in response to different stimuli have been
reported420'560'561. For example, peaks in TNFa production classically appear early (4-
8 hours) and cyclical peaks in protein expression have also been reported562'563.
Thus, the results from this section suggest that rShh differentiallymodulates the
cytokine and chemokine production from human macrophages. Where rShh
upregulates the production of cytokines and chemokines, this effect is markedly
enhanced in the presence of serum.
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FIGURE 5.6
rShh upregulates the production of IL-6, IL-8, MCP-1, IP-10, MIG and RANTES by
macrophages cultured in the presence of serum.
Macrophages were cultured in the presence of rShh (500-2000ng/ml) for 1-72 hours.
Supernatants were harvested and analysed by CBA. Graphs represent cytokine production from
20 donors and chemokine production from 10 donors and results from the 24 hour time point are
illustrated. rShh upregulated the production of IL-6 (a), IL-8 (b), MCP-1 (c), IP-10 (d), MIG (e)
and RANTES (f). For the purposes of statistical analysis, treated macrophages were compared
to untreated controls using a two-tailed paired t-test. A p value of <0.05 was considered
significant (* p<0.05, ** p<0.01, *** p<0.001). The means and individual data points are
shown.
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FIGURE 5.7
rShh fails to modulate the production of IL-ip, IL-12p70, TNFa or IL-10 by macrophages
cultured in the presence of serum
Macrophages were cultured in the presence of rShh (500-2000ng/ml) for 1-72 hours.
Supernatants were harvested and analysed by CBA. Graphs represent cytokine production from
20 donors and results from the 24 hour time point are illustrated. rShh failed to modulate IL-1(3
(a), IL-12p70 (b), TNFa(c) and IL-10 (d) production by macrophages. For the purposes of
statistical analysis, treated macrophages were compared to untreated controls using a two-tailed
paired t-test. The means and individual data points are shown.
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FIGURE 5.8
rShh upregulates the production of IL-6, IL-8, MCP-1, IP-10, MIG and RANTES by
macrophages cultured in the absence of serum.
Macrophages were cultured in the presence of rShh (500-2000ng/ml) for 1-72 hours.
Supernatants were harvested and analysed by CBA. Graphs represent cytokine and chemokine
production from 6 donors and results from the 24 hour time point are illustrated. rShh
upregulated the production of IL-6 (a), IL-8 (b), MCP-1 (c), IP-10 (d), MIG (e) and RANTES
(f). For the purposes of statistical analysis, treated macrophages were compared to untreated
controls using a two-tailed paired t-test. A p value of <0.05 was considered significant (*
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FIGURE 5.9
rShh fails to modulate the production of IL-ip, IL-12p70, TNFa or IL-10 by macrophages
cultured in the absence of serum.
Macrophages were cultured in the presence of rShh (500-2000ng/ml) for 1-72 hours.
Supernatants were harvested and analysed by CBA. Graphs represent cytokine production from
6 donors and results from the 24 hour time point are illustrated. rShh failed to modulate IL-1 (3
(a), IL-12p70 (b), TNFa(c) and IL-10 (d) production by macrophages. For the purposes of
statistical analysis, treated macrophages were compared to untreated controls using a two-tailed
paired t-test. The means and individual data points are shown.
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5.4 Inhibiting Shh signalling using cyclopamine
differentially abrogates the macrophage
response to rShh
From the experiments above, it would appear that macrophages express the receptor
for Shh ligand, Ptc; that Ptc mRNA is upregulated in response to stimulation with
Shh ligand and that the effector function ofmacrophages may be differentially
modulated by Shh.
The purpose of this series of experiments was to determine whether the effect of Shh
on macrophages could be abrogated by specifically inhibiting active Shh signalling.
As described in Chapter 1, in the absence of Hh binding, Ptc exerts a repressive
effect on the key transducer of the Shh signal, Smoothened (Smo)46'47'101'553 and this
repression is lifted with ligand binding.
Although Ptc is not required for signal transduction, Smo activation is required for
signalling64. Thus, to specifically inhibit the Shh pathway, the Veratrum alkaloid and
teratogen, cyclopamine, was used. This has been shown to specifically inhibit the
cellular response to Shh17'64'69 through an interaction with activated Smo60'62'64'70 and
inhibits Shh signalling across a wide concentration range (20nM - 20p.M)17'64'65,68.
In an initial set of experiments, macrophages were pre-incubated in the presence of
5-20pM cyclopamine for 45 minutes. This concentration range was in keeping with
that previously reported for in vitro experimentation in the literature64,65' . rShh was
then added to the culture medium giving a final rShh concentration range of 500-
2000ng/ml. The cells were incubated under these conditions for 24 hours and the
supernatants then harvested for cytokine and chemokine analysis by CBA. In the first
3 donors examined, cyclopamine inhibited 2000ng/ml rShh-induced IL-6 production
at all three concentrations of cyclopamine used (5, 10 and 20pM) and thus, for all
subsequent experiments, 1 OpM cyclopamine was used. At all concentrations of
cyclopamine used and, in keeping with previous studies, there was no apparent
195
evidence of cell toxicity as determined using the MTT assay and trypan blue
exclusion.
As shown in Figure 5.10, cyclopamine inhibited the rShh-mediated upregulation of
IL-6 and MCP-1 in macrophages grown in the presence of serum. The IL-6 induced
by lOOOng/ml and 2000ng/ml rShh was significantly inhibited by lOpM cyclopamine
(p=0.013 and p=0.027 respectively). Similarly, the MCP-1 induced by lOOOng/ml
and 2000ng/ml rShh was also inhibited (p=0.047 and p=0.006 for lOOOng/ml and
2000ng/ml rShh respectively). Neither IL-6 nor MCP-1 were inhibited significantly
when 500ng/ml rShh was used (p= 0.64 and p=0.87 respectively). IL-8 was inhibited
in some donors (4 of 8). Conversely, the rShh-mediated upregulation ofRANTES,
MIG and IP-10 was not modulated by cyclopamine in any of the 8 donors studied
(Figure 5.11).
When the experiments were repeated in serum-free conditions, the effect of
cyclopamine on IL-6 and MCP-1 production was much less marked, only reaching
statistical significance at the highest concentration of rShh used (Figure 5.12). IL-8
was inhibited in 4 of 10 donors and, as in the presence of serum, RANTES, MIG and
IP-10 were not modulated by cyclopamine (Figure 5.13).
Thus, the results from this series of experiments reveal that the specific inhibitor of
the Shh signalling pathway, cyclopamine, differentially modulates the rShh-induced
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Cyclopamine inhibits the rShh-mediated upregulation of IL-6 and
MCP-1 in macrophages cultured in the presence of serum
Macrophages were pre-incubated with 10pM cyclopamine for 45
minutes. rShh was added to the medium to give a final concentration
500-2000ng/ml. As previously, supernatants were harvested for
cytokine and chemokine analysis by CBA. Represented are the results
from 10 individual donors. The rShh-mediated upregulation of IL-6
(Figure 5.10a) and MCP-1 (Figure 5.10b) was inhibited by
cyclopamine at the higher concentrations of rShh used. For the
purposes of statistical analysis, cyclopamine treated macrophages were
compared to rShh-alone controls using a two-tailed paired t-test. A p
value of <0.05 was considered significant (* p<0.05, ** p<0.01, ***
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FIGURE 5.11
Cyclopamine fails to modulate the rShh-mediated upregulation of
RANTES, MIG and IP-10 in macrophages cultured in the presence of
serum
Cyclopamine failed to modulate the rShh-mediated upregulation of RANTES
(Figure 5.11a), MIG (Figure 5.11b) and IP-10 (Figure 5.11c) by
macrophages. Graphs show data from 8 individual experiment. Means and
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FIGURE 5.12
Cyclopamine inhibits the rShh-mediated upregulation of IL-6 and
MCP-1 in macrophages cultured in the absence of serum
Macrophages were pre-incubated with lOpM cyclopamine for 45
minutes. rShh was added to the medium to give a final concentration
500-2000ng/ml. As previously, supernatants were harvested for
cytokine and chemokine analysis by CBA. Represented are the results
from 10 individual donors. The rShh-mediated upregulation of IL-6
(Figure 5.12a) and MCP-1 (Figure 5.12b) was inhibited by
cyclopamine at the higher concentrations of rShh used. For the
purposes of Statistical analysis, cyclopamine treated macrophages were
compared to rShh-alone controls using a two-tailed paired t-test. The
paired data points are shown. A p value of <0.05 was considered









































































Cyclopamine fails to modulate the rShh-mediated upregulation of
RANTES, MIG and IP-10 in macrophages cultured in the absence of
serum
Represented are the results from 8 individual donors. Cyclopamine failed to
modulate the rShh-mediated upregulation of RANTES (Figure 5.13a), MIG
(Figure 5.13b) and IP-10 (Figure 5.13c) by macrophages.
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5.5 Inhibition of CD14 modulates the macrophage
response to rShh
Given recent data suggesting that Shh may be upregulated in epithelium at sites of
inflammation149 and that it may contribute to the development of a proinflammatory
cytokine milieu at sites ofproliferating T cells20, it was tempting to speculate that
Shh may be acting as a type of danger signal in keeping with the theory Polly
Matzinger put forward in the 1990s477'564. This proposed that the immune system
responds to endogenous signals originating from stressed or injured cells. Necrotic,
but not apoptotic cells, have been shown to activate dendritic cells turning them into
powerful APCs565. Endogenous signals implicated as possible danger signals have
included the heat shock proteins (HSPs)476'566'567, including HSP60 and 70, which
have been reported to activate macrophages and dendritic cells, enhancing cytokine
and chemokine production and upregulating costimulatory molecules ' " .
291 300 572' ' That Shh may be upregulated in damaged epithelium and that Shh induces
the production ofproinflammatory cytokines and chemokines made its possible
action as a danger signal an attractive possibility. Recently, a body of evidence has
emerged to suggest that the HSPs, HSP 60 and 70 exert their stimulatory effects on
macrophages through their action on Toll-like receptor 4 (TLR 4) activation. TLRs
are responsible for the recognition of pathogen associated molecular patterns
(PAMPs)300'305'572'573 and, of the 10 TLRs so far described, TLR4 has attracted the
most attention. Not only is it the key transducer of the potent bacterial
lipopolysaccharide (LPS) signal, but also, it has been proposed to be important in the
signal transduction of a wide array of seemingly structurally and functionally
unrelated agonists. These include the HSPs 60319,320'570'574 and 70322"324-575 noted
above, and a wide range of other structurally and functionally unrelated endogenous
agonists576"581. Signalling through TLR4 induces the activation of the NFkB pathway,
the MAP kinases and phosphatidylinositol-3'-kinase (PI-3-K), subsequently resulting
in proinflammatory gene transcription and cell-type specific activation
phenotypes291'300, enhancing antigen presenting activity and providing a key role in
linking innate and acquired immune responses .
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If indeed Shh is acting as a danger signal, how does it act? In Drosophila, there is
some evidence that the Toll and Hh signalling pathways may interact. Chen et al582
demonstrated the expression of a Drosophila homologue of CREB-binding protein
and posited that it may act as a positive activator of both Toll and Hh pathways.
Thus, it is conceivable that the interaction of Shh with Ptc could stimulate similar
cellular responses to those seen with Toll pathway activation. A further possibility is
that Shh may be mediating its effect on macrophage cytokine and chemokine effector
function through TLR4 itself in a similar manner to that proposed for the HSPs.
Signalling through TLR4 requires a number of accessory molecules. MD-2 is a small
coi
molecule, coexpressed with TLR4 and appears to be essential for signalling . Other
important players include LPS-binding protein (LBP), a plasma protein that delivers
584 • • 585
agonists to the TLR4 signalling complex and CD 14, a myeloid marker antigen
which can also be found in a soluble form in plasma (sCD14). LBP and CD 14 are
both components of serum and thus represent candidates which may be responsible
for the enhanced macrophage response seen in the presence of serum in the
experiments presented in this chapter. CD 14 was chosen for initial investigation
since reports by other investigators suggested that other proposed endogenous
activators of TLR4, HSP60 and 70 can use CD 14 to induce the generation of
C-7A CO/"
proinflammatory cytokines ' ' . Thus, the aim of these experiments was to
determine whether CD 14 was important for the Shh-mediated upregulation of
macrophage cytokines and chemokines.
Macrophages were pre-incubated for 45 minutes with the purified CD 14 functional
blocking antibody 61D3 (eBioscience, San Diego, USA) or its isotype control
(functional grade purified mouse IgGl isotype (eBioscience)). The antibody was
used in the concentration range l-100ug/ml as described previously587"589 and the
isotype control was used at 100pg/ml. rShh was subsequently added to the medium
to give a final concentration of lOOOng/ml and the supernatants harvested at 24
hours. As previously, the experiments were performed both in the presence and
absence of serum.
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As shown in Figure 5.14 and 5.15, the antibody successfully and consistently
abrogated all cytokine and chemokine responses induced by rShh, both in the
presence (Figure 5.14) and absence (Figure 5.15) of serum in all 5 donors studied,
suggesting that the effect mediated by Shh appears to be dependent largely on CD 14.
The effect was maximal at the highest concentration of antibody used. Gross cell
morphology was not altered by the antibody and, furthermore, the antibody did not
appear to be toxic to the cells as determined using the MTT assay (Figure 5.16).
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FIGURE 5.14a
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CD14 blockade inhibits the rShh-mediated upregulation of IL-6, IL-8, MCP-1, IP-10, MIG
and RANTES by macrophages cultured in the presence of serum
Macrophages were preincubated in the presence of a functional anti-CD 14 blocking antibody
(aCD14) in the concentration range 1 -100pg/ml or an isotype control at lOOpg/ml. rShh was
subsequently added to the medium to give a final concentration of lOOOng/ml. The left hand
column of each graph represents macrophages incubated with 1 OOOng/ml rShh in the absence of
blocking antibody or isotype. Supernatants were harvested at 24 hours and analysed by CBA as
previously. CD14 blockade abrogated the production of IL-6 (Figure 5.14a), IL-8 (Figure
5.14b), MCP-1 (Figure 5.14c), IP-10 (Figure 5.14d), MIG (Figure 5.14e) and RANTES (Figure
5.141) by macrophages in a dose-dependent manner. Represented are pooled results from 5
individual donors. Means and standard deviations are shown.
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FIGURE 5.15
CD14 blockade inhibits the rShh-mediated upregulation of IL-6, IL-8, MCP-1, IP-10, MIG
and RANTES by macrophages cultured in the absence of serum
Macrophages were preincubated in the presence of a functional anti-CD 14 blocking antibody
(aCD14) in the concentration range l-100pg/ml or an isotype control at 100pg/ml. rShh was
subsequently added to the medium to give a final concetration of lOOOng/ml. The left hand
column of each graph represents macrophages incubated with lOOOng/ml rShh in the absence of
blocking antibody or isotype. Supernatants were harvested at 24 hours and analysed by CBA as
previously. CD14 blockade abrogated the production of IL-6 (Figure 5.14a), IL-8 (Figure
5.14b), MCP-1 (Figure 5.14c), IP-10 (Figure 5.14d), MIG (Figure 5.14e) and RANTES (Figure
5.14f) by macrophages in a dose-dependent manner. Represented are pooled results from 5



















Evaluation of the functional CD14 blocking antibody, 61D3, on
macrophages adhered on plastic for 6 days.
Macrophages were pre-incubated with the CD14 functional blocking
antibody, 61D3, prior to the addition of rShh (to give a final
concentration of rShh of 1000ng/ml).The antibody was used in the
concentration range l-100pg/ml in keeping with previous studies. The
cells were incubated for 24 hours in the presence or absence of the
61D3. Viability at the end of 24 hours was evaluated using the MTT
assay. Results are presented as the ratio of 61D3-treated to untreated
cells (macrophages incubated in 1 OOOng/ml rShh alone) as a percentage
where untreated cells are given a value of 100%. Experiments were
performed in triplicate and means and standard deviations are shown.
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5.6 Endotoxin Considerations
The results from the experiments outlined above suggest that rShh activates
macrophages, that this effect is enhanced by serum, differentially modulated by the
Shh pathway inhibitor cyclopamine and that CD 14 is important in mediating the
macrophage effects seen. Given the dependence ofTLR signalling on CD14,
together these results would implicate the TLRs, either TLR4 and/or TLR2 both of
which are dependent to some extent on cdi4307'59°-5935 in the mechanism of rShh-
induced macrophage activation.
Lipopolysaccharide (LPS), a major component of the outer membrane of Gram
negative bacteria, is the most potent TLR4 agonist known and is capable of inducing
a wide array of cytokines and chemokines at concentrations as low as
10pg/ml342'594'595. Given that the recombinant Shh protein used for these experiments
was produced in an Escherichia coli recombination system, it was important to detect
and quantify any endotoxic contaminants present which could contribute to the
activity of the rShh. Inherently, recombinant proteins potentially contain low levels
of a number of bacterial products. These can include LPS itself, but also bacterial
DNA, and outer wall proteins such as porins and lipid A-associated proteins, fimbrial
proteins, protein A and lipoproteins (reviewed by Henderson et al596) all of which are
capable of inducing cellular activation, via a range of TLRs, including TLR4, TLR2
and TLR9597"600. The rShh ligand used during the present series of experiments was
reported by the manufacturer to contain no more than lEU/pg endotoxin.
The aim of the following experiments was to quantify the endotoxin activity present
in the rShh used and, further, to determine the significance of any endotoxic activity
present in light of the findings to date.
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5.6.1 Endotoxin quantification
The Limulus Amebocyte Lysate (LAL) assay is the gold standard for LPS detection
and quantification. The assay uses a property of amebocyte extracts prepared from
the horseshoe crab Limulus polyphemus which, when in contact with LPS, induce a
series of enzymatic reactions, resulting in gelation of the lysate601. The early assays
relied on the development of a visible clot. Further advances in LAL technology
have resulted in the development of systems adapted for instrumental use, including
turbidometric and chromogenic methods, which can be either endpoint (fixed
incubation time) or kinetic assays (rate of increase of turbidity/colour)602.
Two approaches were used to determine the endotoxic activity of reagents used in
this chapter.
5.6.1.1 LAL chromogenic endpoint assay
To initially evaluate the LPS content of reagents used in these experiments, all
reagents were tested using a LAL endpoint chromogenic assay (Associates of Cape
Cod, Falmouth, Massachusetts, USA). This chromogenic assay uses a modified LAL
reagent (Pyrochrome) incorporating an aqueous extract of the amebocytes ofLimulus
polyphemus and a chromogenic substrate423, cleavage ofwhich releases the yellow
substance p-nitroaniline which absorbs at 405nm. The amount of p-nitroaniline
released is assayed after a fixed incubation time. The results obtained from the
samples are plotted against a standard curve consisting ofmeasured optical density
plotted against known standard endotoxin concentrations.
The following samples were tested using the assay; 2000ng/ml rShh reconstituted in
LAL reagent water (LRW), 5% fetal calf serum reconstituted in LRW, IMDM
medium without FCS and X-vivo 10. None of the samples had been stored or frozen
and all were prepared using the same stock reagents.
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Using this method, 2000ng/ml rShh reconstituted in LAL reagent water was shown
to contain approximately lEU/ml endotoxic activity although, as shown in Figure
5.17, there was marked variation in the values obtained (range 0.75 - 1.50EU/ml).
As shown, quantification of the 5% FCS, IMDM and X-vivo 10 also yielded variable
results with 1.18EU/ml (range 0.80 - 1.45EU/ml), 0.42EU/ml (range 0.21-
0.60EU/ml) and 0.17EU/ml (range 0.05-0.28EU/ml) endotoxic activity respectively.
For all test samples, although there was good reproducibility between the triplicates
of each sample run on an ELISA plate, significant variability was demonstrated
between freshly prepared samples of each and, furthermore, marked inter-plate




rShh contains endotoxic activity
Samples of 2000ng/ml rShh reconstituted in LAL reagent water (LRW), 5% FCS
reconstituted in LRW, IMDM and X-vivo 10 were tested for endotoxic activity
using a LAL endpoint chromogenic assay and plotted against a standard curve.
The results represent pooled data from 10 individual tests. Means and standard
deviations are shown.
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5.6.1.2 LAL kinetic assay
The LAL assay used in section 5.7.1.1 was a chromogenie endpoint assay. Although
easy to use, such assays are reported to lack sensitivity603"605 and, furthermore,
inaccurate results can be achieved when either coloured samples (such as medium
containing phenol red), samples containing serum (such as 5% FCS) or those with
increased turbidity, are used604,605. It is possibly for these reasons that such a wide
variation was seen in the results obtained using the endpoint assay.
To partly circumvent the possible pitfalls of using the endpoint assay, samples were
also sent to an external endotoxin testing service (Cambrex). The service tests the
samples, undiluted and at dilutions of 1:10, 1:100 and 1:100 and uses either of the
sensitive chromogenic or turbidometric kinetic assays to quantify the endotoxin
contained within the samples.
Using this service, 2000ng/ml rShh reconstituted in LRW was found to contain an
average of lEU/ml endotoxic activity (range 0.9-1 .lEU/ml) consistent with the
average results from the in-house assay. 5% FCS contained 1.15EU/ml endotoxic
activity (range 0.75-1.32EU/ml) and IMDM and X-vivo 10 both contained less than
0.05EU/ml endotoxic activity (range 0.01-0.07EU/ml).
5.6.2 The administration of LPS with equivalent endotoxic activity does not
induce the same magnitude of response as rShh
Given that 2000ng/ml rShh reconstituted in LRW contains lEU/ml endotoxic
activity, the following experiments were set up to determine whether E coli LPS of
equivalent endotoxic activity induced the same changes in macrophage effector
function as those seen in response to rShh.
E coli 055. B5 LPS (Sigma) was reconstituted in LAL reagent water to give a
standard range of LPS concentrations 15.6-1000pg/ml. Aliquots of these standards
were sent to Cambrex for endotoxin testing as previously. Using this LPS
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preparation, 125pg/ml LPS in LAL reagent water returned the same level of
endotoxic activity (lEU/ml) as 2000ng/ml rShh reconstituted in LAL reagent water.
Thus, in parallel experiments, rShh and LPS were reconstituted in either IMDM-FCS
or X-Vivo 10 to give equivalent levels of endotoxic activity. Macrophages were then
prepared from PBMCs as for all previous experiments. On day 6, the macrophages
were stimulated with either 2000ng/ml rShh or 125pg/ml LPS.The experiments were
performed in 5 donors using the same stock titrations of LPS and the same stock
preparation of rShh. The results of these experiments are illustrated in Figure 5.18
and Figure 5.19 and, together, suggested that rShh induced an upregulation in
cytokines which exceeded that induced by LPS of equivalent endotoxic activity.
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FIGURE 5.18
rShh induces a greater upregulation in cytokines and chemokines compared to LPS of
equivalent endotoxic activity in the presence of serum
Macrophages were cultured either in 2000ng/ml rShh or E coli LPS of equivalent endotoxic
activity. Pooled results from 5 donors for each cytokine or chemokine are shown. rShh induced
an upregulation in IL-6 (Figure 5.18a), IL-8 (Figure 5.18b), MCP-1 (Figure 5.18c), IP-10
(Figure 5.18d), MIG (Figure 5.18e) and RANTES (Figure 5.18f) exceeding that induced by LPS
of equivalent activity.
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rShh induces a greater upregulation in cytokines and chemokines compared to LPS of
equivalent endotoxic activity in the absence of serum
Macrophages were cultured either in 2000ng/ml rShh or E coli LPS of equivalent endotoxic
activity. Pooled results from 5 donors for each cytokine or chemokine are shown. rShh induced
an upregulation in IL-6 (Figure 5.19a), IL-8 (Figure 5.19b), MCP-1 (Figure 5.19c), IP-10
(Figure 5.19d), MIG (Figure 5.19e) and RANTES (Figure 5.19f) exceeding that induced by LPS
of equivalent activity.
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5.7 Polymixin B abrogates the macrophage
response to rShh
Although rShh induced greater changes in cytokine production than those induced in
response to LPS in all donors, these changes were observed to fall within the margins
of error incorporated within the endpoint LAL assay (50-200%). Thus to further
exclude the possibility that endotoxin may be contributing to the effects on cytokine
and chemokine production seen, it was necessary to adopt a different approach to
differentiating the effects of Shh from any endotoxin contamination present within
the protein preparation.
The following experiments were based on the use of an LPS neutralising agent,
polymyxin B (PMB). PMB is a polycationic peptide antibiotic that binds to the
anionic lipid A portion of LPS and neutralises its endotoxic activity606"608. PMB has
been used widely in the literature315'323'421,566'609"612 to differentiate between effects
due to the protein of interest from those of endotoxin contamination and, although
not active against all species of LPS613, is known to be effective against E coli LPS.
Two experimental approaches were used to attempt endotoxin neutralisation. The
first utilised immobilised PMB in the form of PMB-agarose beads (Sigma) and the
second used PMB as a culture additive.
5.7.1 The use of PMB-agarose beads to remove contaminating LPS
Immobilised PMB adsorption has been used previously in the literature to remove
contaminating endotoxin from a wide variety of solutions611'612'614"616. In the present
set of experiments, the following samples were incubated with PMB agarose beads
for a period of 30 minutes at 37 degrees: 2000ng/ml rShh reconstituted in LRW,
10pg/ml and lOOpg/ml E coli LPS. Samples of each were set aside for later LAL
testing prior to incubation with PMB-coated beads and, furthermore, a sample of
2000ng/ml rShh was set aside for protein assay. Following incubation with the PMB
beads, the mix was centrifuged at 300g to precipitate out the beads. The supernatants
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were then removed and assayed for endotoxic activity and, in the case of the rShh,
for protein content. Whilst PMB beads successfully removed most of endotoxic
activity from 10pg/ml LPS, it failed to remove that from either the lOOpg/ml LPS or
indeed the rShh preparation. Furthermore, significant protein losses in the order of
50% were observed when samples were analysed in a Bradford protein assay (data
not shown), both findings in keeping with other reports in the literature609,610,615'617"
620. In view of these results, other methods had to be employed to attempt endotoxin
removal.
5.7.2 The use of Polymixin B as a culture additive
The problem ofprotein adsorption has been circumvented in previous studies by
using PMB as a culture additive323,421,569,581,609,610,612,62 N625_ Although the recombinant
protein is still tightly adherent to LPS, the premise is that, whilst PMB neutralises the
lipid A component of the LPS it still allows the protein to exert its effect in culture.
Therefore, the following experiments employed PMB as a culture additive to see
whether it modulated the effect of rShh on macrophage effector response. PMB was
used at a concentration of lOpg/ml as previously described in a large number of in
vitro studies involving monocytes, macrophages and dendritic ceus569>581'609>610'625
PMB (lOpg/ml) was added to all macrophage cultures 45 minutes prior to the
addition of the stimulating agent (rShh or LPS lOOng/ml) and the cells were
incubated under these conditions for 24 hours. PMB was also added to macrophage
cultures following the addition of cyclopamine and prior to stimulation with rShh to
see whether PMB could modulate the cyclopamine-mediated inhibition of the rShh-
induced macrophage activation. Supernatants were harvested and analysed using the
cytokine and chemokine CBAs as above.
As demonstrated in Figures 5.20 and 5.21, PMB profoundly abrogated the response
ofmacrophages to rShh at all concentrations used and in all donors tested (n=8).
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These results suggest that the dominant effect of rShh on macrophages is induced by
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FIGURE 5.20
Polymixin B abrogates the rShh-mediated upregulation of cytokines and chemokines in the
presence of serum
Macrophages were preincubated in the presence of lOpg/ml PMB prior to the addition of rShh in
the concetration range 500-2000ng/ml. Supernatants were harvested at 24 hours and analysed by
CBA as previously. PMB markedly inhibited the production of IL-6 (Figure 5.2-a), 1L-8 (Figure
5.20b), MCP-1 (Figure 5.20c), IP-10 (Figure 5.20d), MIG (Figure 5.20e) and RANTES (Figure
5.20f) by macrophages in a dose-dependent manner. Represented are pooled results from 8
donors. Means and standard deviations are shown.
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FIGURE 5.21
LPS neutralisation using Polymixin B abrogates the rShh-mediated upregulation of
cytokines and chemokines in the absence of serum
Macrophages were preincubated in the presence of 1 Opg/ml PMB prior to the addition of rShh
in the concentration range 500-2000ng/ml. Supernatants were harvested at 24 hours and
analysed by CBA as previously. PMB markedly inhibited the production of IL-6 (Figure 5.21a),
IL-8 (Figure 5.21b), MCP-1 (Figure 5.21c), IP-10 (Figure 5.21 d), MIG (Figure 5.21e) and
RANTES (Figure 5.2If) by macrophages in a dose-dependent manner. Represented are the
pooled results from 8 donors. Means and standard deviations are shown.
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5.8 rShh and low concentrations of LPS are
sensitive to heat
Classically, LPS has been considered to be heat resistant322"324'575'626 and this property
has been used extensively in the literature to differentiate the effects of a protein of
interest from the effects of any LPS contamination contained within the protein320"
324,566,570,575,576,581 jy[ore recently, the use of this property to distinguish LPS effects
from those due to a protein of interest has been called into question following recent
reports suggesting that low concentrations of LPS may be very heat sensitive609'610.
Thus, the following experiments were performed to determine whether heating rShh
would modulate the macrophage cytokine and chemokine response. For controls,
lOpg/ml and lOOpg/ml E coli LPS were used in parallel experiments. Samples of
each were heated for 1 hour at 100 degrees in a heating block as previously
described609'610. Macrophages were then cultured in the presence of both untreated
and heat-treated 2000ng/ml rShh, lOpg/ml LPS and lOOpg/ml LPS.
Figure 5.22 shows the effect of these treatments on IL-6 production as an example.
As shown, the macrophage response to lOpg/ml LPS was preserved following
heating, a finding consistent with previous reports. In contrast, heat-treatment
abrogated both the response ofmacrophages to 2000ng/ml rShh and lOOpg/ml LPS.
Similar results were seen irrespective of the cytokine or chemokine examined. These
































rShh and low concentrations of LPS are heat-sensitive
E coli LPS (lOpg/ml and lOOpg/ml) and rShh (2000ng/ml) were heated at 100°C
for 60 minutes prior to macrophage culture for 24 hours. Supernatants were
harvested for cytokine and chemokine analysis as previously. Graph represents
IL-6 production from macrophages from 3 donors cultured in medium containing
serum. Means and standard deviations are shown.
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5.9 Discussion
Although Shh signalling components have been previously identified in murine and
human macrophages19'149, the possible role for Shh in modulating macrophage
effector function has not been explored to date. In this chapter, macrophages have
been prepared from human Buffy coat-derived PBMCs and used to explore the
expression of Shh signalling pathway components and the effect of Shh signalling in
these cells.
The findings reported in the chapter indicate that macrophages express components
of the Shh signalling pathway and that they may thus be able to respond to a Shh
signal. Studies investigating a possible role for Shh in the modulation of cytokine
and chemokine expression by these cells have been significantly hampered by the
presence of contaminating endotoxin contained within the E coli-derived
recombinant protein utilised to investigate the role of Shh in vitro. Indeed, taken
together, the results would suggest that endotoxin contamination rather than Shh per
se is responsible for most, if not all, of the changes in cytokine and chemokine
effector function seen. What follows is a discussion of the results and issues that
have arisen from this work.
5.9.1 Shh signalling pathway expression in macrophages
The results from the early part of this chapter confirm the findings of previous
studies19'149 suggesting that Shh signalling pathway components are expressed in
human macrophages. Stewart et al149 observed Ptc expression in alveolar
macrophages, a finding in keeping with the earlier work of Bhardwaj et al19.
Bhardwaj et al19 employed RT-PCR to demonstrate the expression ofPtc, Smo, Glil,
GU2 and Gli3 in primitive haematopoeitic progenitor cells (CD34+CD38-Lin-) and
the expression ofPtc and Smo in committed CD33+ myeloid cells isolated from cord
blood. The findings of the present work broadly agree with these earlier findings in
that Ptc was found to be expressed in mature human macrophages both at the mRNA
and protein level. Furthermore, Smo expression was observed at the mRNA level
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consistent with the work ofBhardwaj et al19. However, in contrast to this group's
findings, Gli 1 and 2 mRNA were expressed in the PBMC-derived macrophages and,
furthermore, although Bhardwaj et al19 identified Shh expression in both the
primitive precursor and committed CD33+ populations, neither Shh mRNA nor Shh
protein were detected in the PBMC-derived macrophages in the present work. The
reason for these differences is not clear. Lineage and maturation-dependent
differential gene expression in haematopoietic cells have been described previously
for a number of genes includingflt3 , the homeobox genes and the downstream
targets of Shh activation, the bone morphogenetic protein(BMP) family511 and it
remains to be seen whether such differences may account for the conflicting results
seen.
It is interesting that, although macrophages expressed Ptc, Smo, Gli 1 and Gli 2 at the
mRNA level, only Ptc was convincingly demonstrable at the protein level. Indeed
there are few reports in the literature evaluating the protein expression of Shh
pathway components in the peripheral immune system. Stewart et al149 used the same
goat polyclonal antibody as used in this thesis to demonstrate Ptc expression on
alveolar macrophages and the findings of the present study are in keeping with this
report. However, further studies investigating the expression of other components of
the pathway have not been performed. Although, on initial evaluation, Smo, Glil and
Shh appeared to be expressed by macrophages, this staining could not be blocked
using the appropriate specific blocking peptides, thus suggesting that the staining
was non-specific, in nature.
Following the discovery that macrophages expressed the receptor for Shh, Ptc, the
next line of investigation was to determine whether active Shh signalling could occur
in these cells. Indeed, that PBMC-derived macrophages appear to be able to respond
to but not produce a Shh signal would be in keeping with studies in the chick embryo
where Shh and Ptc are often only co-expressed transiently during development99 later
either producing Shh or being able to respond to a Shh signal. In keeping with earlier
reports in the literature8'16'20'32'44'102, Ptc mRNA upregulation was used as a readout of
Shh signalling pathway activation. Using real-time PCR, a 2-fold increase was
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accepted as representing significant gene upregulation consistent with previous
reports20'507'508 and, in the present studies, an average 2.8-fold increase in Ptc
expression was observed in response to stimulation with 2000ng/ml rShh. It may be
that a lower magnitude ofmRNA upregulation is biologically relevant in
macrophages as suggested by others629. That Ptc is upregulated to this extent at 24
hours is in agreement with previous studies in T cells20 and myofibroblasts102 and
would suggest that active signalling through the Shh signalling pathway occurs.
However the significance of this magnitude of upregulation in macrophages is not
clear. Furthermore, it is not known whether this upregulation in mRNA translates
into protein expression. Such changes are difficult to quantify using
immunohistochemistry and further investigation ofprotein expression are difficult
for the reasons noted previously.
Further investigation at the protein level may prove helpful to help delineate whether
the Shh signalling does indeed play an active role in macrophages. To date, it has
been generally considered that Ptc mRNA upregulation specifically reflects active
Shh pathway signalling. However, this may not be the case. Preliminary experiments
performed recently suggested that LPS too may also regulate Ptc expression. Indeed,
in experiments in 2 donors, l-100ng/ml E coli 055:B5 LPS (Sigma) induced Ptc
expression in macrophages after 18 hours in culture (See Appendix 3). This supports
earlier observations suggesting that, in murine peritoneal and bone marrow derived
macrophages, LPS upregulates Ptc (Armenika Etemi, unpublished observations).
Taken together, these results would suggest that either Ptc upregulation is not
specific to the Shh pathway or that LPS signalling and the Shh pathway converge.
Interestingly, PI-3-K, a downstream target of LPS signalling630'632 has been shown
recently to be upregulated in response to rShh in endothelial cells65. Furthermore,
that LPS may regulate components of the Hh signalling pathway has been
demonstrated in other recent studies633.
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5.9.2 rShh and macrophage effector function
The early experiments investigating the effect of rShh on macrophages revealed that
stimulation of these cells with rShh resulted in the upregulation of a large number of
inflammatory mediators including VEGF, IL-6, IL-8, MCP-1, RANTES, IP-10 and
MIG, factors also recognised to be upregulated by LPS. Conversely, other factors
classically upregulated by LPS, such as IL-ip, IL-12p70, TNFa and IL-10 were not
consistently upregulated by rShh. Given that the later results of the chapter support
an argument for LPS mediating the dominant macrophage effect, it is not clear why
LPS, but not Shh, can induce IL-ip, IL-12p70, TNFa and IL-10. One possible reason
for this disparity may reflect the possible heterogeneity of the 2 stimuli being
compared. As noted previously, like other recombinant proteins produced in bacterial
recombination systems, rShh is likely to contain not just LPS but also a wide range
of other bacterial components including lipoproteins and bacterial DNA which are
capable of activating several TLRs including TLRs 2, 4 and 9596"598. Interestingly,
LPS itself rarely exists in a pure form, and is usually found in close association with
LPS-associated lipoproteins, which are difficult to eliminate from LPS
preparations596'598. The importance of such lipoproteins should not be
underestimated. Indeed, in the early studies of LPS signalling, it was initially thought
that TLR2, and not TLR4, was the TLR responsible for E coli LPS signal
transduction. It was subsequently demonstrated that activation ofTLR2 by
commercial LPS disappeared when the LPS was repurified under stringent
conditions highlighting the importance of these lipoproteins as misleading
contaminants634"637. The LPS used for the present studies was of the E coli serotype
055 :B5 and the protein content of this preparation has been reported to be less than
3%. Thus, there exists the possibility that a small amount of lipoprotein (albeit less
than 3%) has the potential to activate the macrophages through TLR2. Furthermore,
very little is known regarding the relative contribution of the possible TLR agonists
present in the rShh peptide. Given that PMB abrogated, but failed to completely
eliminate the rShh-mediated response, it is possible that other TLR agonists present
within the recombinant protein, which may include Shh itself, are responsible for the
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residual cytokine and chemokine production seen. Thus, it can also be seen that
contributions from several TLRs have the potential to significantly modify the
macrophage effector response.
Furthermore, the complexities of the TLR signalling pathways are only just
beginning to be understood. It was originally considered that all TLRs converged on
the same pathways and that there was little specificity between activation events.
More recently, however, a body of evidence has evolved to suggest that the pathways
downstream of different TLRs are differentially activated by the TLR
agonists346'630'631'638"640. Complicating matters further, there are reports of cross-talk
between different TLRs641 and, furthermore, there is evidence that TLR agonists may
act synergistically to induce inflammatory cytokine production. This has been
described for TLR2 and TLR4 agonists637'638'642"645 and bacterial DNA may also
synergise with LPS to induce inflammatory cytokines639'646'647. In another interesting
report, synergy between the TLRs 2, 5, 7 and 9 and adenosine receptors has been
shown to modulate cytokine production resulting in the upregulation ofVEGF and
downregulation of TNFa production648. These findings would concur with the results
of the current work. From Pinhal-Enfeld et al's work, it is suggested that this
upregulation of VEGF together with the down-regulation of TNFa may act as an
angiogenic switch, shifting macrophages from an inflammatory to an angiogenic
phenotype. Given the previous reports linking Shh signalling and VEGF
signalling102'163 and, thus, a possible role for Shh in postnatal angiogenesis, it would
be very interesting to see whether a pure preparation of Shh was capable of inducing
similar changes in macrophages to those seen in this study in response to rShh.
A further possibility has yet to be considered: that synergy may occur between Shh
and endotoxic contaminants present within the recombinant protein. Synergy has
been shown to exist between endotoxins and TNFa649. Given that one possible role
for Shh might be to act as a danger signal when epithelium is damaged, it is tempting
to speculate that Shh released from such cells might synergise with low levels of LPS
present to initiate an immune response to that stress signal. Preliminary experiments
were performed to investigate this possibility. Macrophages were stimulated either
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with rShh, LPS or a mixture of the two. The results from these preliminary
experiments were inconclusive with evidence of both summative effects and reduced
cytokine production when both LPS and rShh were present. Interestingly, in no
instance in the 3 donors examined was there any evidence of synergy. Furthermore,
if cyclopamine and PMB were together added to a macrophage culture prior to the
addition of Shh, the inhibitory effects of cyclopamine and PMB were not seen to be
additive (Appendix 4). Together these results would suggest that synergy between
LPS and Shh is not occurring, although the purity issues outlined above make
interpretation of such experiments difficult.
5.9.3 The effect of cyclopamine
Following the discovery that rShh upregulated a number of cytokines and
chemokines, the specific inhibitor of the Shh pathway, cyclopamine, was used to
determine whether inhibition of signalling modulated the production of these factors.
In these studies, cyclopamine had a differential effect on the upregulation of
cytokines and chemokines with only the rShh-mediated upregulation of IL-6 and
MCP-1 being abrogated significantly in the first 10 donors studied. IL-8 upregulation
was inhibited in only some donors. Although these factors were modulated by
cyclopamine, most factors that were upregulated by rShh, namely RANTES, IP-10,
MIG and VEGF were not affected by the addition of cyclopamine.
The differential effect of cyclopamine in the present work proved an interesting
finding. If the effects originally attributed to Shh are in fact due to residual endotoxin
contained within the recombinant protein, why does cyclopamine have any effect at
all? Differential inhibition of the Shh signalling pathway has been previously
reported in which inhibition of Shh signalling inhibited IL-2 and IFN-y production
20 • •but not IL-10 production from activated T cells . Furthermore, mutations in Smo
have been described23'24 and therefore there is the possibility that these may account
for the differential response to cyclopamine. However, a more fundamental issue
remains. Although cyclopamine has been reported to act by inhibiting activated Smo,
the mechanism by which it does this has not been fully delineated60,650'651. Most of
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the original work performed using cyclopamine was performed in developmental
studies64'652 and there are fewer reports of its use in vitro65'653. Thus, although it did
not appear to have a toxic effect on the macrophages, as determined using trypan
blue exclusion and the MTT assay, that it may have had an effect elsewhere on other
macrophage signalling pathways cannot be excluded. To circumvent this possibility,
it would be ideal to use another inhibitor of the Shh pathway. In this regard, the
monoclonal antibody 5E1, which has been used previously in in vitro studies20'21'147
would appear ideal. Steric interference mapping analysis studies suggested that 5E1
binds to Shh at a site distinct from, but possibly overlapping, the Ptc binding site654.
However, aliquots of this antibody extracted from the myeloma cell line supernatant
grown in-house were found to contain significant amounts of endotoxic activity (in
the range l-5ng/ml) and, thus, were not suitable for use in culture with LPS
responsive cells. Another possible reason for the differential inhibition by
cyclopamine may lie in the preparation of cyclopamine used. Cyclopamine, provided
as a lyophilised pellet was reconstituted in DMSO according to the manufacturer's
instructions. This stock concentration was then further diluted in medium to provide
further stocks to avoid thawing-refreezing cycles and possible loss of activity of the
compound. Of particular interest was the finding that aliquots of the secondary stocks
when diluted in LRW were found to contain varying amounts of endotoxic activity
(0.25 - 0.50 EU/ml). Given that the LRW was free of endotoxic activity, the origin
of this must either be the cyclopamine itself, the DMSO or the tiny quantity of serum
that was present in the medium used to prepare the secondary stocks of cyclopamine.
Interestingly, when a new batch of cyclopamine was reconstituted in new DMSO and
prepared into secondary stocks using LRW, the endotoxic activity of these aliquots
was <0.05EU/ml. Recent preliminary experiments using these new stocks in 3
donors have since showed failure of the cyclopamine to inhibit the rShh-mediated
IL-6 and MCP-1 production previously observed with the older stocks.
One possible reason for the initial observations then might be that pre-treatment of
the macrophages for 45 minutes with cyclopamine containing low concentrations of
endotoxin may have desensitised the macrophage to a subsequent stimulus, provided
in the form of the rShh applied. Previous reports have demonstrated a state of LPS
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hyporesponsiveness induced by pre-treatment with low concentrations of LPS655'656.
This effect is referred to as tolerance or desensitisation and is characterised by the
decreased production of cytokines. The mechanisms responsible for such
desensitisation have not been fully delineated. Previous reports in the literature have
postulated on the induction of inhibitory mediators657, modulation ofmembrane
bound receptors such as CD14658,659 and changes in the intracellular signal
transduction pathway655 following pre-incubation with low doses of LPS.
The differential temporal regulation of cytokines in response to LPS has been
described and upregulation of cytokine mRNA expression occurs early in response to
LPS629'660 for several cytokines. However, whether a 45 minute incubation at such a
low concentration of endotoxic activity is sufficient for such endotoxin tolerance or
desensitisation to occur is not known. Interestingly, in a recent study, a 90 minute
incubation with low dose LPS was sufficient to induce suppressed MAP kinase
activity and tolerance to a second LPS stimulus661.
If indeed desensitisation plays a role in the effects seen, it is interesting that only
some factors (IL-6 and MCP-1) were affected. Recent data supporting such a
differential desensitisation has shown that pre-treatment ofmonocytes with 10-
1 OOOpg/ml LPS was sufficient to induce a markedly reduced response in a distinct set
of chemokines when re-challenged with a higher LPS concentration662. This group
showed a differential desensitising effect with some factors remaining permanently
suppressed (MlP-la, MlP-lb, RANTES, TNF-a and IL-6) while other re-challenged
monocytes were still able to produce the chemokines IL-8, GROa and MCP-1.
287 352 663Alternative activation ofmacrophages has been described (reviewed in ' ' ).
Whether such effects, together with crosstalk between TLRs allows for further
polarisation of the innate response, remains to be seen.
5.9.4 Differentiating effects of Shh from those of endotoxic activity
In light of the above discussion, is there a good way of differentiating between
effects attributable to the protein of interest from those due to contaminating
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endotoxin when both are proposed to signal through the same pathways? In the work
presented here, the initial approach used was to quantify the endotoxic activity
present in the rShh and then compare this directly with a dose of LPS of equivalent
endotoxic activity. Clearly, although rShh apparently induced a greater magnitude of
change than that induced by an equivalent concentration of LPS, in light of the
subsequent data, this process alone was inadequate for differentiating effects related
to the protein of interest from those due to endotoxin contamination. Some of the
reasons why this process was inadequate relate to the possible nature of the bacterial
components present within either the rShh or the LPS used as a control and have
been discussed earlier.
Complicating matters further, there are a number of inherent difficulties associated
with the accurate quantification of endotoxic activity particularly at low
concentrations. These have been highlighted by a number of authors604'605'617'664. Of
note is the fact that, as a bioassay, the LAL assay is much less precise than an
immunologically based test such as an ELISA. Quantitation of the LAL enzyme
activity requires optimal conditions and measurement may be complicated by a
number of interference factors such as coloured or turbid solutions. Also, both
endotoxin and LAL reagent are subject to biological variation665 and the intra-test
coefficient of variability of the LAL assay is not insignificant, previously reported to
be in the order of ~50%604. Consequently, in many respects, the assay is only semi¬
quantitative with a value of, for example 4.5pg/ml LPS, not being significantly
different, in terms of endotoxic activity, from 7pg/ml LPS. Thus, this further
compounds the difficulties outlined above in attempts to extrapolate relative
potencies of rShh solutions from LPS curves. Furthermore, endotoxins exhibit a
significant ability to interact with other proteins and lipids including other bacterial
components and components of serum666"671 and such interactions can readily mask
endotoxin molecules from detection and removal techniques672"674. In addition, the
close association of the protein of interest with endotoxin, as likely to be the case in
recombinant proteins, means that the endotoxic activity present within the sample
A77 A7A A*1 f\
may be significantly underestimated ' ' . Serum, albumin, plasma and medium
also can interfere with p-nitroaniline-based chromogenic assays because of their
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yellow colour and turbidity and it is thus perhaps not surprising that apparently
higher results were obtained for IMDM and X-vivo 10 in the endpoint assay
compared with results obtained from the thermokinetic assay.
Differentiating effects attributable to a protein of interest from endotoxin effects has
received considerable recent attention in the field ofTLR biology. As noted
previously, a wide range of structurally and functionally diverse agonists have been
proposed for TLR4, more so than for any other TLR (Reviewed in 291'305'573)_ Given
that the majority of these studies have used bacterially-derived or recombinant
proteins, one longstanding concern has been that the effects seen may be attributable
to endotoxin contamination of the proteins used. Indeed, recent data adds to these
concerns with convincing evidence suggesting that cytokine effects attributed to
rHSP60 and rHSP70 are caused by endotoxin contaminants595'609'610. Commonly
employed techniques to differentiate between effects related to the protein of interest
from those of endotoxin have included the differential sensitivity of the protein and
endotoxin to the LPS neutralising agent PMB. However, although PMB is an
effective neutraliser of several types of LPS (and, indeed, was particularly successful
in its action in the work presented here), it is not capable of neutralising all forms of
Lps613,677,678 purthermore, in some instances, it has been reported to stimulate
/T"7Q f.Q(\
cytokine and complement production ' , especially at high concentrations
(~100pg/ml) and may even synergise with LPS613. A further consideration is that the
lipoprotein and/or phospholipid components of endotoxins and commercial LPS
preparations are not reliably inhibited by PMB634'681. For these reasons, PMB may
not always be a suitable method for differentiating between protein-related and
endotoxin-related effects. The differential sensitivity ofproteins and LPS to heat is
another method commonly employed in the literature to differentiate between a
protein of interest and endotoxin. Classically, LPS has been reported to be heat
999 99A S7S
resistant " ' . However, recently, Gao and Tsan have suggested that, depending
on the concentration of LPS present, it may be very heat sensitive609'610. They posited
that if 99% of LPS was inactivated by heat, then the significance of this would be
different depending on the starting concentration of LPS present. The work presented
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in this chapter is in keeping with the reports of Gao and Tsan, finding that both
2000ng/ml rShh and lOOpg/ml LPS are, indeed, heat-sensitive.
Thus, from the above it can be seen that differentiating protein-related effects from
those of contaminants in bacterially-derived recombinant proteins is difficult. The
experiments outlined in this chapter would be aided considerably if pure Shh ligand
could be used. Currently such a protein is not commercially available. It may be
possible to generate Shh protein in a non-bacterial expression system such as
Chinese hamster ovary (CHO) cells, which, although not eliminating the effects of
possible exogenous endotoxin contamination, has the potential to result in the
production of a purer protein. Alternatively, with the development of better
antibodies to Shh, it may be possible to extract Shh from tissues, although such a
process is complicated by the relatively low expression of Shh in adult tissues. Under
this circumstance, use of embryonic tissue such as murine brain may prove a more
viable alternative. The production of a pure preparation of Shh would dramatically
aid our understanding of how macrophages may respond to Shh and, indeed, whether
Shh has any effect on macrophage cytokine and chemokine effector function.
5.9.5 Summary
The work presented in this chapter describes the expression of Shh signalling
pathway components in human PBMC-derived macrophages and, further, reports on
the effect of recombinant Shh protein on the cytokine and chemokine effector
function of these cells. The effects on cytokine and chemokine effector function are
enhanced by serum, differentially modulated by the specific Shh signalling pathway
inhibitor, cyclopamine, and consistently abrogated by anti-CD 14 blockade. These
results together with the dramatic inhibition of the response by the LPS neutralising
agent PMB suggest that endotoxin contamination present within the E coli - derived
recombinant Shh protein utilised to test the effect of Shh in vitro, is primarily
responsible for the stimulatory effects seen. Further clarification of a possible role for








A growing body of evidence suggests that Hh signalling may play a role in the
developing and mature immune system. Outram et al147 demonstrated that Shh
signalling is present during murine thymocyte development and that it regulates the
development of double positive from double negative thymocytes. Subsequently,
work by Bhardwaj et al19 observed that Shh signalling is important in the
proliferation of haematopoietic stem cells. More recent data from our group has
suggested that Shh signalling may play a role in the adult immune system. Most
notably, adult murine and human CD4+ T cells have been shown to express
transcripts for Shh and Ptc and, that these cells can produce and respond to a Hh
signal, has been demonstrated in 2 studies20'21. Lowrey et al21 observed that the
addition of rShh protein to cultures ofmurine CD4+ T cells, sub-optimally activated
using anti-CD3 and anti-CD28 antibodies, enhanced T cell proliferation, an effect
subsequently shown to occur through the enhanced entry into the S/G2 proliferative
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phase of the cell cycle. Stewart et al extended this work further, investigating Shh
signalling in human CD4+ T cells. The results were broadly in agreement with the
earlier findings of Lowrey et al21. Notably, the proliferation of activated CD4+ T
cells was enhanced by exogenous Shh in approximately 50% of human donors
studied, an effect accompanied by a modulation in cytokine effector function.
The reports outlined above present a number of interesting avenues for further
enquiry. For example, although Hh signalling has been shown to modulate the
proliferation and cytokine effector function of CD4+ T cells in vitro using anti-CD3
and anti-CD28 antibodies, it is not known whether, if antigen presenting cells are
substituted for these activation signals, the same effect on CD4+ T cell effector
function will occur. Furthermore, given that Shh is upregulated at sites of epithelial
damage149, that rShh enhances the proliferation of activated CD4+ T cells20'21 and
that macrophages express Ptc149, it is conceivable that Shh signalling may be
involved in or fuel interactions occurring at the epithelial-immune cell interface
during inflammation or repair.
234
6.2 Shh signalling and the effector function of
depletion-purified, anti-CD3£/anti-CD28 activated,
CD4+ T cells
In light of the previous observations that rShh enhances the proliferation and
cytokine effector function of activated, but not resting, murine and human CD4+ T
cells20'21, the aim of this section was to repeat the experiments previously reported by
Stewart et al20 determining the effect of rShh on human CD4+ T cells. In these
experiments, exogenous rShh was shown to enhance the proliferation of depletion-
purified CD4+ T cells in 6 of 13 donors20. Also, in those donors where proliferation
was enhanced, the cytokine production by these cells was also modulated by
exogenous rShh administration.
Therefore, the aim of this section was to see whether I could reproduce these results
using rShh and human peripheral blood mononuclear cell (PBMC)-derived CD4+ T
cells.
6.2.1 Isolation and depletion purification of human CD4+ T cells
As described in Chapter 2, PBMCs were isolated from normal, single donor Buffy
coats obtained from Scottish National Blood Transfusion Service, Edinburgh. Each
Buffy coat was made up to 200mls using PBS and PBMCs were obtained by
centrifugation over Lymphoprep (Gibco) for 25 minutes at lOOOg. The PBMCs,
appearing at the interface between the Lymphoprep and serum were removed and
washed twice in PBS to remove platelets. The PBMCs were reconstituted in serum-
free RPMI and plated into culture flasks at 5 x 106/ml. The cells were incubated for 1
hour at 37°C to allow adherent monocytes to be depleted from the PBMCs, by
adherence to the plastic culture flask. Non-adherent cells were removed, counted and
washed in PBS prior to proceeding to cell separation.
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As previously20, CD4+ T cells were isolated from the PBMCs using CD4+ depletion
columns (R&D Systems) according to the manufacturer's instructions. Briefly, 20 x
107 PBMCs were reconstituted in 1 x column buffer (R&D Systems) and then mixed
with the antibody cocktail (R&D Systems). B cells and other non-CD4 cells bind to
anti-Ig coated glass beads via Fc interactions, leaving the CD4+ T cells unbound.
Following washing, the cell-bead mix was transferred to the separation column
(R&D Systems) and the cells were incubated on the column for 10 minutes at room
temperature. CD4+ T cells were eluted from the column using lOmls of column
buffer, leaving bound cells (and, thus, non-CD4+ T cells) retained on the column.
The cells were then counted, washed and reconstituted into RPMI containing 10%
(heat inactivated) human AB serum (Sigma).
Following this isolation, purities of CD4+ T cells in the order of 85% (range 82 -
88%) (Figure 6.1) were obtained as determined by flow cytometry employing
double-staining techniques using Phycoerythrin (PE)-labelled, mouse anti-human
CD3 and Allophycocyanin (APC)-labelled, mouse anti-human CD4 antibodies (BD
Pharmingen, San Diego, CA, USA).
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FIGURE 6.1
Representative flow cytometry data demonstrating purities of CD4+ T cells isolated
using depletion techniques
Following centrifugation over Lymphoprep, CD4+ T cells were isolated from PBMCs uisng
CD4 depletion columns (R&D Systems). Representative flow cytometry scatter plots for
non-adherent PBMCs (Figure 6.1a), unstained depletion-purified CD4+ T cells (Figure
6.1b) and the isotype controls (Figure 6.1c) are shown. Purities ofCD3+CD4+ T cells were
confirmed using PE-labelled and APC-labelled mouse anti-human antibodies to CD3 and
CD4 respectively (Figure 6.Id). Depletion-purified CD4+ T cells yielded purities in the
range 82-88%.
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6.2.2 Shh and CD4+ T cell proliferation
In this series of experiments, depleted CD4+ T cells were prepared as outlined in
6.2.1. As described previously20'21, the CD4+ T cells were activated using
monoclonal antibodies to anti-CD3 and anti-CD28 (BD Pharmingen). Prior to cell
culture experiments, the anti-CD3s antibody (BD Pharmingen) was immobilised onto
the wells of 96-well plates by diluting the antibody in PBS to final concentrations of
either 0.2 or lpg/ml as previously20'21. The plates were incubated for 2 hours at 37°C
and then washed 3 times with PBS to remove unbound antibody. The plates were air-
dried for 30 minutes at 37°C prior to use. Depleted CD4+ T cells were incubated at 2
x 105 cells per well either in medium alone (resting T cells) or in the presence of
plate-bound anti-CD3s and soluble anti-CD28 antibodies (activated T cells). Each
condition was replicated in quadruplicate on the 96-well plate. Anti-CD3s at
0.2pg/ml with lpg/ml anti-CD28 constituted a "suboptimal" activation stimulus and
anti-CD3s at lpg/ml and anti-CD28 at 5pg/ml constituted an "optimal" activation
stimulus in keeping with previous studies20'21. Parallel experiments were performed
in which 10-1000ng/ml rShh was added to these cultures at the initiation of culture.
After 72 hours in culture, 20pl of cell culture supernatant was removed from each
well (thus providing 80pl for each culture condition) and set aside for later cytokine
analysis. To evaluate proliferation, the cells were pulsed with tritiated methyl
thymidine (lpCi/well)(3H-TdR-Amersham Pharmacia Biotech, Amersham, UK) and
incubated for a further 18 hours. 3H-TdR incorporation was evaluated using a
Betaplate 1205 liquid scintillation counter (Wallac, Milton Keynes, UK). The
experiment was performed in 12 donors.
Cytokine analysis on the supernatants was performed using the Thl/Th2 cytometric
bead array (CBA) (BD Biosciences), as described in Chapter 2. Using the Thl/Th2
CBA, the following cytokines can be detected: Interferon-gamma (IFNy), Tumour
Necrosis Factor-alpha (TNFa) and interleukins IL-10, IL-6, IL-4 and IL-2.
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The results are shown in Figure 6.2. Consistent with previous reports ' , rShh failed
to modulate the proliferation ofunstimulated CD4+ T cells (Figure 6.2a). However,
in contrast to the previous studies, enhanced proliferation in response to rShh in
activated CD4+ T cells was not observed across any of the concentrations of rShh
used. Furthermore, this failure to modulate the proliferation of CD4+ T cells was
observed, irrespective of whether sub-optimal (Figure 6.2b) or optimal (Figure 6.2c)
activation conditions were employed.
Figure 6.3 and Figure 6.4 demonstrate the effect of rShh on cytokine release from
suboptimally (Figure 6.3) and optimally (Figure 6.4) activated CD4+ T cells at 72
hours. For the purposes of statistical analysis, rShh-treated CD4+ T cells were
compared to untreated controls using a two-tailed t-test for paired samples. A p value
of <0.05 was considered significant (* p<0.05, ** p<0.01, *** p<0.001). As shown,
the addition of rShh upregulated significantly the production of IFN-y, TNFa, IL-10,
IL-6 and IL-2, but not IL-4, in suboptimally activated CD4+ T cells. Conversely, in
optimally activated CD4+ T cells, the addition of rShh failed to modulate
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FIGURE 6.2
rShh fails to modulate the proliferation of resting or activated depletion-purified
CD4+ T cells
Resting (Figure 6.2a) or anti-CD3e/anti-CD28 activated CD4+ T cells were cultured in
the presence or absence of 10-1000ng/ml rShh for 72 hours. Proliferation was assayed
by 3H-TdR incorporation over 18 hours. Irrespective ofwhether the cells were
suboptimally (0.2 ug/ml anti-CD3e: lpg/ml anti-CD28) (Figure 6.2b) or optimally
(lpg/ml anti-CD3s: 5pg/ml anti-CD28)(Figure 6.2c) activated, rShh failed to modulate
the proliferation of the activated T cells. The experiment was performed in 12
individual donors. Results are representative of at least 5 experiments and means and
































Ong/ml 10ng/ml 100ng/ml 1000ng/ml
rShh
FIGURE 6.3
rShh upregulates the production of IFNy, TNFa, IL-10, IL-6 and IL-2 from suboptimally
activated CD4+ T cells
Depletion-purified CD4+ T cells were suboptimally activated using monoclonal anti-CD3s and
anti-CD28 antibodies at 0.2pg/ml and lpg/ml respectively for 72 hours in the presence and
absence of 10-1000ng/ml rShh. Supernatants were analysed for cytokine production using
cytometric bead arrays. rShh upregulated the production of IFNy (a), TNFa (b),IL-10 (c), IL-6
(d) and IL-2 (f). Conversely, IL-4 was not modulated by rShh (e) For the purposes of statistical
analysis, treated CD4 T cells were compared to untreated controls using a two-tailed paired t-
test. Results shown are representative of at least 5 donor experiments and means and standard
deviations are shown.
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FIGURE 6.4
rShh fails to modulate the production of IFNy, TNFa, IL-10, IL-6, IL-4 and IL-2 from
optimally activated CD4+ T cells
Depletion-purified CD4+ T cells were optimally activated using monoclonal anti-CD3e and
anti-CD28 antibodies at lpg/ml and 5pg/ml respectively for 72 hours in the presence and
absence of 10-1000ng/ml rShh. Supernatants were analysed for cytokine production using
cytometric bead arrays. rShh failed to modulate the production of IFNy (a), TNFa (b),IL-10 (c),
IL-6 (d), IL-4 (e) and IL-2 (f). For the purposes of statistical analysis, treated CD4 T cells were
compared to untreated controls using a two-tailed paired t-test. Results shown are representative
of at least 5 donor experiments and means and standard deviations are shown.
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6.3 Shh signalling and the effector function of
depletion-purified CD4+ T cells in the presence
of an antigen presenting cell
From the experiments outlined above, it was apparent that, although rShh failed to
modulate the proliferation of depletion-purified CD4+ T cells, rShh did appear to
modulate the cytokine effector function of suboptimally activated CD4+ T cells, a
finding in keeping with those of Stewart et al20.
Thus, the aim of these experiments was to determine whether, if the anti-CD3s/anti-
CD28 ligation was replaced by the presence of antigen presenting cells, the same
effect of rShh on CD4+ T cell effector function would be observed. For these
experiments, given that macrophages express the receptor for Shh, Ptc, and, thus,
have the potential to interact with CD4+ T cells via the Shh signalling pathway,
macrophages were selected as the antigen presenting cells of choice in this system.
Monocytes were isolated from human PBMCs as described in Chapter 2 and adhered
into macrophages over a period of 6 days as in Chapter 5. Following this incubation,
the cells were treated with Mitomycin-C (MMC)(Sigma), an antibiotic that inhibits
nucleic acid synthesis. Briefly, cells were mixed with 50pg/ml MMC and incubated
for 30 minutes at 37°C. The cells were then thoroughly washed 4 times with ice-cold
medium to remove any residual MMC. Cells prepared in this way were counted and
plated out into round-bottomed 96 well culture plates at a range of concentrations
from 104 - 5 x 105 cells per well.
Depletion-purified CD4+ T cells from a third party donor were prepared as outlined
in Section 6.2.1 above and added to the MMC-treated macrophages using 2 x 105
CD4+ T cells per well in the presence and absence of 10-1000ng/ml rShh. As
previously, each culture condition was performed in quadruplicate. The mixed
lymphocyte reactions (MLRs) so prepared were left in culture for a period of 72
hours. At the end of this time, 20pl of cell culture supernatant was removed from
each well and set aside for later cytokine analysis using the Thl/Th2 CBA as in
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Section 6.2. The cells were pulsed with H-TdR (lpCi/well) and incubated for a
further 18 hours. 3H-TdR incorporation was evaluated as in Section 6.2. The
experiment was performed in 8 T cell donors.
The results from these experiments are shown in Figures 6.5 and 6.6. As shown in
Figure 6.5, irrespective of the number ofMMC-treated macrophages in culture, rShh
failed to modulate the proliferation of the MLRs at any of the concentrations of rShh
employed. Figure 6.6 demonstrates the effect of rShh on the cytokines produced in
the MLRs. As shown, the addition of rShh failed to modulate either the cytokine
profile or the magnitude of the cytokine response seen and this was observed
irrespective of the number of antigen presenting cells present or the concentration of
rShh used.
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rShh fails to modulate the proliferation of T cells in mixed leukocoyte reactions (MLRs)
Depletion-purified CD4+ T cells were added to cultures ofmitomycin C (MMC)-treated
macrophages. 104 (Figure 6.5a), 5xl04 (Figure 6.5b), 105 (Figure 6.5c) and 5xl05 (Figure 6.5d)
MMC-treated macrophages were used to stimulate the CD4+ T cells. For each set of culture
conditions, T cells alone (T) and MMC-treated macrophages alone (M) were run alongside the
MLR reaction (T+M) and in the presence of 10-1000ng/ml rShh. Irrespective of the number of
MMC-treated macrophages used as stimulator cells, rShh failed to modulate the proliferative
response of the CD4+ T cells. The experiment was performed in 8 T cell donors. Results are
representative of at least 4 experiments and means and standard deviations are shown.
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Figure 6.6a Figure 6.6b
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rShh fails to modulate the cytokine effector function of T cells in MLRs
Depletion-purified CD4+ T cells were added to cultures ofmitomycin C (MMC)-treated
macrophages in the concentration range 104 - 5xl05 per well. 72 hour culture supernatants were
analysed for cytokine production using cytometric bead arrays. For each set of culture
conditions, T cells alone (T) and MMC-treated macrophages alone (M) were run alongside the
MLR reaction (T+M) and in the presence of KMOOOng/ml rShh. The results using 5x104 MMC-
treated macropahges are shown. rShh failed to modulate the proliferative response of the CD4+
T cells, irrespective of the number of stimulator macrophages used. The experiment was
performed in 8 T cell donors. Results are representative of at least 4 experiments and means and
standard deviations are shown.
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6.4 The effect of Shh blockade on T cell effector
function
CD4+ T cells have been demonstrated to express Shh at both the mRNA and protein
level20'21. Furthermore, it has been shown that, in anti-CD3s/anti-CD28 activated,
depletion-purified CD4+ T cells, blockade of Shh signalling, using the monoclonal
antibody, 5E1, inhibits the proliferation of CD4+ T cells20'21. In the C57BL/6J
mouse, this effect was consistent across all experiments21. Conversely, in human
20CD4+ T cells, Stewart et al observed inhibition ofproliferation in only 50%
donors. In those 'responding' donors, the upregulation of IL-2 and IFN-y, but not IL-
5 and IL-10, could also be abrogated by 5E120. The aim of this series of experiments
was to determine the effect of Shh signalling blockade on T cell function.
6.4.1 Blocking Shh signalling in anti-CD3/anti-CD28 activated, depletion-
purified CD4+ T cells fails to modulate T cell effector function
In light of the previous findings of Stewart et al20 and Lowrey et al21, suggesting that
5E1 could abrogate the proliferation and cytokine effector function, the aim of these
experiments was to determine whether these results could be reproduced in my
experiments using depletion-purified CD4+ T cells. As previously, the mouse
monoclonal antibody, 5E1, was employed. This antibody is thought to bind to Shh at
a site distinct from, but possibly overlapping, the Ptc binding site654. Thus, it might
be postulated that the addition of 5E1 to the cultures prevents endogenous CD4+ T
cell-derived Shh from activating the Shh signalling pathway in CD4+ T cells.
As outlined previously in this chapter, human CD4+ T cells were purified from
PBMCs using negative selection affinity columns (R&D Systems). These cells were
plated at 2 x 105 cells per well of a 96 well plate in the presence of sub-optimal and
optimal activation using anti-CD3e and anti-CD28 antibodies as in Section 6.2.2. At
the initiation of culture, 5-50pg/ml 5E1 antibody was added to the wells, in keeping
with previous studies19"21. Mouse IgG used at 50pg/ml served as the isotype control
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as previously20'21. By way of a positive control, lOog/ml ciclosporin was added to the
cultures in place of the 5E1 antibody.
The results are shown in Figures 6.7 and 6.8. Although ciclosporin successfully
abrogated the proliferation of suboptimally and optimally activated CD4+ T cells,
proliferation of these cells failed to be modulated by the addition of 5E1 (Figure 6.7).
Furthermore, 5E1 failed to abrogate the cytokine effector function of suboptimally
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FIGURE 6.7
The proliferation of suboptimally and optimally activated
depletion-purified CD4+ T cells is not modulated by inhibition of
Shh signalling
Depletion-purified CD4+ T cells were suboptimally or optimally
activated using anti-CD3s and anti-CD28 antibodies, in the presence or
absence of 5-50ug/ml 5E1. 50ug/ml mouse IgG served as a negative
control. lOng/ml ciclosporin (CsA) was used as a positive control.
Irrespective of whether the CD4+ T cells were suboptimally or
optimally activated, ciclosporin abrogated T cell proliferation.
Conversely, 5El failed to modulate the proliferation of activated T
cells, irrespective of the concentration of 5E1 used. The results
obtained using 50ug/ml 5E1 are shown. Results are representative of at
least 4 experiements and means and standard deviations are shown.
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Figure 6.8a
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Figure 6.8d
Suboptimally 50ug/ml5E1 Optimally 50ug/ml5E1
activated CD4+ T activated CD4+ T
cells cells
Figure 6.8e
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activated CD4+ T activated CD4+ T
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Figure 6.8f
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FIGURE 6.8
The cytokine effector function of suboptimally and optimally activated depletion-purified
CD4+ T cells is not modulated by inhibition of Shh signalling
Depletion-purified CD4+ T cells were suboptimally or optimally activated using anti-CD3s and
anti-CD28 antibodies, in the presence or absence of 5-50ug/ml 5E1. 5E1 failed to modulate the
cytokine effector function of activated T cells, irrespective of the concentration of 5E1 used.
The results obtained using 50ug/ml 5E1 are shown. Results are representative of at least 4
experiments and means and standard deviations are shown.
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6.4.2 Blocking Shh signalling in MLR cultures fails to modulate T cell effector
function
In parallel experiments to those outlined in Section 6.4.1 above, MLRs were
prepared as described in Section 6.3. Briefly, 104 - 5 x 105 macrophages were treated
with MMC and used to stimulate 2 x 105 third party, depletion-purified CD4+ T
cells. At the initiation of culture, 5E1 or lOng/ml ciclosporin were added to the
cultures. Proliferation following 72 hours in culture was evaluated and 20pi of
supernatant per well was set aside for later cytokine analysis.
The results are shown in Figures 6.9 and 6.10. Ciclosporin abrogated the MLR













MLR proliferation is not modulated by inhibition of Shh signalling
Depletion-purified CD4+ T cells were added to cultures ofmitomycin C (MMC)-
treated macrophages. 104 (10_4), 5xl04 (5xl0_4), 105 (10_5) and 5xlCP (5xl0_5)
MMC-treated macrophages were used to stimulate the CD4+ T cells and 50ug/ml
5E1 or lOng/ml ciclosporin (CsA) were added at the initiation of culture.
Ciclosporin abrogated the MLR response. 5E1, however, failed to modulate the
MLR proliferative response. Results are representative of at least 4 experiments and
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FIGURE 6.10
The cytokine effector function of CD4+ T cells in an MLR is not modulated by
inhibition of Shh signalling
Depletion-purified CD4+ T cells were added to cultures ofmitomycin C (MMC)-
treated macrophages. An MLR using 5xl04 MMC-treated macrophages is
illustrated. 5E1 failed to abrogate the production of IFNy (IFNg), TNFa (TNFa),
IL-10, IL-6, IL-4 and IL-2 in the MLR. Results are representative of at least 4
experiments and means and standard deviations are shown
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6.5 Shh signalling and the effector function of CD4+
T cells purified using positive CD4+ selection
The results so far presented in this chapter are somewhat at odds with those
previously reported in previous studies20'21. Although rShh enhanced the cytokine
effector function of suboptimally activated T cells, it failed to modulate the
proliferation of suboptimally or optimally activated T cells and, indeed, failed to
modulate cytokine effector function of the latter. Both Lowrey et al21 and Stewart et
70 • •
al reported an effect of rShh on T cell proliferation. In Lowrey's study using
murine depletion-purified CD4+ T cells, it was shown that rShh enhanced the
proliferation of sub-optimally activated CD4+ T cells. Subsequently, in human
studies, Stewart et al20 demonstrated enhanced proliferation by rShh of optimally, but
not suboptimally, activated CD4+ T cells in 50% donors studied, attributing this
differential response to possible polymorphisms in the Shh pathway. Indeed, Ptc and
Smo mutations can result in the constitutive activation of the Shh pathway24'25'682
and, thus, it is possible that inactivating mutations may also occur, thereby offering a
possible explanation for the differential effects seen.
In the present work, the proliferation of neither suboptimally nor optimally activated
T cells was enhanced by the addition of rShh. Furthermore, the addition of the
monoclonal antibody to Shh, 5E1, failed to modulate the proliferation of activated
20 21
CD4+ T cells, a finding in contrast to both previous studies ' . Furthermore, in the
extended experiments introducing third party antigen presenting cells into the
culture, neither the addition of rShh nor the addition of 5E1 modulated T cell
proliferation.
Thus, these findings are interesting. That they are odds with the findings of Lowrey
et al21 might possibly be explained on account of the earlier study employing T cells
from an inbred mouse population (C57BL/6J). However, that the findings are not
entirely in keeping with those of Stewart et al20 using the same sources ofPBMCs
and the same methodologies for cell isolation and purification is of some concern.
70
One striking difference between this work and that of Stewart et al and, indeed, that
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21of Lowrey et al relates to the reported purities for the depletion columns used. In
the present work, the purities of CD4+ T cells were in the order of 82-88%. This is in
marked contrast to the purities of human CD4+ T cells reported by Stewart et al20.
Using the same depletion columns to isolate human CD4+ T cells, purities >93%
20
were consistently achieved . This discrepancy in the percentage of contaminating
non-CD3+CD4+ cells has the potential to skew the results of these experiments.
Indeed, if the contaminating cell fraction contains cells which can respond to a Shh
signal and/or stimulate a T cell response, it is conceivable that the presence of such
cells could have a profound effect on the proliferative or cytokine effector response
of the CD4+ T cells present. It is also possible that any effect of rShh on the CD4+ T
cells may be overshadowed by its effects on such contaminating cells present in the
system.
Thus, the aim of these experiments was to optimise the purity of the CD4+ T cells. It
is well recognised that the purities achieved using depletion systems are inferior to
those obtained using positive selection techniques683'684. Thus, positive selection
techniques were employed to generate a CD4+ cell population of higher purity.
PBMCs were prepared from human Buffy coats as described above and in Chapter 2.
Following the adherence step, to remove the majority of the monocytes, the non¬
adherent cells were removed, washed in PBS and counted. 20 x 107 cells were
reconstituted in MACs buffer and the mixture incubated for 15 minutes at 4°C with
magnetic anti-CD4+ beads (Miltenyi Biotech, Bisley, Surrey, UK) according to the
manufacturer's instructions. The mixture was washed twice to remove unbound
beads and then applied to the selection column placed in a magnetic field. Beads
attached to the CD4+ cells are retained by the column whereas non-CD4+ T cells
pass through. Following washing, the column was removed from the magnetic field,
thus allowing the CD4+ cells to be eluted from the column. The cells were washed
and counted as previously.
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As in the earlier part of this chapter, resting or anti-CD3/anti-CD28 activated CD4+
T cells were incubated either in medium alone or in the presence of 10-1000ng/ml
rShh.
The results are shown in Figures 6.11, 6.12 and 6.13. The purities obtained by CD4+
positive selection were better than those obtained using the depletion columns.
Indeed, flow cytometry using PE- and APC-labelled mouse anti-human antibodies
revealed purities consistently >95% (Figure 6.11). These purities were in keeping
with those reported by Stewart et al20 using the R&D depletion columns.
Using positively selected CD+ T cells, rShh failed to modulate the proliferation of
20 21
resting T cells, a finding in keeping with previous reports ' . However, despite
improved purities, the proliferation of both the suboptimally or optimally activated
CD4+ T cells was not modified by the addition of rShh (Figure 6.12).
In cells suboptimally (Figure 6.13), but not optimally (Figure 6.14) activated by anti-
CD3/anti-CD28 ligation, IFN-y, TNFa, IL-10, IL-6 and IL-2 were however increased
in a dose-dependent fashion by rShh.
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FIGURE 6.11
Representative flow cytometry data demonstrating purities of CD4+ T cells isolated
using positive selection techniques
Following centrifugation over Lymphoprep, CD4+ T cells were isolated from PBMCs by
magnetic bead separation using CD4 positive selection beads. Representative flow cytometry
scatter plots for non-adherent PBMCs (Figure 6.1 la), unstained positively selected CD4+ T
cells (Figure 6.1 lb) and the isotype controls (Figure 6.1 lc) are shown. Purities of
CD3+CD4+ T cells were confirmed using PE-labelled and APC-labelled mouse anti-human
antibodies to CD3 and CD4 respectively (Figure 6.1 Id). Cells purified using positive
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FIGURE 6.12
rShh fails to modulate the proliferation of resting or activated positively-selected
CD4+ T cells
Resting (Figure 6.12a) or anti-CD3s/anti-CD28 activated CD4+ T cells were cultured in
the presence or absence of 10-1000ng/ml rShh for 72 hours. Proliferation was assayed
by 3H-TdR incorporation over 18 hours. Irrespective ofwhether the cells were
suboptimally (Figure 6.12b) or optimally (Figure 6.12c) activated, rShh failed to
modulate the proliferation of the activated T cells. Results are representative of at least
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rShh upregulates the production of IFNy, TNFa, IL-10, IL-6 and IL-2 from suboptimally
activated CD4+ T cells
Positively-selected CD4+ T cells were suboptimally activated using monoclonal anti-CD3s and
anti-CD28 antibodies at 0.2pg/ml and 1 pg/ml respectively for 72 hours in the presence and
absence of 10-1000ng/ml rShh. Supernatants were analysed for cytokine production using
cytometric bead arrays. rShh upregulated the production of IFNy (a), TNFa (b),IL-10 (c), IL-6
(d) and IL-2 (f). Conversely, IL-4 was not modulated by rShh (e) For the purposes of statistical
analysis, treated CD4 T cells were compared to untreated controls using a two-tailed paired t-
test. Results shown are representative of at least 5 donor experiments and means and standard
deviations are shown.
* p<0.05, ** p<0.01, *** p<0.001
259
Figure 6.14a Figure 6.14b
40000 -I
36000 - -r T J
30000 j [ Jj j ^ ■. ,.T . j
I260™"
C.20000 -
g 15000 ^ j j j j
— 10000 -I ! j ! i I
~ M
, Li U , I: i










Ong/ml 10ng/ml 100ng/ml 1000ng/ml
FIGURE 6.14
rShh fails to modulate the production of IFNy, TNFa, IL-10, IL-6, IL-4 and IL-2 from
optimally activated CD4+ T cells
Positively-selected CD4+ T cells were optimally activated using monoclonal anti-CD3s and
anti-CD28 antibodies at lpg/ml and 5pg/ml respectively for 72 hours in the presence and
absence of 10-1000ng/ml rShh. Supernatants were analysed for cytokine production using
cytometric bead arrays. rShh failed to modulate the production of IFNy (a), TNFa (b),IL-10 (c),
IL-6 (d), IL-4 (e) and IL-2 (f). For the purposes of statistical analysis, treated CD4 T cells were
compared to untreated controls using a two-tailed paired t-test. Results shown are representative
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6.6 Shh and cell sorted CD3+CD4+ cells
Although the use of the CD4+ positive selection beads produced better purities and,
indeed, better yields, of CD4+ T cells, rShh failed to modulate the proliferation of
CD4+ T cells. Furthermore, the effect on cytokine effector function mirrored those
observed in depletion-purified cells i.e. increased in suboptimally, but not optimally,
activated cells. Although this finding supported the earlier findings of this chapter
using depletion-purified cells, one point of concern is the observation that the use of
CD4+ positive selection appeared to be associated with an element ofCD4+ T cell
activation, as evidenced by relatively high background levels ofproliferation and
cytokine production in the unstimulated CD4+ T cells. Indeed, this effect has been
/or
described previously in positively selected T cells . Clearly, this has implications,
not least because any possible effect relating to the rShh may be masked by this
activation.
Thus, in a further attempt to generate a highly purified, but not pre-activated, CD4+
T cell population, FACS cell sorting was employed. PBMCs were prepared and the
depletion columns (R&D Systems) utilised as previously to isolate a crude
population ofCD4+ T cells with purities in the range 82-88% as described above in
Section 6.2.1. These cells were then incubated in the presence of an excess ofPE-
and APC- mouse anti-human CD3 and CD4 antibodies respectively. Following
washing to remove unbound antibody, the cells were sorted by Shonna McCall (flow
cytometry technician, University of Edinburgh) using a FACS Vantage cell sorter
(BD Biosciences) to produce a highly purified population of CD3+CD4+ T cells.
The purities achieved using this method were consistently >98.8%.
Resting or activated CD3+CD4+ T cells were then incubated in the presence or
absence of 10-1000ng/ml rShh. As previously, cytokines were removed after 72
hours for evaluation by Thl/Th2 CBA and proliferation was assessed by 3H-TdR
incorporation. The experiment was repeated in 5 donors.
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The results are shown in Figures 6.15, 6.16 and 6.17. As previously in this chapter,
the proliferation of resting, suboptimally and optimally activated, highly purified,
CD4+ T cells failed to be modulated by the addition of rShh (Figure 6.15). Flowever,
cytokine production was modulated, with Shh effecting an upregulation in IFNy,
TNFa, IL-10, IL-6 and IL-2 in both suboptimally (Figure 6.16) and optimally (Figure







rShh fails to modulate the proliferation of resting or activated cell-sorted CD4+ T
cells
Resting (Figure 6.15a) or anti-CD3s/anti-CD28 activated CD4+ T cells were cultured in
the presence or absence of 10-1000ng/ml rShh for 72 hours. Proliferation was assayed
by 3H-TdR incorporation over 18 hours. Irrespective ofwhether the cells were
suboptimally (Figure 6.15b) or optimally (Figure 6.15c) activated, rShh failed to
modulate the proliferation of the activated T cells. Results are representative of at least
4 experiments and means and standard deviations are shown.
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Figure 6.16a
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FIGURE 6.16
rShh upregulates the production of IFNy, TNFa, IL-10, IL-6 and IL-2 from suboptimally
activated cell-sorted CD4+ T cells
Cell-sorted CD4+ T cells were suboptimally activated using monoclonal anti-CD3s and anti-
CD28 antibodies at 0.2pg/ml and lpg/ml respectively for 72 hours in the presence and absence
of 10-1000ng/ml rShh. Supernatants were analysed for cytokine production using cytometric
bead arrays. rShh upregulated the production of IFNy (a), TNFa (b),IL-10 (c), IL-6 (d) and IL-2
(f). Conversely, IL-4 was not modulated by rShh (e) For the purposes of statistical analysis,
treated CD4 T cells were compared to untreated controls using a two-tailed paired t-test. Results
shown are representative of 5 donor experiments and means and standard deviations are shown.
* p<0.05, ** p<0.01, *** p<0.001
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FIGURE 6.17
rShh upregulates the production of IFNy, TNFa, IL-10, IL-6 and IL-2 from optimally
activated cell-sorted CD4+ T cells
Cell-sorted CD4+ T cells were optimally activated using monoclonal anti-CD3e and anti-CD28
antibodies at lpg/ml and 5pg/ml respectively for 72 hours in the presence and absence of 10-
lOOOng/ml rShh. Supernatants were analysed for cytokine production using cytometric bead
arrays. rShh upregulated the production of IFNy (a), TNFa (b),IL-10 (c), IL-6 (d) and IL-2 (f).
Conversely, IL-4 was not modulated by rShh (e) For the purposes of statistical analysis, treated
CD4 T cells were compared to untreated controls using a two-tailed paired t-test. Results shown
are representative of 5 donor experiments and means and standard deviations are shown.




The work presented in this chapter has aimed to delineate further the effect of rShh
on activated CD4+ T cell effector function.
6.7.1 Shh and T cell effector function
This work followed 2 recent publications from our group. The first, using murine
CD4+ T cells, reported that rShh enhances the proliferation of sub-optimally
• 91 •
activated murine CD4+ T cells , an effect demonstrated to be mediated via the
90
enhanced entry of activated T cells into the cell cycle. Subsequently, Stewart et al
demonstrated that rShh enhanced the proliferation of optimally activated, but not
sub-optimally activated human PBMC-derived CD4+ T cells, in 50% donors studied.
Furthermore, the work of Stewart et al20 demonstrated that the addition of rShh
differentially modulated the cytokine effector response of optimally activated human
CD4+ T cells. Most notably, IFN-y, IL-2,11-5 and IL-10 were upregulated in these
cells.
Both Lowrey et al21 and Stewart et al20 also reported on the effect of the monoclonal
antibody, 5E1, on cultures of activated CD4+ T cells. Lowrey et al21 demonstrated
that 5E1 abrogated the proliferation of suboptimally activated CD4+ T cells. Stewart
et al20, using optimally activated human depletion-enriched CD4+ T cells,
demonstrated similar abrogation ofproliferation, but in only 50% donors studied. In
those donors where an abrogated proliferative response was observed, 5E1 was also
shown to inhibit the production of IFNy and IL-2. Conversely, IL-10 and IL-5
production were not abrogated by the addition of 5E1.
Thus, together, the results from these 2 studies would suggest that Shh signalling
may be important in modulating both the proliferation and cytokine effector function
of adult peripheral CD4+ T cells, although the reasons for the differential response of
human and murine T cells is not clear. In attempting to reproduce these findings in
the human system, CD4+ depletion using negative selection affinity columns (R&D
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Systems) was employed as previously20. However, in the work presented here,
depletion-enriched CD4+ T cell proliferation failed to be modulated by the addition
of rShh in any of the donors studied. An effect of rShh on cytokine effector function
was observed but only when suboptimal activation was used. Interestingly, when a
third party antigen presenting cell was substituted for anti-CD3/anti-CD28 activation,
neither proliferation nor cytokine production were modulated by the addition of
rShh. Furthermore, the addition of 5E1 to activated T cells or MLRs failed to
modulate either proliferation or cytokine effector function in this system. In light of
these results and the disparity from those previously reported20'21, it was necessary to
re-evaluate why these results were not in keeping with the earlier reports. One
possible reason for the differences may have been due to differences in the reported
purities. Indeed, in the present work, using depletion techniques alone resulted in a
population of cells with 82-88% purity, far lower than those previously described
• 91 90
using depletion-enrichment techniques for both murine and human CD4+ T cells.
In both of these studies, purities were reported to be consistently >93%. Therefore, it
was necessary to further optimise the purity of the CD4+ T cells used for culture. In
the first instance, positive selection techniques were employed. Such techniques
generated high purities and yields of CD4+ T cells although it was readily apparent
that positive selection was inherently complicated by the induction of T cell
activation as evidenced by high background levels of proliferation and cytokine
activity in resting T cells. Subsequently, CD4+ T cell depletion followed by FACS
cell sorting was employed to produce CD4+ T cells of high purity (consistently
>98.8%). In contrast to the results using positively selected CD4+ T cells, the
background activity of the resting cells was in keeping with that observed using
depleted T cells alone.
Interestingly, irrespective of the method used to purify the CD4+ T cells, this work
has failed to demonstrate an effect of rShh on the proliferative response of either sub-
optimally or optimally activated CD4+ T cells. This is in marked contrast to the
findings in the mouse where rShh maximally augmented CD4+ T cell proliferation at
lOOng/ml rShh21. Similarly in the work of Stewart et al20, enhanced proliferation was
maximal at lOOng/ml, albeit that this effect was demonstrated in only 50% donors
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studied. It is not clear why the present work has failed to demonstrate the changes in
91 9f)
proliferation previously reported by Lowrey et al and Stewart et al . However, that
the effects on proliferation and other markers ofT cell activation may be dissociated
has been described previously in the literature. Indeed, there are a number of reports
suggesting that the use ofproliferation as a marker of T cell activity may mask
changes in T cell effector function686"689. The changes in cytokine effector function
seen here in response to rShh in the absence of changes in proliferation would largely
be in keeping with these reports. In this regard, a further interesting point arises. In
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the work of Stewart et al , although the optimal effect on proliferation ofCD4+ T
cells occurred at lOOng/ml, the effect of rShh on cytokine effector function was
maximal at lOOOng/ml, the latter finding consistent with the results presented in this
chapter. Why this should be the case remains unclear although this point will be
raised again later in this discussion.
In this study, CD4+ T cells have been either suboptimally activated or optimally
activated using anti-CD3s and anti-CD28 antibodies in keeping with the work of
Lowrey et al21 and Stewart et al20 respectively. Interestingly, rShh only modulated
the cytokine effector function of both suboptimally and optimally activated T cells
when highly purified cell sorted cells were used. In contrast, when either depletion-
purified or positively selected CD4+ T cells were used, only those cells suboptimally
activated by anti-CD3/anti-CD28 responded to rShh through altered cytokine effector
function and the cytokine profile induced by optimal anti-CD3/anti-CD28 activation
was not augmented by the addition of rShh. Why this is the case is not clear. It may
be that rShh fails to augment the effector function ofT cells when the cells are
already highly activated. Indeed, the levels ofT cell activity (in terms ofproliferation
and background cytokine release) in depletion purified and positively selected T cells
were generally higher than when cell sorted cells were used. It may be that the
presence of contaminating APCs in the depletion-enriched cells and the inherent
activation ofT cells together with an albeit small number of contaminating non-
CD4+ cells in cells purified by positive selection techniques contributed to this
relatively high level of background activation. In keeping with this possibility is the
finding that when stimulating third party APCs were substituted for anti-CD3 anti-
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CD28 stimulation, rShh failed to augment the cytokine activity of the T cells. Thus, it
may be that when the CD4+ T cells are already highly activated, the effect of a
further possible stimulatory source such as rShh, may be masked by the highly
activated state of the T cells. Conversely, highly purified CD4+ T cells, suboptimally
or optimally activated by anti-CD3 and anti-CD28 antibodies, but not by the
presence of additional contaminating cells may well retain the ability to respond to a
low concentration of rShh through further increases in cytokine production. This
avenue could be further pursued by extending the range of activating stimuli and
modulating the relative contributions of TCR ligation and costimulation accordingly.
However, the finding that Stewart et al20 demonstrated effects on T cell proliferation'
and cytokine effector function only when optimal stimulation was employed would
not lend support to this argument.
In this and the previous series of experiments20'21, the effect of the monoclonal
antibody, 5E1, has been explored. This antibody has been used previously to inhibit
the binding of endogenous Shh protein to the Ptc receptor19"21'147. Lowrey et al21
demonstrated that 5E1 inhibited the proliferation of anti-CD3, anti-CD28 activated
CD4+ T cells. Stewart et al20 demonstrated the same effect in 50% human donors
and, further, demonstrated that 5E1 was able to inhibit the upregulation of IFNy and
IL-2, but not IL-5 and IL-10, in optimally activated CD4+ T cells in those donors
responding to 5E1. Interestingly, in the present work, it was not possible to
demonstrate an abrogating effect of 5E1 on proliferation or cytokine effector
function irrespective ofwhether suboptimal or optimal activation was used.
Similarly, 5E1 was ineffective at inhibiting the MLR response, although low dose
ciclosporin could abrogate the MLR response. The reasons for these disparities are
not readily apparent. It may be that the antibody was not used at high enough
concentrations. 5E1 has been shown previously to inhibit Shh binding to Ptc when
used at 20pg/ml20'21. In the present series of experiments 10-50pg/ml 5E1 was used
but, even at high concentrations, an abrogating effect was not demonstrated. Another
possibility is that either of the 2 aliquots of 5E1 antibody may have lost functionality,
perhaps explaining why other workers in the laboratory20'21 demonstrated results
using this 5E1 in earlier studies which are at odds with the present findings. In light
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of these results, preliminary experiments in 2 donors were performed in which cell
sorted activated CD4+ T cells were incubated with 10pM cyclopamine prior to the
addition of exogenous rShh (See Appendix 5). Cyclopamine, like 5E1 also failed to
modulate the proliferation or cytokine effector function of the T cells. Taken
together, these results would suggest that, at least in my hands, inhibition of Shh
signalling fails to modulate the proliferation or cytokine effector function ofCD4+ T
cells. However, polymorphisms in the Shh signalling pathway exist and, thus,
extrapolating conclusions from these experiments performed in only 2 donors should
proceed with caution. Future experiments using a larger donor pool would help to
further clarify the effect of cyclopamine on the effector function of CD4+ T cells.
Furthermore, other possible explanations exist. For example, it may be that the effect
of Shh on CD4+ T cell activation occurs independently of the Ptc-Smo-Gli pathway
and, indeed, effects attributed to Shh signalling independent of the Ptc-Smo-Gli axis
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have been proposed to occur elsewhere in the literature . This could explain both
the inability of 5E1 and cyclopamine to inhibit the cytokine effector response of the
T cells in the work presented here.
6.7.2 The Nature of the Stimulus
The results presented in this chapter raise interesting questions regarding the role for
Shh signalling in T cells. The original experiments described in the early part of this
chapter suggested that rShh enhanced the cytokine effector function of depletion-
purified and positively-selected CD4+ T cells. Notably, IFN-y, IL-2 and IL-10 were
... . . 90
shown to be upregulated in keeping with the earlier findings of Stewart et al .
Furthermore, it has also been shown that IL-6 and TNFa are upregulated in response
to rShh. This pattern of cytokine response is interesting since cytokines typically
associated with Thl (IFN-y, IL-2 and TNFa) and Th2 (IL-10) responses are
generated together with the non-Thl, non-Th2 cytokine IL-6. Given this pattern of
cytokines, one possibility is that both T cells and cells contaminating the preparations
ofCD4+ T cells may be contributing to some of the cytokine effector response
observed. Indeed, it is known that B cells, CD8+ T cells and monocyte/macrophages
express Ptc and, thus, any or all of these cells, if contaminating the CD4+ T cell
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preparations, may be capable of responding to a rShh signal. Furthermore, from the
observations ofChapter 4 and the knowledge that endotoxin is an extremely potent
stimulus particularly to cells of the monocytic lineage, it was considered extremely
important to generate cells of very high purity to eliminate any possible contribution
from a small population of contaminating cells, capable of responding to endotoxin
contained within the protein preparation used to explore the effect of Shh in vitro.
Thus, to address these concerns, cell sorting was employed to generate a highly
purified population of CD4+ T cells. Of considerable interest was the finding that, in
the absence of contaminating cells, the CD4+ T cells still responded to the rShh
through enhanced cytokine production, the profiles seen being similar, albeit of
lower magnitude, to those observed when less pure populations ofCD4+ T cells
were used. Thus, from these results, it would seem that T cells are capable of
responding to the rShh used to stimulate them through the production of a variety of
different cytokines. In this regard, reports suggesting that the Ptc/Smo receptor
complex may be associated with lipid rafts35'56 are interesting since the importance of
lipid rafts in T cell activation is becoming increasingly well understood386'690"692 and
this may provide a mechanism by which Shh signalling may be integral to T cell
signalling and effector function. Furthermore, the finding that phosphatidylinositol 3-
kinase activity may be triggered by Shh signalling65 may provide further evidence for
a link between Shh signalling and T cell effector processes.
Nevertheless complex issues remain. For example, can we be certain that the
response ofCD4+ T cells to rShh is in fact a response to Shh itself? Indeed, in the
present work it has not been possible to confirm specificity of the response since
neither 5E1 nor cyclopamine appeared to modulate the proliferative or cytokine
effector response of activated CD4+ T cells, irrespective ofwhether suboptimal or
optimal activation conditions were employed. Furthermore, the findings from
Chapter 4 together with several reports demonstrating TLR expression on T cells693"
698 adds a further interesting dimension to this discussion. Most notably, the presence
of TLRs on T cells raises the possibility that T cells can respond to LPS and other
bacterial components present within the recombinant Shh protein used in these
experiments. Although the concentrations of LPS present in the rShh are low, its
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presence precludes certainty regarding the role of Shh in these cultures. It is also of
importance that whilst LPS is likely to be one of the most potent of the contaminants
present, other bacterial contaminants are likely to include bacterial DNA and outer
wall proteins such as porins and lipid A-associated proteins, fimbrial proteins,
protein A and lipoproteins all ofwhich are capable of inducing cellular activation,
via a range ofTLRs, particularly including TLR4, TLR2, and TLR96". Such
contaminants are not readily detectable using the LAL endotoxin assays and thus are
difficult to quantify. This knowledge is important given that, in a number of studies,
activation of T cells using bacterial products such as LPS has been demonstrated700"
702. y8 T cells proliferate in response to activation by E coli or native lipid a696-703-704
and regulatory CD4+CD25+ T cells upregulate activation markers and proliferate in
response to LPS697, the latter effect shown to be augmented by TCR triggering and
IL-2 stimulation. In a further study, activation of T cells using TLR3 and TLR9
agonists was shown to result in enhanced activated CD4+ T cell survival without
augmenting proliferation693.
In light of the findings from this chapter, several other reports are also of interest. For
example, resting murine CD3+ T cells express TLR2 and TLR4 mRNA695 and TCR
engagement using anti-CD3s antibodies and cytokines such as IL-2 have been shown
to rapidly induce TLR2 expression in T cells, an effect involving various LPS- and
cytokine-sensitive transcription factors including NF-kB, CREB and STAT694'695.
Thus, it can be seen how recombinant Shh containing the TLR2 agonist bacterial
lipoprotein, which closely associates with LPS, might stimulate T cell events
• • • 6qr
downstream of TLR2 activation. Indeed, recent reports from Liew et al would lend
significant support to this notion. Using highly purified anti-CD3 activated CD4+
human T cells, Liew et al698 demonstrated the expression ofmRNA and intracellular
proteins of TLR2, TLR4 and MD2. Interestingly, naive cells failed to express CD 14.
Significant levels of cell surface expression of TLR2 and TLR4 were shown to peak
between 12 and 72 hours following activation demonstrated using a combination of
kinetic and immunofluorescence studies. The immunofluorescence studies further
helped delineate the pattern of expression ofTLRs on T cells. Of note were the
findings that, not only were all T cells in a highly purified population positive for the
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TLRs, but also TLRs appeared to polarise on the T cells. Whether this reflects the
requirement of TLRs for lipid rafts for effective function in a similar manner to the
TCRs is not clear. Interestingly, Liew et al698 demonstrated that, in anti-CD3
activated CD4+ T cells, proliferation was enhanced and cytokine effector function
modulated by the addition of the TLR2 agonist, bacterial lipoprotein. Bacterial
lipoprotein was shown to markedly enhance the production of IFNy, IL-2 and TNFa
by anti-CD3 activated CD4+ T cells. These results prove particularly interesting in
light of the results presented in this chapter where the addition of rShh modulated the
production of these and other cytokines.
In a further report, both Lipid A and LPS have been shown to upregulate IFNy and
downregulate IL-4 production from purified murine CD4+ T cells. This is also an
interesting finding in the context of the current results since IL-4 failed to be
modulated by rShh in any experiments irrespective of the isolation method
employed.
Taken together, the findings from these studies highlight the need for alternatives to
the use ofE coli-derived recombinant Shh for the investigation of Shh signalling, in
cells perhaps previously disregarded as responders to endotoxin signals. Indeed,
although the levels of LPS present within rShh used in the concentration range 10-
1 OOOng/ml are low, that other endotoxic contaminants will invariably be present
(including, of note, TLR2, TLR3 and TLR9 agonists), that T cells upregulate TLR2
mRNA in response to TCR ligation thus enhancing subsequent stimulation by TLR2
agonists and that CD4+ T cell cytokine effector response can be directly modulated
by bacterial components, ensures that the investigation of Shh signalling in T cells
using recombinant proteins will be difficult. Recent evidence suggesting that CD4+
T cells express several TLRs together with data suggesting that synergy can occur
between TLRs348'349 and that TLR4 signalling can induce TLR2 expression350 would
further add to these concerns. Furthermore, that TLR agonists might synergise with
Shh itself is a possibility, although further pursuit along this line of enquiry would
prove difficult using bacterially-derived recombinant Shh protein.
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Distinguishing between effects due to Shh protein from those due to bacterial
contaminants relies on specific pathway inhibitors. In the present work, 5E1 failed to
modulate either the proliferation or cytokine effector function of activated T cells,
suggesting that the effects observed are not specific to the Shh signalling pathway. It
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is interesting in this regard that Stewart et al , using the 5E1 antibody in cultures of
activated T cells, found inhibition of cytokine effector function in approximately
50% donors. In those responding donors, IFN-y and IL-2, but not IL-10 or IL-5 were
inhibited by 5E1. Whether this indicates effects of rShh attributable to both a Shh
element and a non-specific stimulatory component of the protein used remains to be
determined. It is unfortunate that LPS neutralisers such as polymyxin B (PMB), as
employed in Chapter 4, are unlikely to be useful since they have an unpredictable
effect on lipoproteins and other bacterial components681'705 which may be of greater
importance given the reports of upregulated TLR2 expression in activated CD4+ T
cells694,695. More clarity would doubtless be achieved through the employment of
non-bacterially-derived and endotoxin-free ligands. Such Shh preparations are not
currently commercially available.
6.7.3 Summary
The work presented in this chapter has explored the effect of rShh on T cell effector
function following recent reports in the literature suggesting that rShh enhanced the
proliferation and cytokine effector response of anti-CD3s/anti-CD28 activated CD4+
T cells. Three different purification techniques (CD4+ depletion, CD4+ positive
selection and CD4+ depletion followed by CD4+ CD3+ FACS cell sorting) were
employed to generate CD4+ T cells. Irrespective of the technique used, rShh failed to
modulate the proliferation of suboptimally or optimally activated CD4+ T cells and,
furthermore, rShh failed to have any effect on the proliferation or cytokine effector
function ofCD4+ T cells utilised in a mixed leukocyte reaction with third party,
mitomycin-C treated, macrophages. Conversely, rShh modulated the cytokine
effector function of anti-CD3s/anti-CD28 activated CD4+ T cells effecting an
upregulation of IFN-y, IL-2, IL-6, TNFa and IL-10, these findings broadly in
agreement with those previously published. In keeping with the previous work of
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Lowrey et al and Stewart et al , the monoclonal antibody, 5E1 was used to
determine whether inhibition of the Shh signalling pathway could result in
abrogation of the proliferative or cytokine effector response of activated CD4+ T
cells. In contrast to these published reports, 5E1 failed to modify the effector
function ofCD4+ T cells. Furthermore, in preliminary experiments using
cyclopamine, a specific inhibitor of the Shh signalling pathway, no effect of
cyclopamine on T cell effector function was observed. Accepting that this failure of
T cells to respond to 5E1 and cyclopamine may reflect antibody failure or
polymorphisms within the Shh signalling pathway, particularly when the
experiments using cyclopamine were performed in only 2 donors, other possibilities
must also be considered. In particular, recent reports in the literature demonstrating
the expression ofTLRs in T cells adds an interesting but complicating dimension to
the use ofbacterially-derived recombinant Shh protein in cultures of T cells.
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General Discussion and Conclusions
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The highly conserved Sonic hedgehog signalling pathway plays an important role in
the determination of cell fate and proliferation during development. To date, the vast
majority of the published reports on Shh signalling have concentrated on
developmental processes in the embryo. Much less is known regarding possible roles
for Shh signalling in the adult. More recently, however, a few reports have emerged
to suggest possible roles for Shh signalling in repair and/or remodelling processes
and the maintenance of peripheral immunity in the adult. These reports were central
to the development of the work presented in this thesis. In this discussion, the
evidence leading up to the hypotheses underlying the work will be outlined briefly.
The hypotheses and the findings from the experimental work exploring these
hypotheses will then be discussed followed by some conclusions relating to the
findings. Areas of possible future investigation are also discussed.
Chronic renal allograft nephropathy is a significant cause of allograft loss in the renal
transplant recipient. It is a poorly understood process characterised by interstitial
fibrosis, tubular dilatation and atrophy, vasculopathy and an inflammatory cell
infiltration. The progressive fibrosis that occurs is considered to be the main cause
for the gradual deterioration in renal function and graft failure. That the Shh
pathway may be of relevance to the aetiology of CAN is suggested by several lines
of evidence. Firstly, although Shh expression has not been reported previously in
adult kidney, Shh is expressed in the epithelium of the developing metanephric
kidney and Hh signalling is thought to play an early role in renal development.
Secondly, Stewart et al149 recently demonstrated the upregulation of Shh in epithelial
cells at sites of fibrotic disease in both human fibrotic lung disease and in murine
models of fibrotic lung disease, suggesting that the pathway may play a role in the
development of fibrosis. Furthermore, components of the Shh pathway have been
demonstrated in immune cells recognised to play a role in the pathogenesis ofCAN.
Both T cells and macrophages are present in the inflammatory cell infiltrate in CAN
with macrophage infiltration and activity correlating directly with graft survival. Shh,
Ptc and Glil expression have been demonstrated in T cells20'21, and Ptc expression
has also been reported in macrophages149. Furthermore, other factors known to be
upregulated in CAN may also be upregulated by Shh. These include the growth
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factors, Transforming Growth Factor-p (TGF-P) and Vascular Endothelial Growth
Factor (VEGF).
Another recently identified area in which Shh signalling may be important in the
adult is peripheral immunity. Stewart et al149 provided evidence to suggest that
alveolar macrophages express the receptor for Shh, Ptc, thus raising the possibility
that macrophages may be capable of responding to a Shh signal. Two further reports
in the literature provided evidence that human and murine CD4+ T cells expressed
components of the Shh signalling pathway and that these cells could respond to a
20 21Shh signal ' . In the first of these reports, Lowrey et al demonstrated that the
addition of exogenous recombinant Shh protein to cultures of activated murine CD4+
T cells augmented the proliferative capacity of these cells, an effect mediated
through enhanced entry into the S/G2 phase of the cell cycle21. Furthermore,
inhibition of endogenous Shh using the monoclonal antibody, 5E1, abrogated the
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proliferative response of activated CD4+ T cells. Subsequently, Stewart et al
published a report regarding human CD4+ T cells. These findings were broadly in
21
keeping with the earlier work of Lowrey et al and suggested that the addition of
recombinant Shh to cultures of human CD4+ T cells enhanced the proliferation of
these cells, but that this effect was observed only in 50% of the donors studied. In
those responding donors, the enhanced proliferation was associated with the
increased production of cytokines, notably IFN-y, IL-2, IL-5 and IL-10. These
reports together highlighted a previously unexplored role for Shh signalling in adult
peripheral immunity.
Thus, from the above body of evidence, the two central hypotheses to this thesis
were drawn. The first of these was that Shh signalling components are expressed in
and relevant to normal and CAN kidney. The second hypothesis was that Shh
signalling plays a role in peripheral immunity. In the following discussion, the
findings from the work exploring these hypotheses will be addressed.
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Hypothesis 1 - Shh signalling components are expressed in and relevant to
normal and CAN kidney.
Chapters 3 and 4 of this thesis have explored the hypothesis that Shh signalling is
relevant to normal and CAN kidney. In Chapter 3, immunohistochemistry and real¬
time PCR were used to explore the expression of Shh and Ptc by normal and CAN
kidney. Of considerable interest was the finding that Shh expression was
demonstrated in the proximal tubular epithelium of normal adult human kidney but
that, in contrast to the situation in the fibrotic lung, expression was absent in the
kidneys affected by CAN. In contrast, Ptc expression could not be demonstrated in
the normal kidney but was present on the infiltrating inflammatory cells of the CAN
kidney. These findings prompted speculation as to why the Shh expression seen in
normal kidney might be absent from CAN kidney. Clearly, one possibility for these
observations is that the decline in number of viable tubules characteristically seen in
CAN might preclude the detection of Shh expression in the tissue sections, although
it is interesting to note that Shh expression was absent even in tissue sections where
grossly normal tubular structure was apparently retained. Thus, it was postulated that
the Shh expression seen in the normal kidney had been lost at some stage during the
lifespan of the allograft and the subsequent investigation presented in Chapter 4
aimed to investigate factors that may modulate epithelial expression of Shh in the
context of transplantation. In this regard, both a human renal adenocarcinoma cell
line (ACHN) and primary cultures of murine renal epithelial cells were used to
explore possible factors affecting Shh expression in normal renal epithelium. Clearly
a large number of factors may have impacted on the Shh expression in normal kidney
since the transplanted kidney is subjected to a variety of physiological, pathological
and iatrogenic insults through the course of its lifespan. With this in mind, the factors
chosen for further investigation included the immunosuppressive agents ciclosporin
and dexamethasone, and the effects of epithelial cell damage (in the form of either
hydrogen peroxide or ultraviolet irradiation). That epithelial damage may modulate
Shh expression and cause release of Shh from sites of damage was suggested both by
the work of Stewart et al149 and also by preliminary experiments by another student
in the laboratory, Mr Paul Fitch. Furthermore, that Shh may interact with immune
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cells at the epithelium-immune cell interface at sites of damage and/or repair lent
support to further investigation along this line of enquiry. Two approaches were used
to evaluate the effects of the immunosuppressants and damage on renal epithelium;
Shh protein and RNA expression were evaluated in the cells in the presence and
absence of either the immunosuppressants or the damaging agent and, furthermore,
attempts were made to evaluate and quantify any Shh protein release into the culture
medium in response to these agents. These experiments were not without their
complications. Most notably, although it was interesting to find that ciclosporin, but
not dexamethasone, upregulated Shh expression in the ACHN cell line, further
investigation of this effect in the primary cultures ofmurine epithelial cells was
hampered by an inability to reproducibly detect Shh mRNA expression in the cells.
Furthermore, attempts to detect and quantify Shh protein release from cells were also
inadequate. Few reagents are available commercially for investigation of the Shh
pathway; only a murine Shh ELISA is available but this failed to detect Shh in the
supernatants of primary murine renal tubular cultures irrespective of the treatment
applied to the cells. Since the upregulation of Shh mRNA could only be
demonstrated in the human ACHN line but not the primary murine cultures (due to
difficulties with primers for both real—time and RT-PCR), the relevance of these
findings is not immediately clear although possible explanations for these results are
discussed in greater detail in Chapter 4. Indeed, at this stage, one can only speculate
as to whether Shh is in fact released from renal epithelial cells since the results
presented in Chapter 4 currently fail to support such a mechanism. Clearly, as more
reagents become available, it may be more feasible to determine whether Shh is
upregulated and/or released from epithelial cells in vivo.
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Hypothesis 2 - Shh signalling plays a role in peripheral immunity
Chapters 5 and 6 of this thesis have explored the hypothesis that Shh signalling plays
a role in peripheral immunity. Specifically, and relevant to the recent reports in the
literature identifying peripheral immune cells as targets of Shh signalling, this work
has sought to evaluate Shh signalling in macrophages and CD4+ T cells.
Shh andMacrophages
The work presented in Chapter 5 explored entirely new territory since the expression
of Shh signalling pathway components and the possible role that Shh signalling may
play in human peripheral blood-derived macrophages had not previously been
explored. The results from Chapter 5 demonstrated that such macrophages express
Ptc, Smo, Glil and Gli2 suggesting that macrophages may be able to respond to a
Shh signal. Furthermore, macrophage Ptc expression was upregulated in response to
recombinant Shh administration suggesting that active signalling through the Shh
signalling pathway was occurring. The subsequent experiments investigated the
effect of Shh on human macrophages using the same recombinant Shh peptide (rShh)
employed in the earlier in vitro work of Lowrey and Stewart. The results from these
experiments were initially very interesting demonstrating that Shh upregulated a
number ofproinflammatory cytokines and chemokines. Ofparticular interest was the
observation that certain proinflammatory cytokines such as TNFa, IL-1 and IL-12,
factors were not reliably upregulated by rShh whereas others such as IL-6, IL-8,
MCP-1, LP-10, RANTES and MIG were upregulated. The other interesting
observation was that use of the specific inhibitor of the Shh signalling pathway
cyclopamine inhibited the upregulation of IL-6 and MCP-1 but failed to modulate the
upregulation of other cytokines in response to Shh. This was an interesting
observation that could not readily be explained. Although, IL-6 and MCP-1 did
respond to the cyclopamine, the fact that the upregulation of the other cytokines and
chemokines evaluated failed to respond to cyclopamine suggested that either parallel
Shh signalling pathways were operating, one Smo-dependent and one Smo-
independent, or that Shh was not the only driving stimulus present. Given that the
recombinant Shh peptide utilised for these experiments was E coli derived, one
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significant possibility was that endotoxin contamination of the recombinant protein
was responsible for at least some of the effects observed. Subsequent experiments
using macrophages grown with and without serum, in the presence of an anti-CD 14
antibody and in the presence of polymyxin B were, finally, strongly in favour of LPS
exerting the effects observed in the macrophages in response to rShh. Why
cyclopamine was able to abrogate the response of IL-6 and MCP-1 is not clear,
although the use of cyclopamine reconstituted in LAL reagent water rather than
serum-containing medium failed to demonstrate abrogation of the Shh-mediated
effect, lending support to the possibility that preincubation of the macrophages with
serum (and, therefore, endotoxin) containing cyclopamine may somehow have
partially desensitised the macrophages to the subsequent Shh administration and the
endotoxin contained therein. Thus, although initially very interesting, the subsequent
results presented in Chapter 5 strongly favour endotoxin-mediated effects on
macrophages rather than effects due to Shh protein itself. Furthermore, of interest
were some preliminary results suggesting that exogenous LPS could also upregulate
Ptc expression, an important observation given that upregulation ofPtc, itself a
transcriptional target of Shh signalling, has traditionally been used as a readout of
Shh signalling pathway activation.
Shh and CD4+ T cells
The work presented in Chapter 6 attempted to reproduce the experiments reported
previously by Stewart et al20 in human CD4+ T cells. Both Lowrey et al21 in the
murine system and Stewart et al20 in human cells had demonstrated an augmented
proliferation of activated CD4+ T cells, an effect maximal at lOOng/ml rShh. The
initial aim of this chapter had been to reproduce these experiments and then to extend
the work further to investigate whether the same effect could be demonstrated when
a third party antigen presenting cell was substituted for the anti-CD3s/anti-CD28
stimulation. However, despite employing 3 different methods to purify the CD4+ T
cells, including the depletion techniques used by both Lowrey et al21 and Stewart et
al20 in their recent publications, it was not possible to demonstrate an effect of rShh
on activated CD4+ T cell proliferation in the experiments presented in this thesis. It
was also not possible to demonstrate an effect of the monoclonal antibody, 5E1, on
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activated CD4+ T cell proliferation which was in contrast to these earlier
publications. Possible reasons for these discrepancies are discussed in Chapter 5. The
main positive finding from Chapter 5 was that, in agreement with the earlier work of
Stewart et al20, rShh modulated the cytokine effector function of anti-CD3e/anti-
CD28 activated CD4+ T cells, although it is of interest that it failed to modulate the
magnitude or nature of the cytokine profile of the MLRs. It may be that, in these
instances, the CD4+ T cells were in a state ofmaximal activation, such that the
presence of a further stimulus failed to further amplify the T cell effector function
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The earlier work of Stewart et al employed ELISAs to demonstrate the
upregulation of IFN-y, IL-2, IL-5 and IL-10. The experiments presented in this thesis
add to these findings demonstrating that IL-6 and TNFa are also upregulated by
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rShh. Stewart et al had also shown that 5E1 was able to prevent the upregulation of
IFN-y and IL-2, but not IL-10 or IL-5, in 50% donors studied. In the present work, it
has not been possible to demonstrate any effect using 5E1. Whether the antibody had
lost activity or whether the donors used in this work were simply similar to the non-
responders in Stewart's study is not clear. It is interesting to note that in 2
preliminary studies using the teratogenic Shh signalling pathway inhibitor,
cyclopamine, no effect on either CD4+ T cell proliferation or cytokine effector
function was demonstrated. Clearly, however, such experiments would have to be
repeated using a much larger donor pool before firm conclusions can be drawn from
these observations using cyclopamine.
Conclusions and Future Directions
What conclusions can then be drawn from this work? Perhaps the first conclusion
would be that Shh is apparently expressed by normal human renal epithelial cells but
not epithelial cells in CAN. This novel observation raises a number of interesting
questions, not least: what is the relevance of this expression and what causes loss of
expression in CAN? As discussed at length in Chapter 1, Shh may perform a number
of roles including the maintenance of cell viability and differentiation or possible
involvement in endocytic processes across the tubular cells in association with
megalin. Further investigation of such roles would be an interesting avenue of future
enquiry. Both Shh -/- and Ptc -/- mutations in mice are embryonically lethal and
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death occurs prior to the development of the kidneys. However, it would be possible
to explore the effect of Shh signalling pathway blockade using in vivo administration
of the 5E1 antibody. Blockade of active signalling followed initially by simple
evaluation of renal architecture using immunohistochemistry and electron
microscopy would allow analysis of gross changes in structure to be observed. As
mentioned previously, further evaluation in vitro would be aided greatly by better
reagents for evaluating the Shh signalling pathway. As raised in Chapter 4, systems,
other than the commercially available murine ELISA, for evaluating activation of the
Shh pathway are in use in other laboratories albeit that such systems are not yet
available commercially. Three such assays include the use of activation of alkaline
phosphatase in C3H10T1/2 cells, activation ofPtc transcription in C3H10T1/2 and
activation of a Gli-luciferase reporter in Shh-Light2 cells.
The results from Chapters 5 and 6 raise interesting dilemmas regarding the
exploration of Shh signalling in immune cells. It is clearly desirable to investigate the
role only of Shh protein in such cells where other immune stimulation, such as that
provided by bacterial products, may simply cloud the issue. Indeed, that
macrophages may not be the only cells capable of responding to such bacterial
products adds to these concerns and means that investigation of the effect of Shh
when using bacterially-derived recombinant proteins should proceed with caution.
Furthermore, this point highlights the need to address the use of serum in in vitro
culture systems since, as discussed in Chapter 5, serum also contains significant
levels of endotoxic activity. Although the influence of serum components on
macrophage effector function has been considered previously, the same
consideration has not been extended to work with T cells. Given that T cells may be
able to respond to such endotoxic contaminants, the significance of using serum in
such cultures should not be underestimated. The soluble CD 14 content of serum may
also be of similar relevance particularly in the context of T cell cultures, a cell type
not characterised by high levels of surface CD 14 expression.
The avoidance of the use of recombinant proteins necessitates that other alternatives
are available. One possibility might be to use tissue-derived Shh for the in vitro
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studies. This would be particularly useful since tissue-derived Shh is reported to be
more bioactive than the recombinant peptide form. Extracting protein from
mammalian tissues is not without its difficulties not least since few anti-Shh
antibodies are available and most of these are polyclonal antibodies. One laboratory
in the USA (that ofPA Beachy) has taken some time to produce the octylated (and
more active) form of Shh and it may be that collaboration with this laboratory or the
development of such techniques in our laboratory may hold the key to the further
investigation of Shh signalling using a non-bacterially derived protein. It might be
anticipated that such an approach would at least partly circumvent the difficulties
associated with interpreting effects seen in response to rShh. There are, however,
other approaches that could be used. For example, eliminating the ability of the cells
to respond to Shh or bacterial products might be one approach. It is not clear why
5E1 failed to have the same effect as that previously reported in activated T cells by
Lowrey and to a lesser extent by Stewart. 5E1 is believed to bind to Shh at an area
overlapping that to which Ptc binds and should thus prevent the binding of the Shh to
Ptc. Perhaps simply generating fresher antibody might circumvent the problem
although the high levels of endotoxin contamination precludes the use of 5E1 in
macrophages and, probably, also future T cell studies. Repeating the cyclopamine
experiments in more T cell donors would help to further clarify what effect, if any,
cyclopamine has on T cell Shh signalling and may be a more reliable way of
assessing Shh signalling in these cells. Other methods of eliminating the ability of
cells to respond to a Shh signal might include conditionally knocking out Ptc or other
components of the signalling pathway, a technique which would be easier to perform
in primary T cell cultures or cell lines rather than primary macrophage cultures. An
alternative approach if bacterially-derived recombinant proteins are to be used might
be to attempt to eliminate the effect of the bacterial components likely to be present.
Detection of such components is really only limited to the detection of LPS using the
LAL assay and other components are not reliably detected by this assay. This has
important implications particularly when TLR4 is not the only TLR expressed on
macrophages and T cells and this further hampers the reliability of using TLR
knockout mice for the investigation of Shh signalling events.
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Indeed, exclusion of a single TLR, such as TLR4 using the C3H/HeJ or
C57BL/10ScCr mice, may be more misleading than helpful since more than one TLR
is likely to be involved in the cellular response to recombinant proteins. Furthermore,
aside from the bacterial components present in the recombinant protein, Shh
signalling itselfmay even involve the TLRs and, thus, the importance of a non-
bacterially derived protein for such experiments is firmly reiterated. That at least LPS
might be neutralised by agents such as polymyxin B is highlighted in the discussions
of Chapters 5 and 6. However, it is emphasised that the elimination of LPS may not
be the only issue. That some contribution may be made by other TLR agonists is
highlighted also by the fact that polymyxin B abrogated significantly but could not
completely eliminate cytokine production from the macrophages. The extra
contribution seems unlikely to be Shh in this instance since the use of cyclopamine
and PMB together could not prevent cytokine production although the possibility that
the Shh and TLR pathways may interact downstream of the TLRs must preclude firm
conclusions from this observation. That other TLR agonists are not reliably inhibited
by PMB is of specific importance for the investigation ofT cell events not least since
reports in the literature suggest that TLR2 may be more important in the T cell with
TLR2 expression reported to be linked to T cell activation events and sensitising the
T cell to further stimuli. It is clearly important that future investigations of T cell
responses, like those ofmacrophages, avoid the use of bacterially-derived proteins
containing TLR agonists such as LPS and bacterial lipoproteins.
Aside from the issues highlighted above, the results from Chapters 5 and 6 do raise
some interesting questions. For example, what other roles may Shh play, if any, in
macrophages and CD4+ T cells? Does the expression of Shh pathway components
serve another purpose? Indeed, it has been proposed that Shh may play a role in
lC\f\ • •
commissural axon guidance and other studies have lent support for a possible role
for hedgehog family members in the control ofmigration and motility707. Whether
Shh might play a role in such processes in immune cells is a line of enquiry yet to be
pursued. Clearly, there is still much headway to be made in determining the role of
Shh signalling in the adult, a process that would be considerably aided by the
286
availability ofnon-bacterially derived Shh and improved reagents for the
quantification of Shh expression.
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Megalin is expressed on the apical surface of proximal
convoluted tubular cells
Sections of normal human kidney were investigated for the
expression of megalin. Immunohistochemistry was performed as
outlined in Chapter 2 using a goat polyclonal antibody to megalin
(Santa Cruz) at a dilution of 1:40. This confirmed the expression of
megalin on the apical surface of proximal convoluted tubular cells
(Mag x 400), a finding in keeping with other reports in the




Megalin fails to be expressed in CAN
Sections ofCAN were investigated for the expression of megalin.
Immunohistochemistry was performed as outlined in Chapter 2
using a goat polyclonal antibody to megalin (Santa Cruz) at a
dilution of 1:40. This failed to demonstrate the presence ofmegalin
in samples ofCAN (Mag x 400). Results represent experiments
performed on renal tissue from 5 donors.
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APPENDIX 3
Ptc expression is upregulated in macrophages in response to LPS
Real-time PCR was performed to determine the expression ofPtc mRNA in
macrophages in response to l-100ng/ml E coli 055.B5 LPS following an 18 hour
incubation. Values are expressed as a ratio of the concentration ofPtc mRNA
relative to untreated macrophages grown in medium alone. The untreated
(Ong/ml LPS) macrophages are given a value of 1. Ptc mRNA expression is
upregulated in response to treatment with LPS. Results represent experiments
performed on 2 donors.
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APPENDIX 4
The inhibitory effects of cyclopamine and polymixin B are not additive
Macrophages were pre-incubated with either 10pM cyclopamine, 10pg/ml polymixin B or both
1 OpM cyclopamine and 1 Opg/ml polymixin B for 45 minutes prior to the addition of rShh. rShh
was added to give a final concentration of lOOOng/ml and the cells were incubated in these
conditions for 24 hours. The supernatants were harvested after 24 hours and CBAs employed to
quantify cytokine and chemokine production. The graphs above illustrate IL-6 production under
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APPENDIX 5
Cyclopamine fails to modulate the response of cell-sorted CD4+ T cells to Shh
Preliminary experiments were performed in two human T cell donors to determine the
response to CD4+ T cells to rShh when pre-incubated with the specific inhibitor of the Shh
signalling pathway, cyclopamine. 2xl05 FACS sorted CD4+ T cells per well were pre-
incubated for 45 minutes at 37°C with lOpM cyclopamine. rShh was then added to the wells to
give a final concentration of 10-1000ng/ml rShh. Each experiment was repeated in
quadruplicate. As previously, the cells were incubated for a period of 72 hours. At the end of
this incubation period, 20pl of culture medium was removed from each well for later cytokine
analysis.The cells were pulsed with 3H-TdR (lpCi/well) and incubated for a further 18 hours.
3H-TdR incorporation was evaluated to assess proliferation of the T cells. Results represent the
proliferation experiments performed on 2 donors. As shown, resting (A), suboptimally
activated (B) and optimally activated (C) CD4+ T cell proliferation were unaffected by
cyclopamine. Similarly cytokine effector function was not modulated by cyclopamine
administration in either of the donors (data not shown).
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APPENDIX 6
Publications arising from work presented in this thesis:
> Wakelin SJ, Marson L, Howie SEM, Garden OJ, Lamb JR, Forsythe JRL.
The Role ofVascular Endothelial Growth Factor in the Kidney in Health and
Disease. Nephron Physiol 2004; 98:73-79.
> Fitch PM, Wakelin SJ, Lowrey JA, Wallace WAH, Howie SEM. Chapter 18
on 'Shh Expression in Pulmonary Injury and Disease' in Hedgehog-Gli
Signalling and Human Disease.
> Stewart GA, Lowrey JA, Wakelin SJ, Fitch PM, Lindey S, Dallman MJ,
Lamb JR, Howie SEM. Sonic hedgehog signalling modulates activation of




ivsioloav Nephron Physiol 2004;98:p73-p79
' DOI: 10.1159/000080686
he Role of Vascular Endothelial
irowth Factor in the Kidney in Health
ind Disease
onia J. Wakelin3' b Loma Marson3 Sarah E.M. Howie0 James Gardend
inathan R. Lambe John L.R. Forsythe3
enal Transplant Unit, Royal Infirmary of Edinburgh, blmmunobiology Group, MRC Centre for Inflammation
search, Medical School, University of Edinburgh, cDivision of Pathology, School of Molecular and Clinical
idicine, University of Edinburgh, dSchool of Clinical Sciences and Community Health, Clinical and Surgical
iences, Royal Infirmary, Edinburgh, "GlaxoSmithKline, Translational Medicine and Technology, Greenford,
ddlesex, UK
>y Words
iscular endothelial growth factor • Renal
ivelopment • Glomerular disease
bstract
iscular endothelial growth factor (VEGF) is a potent
idotholial coll mitogon, angiogenic factor and cnhanc
of vascular permoability. Exprocccd in the epithelial
lis of the developing glomerulus and tubular epitheli-
n, VEGF plays an important role in the development
id maintenance of the early vasculature of the kidney,
ire, we review the available literature regarding the
pression and function of VEGF both in the developing
id healthy adult kidney. Furthermore, we highlight how
!GF expression is altered in the diseased kidney and
iwthis modulated expression may impact on and re-
»ct underlying functional changes occurring during tho
sease process. As discussed, many controversial is-
es remain, particularly concerning the role of VEGF in
e diseased kidney. That VEGF has been proposed as a
itential future therapeutic target for the management
some renal diseases requires first that the precise role
VEGF in the normal kidney and various renal patholo-
es be further and more clearly defined.
Copyright © 2004 S. Karger AG, Basel
Introduction
In 1983, Senger et al. first described a protein secreted
from tumours that increased the permeability of vessels
[1], This factor, originally named Vascular Permeability
Factor, was later renamed Vascular Endothelial Growth
Factor (VEGF) following the observation that, in addi¬
tion to its effect on vascular permeability, it acted as a
powerful angiogenic factor and a specific endothelial cell
mitogen [2]. Given its action as an endothelial cell mito¬
gen and angiogenic factor, much attention has focused on
possible roles for VEGF in a number ofphysiological and
pathophysiological processes including organogenesis,
wound healing and tumour growth. However, these func¬
tions also suggest that VEGF may play an important role
at sites where maintenance of a capillary bed may be crit¬
ical for function. One of the best examples of such a cap¬
illar,- bed is in the kidnoy where an intact capillary net
work is integral to the filtration function of the nephron.
The aim of this paper is to review the current understand¬
ing of VEGF and its receptors with particular reference
to potential roles for the growth factor in the kidney in
health and disease.
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VEGF and Its Receptors
VEGF, also referred to as VEGF-A, was the first mem-
r of the VEGF family to be identified [ 1 ]. Other family
;mbers now include VEGF B-E and placental growth
(tor. The gene for VEGF is located on chromosome
21.3. Containing 8 exons, the coding region spans
4 kb and alternative splicing of this gene gives rise to
ceral isoforms encoding polypeptides of 121, 145, 148,
2, 165, 183, 189 and 206 amino acids [3, 4]. A further
(form, 165b, is unusual in being proposed as an endog-
ous inhibitory isoform ofVEGF [5]. The different iso-
rms vary in their ability to bind heparin, a property
pendent on exon 6 and 7 expression. For example,
IGF189 and 206 contain both cxons, bind heparin
ongly and, once produced, they remain attached to ex-
icellular matrix heparan sulphates. In contrast,
IGF 165 and VEGF 145 have exon 7 and exon 6, re
ectively, and VEGF 121 contains neither exon. These
2 the more freely diffusible forms of VEGF.
VEGF is expressed by and secreted from awide variety
cells and several variants may be expressed by one cell
pe simultaneously [6], The repertoire ofVEGF-produc-
g cells includes macrophages, neutrophils, fibroblasts,
atelets, eosinophils, mast cells, vascular smooth muscle
lis, hepatocytes, epithelial cells, several tumours and
11 lines and endothelial cells in vitro. Most VEGF-pro-
icing cells preferentially express VEGF variants 121,
i5 and 189, the other isoforms being less ubiquitously
pressed.
VEGF, once secreted, may bind to several function-
y distinct receptors, including VEGFR1 (Fltl), VEG-
12 (Flkl), VEGFR3 and neuropilin-1. Binding to these
ceptors mediates a variety of effects. VEGF is a potent
dothelial cell mitogen, and mediator of angiogenesis
(viewed in 7], In the embryo, it appears to be essential
r normal vascular development, and mice, homo- or
terozygous for transgenic mutations that inactivate
EGF, die from vascular abnormalities in utero [8], Con-
rsely, embryos subjected to excessively high levels of
EGF exhibit hyperproliferation of vessels resulting in
e formation of dysfunctional vessels and impaired or-
nogenesis [9].
VEGF has profound effects on permeability [10], an
feet possibly mediated via an increase in fenestration
rmation [ 11 ], the induction of transcellular gaps [ 12] the
rmation of caveolae [ 13] and the formation of interen-
(thelial cell gaps [14], Furthermore, VEGF acts as an
idothelial cell survival factor [15], effects vasodilatation,
obably via nitric oxide (NO) synthesis [16], and acts as
chemoattractant for monocytes [ 17]. It may also affect the
maturation of dendritic cells [18] and the polarisation of
T cells [19] and, thus, play a role in immune responses.
A multitude of factors upregulate VEGF at the mRNA
level or affect VEGF release from cells. One of the stron¬
gest signals for VEGF expression is hypoxia, but other
factors also upregulate VEGF. These include growth fac¬
tors, cytokines, interleukins, prostaglandins, angiotensin
II, adenosine, NO and hypo- and hyperglycaemia.
Expression of VEGF in the Kidney
VEGF expression has been reported in several cell
types within the human and rodent kidnoy. Most consis
tently, VEGF has been observed in the podocytes [20-
22]. Outwith the glomerulus, VEGF expression has been
detected in the renal tubular cells, distal more commonly
than proximal [20, 23], and the collecting ducts [21]. In
the developing kidney, VEGF is expressed in the podo-
cytc, tubular epithelium, collecting ducts and mesenchy
mal cells [21],
Other areas of expression have been more controver¬
sial. For example, although several groups have reported
the expression of VEGF by glomerular endothelial cells
in vitro [24], many in situ localisation studies have failed
to identify endothelial expression ofVEGF [20,25], Fur¬
thermore, mcsangial expression has been reported in vi
tro [26] and in models of disease [27, 28] but not in nor¬
mal kidney [20, 25],
Expression of Receptors for VEGF in the
Kidney
VEGFR1 and 2 expression have been demonstrated,
using 125I-VEGF165 binding experiments and immunolo-
calisation in glomerular endothelial colls, peritubular cap
illaries and in pre- and post-glomerular vessels in the hu¬
man and rodent kidney [21-23]. Neuropilin-1 is also ex¬
pressed in the visceral epithelial cells of the glomerulus
[29], mesangial cells [30] and in the afferent arterioles and
glomerular capillaries [29].
Functions of VEGF in the Normal Kidney
The enhanced expression of VEGF in the embryonic
kidney suggests that it may have a specific role in renal
development and, given its persistent presence in the
4 Nephron Physiol 2004;98:p73-p79 Wakelin/Marson/Howie/Garden/Lamb/
Forsythe
ult, it is tempting to speculate that it may continue to
involved in the mature kidney.
Development
The definitive kidney or metanephros appears around
1 in the mouse and renal development continues into
e second post-natal week. The excretory units develop
rm themetanephric mesoderm, and the collecting ducts
rm the ureteric bud, an outgrowth from the mesoneph-
: duct. The ureteric bud invades the metanephric tissue,
d islands of the latter cap the distal ends of the branch-
g ureteric bud. The cells of the metanephric tissue cap
e induced to become aggregates ofepithelial cells. These
iundantly express VEGF [21] and form small vesicles
rich subsequently give rise to comma- and S-shaped
idies. Small clefts develop, representing entry points for
e developing glomerular vasculature probably occur-
rg through a combination of angiogenesis and vasculo-
nesis. The former involves the sprouting of new vessels
rm pre-existing vessels and the latter involves the in situ
fferentiation ofendothelial cell precursors (angioblasts)
rich then form vessels through coalescence.
It was previously thought that the metanephric vascu-
:urc was derived from angiogcncsis. However, cxperi
ents involving renal grafts implanted into the anterior
amber of the eye suggested that VEGFR1- and VEG-
12-expressing angioblasts are primarily responsible for
icrovessel development in the kidney [31] suggesting a
le for VEGF in the development process. Other work
:monstrated that VEGF could convert a VEGFR2(-)
ecursor cell to a VEGFR2(+) haemangioblast [32] in
tro and, in metanephric organ cultures, high levels of
EGF were present in the medium at active stages of glo
erulogenesis [33]. Furthermore, the differentiation of
igioblasts into endothelial cells could be blocked by the
[ministration of antibodies to VEGF [34]. Podocyte se
:tive deletion ofVEGF results in marked endotheliosis
id progression lo the nephrotic syndrome in heleiozy-
ites. Homozygotes die soon after birth with renal failure
id abnormal glomeruli lacking mature endothelial cells
5], Overexpression of VEGF in the same system result
I in end-stage renal failure due to a collapsing glomeru-
pathy.
VEGF may also play a role later in the neonatal period
ith continued development of the kidney. Very high lev-
> of VEGFR2 expression were demonstrated in the de
doping glomerular endothelium [34, 36], and blocking
EGF with antibodies in newborn mice resulted in ab-
rrmal glomerulogenesis, decreased glomerular forma-
m and a significant reduction in glomerular vascularity
[33]. Furthermore, in antibody-treated mice, the capillar¬
ies failed to create useful glomerular vascular networks,
suggesting that an intact VEGF gradient may be neces¬
sary to sustain rapid glomerular growth and development
within a limited time frame [33].
Adult
In the adult, renal VEGF expression persists albeit at
a much lower level than that seen in the developing kidney
[21, 36]. Given the pattern of VEGF and VEGFR expres¬
sion in the adult kidney, it is possible that VEGF has a
specific functional role, particularly in the glomerulus.
The glomerular capillaries are structurally different
from other peripheral capillaries. The luminal layer is
covered with fenestrated endothelium, which is unusual
in not possessing bridging diaphragms, a finding in con¬
trast to most other types of endothelial cell fenestrations.
The endothelial cells are attached to the glomerular base¬
ment membrane consisting of extracellular matrix pro¬
teins. Outside the capillaries lie the podocytes, highly spe¬
cialised cells with processes extending from the cell body
providing support for the glomerular capillary network
and synthesising the glomerular basement membrane.
The glomerular capillary network is also supported by the
mesangium (mesangial cells and extracellular matrix).
Several possible roles for VEGF signalling in the glo¬
merulus have been proposed. That its role is outwith one
of angiogenesis is suggested by the predominance of
VEGFR1, rather than VEGFR2, in the glomerulus [22],
It may be that VEGF plays a role in regulating glomerular
circulation and the maintenance ofnormal renal function
[37], The VEGF-producing podocytes sit in very close
proximity to the glomerular endothelium expressing the
VEGF receptors [21] with only the glomerular basement
membrane interposed between them. For VEGF to bind
to its receptors on the endothelium it must move up
stream against the established ultrafiltration gradient
tending to move water and solutes from the capillaries
into the Bowman's space. It is therefore not clear wheth¬
er or not VEGF signalling can occur. With data showing
that cultured glomerular epithelial cells produce heparin
binding variants ofVEGF, Chen et al. [13] proposed that
VEGF produced by the glomerular epithelial cells may be
deposited into the basement membrane, thus acting as a
site for VEGF accumulation and storage. Alternatively,
VEGF may act in an autocrine manner on podocytcs, as
evidenced by recent studies suggesting altered calcium
handling and reduced cell death resulted when podocytes
were cultured in the presence of VEGF [38],
EGF and the Kidney in Health and
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Given that VEGF was originally described as a perme-
>ility factor and that selective filtration or permselectiv-
is a property integral to the glomerulus, it has been
tstulated that VEGF may have a role in this filtration
'occss [20, 21, 25], VEGF is known to induce fenestra
ans in endothelial cells in vitro [11], It has also been
ported to induce transcellular gaps [12], caveolae [13]
id interendothelial gaps [14], and it has been suggested
iat VEGF may be involved in the induction and main-
nance of the fenestrations in the capillaries of the kid-
;y [22], In support of this, VEGF inhibition was shown
i reduce the number of fenestrations in glomerular en-
athelial cells [39], In contrast, in normal kidney, and
>ing VEGF antagonists, others have failed to demon-
rate an effect of VEGF165 on the constitutive fenestra-
an of the glomerulus [40], suggesting that it is not re
aired to maintain the fenestrated endothelial pheno
pe.
Irrespective of any possible role for VEGF in mediat-
ig endothelial cell fenestration, this may have limited
nportance in mediating glomerular permselectivity. En-
Dthelial fenestrations may only be partly involved, if at
1, in mediating filtration. Indeed, the glomerular BM,
ie negatively charged surface of the endothelial and ep
helial cells and the podocytes with their interconnecting
it diaphragms may prove more of a barrier than the en
othelial cells. However, VEGF may play some role in
etermining the composition of the glomerular basement
tembrane as evidenced by its ability to induce extracel-
ilar proteolysis, a function integral to its role as an an-
ogenic factor [41],
It is not entirely clear whether VEGF can truly affect
le normal filtration of the glomerulus. VEGF is a potent
asodilator through its action on NO synthesis and thus
as the potential to have profound effects on end-organ
lood flow. In the kidney, such an effect will inevitably
ad to enhanced macromolecular extravasation irrespec-
ve of any effects on permeability per se. Indeed, inhibi¬
ts ofNO synthase are reported to increase renal vascu-
ir resistance and decrease the glomerular ultrafiltration
aefficient [42], Nevertheless, there is some evidence to
rggest that VEGF may play a role in maintaining the
ormal filtration barrier of the kidney [43-46]. In normal
ealthy mice and pregnant rats, it has been demonstrated
lat VEGF blockade induces proteinuria in association
ith glomerular structural changes [43, 45]. In a clinical
:udy, the monoclonal VEGF antibody bevacizumab was
lown to induce proteinuria in some patients [44] and,
lore recently, in a large study of the general population
i the Netherlands, elevated plasma VEGF levels were
associated withmicroalbuminuria [46]. Conversely, how¬
ever, in other studies, VEGF antagonism using aptamers
failed to induce glomerular pathology or proteinuria [40],
and in isolated perfused rat kidneys, the glomerular per¬
meability for albumin was not apparently affected by
VEGF [47]. Thus, it would seem there is some headway
to be made to determine what role, if any, VEGF plays
in maintaining the normal filtration barrier of the glo¬
merulus.
VEGF may play a role in aspects of nephron function
outwith possible glomerular functions. For example,
there are reports of VEGF expression in the distal and
proximal convoluted tubules [6, 20, 23] and in the col¬
lecting ducts [21]. Thus, it is possible that VEGF may
modulate the selective permeability in the tubules and
collecting duct system ormaintain the endothelium of the
peritubular capillaries. Whether this is in fact the case has
yet to be determined.
VEGF and the Diseased Kidney
A multitude of pathologies can damage the kidney.
Some, such as minimal change nephrotic syndrome, may
be benign and reversible whilst others, including forms of
glomerulonephritis and diabetic nephropathy can cause
irreparable damage ultimately leading to end stage renal
failure.
Acute Renal Damage
Although conflicting results exist, there is a body of
evidence to suggest that VEGF may be upregulated in the
early stages of a number of pathologies, including several
models of acute glomerulonephritis [23, 48] and early di¬
abetic nephropathy [49, 50].
It is tempting to speculate that upregulated VEGF may
play a reparatory role in the early stages of renal disease,
perhaps in an attempt to recapitulate processes occurring
in the embryo. No more so has this proved such an attrac¬
tive possibility as for the glomerulus. Glomerular damage
is common to many forms of renal pathology and, irre¬
spective of the underlying injury, capillary destruction is
almost invariable. In many experimental models of glo¬
merular injury, simple damage to the glomerulus is usu
ally followed by a period of repair and recovery of glo¬
merular structure and function [51,52], Exogenous VEGF
appears to enhance this process [53-55] whilst VEGF ab¬
rogation inhibits glomerular repair [28, 40],
The reparatory role of VEGF in these early disease
states may not be limited to its mitogenic effect on glo-
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lerular endothelial cells. VEGF has been shown to in-
ace tubular proliferation in metanephric organ culture
tperiments [34], and work in the remnant kidney mod-
suggests that VEGF may have a tubuloprotective effect
13],
From the above observations, it seems possible that
EGF may be responsible for initiating an element of
:pair in the acutely and minimally damaged kidney,
/hether these models of glomerular disease reflect the
ue situation in vivo however, is not clear. Indeed, most
.omerular diseases are insidious rather than acute in na-
trc and thus extrapolating the findings from these acute
omerular insult models to clinical disease must proceed
ith caution.
Progressive Renal Disease
Although not fully characterised, progressive renal dis-
ise is likely to reflect amultifactorial processwith a com-
lon endpoint. Persistent injury, subsequent reduction in
mctioning nephron mass and the inability to sustain ad-
guate glomerular filtration rate and the progressive loss
fglomerular and interstitial microvasculature are all be-
eved to be critical factors in the development of chron-
: renal disease.
Whilst VEGF is apparently upregulated in acute in-
rlts to the kidney, most studies would suggest that re-
uced VEGF expression is associated with progressive
nd advanced renal disease [40, 54, 56-60]. Human im-
tunolocalisation studies have shown reduced or absent
'EGF expression in a variety of advanced renal diseases
13, 60], and work in rodent models, including models of
irombotic microangiopathy (anti-glomerular endothe-
al cell antibody model) [55], tubulointerstitial injury
milateral ureteral obstruction model) [57] and chronic
;nal failure (remnant kidney model) [53], has corrobo-
rted these findings.
Several groups have made the observation that the
ownregulation of tissue VEGF expression coincides
'ith the infiltration of inflammatory cells into the kidney
>3, 56, 57, 61]. Indeed Kang et al. [53] found that sev-
ral macrophage-associated cytokines (IL-ip, IL-6 and
NF-a) inhibited VEGF mRNA expression and protein
;cretion by cultured tubular cells under both normoxic
nd hypoxic conditions. If macrophage products reduce
te VEGF expression of tubular cells in vivo, it may be
ostulated that this will have an impact on the develop-
tent of interstitial fibrosis, particularly if tubular VEGF
; cytoprotective.
As alluded to above, it is not altogether clear what me-
iates disease progression in the kidney. Although un¬
likely to apply universally to all forms of renal pathology,
one attractive and longstanding hypothesis is that, in re¬
sponse to progressive disease, the kidney attempts to
compensate for the resulting inadequate glomerular filtra¬
tion through a combination of glomerular hypertension
and hypertrophy in the remaining nephrons [62], Glo¬
merular hypertension may then cause further damage by
injuring the glomerular endothelium and mcsangium,
thus precipitating proteinuria.
There are interesting reports suggesting a possible role
for VEGF in these elements of disease progression. For
example, in mechanical stretch models of intraglomeru
lar hypertension, early mesangial cell VEGF upregulation
has been observed [27], providing a potential molecular
mechanism bywhich a haemodynamic insult might trans
late into increased filtration of macromolecules resulting
in proteinuria. Although this would suggest a possible link
between glomerular hypertension with VEGF, is there
any good evidence linking VEGF with proteinuria in dis¬
ease? Proteinuria is an adverse prognostic feature in ad¬
vancing renal disease and there is some evidence to sug¬
gest that VEGF may induce proteinuria in non-diseased
kidneys [43-45], However, there is marked variation be¬
tween studies reporting on the relationship between
VEGF and proteinuria in diseased kidneys. Indeed, both
upregulated [48, 63, 64] and downregulated [65] VEGF
have been associated with proteinuria in various diseases.
In diseasemodels, VEGF administration is mostly unsuc¬
cessful in inducing proteinuria [66, 67] and, indeed, sev¬
eral studies have shown no relationship between protein¬
uria and VEGF expression [65-69].
Conclusions
From the evidence presented in this review, it appears
that VEGF may play a number of roles. Whilst a role for
VEGF in the embryonic kidney is being increasingly well
defined, the role of VEGF in the normal adult kidney is
less clear. Studies of acute renal damage using animal
models would suggest that simple reversible damage to
the finely balanced capillary network can be managed in¬
trinsically within the kidney through the upregulation of
epithelial VEGF, thus allowing repair to occur. Whether
this can and does occur in adult human disease remains
to be determined. It is conceivable that the transition
from reversible to irreversible injury occurs when the up¬
regulation of VEGF expression occurring in response to
simple injury fails to restore adequate circulation for ad¬
equate oxygen and nutrients to be provided.
'EGF and the Kidney in Health and
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Persistent or extensive injurymay tip the balance away
om intrinsic repair mechanisms and towards progres-
ve renal disease and renal failure. Whilst the adminis-
ation ofVEGF appears to be generally beneficial in both
acute and progressive renal disease [53-55], its role in
underlying pathophysiological processes has to be further
determined before therapeutic agents can be optimally
utilised.
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Chapter 18
Shh Expression in Pulmonary Injury
and Disease
Paul M. Fitch, Sonia J. Wakelin, Jacqueline A. Lowrey,
William A.H. Wallace and Sarah E.M. Howie
Abstract
The Hedgehog signalling pathway is crucial for normal vertebrate growth and development. Recent studies would suggest that signalling capability is retained in thepost-embryonic organism. Shh signalling has been identified in the adult immune sys¬
tem, participating in CD4* T lymphocyte activation. Studies on fibrotic pulmonary disorders
have demonstrated Shh in both human and mouse lung restricted to areas of active disease.
Acute lung injury has also shown upregulated expression and together this data is highly sug¬
gestive for a functional role for Shh signalling in adult lung injury and disease. We propose that
hedgehog signalling may contribute to epithelial injury and repair and act as an intermediary
in cross-talk between damaged epithelium and the immune/inflammatory system.
Introduction
Work within our group has identified the up-regulated expression of the Hedgehog (Hh)
signalling pathway in Idiopathic Pulmonary Fibrosis (IPF) and murine models of fibrotic lung
disease.1 That Hh signalling may also play a role in lung injury is also suggested by the work
of2'3 in their murine model of acute lung injury, and further confirms a role for hedgehog
signalling in post embryonic pulmonary tissues.
Another area of interest to our group is the role ofHh signalling in the peripheral immune
system. Active hedgehog signalling has been identified in cells of the peripheral immune sys¬
tem.1'4"6 Since these immune cells are integral to inflammation and repair in the damaged
lung, these observations have led to the emergence of the hedgehog signalling pathway as a
possible target for therapeutic intervention in conditions of pulmonary damage and disease.
The aim of this chapter is to review divergent avenues of research into the hedgehog signalling
pathway and relate them to observations made with this pathway at the pulmonary interface.
The Hedgehog Pathway
The hedgehog signalling pathway has been reviewed extensively elsewhere in this volume
and in recent publications, thus will be covered only briefly in this review. There are three
vertebrate hedgehog signalling molecules, Sonic Hedgehog (Shh), Desert Hedgehog (Dhh)
and Indian Hedgehog (Ihh). Of these, most studies have concentrated on the Shh signalling
pathway. Shh mRNA generates an inactive 45kD precursor protein which auto-catalytically
cleaves, and is post-translationally modified to produce a highly hydrophobic cholesterol/palmi-
tate modified Shh signalling molecule. This signals either as a cell surface molecule or is secreted
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following association with the dispatched molecule. Binding of its receptor Patched (Ptc), re¬
leases Ptc mediated inhibition of Smoothened (Smo), a G protein like signalling molecule,
allowing Smo to influence gene expression through the GLI zinc finger transcription factors.
Signalling upregulates Ptc in an auto-regulatory loop, similar to many developmental path¬
ways.
Studies have shown Shh to be a crucial morphogen in a number of developmental systems,
including the limbs, lung, gut, nervous and immune systems (fo a review see Ref. 8). It is only
relatively recently that a role for the hedgehog signalling pathway has been elucidated in the
post embryonic organism.
Hedgehog Signalling in Normal Pulmonary Tissues
Adult lung tissue contains several cell types, including Type I and II epithelial cells, Clara
cells, mesenchymal cells (fibroblasts and endothelium), and resident immune system cells in¬
cluding alveolar and interstitial macrophages. Immunolocalisation studies from our group have
demonstrated the expression of Shh protein in the lung is restricted to focal patches of epithe¬
lium in areas of injury and repair. The hedgehog receptor Patched (Ptc) is detectable on bron¬
chial and alveolar epithelium and in alveolar macrophages.1 Watkins and colleagues have also
identified normal expression ofPtc in the basal layer of bronchial epithelium.3
Continued expression of Ptc in the absence of ligand, might indicate regulation and/or
signalling via another pathway.' However, data emerging from studies in the gastrointestinal
tract would suggest that Hh signalling may continue in tissue, in the apparent absence of
immunodetectable ligand.
Gastrointestinal tract Shh protein expression is localised to areas of regeneration, such as the
fundic glands of the stomach. 0-13 Initially protein expression appeared to be absent from many
areas of the adult mammalian tract such as the oesophagus, small intestine and colon, although
some cells in these regions appeared to retain the ability to generate rnRNA.10'11'14 Further to
this, many of these areas lacked apparent Ptc expression.12 However, treatment of mice with
cyclopamine, a Smo inhibitor, resulted in marked decreases in small intestine epithelial cell
proliferation, as evidenced by BrdU incorporation and PCNA studies, suggesting active signal-
ling-U
Of interest is the finding that in the mature colon, cyclopamine inhibition ofHh signalling
results in a marked increase in colonic epithelial proliferation and reduced differentiation of the
colonocytes. This alternate response to that of the small intestine may represent a Hh specific
effect, with variation in Ihh/Shh expression, or may simply reflect the presence or absence of
another signalling factor or downstream effector in the tissues of the colon.
F.xplanations for signalling in the absence of ligand include the existence of another path¬
way upstream of Smo (indeed, Ptc-independent pathways have been postulated previously,15)
or that Hh signalling continued, but at a concentration below immunohistochemical detec¬
tion. Recent research would support the latter explanation, for Hh expression has now been
immunolocalised to areas of the colon, previously described as negative. This was achieved
through variations in antibody concentration and technique. Thus, future improvement in
antibodies, detection methods and specific inhibitors may further clarify this issue for both the
gastrointestinal and pulmonary systems.
Hedgehog Signalling in Injury and Disease
Whilst the studies ofWatkins et al demonstrated bronchiolar epithelial expression of the
Shh signalling components,3 we have demonstrated Shh restricted to type II like cells in the
alveoli ofpatients with IPF.1 Expression was localised to areas of remodelling epithelia, particu¬
larly those areas with underlying fibrosis. Interestingly, whilst an irritant induced murine model
of fibrosis illustrated similar localisation, a murine model of allergen induced inflammation
showed no such upregulation. Whilst both models illustrated evidence of inflammation, the
allergen model lacked progressive fibrosis.1,16
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Figure 1. (A) Epithelial cells Shh has the potential to signal to neighboring cells to warn ofcellular injury,
and generate matrix deposition and proliferation in underlying fibroblasts, preventing transudation in the
event of epithelial shedding. Communication with Macrophage and T lymphocytes is also possible, as is
fibroblast-epithelial signaling. (B)Type II cells are restricted to junctional positions at the entrance to alveoli,
as shown this aerial diagram. In the event of type 1 cell loss, type II cells form intermediate cells which
differentiate and spread into type I cells. Shh upregulation may represent a differentiation inhibitor, to
which cells adjacent to denuded areas are nonresponsive.
The upregulation of Shh at sites of epithelial injury comes amongst a plethora of other
modulating signals and could therefore represent a downstream marker of a much larger pro¬
cess initiated by the underlying mesenchymal/fibroblastic cells, which play a crucial role in
epithelial maintenance. Mesenchymal cells produce specific epithelial growth factors such as
keratinocyte growth factor (KGF) and fibroblast growth factor 10 (FGF-10). These are
upregulated in response to injurious stimuli, resulting in increased epithelial proliferation and
rapid reestablishment of an intact epithelial layer, (for a review see Ref. 17). Studies using
FGF-10, FGFR2b and Shh knockout mice have recently confirmed Shh to be downstream of
FGF-10 signalling.18 Shh expression on epithelium at sites of fibroblastic proliferation, such as
that observed in IPF, may be a consequence of this repair process rather than an instigator of
repair. Thus, Shh could be considered a regulatory factor in this instance, given its ability to
downregulate FGF-10,19 (see Fig. 1A).
Alternatively expression at the alveolar surfaces of IPF patients might relate to a specific
element of the disease process, which maybe mirrored in the FITC mouse model, where we
observe a similar pattern of expression.1
IPF is a chronic fibrotic condition of the lung, associated with inflammation, where median
survival after diagnosis is limited to five years. Although without known cause, progression is
believed to have an immunological basis, linked in some way with aberrant epithelial mesen¬
chymal interaction.20 Previous work in this laboratory identified circulating antibodies to a
70-90KD protein in IPF patient serum, which were not observed in normal controls.21 This
protein was later localised to type II cells (Fig. 2), suggesting an autoantigen.22 Experiments in
vivo with a polyclonal antibody raised against the antigen and a human type II epithelial cell
line showed upregulated tenascin andTGF-f5 production.23 Tenascin is an extracellular matrix
protein associated with active scar formation, whilst TGF-b can be pro-fibrotic. Both have
been well characterised as being present in the lungs of patients with IPF,24'25 and tenascin has
been shown to be localised to areas of active fibroplasias or 'fibroblastic foci'.23 It will be inter¬
esting to discover whether Shh is also upregulated by this interaction, as it would explain its
localised expression, at areas of putative antibody interaction, and Shh also has the potential to
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be profibrotic. Shh and FGF signalling are well linked in neural systems both pre and postna-
tally'9,26-28 and hedgehogs have been linked with collagen fibre induction in the neural sys¬
tem.29 Shh also has substantial cell cycle modulating capabilities30,31 and participates in well
characterised proliferative mesenchymal interactions in the developing lung. Thus the localisation
of Shh at fibrotic foci in IPF may also present a causal relationship with fibrosis in the IPF
patient.
Similar hypotheses can be drawn from the observations made in the fibrotic FITC mouse
model of IPF pathology.16 Fibrosis and inflammation are believed to be induced in this model
through the persistence of the intratracheally instilled irritant FITC, which lodges in the inter-
stitium and binds resident proteins. Antibodies are raised to FITC, and mice develop a pathol¬
ogy similar to that of IPF patients, where Shh expression is localised to sites of damage.1
Interestingly, recent work has illustrated a requirement for cell confluence for Shh respon¬
siveness, in a Ptc expressing Shh bioassay.32,33 Thus, Shh and Ptc expression at a site of prolif¬
erative repair, may not automatically indicate that active signalling is occurring. Indeed, the
broad expression area ofPtc in the lung might represent a "Shh sponge", to endocytose, in the
absence of signalling, free Shh, as described by Torroja and colleagues.34 However, whilst this
may, in part, be true for some expression studies in the lung, work performed in our laboratory
and that of others has identified alterations in target gene expression such as Ptc and Glil,
coincident with Shh expression, suggesting that at least some active signalling results from Shh
expression.3
Shh would appear to share many of its effects with KGF and FGF-10,30 most notably,
stimulation of increased cellular resistance to injury and death.35,36 Shh exhibits this effect in a
number of cell types,30,37,38 but has yet to be established at the pulmonary interface. Perhaps
the best example of this activity is in Parkinson's disease, where exogenous administration of
Shh in both a marmoset and mouse model of the disease results in improved locomotion and
function.39,40 Tsuboi and colleagues,40 citing work by Miao et al,38 have suggested that this is
likely due to Shh acting as a neuroprotective agent against dopaminogenic neuron cell death,
which is central to disease progression.
Indeed current research would show that Shh can induce the anti-apoptotic protein Bcl-2
in keratinocytes, and that its presence prevents the apoptosis of neuroepithelial cells.37 There¬
fore in a pulmonary situation of injury, such as exposure to environment oxidants, Shh release,
along with KGF and FGF-10, may serve to temporarily increase surrounding epithelial cell
resilience, and prevent complete denudation of an epithelial surface and the risk of secondary
infection, (Fig. 1A).
Sustaining viability of injured cells carries with it the increased probability of populating
the epithelium with cells which have incurred genetic damage. Indeed, this may help to explain
the higher incidence of small and nonsmall cell lung cancers following epithelial trauma, and
the preponderance for the involvement of Shh signalling in these carcinomas.41
Upregulation of Hh signalling following injury, can be found in a number of model sys¬
tems 2,4 have demonstrated the upregulation of Shh and Ptcl expression in a rodent hind
limb ischemia model. Furthermore, the same group demonstrated that the administration of
Shh induced robust neovascularisation, enhanced blood flow, and the upregulation of the an¬
giogenic factors, vascular endothelial growth factor (VEGF) and the angiopoietins, Angl and
Ang2,43 although any direct association is a matter ofconjecture.44,45 The findings from other
groups have been broadly in keeping with those of43 demonstrating that Shh is capable of
inducing VEGF expression44 and angiogenesis.45
Such angiogenic modulation could have important implications at the respiratory surfaces
of IPF patients, where we have observed Shh expression in association with fibrotic foci.1 Shh
expression here may represent an attempt by the lung to revascularise and remodel the fibrotic
architecture. Alternatively, it may represent a step in the progression of the fibrosis, where
VEGF itself is found upregulated with epithelial injury.46 Perhaps the greatest implication is in
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the neoangiogenic advancement of pulmonary malignancies, which are associated with the
expression of Hh pathway components.3
Shh in the Immune System
A functional role for hedgehog signalling in the adult immune system is perhaps not sur¬
prising given the well documented role of Shh in lymphoid development and differentia¬
tion.4, 7,48 Work in our laboratory has found evidence for expression of Shh and Ptc in both
resting and activated murine and human CD4* and CD8+ T lymphocytes, human macroph¬
ages and secondary lymphoid tissue,5'6 both at the mRNA and protein level. This lends sup¬
port to a possible role for immune-epithelial cell interaction at sites of injury and repair.
It has been postulated that the expression of Hh in a large range of diversified tissues and
cell types, might represent a common method of sensing the cellular environment and
neighbouring cell health.49 Given the expression of the Ptc molecule on human macrophages,
it may be postulated that Shh expression acts as an advertisement of epithelial damage both to
the macrophage, to facilitate attention, and to the adjacent cells as awarning signal for defence
and repair initiation (Fig. 1A).
Further to this, Lowrey and coworkers5,6 have demonstrated that exogenous Shh has the
capacity to push sub-optimally activated peripheral CD4* T lymphocytes through further cell
cycles, whilst addition of a blocking antibody to endogenous Shh results in decreased prolifera¬
tion. Together these results would suggest that exogenous Shh administration enhances an
endogenous stimulatory effect of Shh. Indeed, further work from our group has demonstrated
that Shh can act as a costimulatory molecule to T-celis activated via the T cell receptor using
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anti-CD3 antibodies (Lowrey et al, unpublished observations). This explains the upregulation
of the activation antigens CD25 and CD69, by exogenous Shh, along with the production of
Interleukin 2 (IL-2), aT lymphocyte proliferative factor, interleukin 10 (IL-10) and Interferon
gamma (IFN-y). Thus Shh expression at sites ofdisease and damage has the potential to sustain
T lymphocyte mediated immune responses and even to influence the effector function of im¬
mune responses, through an IFN-y bias.
Shh has also been shown to upregulate Bd-2 in T lymphocytes, a step linked with memory
T lymphocyte generation,4 and thus, Shh at sites of injury might also serve to ensure adaptive
immunity to damaging antigens, or an exacerbation ofautoimmunity. Given that many of the
diseases associated with Shh expression contain elements of autoimmunity or immune
dysregulation, this crosstalk could have important implications both for the initiation and
maintenance of a disease process.
Hedgehogs and Pulmonary Progenitor Cells
Watkins and colleagues3 depleted Clara cells from mouse airways via their sensitivity to
naphthalene injury. This resulted in a transient peak in Shh and Gli expression 3 days post
depletion that coincided with the reestablishment of a complete epithelial barrier. It was sug¬
gested that Shh signalling might be involved in this repopulation step, since this peak preceded
an increase in the number ofpulmonary neuroepithelial cells - a cell type identified as a poten¬
tial epithelial progenitor.41,50 Subsequently, Watkins and colleagues identified clusters of epi¬
thelial cells expressing Ptc and the neuroendocrine marker, Calcitonin Gene Related Peptide
(CGRP), associated with Shh expressing cells in the developing lung.3 It was suggested that
this clustered interaction might continue into the adult pulmonary system, where Shh expres¬
sion might influence neuroepithelial differentiation.
Presently, progenitor cell phenotypes are characterised via their longevity via nucleotide
analogue incorporation, and are defined as label retaining cells. In the mouse these cells are
localised to glandular submucosal glands in the distal trachea and bronchi.51 In the absence of
these glands, such as in the bronchioles and alveoli, LRCs occur in localised foci,52 referred to
as neuroepithelial bodies41 (Fig. 2). These foci are populated by Clara Cell secretory protein
(CCSP)-expressing epithelial cells, known as variant Clara cells (vCC), which are naphthalene
resistant. Associated with these are CGRP-expressing epithelial cells which show intermediate
morphology between a pulmonary Neuroendocrine Cells (PNEC) and a Clara cell41,50 (Fig.
2). Infiltration of blood borne progenitors in this regenerative process, add a further level of
complexity outwith the scope of this chapter, but covered elsewhere.53
Label retaining cells undergo hyperplasia in the event of Clara cell death, such as that in¬
duced by naphthalene, resulting in the rapid reestablishment of a functional epithelial cell
layer. Selective depletion of vCC using a Herpes simplex virus thymidine kinase linkage sys¬
tem, prior to naphthalene injury, results in a failure to repopulate a differentiated ciliated epi¬
thelium, despite PNEC hyperplasia.50 Whether this highlights the CCSP expressing cells as
progenitor cells, producers of a signal necessary for PNEC progenitor cell function or as
coprogenitors with the PNEC is still an area of conjecture.
As to a potential role for Shh in this process, epithelial coverage is completed at the peak of
Shh expression, thus a causative role in nonspecific epithelial proliferation is unlikely, and this
is confirmed in our studies where we observe bronchiolar Shh expression restricted to areas of
complete epithelial coverage. It is interesting that coverage normally occurs in the absence of
differentiation, which typically occurs following reestablishment of epithelial integrity Given
the necessity for confluence for Shh signalling in some cell lines, as mentioned previously, one
might speculate that it is in this differentiation step that Shh might play a role.
Reasoning for such speculation arises through the well characterised progenitor modulating
role of Hh in a range of post embryonic systems including T lymphocyte development47 and
haematopoiesis.54 The work by Bhardwaj in haematopoiesis was notable for it clearly defined
the downstream effector ofShh function as BMP-4, where Shh addition to an enriched popu-
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Iation ofhuman CD34+Lin-CD38- progenitor cells resulted in increased self renewal, albeit in
combination with many other growth factors.
An example ofHh mediated progenitor modulation in injury comes indirectly from several
sources.55,51"' Pepinsky et al demonstrated that Shh administration can accelerate nerve recovery
following sciatic nerve crush injury.55 A Possible explanation for this response comes from
studies by Bambakidos et al, using a rat demyelination model.56 These authors observed in¬
creased proliferation of nestin+ve stem cell like progenitors in areas of chemical demyelination
following direct Shh administration. This suggests that exogenous Shh at a site of injury in¬
duces proliferation in stem cell populations, although the specificity of this progenitor prolif¬
eration was not addressed in this study.
The manner in which hedgehog signalling might facilitate this stem cell influence has yet to
be characterised, but is likely to lie in its ability to regulate differentiation. Evidence in support
of such a role comes from studies of fracture repair, in which Ihh may play a role. Following a
fracture, pluripotent mesenchymal cells invade and differentiate into osteoblasts, to initiate the
production of hard callus comprising bone matrix, and chondrocytes for the formation of the
soft callus. A balanced secondary chondrocyte differentiation step facilitates the remodelling of
bone until the bone shape is restored.57,58 Ihh expression is induced by 3 days post fracture
persisting past 2 weeks in a murine model, with the greatest level of expression found in
chondrocytes undergoing their secondary differentiation step.5' 60 Ihh expression here induces
further chrondrocyte proliferation, but prevents further chondrocyte differentiation via PTHrP
signalling.61"63 Given the osteoblast upregulation of PTHrP in the presence of rShh shown by
Jemtland and colleagues64 and the osteoblastic lineage bias induced by Ihh,65 it is likely that in
this system. Ihh is central to restricting differential fates of invading pluiripotent mesenchymal
cells and facilitates an accurate bone remodelling response.
Central to the stem cell maintenance function of Shh observed in haematopoiesis, is its
ability to upregulate BMP-4. These molecules are crucial in early lung morphogenesis and thus
have substantial signalling potential in the post embryonic lung. Indeed, studies in a mouse
model ofallergic inflammation have demonstrated an upregulation ofBMI's at sites of inflam¬
mation, including BMP-4.66 In-vitro studies would suggest that BMP-4 has anti-proliferative
effects in cancer derived cell lines,67 however these effects can often be contradictory and de¬
pendant on the cosignals and cell types present in culture.
In-vivo studies into pulmonary BMP functions are limited by the lethality ofBMP-4 knock¬
outs. However, innovative in vivo studies in this field from the lab of Brigid Hogan and col¬
leagues have demonstrated a potential progenitor modulating function for BMP's in epithe¬
lium. Cells exposed to high levels of BMP-4 retained undifferentiated characteristics.6 ,69 In
light of these studies, were Shh to modulate progenitor function through the BMP's, it would
likely be in conjunction with a number ofother signals, such as FGF-10. Perhaps in a recapitu¬
lation of the process of cell fate designation in the embryonic lung.68
Shh and Type II Epithelial Cells
Studies thus far have focused on roles for Shh expression at the bronchi and bronchiolar
levels, however immunohistochemical data suggest that the hedgehog signal might persist in
the larger and smaller airway systems. Watkins and colleagues observed a persistence of Ptc
signalling in the progenitor cells of the trachea and bronchi, whilst our lab has identified ex¬
pression of Shh and Ptc in type II like cells of the terminal bronchioles and alveoli, (Fig. 2).
Pulmonary epithelial regeneration occurs rapidly at the alveolar level. Here, in response to
the removal of contact inhibition and KGF,36 type II cells downregulate specific functional
machinery, proliferate and spread out to become thinly spread type I cells, specialised for gas¬
eous exchange. This process occurs almost continually as type I cells are highly susceptible to
injury by exogenous factors, i.e., pneumotoxic environmental pollutants and by factors in¬
volved in both innate and adaptive pathogen clearance in the lung.
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Whilst lack of contact inhibition and KGF are triggers for type II differentiation, no main¬
tenance signal for type II cell number has yet been identified. Perhaps Shh has a modulating
function here too. Certainly immunolocalisation in IPF patient biopsies has identified Shh
upregulation in individual type II like cells amongst adjacent negative cells, with expression
isolated to areas of injury.1
This makes for an attractive hypothesis. Damage upregulates type II cell expression ofShh,
this induces type II proliferation and inhibits differentiation. However, type II cells adjacent to
areas of denuded basement membrane have incomplete confluence and thus lose responsive¬
ness to the Shh, allowing them to differentiate and cover the exposed area (Fig. IB). However,
were Shh a maintenance factor in this continual type II—I transition, it might be expected that
normal lung might exhibit some limited immunohistochemical reactivity, and this is not ob¬
served. Whether this represents true absence ofShh protein, or the limits of immunohistochemi¬
cal detection, remains to be determined.
Concluding Comments
The potentiaJ for post embryonic recapitulation of developmental signals in injury and
disease presents many exciting targets for therapeutic modulation. This is particularly true for
the pulmonary system, where the air interface facilitates the direct and rapid delivery of short
half life Hh modulating agents to target cells. This will avoid the systemic complications of
treatment that might be expected in the treatment of conditions such as multiple sclerosis and
Parkinsons disease. Our knowledge of the Hh signalling pathway and its role in development
has made great advancements over recent years and has led to the development of many new
and exciting ideas which may identify functions for the Hh pathway in post-embryonic sys¬
tems.
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tonic Hedgehog Signaling Modulates Activation of and
Cytokine Production by Human Peripheral CD4+ T Cells1
Jareth A. Stewart,*+ Jacqueline A. Lowrey,** Sonia J. Wakelin,** Paul M. Fitch,**
iusannah Lindey,** Margaret J. Dallman,8 Jonathan R. Lamb,** and Sarah E. M. Howie2**
onic hedgehog (Shh) is important in the growth and differentiation of a variety of cell types, including the development of T cells
1 the thymus. This prompted us to investigate whether Shh signaling is a functional component of the physiological response of
uman mature CD1 + T cells following Ag recognition. In this study, wc demonstrate that Shh and its receptor Patched (Ptc) arc
sprcsscd on resting and activated human peripheral CD4+ T cells. In approximately one-half of the randomly selected, anon
mous blood donors tested, exposure of anti CD3/28 Ab activated CD1+ T cells to the biologically active N terminal Shh peptide
lcrcascd the transcription ofptc, thereby demonstrating that Shh signaling had occurred. Furthermore, the addition of exogenous
hh amplified the production of 1L-2, IFN-y, and IL-10 by activated CD4+ T cells. The synthesis of IL-2 and IFN-y, but not IL-10,
y CD4+ T cells was down-regulated by the addition of neutralizing anti-Shh Ab. Cell surface expression of CD25 and CD69 on
ctivatod T cells was up regulated by exogenous Shh, whereas in the presence of the neutralizing anti Shh Ab expression it was
educed. Collectively, our findings demonstrate that Shh mediated signaling is a physiological component of T cell responses,
'hich acts to modulate CD4+ T cell effector function. The Journal of Immunology, 2002, 169: 5451-5457.
Hedgehog proteins are highly conserved intercellular sig¬naling molecules that function as morphogens in the de¬velopment, patterning, and cell fate induction in a range
f tissues, such as the CNS, limbs, gastrointestinal tract, and lung
;.g., see Refs. 1-4). Originally described in Drosophila as a po-
irity gene (5), three homologs of these proteins have now been
ientified in vertebrates of which the biological activity of sonic
edgehog (Shh)3 has been investigated most extensively (1, 2).
hh is synthesized as a precursor protein that is autoproteolyzed to
enerate an N-terminal domain (Shh-N) in which the biological
ctivity resides and a C-terminal protein that mediates the auto-
rocessing (6, 7). The biologically active Shh-N domain, through
almitic acid and cholesterol at its N and C termini, respectively,
an remain membrane associated and function as a short-range
ignaling molecule interacting with neighboring cells. Further-
tore, as a secreted diffusible molecule, Shh may also deliver long-
mge signals (8-10). Shh interacts with a receptor complex, which
: comprised of two multitransmembrane proteins, Patched (Ptc)
nd Smoothened (Smo) (11, 12). Ptc is the ligand-binding subunit,
/hich in the absence of Shh inhibits Smo signaling. However,
nee Shh has bound, Smo is derepressed through a conformational
hange and transduces the Shh signal across the cell membrane,
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which is then mediated by the Gli family of zinc finger transcrip¬
tion factors (1-3).
Shh signaling can induce proliferation in a variety of cell types,
which include keratinocytes (13), neuronal precursor cells (14),
and hemopoietic stem cells (15). Mutations in Ptc and Smo, which
result in constitutive activation of this signaling pathway, have
been demonstrated in proliferative diseases, such as basal cell car¬
cinoma (16), further illustrating the ability of Shh signaling to
induce proliferation. Components of the Shh pathway have now
been detected in thymus, in which they are reported to contribute
to T cell development (17). However, while the receptors Ptc
and Smo are expressed on thymocytes, Shh was found only to
be present on thymic epithelial cells. By neutralizing the activ¬
ity of Shh, it was observed that the differentiation of thymocytes
from the double-negative (CD4 CD8~) to double-positive
(CD4+ CD8 + ) stage was increased, whereas the addition of Shh
arrested thymocyte development at the double-negative stage
(17). It has been reported that Shh can also induce proliferation
in human hemopoietic stem cells, and, in addition, the presence
of transcripts for shh, Pic, and smo has been demonstrated in
mature CD19+ and CD3+ cell populations (15). However, in¬
formation on the effects of Shh signaling on the function of
peripheral T cells is limited (18).
The contribution of the Shh signaling pathway in the develop¬
ment and differentiation of the immune system prompted us to
determine whether the activation of this pathway can influence the
human peripheral CD4 f T cell repertoire. We report in this study
that Shh and Ptc are present on resting and activated peripheral
CD4+ T cells and that Ptc expression is increased in approxi¬
mately one-half of the randomly selected, anonymous blood do¬
nors tested, by the addition of exogenous Shh, indicating, there¬
fore, that Shh signaling had occurred in the T cells. The addition
of Shh enhanced the expression of CD25 and CD69 and cytokine
production, namely IL-2, IL-10, and IFN-y, by CD4+ T cells ac¬
tivated by anti-CD3 and anti-CD28 Abs. In the absence of exog¬
enous Shh, the addition of a neutralizing anti-Shh Ab, which rec¬
ognizes an epitope that overlaps the Ptc binding site of Shh and
0022-1767/02/S02.00
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us blocks signaling by preventing Shh binding (19-23), reduced
11 surface expression of CD25 and CD69 on activated T cells,
te production of IL-2 and IFN-y, but not IL-10, was inhibited by
e anti-Shh Ab. Taken collectively, our results demonstrate that
e induction of Shh signaling in peripheral human CD44 T cells
odulates T cell activation and cytokine production.
[aterials and Methods
olation of human CD4+ T cells
iman PBMCs were isolated from randomly selected, anonymized, sin-
:-donor Buffy coats, obtained from the Blood Transfusion Center (Royal
firmary of Edinburgh, U.K..), by centrifugal separation over Histopaque
>77 (Sigma-Aldrich, Dorset, U.K.). CD4+ T cells were separated using
gative selection affinity columns (R&D Systems, Abingdon, U.K.), ac-
rding to the manufacturer's instructions. After separation, the T cells
:re washed and resuspended in RPMI 1640 culture medium supple-
snted with 5% heat-inactivated human AB serum, 100 IU/ml penicillin,
10 /J-g/ml streptomycin, and 2 mM L-glutamine (Life Technologies, Pais-
/. U.K.). Purity of the CD4+ T cell preparations was analyzed by flow
tometry and was consistently >93%.
imunocytochemistry
irified CD44 T cells were spun onto Vectabond-treated microscope slides
'ector Laboratories, Peterborough, U.K.) using a Cytospin 3 (Shandon
lientific. Runcorn, Cheshire, U.K.), set at 300 rpm for 3 min. The cells
;re air dried and fixed with methanol. After blocking endogenous per-
;idase in 3% H202, sections were loaded onto a Sequenza (Shandon Sci-
tific). Nonspecific binding was blocked using normal rabbit serum, and
Oogenous biotin was blocked using Vector blocking kit (Vector Labo-
tories), according to the manufacturer's instructions. Slides were incu-
ted with the primary Ab diluted in appropriate serum for 30 -120 min at
om temperature, washed with PBS, and incubated with a biotinylated
condaiy Ab for 30 min. They were washed again, and Vector RTU ABC
'ector Laboratories) was applied and positive signal was detected by the
dition of diaminobenzidine (DAKO U.K., Ely, U.K.), with a hematox-
in counterstain. Primary Abs to the N terminus of Shh (N-19, 5 /u,g/ml,
40 dilution; Santa Cruz Biotechnology, Santa Cruz, CA; Insight Biotech-
ilogy. Wembley, Middlesex, U.K.) and to the C terminus of Ptc (C-20, 5
g/ml, 1/40 dilution; Santa Cruz Biotechnology) were used, with a bio-
tylated anti-goat IgG secondary Ab (DAKO). Both anti-Shh and anti-Ptc
bs are completely blocked by the use of the relevant peptide (data not
own). Images were captured using a Progress 3012 camera (Kontron
ektronik, Zurich, Switzerland) through a Zeiss Axioskop microscope
Jberkochen, Germany).
D4+ T cell cultures
irified CD4+ T cells (5 x 105/ml) were stimulated by the combination of
imobilized anti-CD3 (1 /ug/ml) and soluble anti-CD28 (5 jug/ml) Abs
ID PharMingen, San Diego, CA). In experiments in which either exog-
ious soluble N-Shh peptide or anti-Shh Ab and isotype control was added,
is was performed at the initiation of the cultures.
The mouse rShh, a 180-residue N-terminal peptide (R&D Systems), was
constituted in filter-sterilized PBS containing 0.2% endotoxin-free BSA,
a final concentration of 50 jug/ml.
The neutralizing anti-Shh Ab (5E1; Developmental Studies Hybridoma
ank, Iowa City, 1A) (19-23) and the murine IgGl isotype control (P3 X
IAg8; European Cell Culture Collection, Porton Down, Wiltshire, U.K.)
ere purified from hybridoma supernatants using protein G columns (Am-
sham Pharmacia Biotech, Piscataway, NJ). Western blotting confirmed
at 5E1, but not the isotype Ab bound to the Shh peptide (data not shown).
D4+ T cell proliferation
D44 T cells were cultures as above in 96-well plates with and without the
Idition of exogenous Shh or anti-Shh Ab. Proliferation was assessed by
e incorporation ofmethyl tritiated thymidine (['H]TdR; Amersham Phar-
acia Biotech). Cultures were pulsed after 48 h of anti-CD3/28 activated
ith 1 piCi/well of [3H]TdR and at 72 h harvested onto glass fiber filters
Vallac, Milton Keynes, U.K.). [3H]TdR incorporation was measured us-
g a Betaplate counter (Wallac).
low cytometry
tenotypic analysis was performed using PE- and FITC-conjugated mAbs
lecific for CD3, CD4, CD25, CD69, and the appropriate isotype controls
ID PharMingen) using a BD Biosciences FACSCalibur (BD Immunocy-
tometry Systems, San Jose, CA). Viable CD4+ T cells were gated using
forward and side scatter.
Measurement of cytokine, production by ELISA
Cytokine production by purified human CD4+ T cells (IL-2, IL-10, and
IFN-y was measured using Duoset ELISA development system kits (R&D
Systems), following the manufacturer's protocols.
Isolation ofRNA and RT-PCR
Extraction of total RNA from purified CD44 T cells was performed using
TRIzol reagent (Life Technologies), as per the manufacturer's recommen¬
dations. The RNA pellets were air dried and resuspended in prewarmed
nuclease-free H20 (Promega, Southampton, U.K.). To remove any con¬
taminating DNA, the RNA was DNase treated. Total RNA from the CD4+
T cells was transcribed into cDNA using Access RT-PCR kit (Promega),
according to the manufacturer's instructions. The PCR program was as
follows: 35 cycles of 30 s at 94°C, 1 min at melting temperature (Tm)
annealing temperature, and 2 min at 68°C, followed by a final extension of
7 min at 68°C. This was performed on a PTC-200 Peltier thermal cycler
(MJ Research, Massachusetts, MA).
The following primers were used to detect ptc, with a Tm of 58°C,
giving a PCR product of 462 bp: forward primer, CCATGTTCCAGTTA
ATGACTC; reverse primer, ACATCATCCACACCAACA.
The following primers were used to detect Shh, with a Tm of 60°C,
giving a PCR product of 335 bp: forward primer, CAGCGCGTGTACGT
GGTGGC; reverse primer, GGAGCGTCGGCAGCACCTG.
The demonstration that transcripts for both Shh and Ptc are present in
the human lung epithelial cell line A549 served as a positive control.
Real-time RT-PCR
Primers and probes were designed using Primer Express software (PE Bio-
systems, U.K.). RNA samples for real-time PCR were reverse transcribed
into cDNA using TaqMan MultiScribe Reverse Transcriptase kit (PE Bio-
systems), as per the manufacturer's instructions. The thermocycler was
programmed as follows: 1 cycle at 25°C for 10 min, 1 cycle at 48°C for 30
min, and 1 cycle at 95°C for 5 min. The probe specifically annealed the
template between the PCR primers. A sequence detector (ABI Prism 7700;
PE Biosystems) measured amplification of the product. Each sample was
run in duplicate in 96-well optical reaction plates (PE Biosystems). A total
of 25 p.1 of the PCR was added per well.
The thermocycler was programmed as follows: 40 cycles of 50°C for 2
min, 95°C for 10 min, 95°C for 15 s, and 60°C for 1 min. All the values
obtained were normalized to 18S rRNA, which was included in the Mul¬
tiplex PCR with its own set of primers and probe, as an internal endoge¬
nous control.
The following primers and probe were used for analysis of Ptc expres¬
sion: forward primer, CGGCAGCCGCGATAAG; reverse primer, TTA
ATGATGCCATCTGCATCCA; probe, ATCGACATCAGCCAGTT GAC
TAAACAGCGTC.
The software then analyzed the data and output a pair of ct values for
each sample. Ct is the number of cycles needed to result in a signal crossing
at set threshold. Each sample yielded two ct values, one for the gene of
interest and one for the 18S housekeeping control. The ct values were then
analyzed to give a value representing the relative mRNA levels present for
the gene of interest linearly.
Statistical analysis
A paired t test using a one-tailed p value was used to test the significance
of the increase in expression ofCD25 and CD69. For comparing data from
[3H]TdR incorporation and cytokine production, a one-way ANOVA was
performed with a Tukey-Kramer multiple comparisons post test. Values of
p < 0.05 were considered significant.
Results
Shh signaling pathway is expressed and functional in human
peripheral CD44 T lymphocytes
To determine the expression of the Ptc and Shh proteins on human
peripheral CD4+ T cells, cytospin preparations of purified CD44
T cells were analyzed using immunocytochemistry. Cell surface
expression of both Ptc (Fig. 1A) and Shh (Fig. IS) was observed.
Cells stained with normal goat IgG at the same protein concentra¬
tion were negative (Fig. 1Q. The presence of the Shh signaling
pathway in CD44 T cells was confirmed by RT-PCR because spe¬
cific mRNAs for both Ptc and Shh were detected in purified




























FIGURE 1. Shh signaling pathway is expressed and functional in human peripheral CD4+ T lymphocytes. Cell membrane expression ofPtc (A) and Shh
(B) on cytospins of purified CD4+ T cells detected by immunocytochemistry with hematoxylin counterstain; cells stained with normal goat IgG are shown
in C. Ptc and Shh mRNA (D) expression is shown, as measured by RT-PCR in CD4+ T cells (track 2, Ptc; track 6, Shh), and in a positive control cell
line (A549) derived from a human lung carcinoma (track 4, Ptc; track 8, Shh); DNA ladder bands are shown in tracks 1, 3, 5, and 7. Expression of Ptc
mRNA in resting (£) and anti-CD3/28 Ab-activated (F) CD4+ T cells culPtred in the presence of increasing concentrations (10-1000 ng/ml) of N-Shh
peptide is shown at 24 h, evaluated by real-time RT-PCR. The real-time reaction is conducted as a multiplex, with 18S RNA as an internal control. Levels
of mRNA transcripts are expressed relative to resting (£) and activated CD4+ T cells (F) cultured in the absence of any N-Shh peptide, which are given
a value of 1. Representative experiments of n = 5 are presented.
CD4+ve T cells and in a control cell line (A549) derived from a
human lung carcinoma (Fig. ID).
It is documented that activation of the Shh pathway results in
increased expression of the receptor Ptc. Therefore, to determine
whether Shh signaling is active in peripheral CD4+ T cells, the
expression of Ptc was analyzed by real-time PCR in both resting
(Fig. IF) and anti-CD3/28 Ab-activated (Fig. IF) CD4+ T cells in
the presence and absence of exogenous Shh. It has previously been
reported that a 2-fold increase in gene expression in two or more
independent experiments is considered significant (24, 25). The
expression of FVc-specific mRNA induced in resting CD4+ T cells
by exogenous Shh is presented relative to the level present in
CD4+ T cells cultured in medium alone at 24 h. We observed that
the addition of the N-terminal Shh peptide to resting CD4+ T cells
over a concentration range of 10-1000 ng/ml failed to induce a
significant increase in Ptc transcripts, although 100 ng/ml had a
marginal effect (Fig. IF). In contrast, relative to anti-CD3/CD28
Ab-activated CD4+ T cells that were maintained in medium alone,
the addition of the exogenous Shh peptide at concentrations of 10
ng/ml or greater resulted in a marked increased in transcription of
ptc (i.e., >2-fold; Fig. IF).
Shh signaling amplifies CD4+ T cell effector function
To determine whether Shh signaling contributes to CD4 * T cell
effector function induced following Ag recognition, T cells were
stimulated with anti-CD3/CD28 Abs in the presence of exogenous
Shh. We observed that the addition of exogenous Shh added at the
initiation of the T cell cultures led to a significant enhancement of
anti-CD3/CD28 Ab-induced T cell proliferation (Fig. 2), in a dose-
dependent manner (p < 0.05 at 0.01 ng/ml of Shh, and p < 0.001
at 1 ng/ml of Shh), but had no effect on resting CD4+ T cells (data
not shown). To further investigate the influence of Shh signaling
on T cell function, cytokine production by activated CD4+ T cells
exposed to increasing concentrations of exogenous N-Shh peptide
was determined. We observed that the addition of Shh (>100 ng/
ml) significantly (p < 0.001) enhanced the levels of IL-2 (Fig.
3,4), IL-10 (Fig. 35), and IFN-y (Fig. 3Q. In approximately one-
half (6 of 13) of the individuals tested, we noted that the addition











FIGURE 2. Exogenous N-Shh enhances the proliferative response of
TCR-activated CD4+ T cells. Purified CD4+ T cells were activated with
immobilized anti-CD3 (1 p.g/ml) and soluble anti-CD28 (5 pg/ml) Abs in
the presence of increasing concentrations (0.01-100 ng/ml) of exogenous
N-Shh peptide. Proliferation as determined by [3H]TdR incorporation was
measured at 72 h and compared with cultures of anti-CD3/28-activated T
cells in the absence of Shh. ***,p < 0.001; *, p < 0.05. Representative
experiment of n = 6 is presented.
454 Shh MODULATES CD4+ T CELL EFFECTOR FUNCTION
IGURE 3. Exogenous N-Shh pep-
de augments the cytokine production by
ctivated human CD4+ T cells. Purified
1D4+ T cells were activated with immo-
ilized anti-CD3 (1 (xg/ml) and soluble
nti-CD28 (5 /tig/ml) Abs in the presence
nd absence of increasing concentrations
10-1000 ng/ml) of exogenous N-Shh
eptide. Supematants were collected at
2 h, and the levels of IL-2 (A), 1L-10
B), and IFN-y (Q were measured by
iLl SA and comparedwith cultures ofanti-
lD3/28-activated T cells in the absence
f Shh. ***, p < 0.001. Representative
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In an extension of these studies, the effect of a neutralizing anti-
Ihh Ab (5E1) on T cell function was investigated. We observed
hat the addition of the 5E1 at the initiation of the culture period
ignificantly (p < 0.01 for 5 p-g/ml of 5E1) inhibited the produc-
ion of IL-2 (Fig. 4A) and IFN-y (Fig. 4Q by anti-CD3/28 Ab-
reated CD4+ T cells in a dose-dependent manner. In contrast,
ynthesis of IL-10 was unaffected by the addition of 5E1 (Fig. AB).
n the presence of the isotype control at equivalent concentrations,
10 inhibitory effects on cytokine production were noted (data not
hown).
dodulalion of CD25 and CD69 expression on CD4+ T cells by
xogenous Shh and neutralizing anti-Shh Ab
"o further investigate the effects of Shh on CD4+ T cell activation,
he cell surface expression of CD25 and CD69 was analyzed. N-
>hh peptide (1000 ng/ml) was added to anti-CD3/28 Ab-activated
ID4+ T cells, and cell surface expression of CD25 and CD69 was
neasured by FACS analysis at 48 and 72 h after treatment. The
•■ACS profiles for the expression of CD25 and CD69 for activated
"
cells in the presence and absence of Shh (1000 ng/ml) are shown
n Fig. 5, A and B. respectively. Optimum up-regulation of CD25
vas seen at 72 h of culture, and of CD69 at 48 h of culture. This
ras further investigated by titrating the dose of Shh used and ob-
erving the increase in these activation markers at their optimum
ime of induction. The increase in expression was dose dependent
Fig. 5C). In the presence of 5E1 (50 pig/ml), the percentage of
ells expressing CD25 was reduced, as was the geometric mean
luorescence intensity (Fig. 6A). Similarly, the percentage of T
cells expressing CD69 was also increased, as was the geometric
mean fluorescence intensity (Fig. 6B).
Discussion
In this study, we have demonstrated that Shh and its receptor Ptc
are expressed on human peripheral CD4+ T cells. We also report
that the addition of exogenous Shh enhances the effector function
of activated T cells, in approximately one-half of the randomly
selected individuals tested, confirming that the Shh signaling path¬
way is active in the peripheral immune system and has proinflam¬
matory activity. Furthermore, the ability of a neutralizing anti-Shh
Ab to inhibit proliferation, the expression of activation Ags, and
cytokine production following TCR-mediated activation suggest
that the induction of Shh signaling is a physiological component of
peripheral CD4+ T cell responses.
The recognition of peptide/MHC class II complexes expressed
on the cell surface of APCs together with secondary signals, such
as ligation of costimulatory receptors, are required for the activa¬
tion, the expansion, and the induction of effector function ofCD4+
T cells (e.g., reviewed in Ref. 26). The results of this study indicate
that one action of Shh on the peripheral immune system is to
potentiate TCR and costimulatory receptor-mediated signaling and
both amplify clonal expansion and enhance the effector function of
CD4+ T cells.
We have shown that human peripheral CD4+ T cells express
both Shh and Ptc, as determined by immunocytochemistry and
RT-PCR. Furthermore, we have noted that both Shh and Ptc are






























TGURE 4. Neutralizing anti-Shh Ab (5E1) down-regulates cytokine production. Anti-Shh Ab (5E1) was added at increasing concentrations (5-20
t-g/ml) at the initiation of cultures of purified CD4+ T cells activated by immobilized anti-CD3 (1 jug/ml) and soluble anti-CD28 (5 jug/ml) Abs.
lupematants were collected at 72 h, and the levels of IL-2 (4), IL-10 (B), and IFN-y (Q were measured by ELISA and compared with cultures of
nti-CD3/28-activated T cells without added 5E1. ***, p < 0.001; **,p < 0.01. Representative experiment of n = 3 is presented.
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N-Shh [ 1000ng/ml]Isotvpe No peptide
CD25 at 72 hours
FIGURE 5. Kinetics of modulation of cell surface
expression of CD25 and CD69 by N-Shh peptide. Pu¬
rified CD4+ T cells were activated with immobilized
anti-CD3 (1 jug/ml) and soluble anti-CD28 (5 p.g/ml)
Abs in the presence of 1000 ng exogenous N-Shh pep¬
tide. Cell surface expression ofCD25 (A) and CD69 (B)
at 48 and 72 h was compared with that on anti-CD3/
28-activated T cells in the absence of N-Shh and to an
isotype control. Maximum N-Shh up-regulation of
CD69 was observed at 48 h, and ofCD25 at 72 h; flow
cytometric data showing titration curves for this effect
at these time points are summarized in C. Representa¬
tive experiment of n = 6 is presented.
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Treatment % CD69+ve cells
[GMI] at 48 hr
% CD25+ve cells
|C;MI] at 72hr
No peptide 28.32 f65,76 31.36 [110.841
N-Slth lOng/ml 44.98 [59.23] 44.23 [126.97]
N-Shh lOOngfml 74.35 [89.451 80.11 [142.25]
N-Shh lOOOng/ml 70.99 [80.29] 84.06 [148.591
in agreement with and extend those of Bhardwaj et al. (15), who
demonstrated using RT-PCR that mature human CD3 + cells ex¬
press Shh, Ptc, and smo. In contrast to peripheral T cells, it has
been reported that thymocyte populations appear to express only
the receptors Ptc and smo (17), which implies that Shh neither
mediates interactions between thymocyte populations nor influ¬
ences the differentiation and expansion of thymocytes through its
autocrine activity. Shh signaling induces the expression of Ptc (11)
and, therefore, the ability of exogenous Shh to up-regulate ptc
expression on human CD4 * T cells activated by anti-CD3/CD28
Ab treatment confirms that this pathway is functional in T cells.
It is well documented that Shh has proliferative effects on a wide
range of different cell types, including those of the hemopoietic
system (15). In this study, we demonstrate that exogenous Shh
enhances TCR-mediated proliferation by CD4+ T cells. The fail¬
ure of Shh to induce proliferation or increase expression of Ptc on
resting CD4+ T cells suggests that it acts a cofactor, which po¬
tentiates TCR-mediated signaling and amplifies clonal expansion.
The proliferative activity of Shh is, in part, through it effects on
cell cycle (e.g., Refs. 13, 14, 27, 28) and, for example, it has been
reported that Shh can increase the number of neuronal precursors
in S phase (14). In parallel studies on murine CD4+ T cells, we
have noted that Shh promotes their entry into the proliferative S/G2
phase of cell cycle (18). Kenney and Rowitch (14) observed that
Shh failed to advance quiescent neuronal cells into the cell cycle,
which is consistent with our results that Shh has no activity on
resting T cells. Furthermore, although it has been reported that Shh
can induce bcl-2 (29), we observed that the addition of Shh failed
to increase survival in activated T cells (data not shown) and,
therefore, it is unlikely that enhancement of T cell proliferation by
Shh is brought about through a reduction in apoptosis (30-32).
For some individuals, we observed that the addition of exoge¬
nous Shh failed to enhance the proliferation response. Mutations in
Ptc and smo, resulting in constitutive activation of Shh signaling,
have been reported (33). Thus, polymorphisms that bring about
loss or modulation of function are also possible and would provide
one explanation for our observations. Furthermore, there is a large
body of evidence, which demonstrates that proliferation can be
dissociated from other T cell effector functions, such as cytotoxic
activity and the production of cytokines (e.g., reviewed in Ref. 33).
Therefore, we investigated the ability of Shh to modulate cytokine
production by CD4+ T cells activated by anti-CD3/CD28 Ab treat¬
ment. The addition of exogenous Shh to activated T cells increased
production of the different cytokines measured in this study,
namely IL-2, IL-10, and IFN-y. There was no evidence that Shh
had selective effects on the synthesis of these cytokines. This is in
contrast to a previous report in which increasing the threshold of
TCR-mediated signaling enhanced IFN-y production, but had no
effect on IL-10 production or T cell proliferation (34). Further¬
more, we demonstrate that the addition of exogenous Shh to acti¬
vated CD4+ T cells results in the up-regulation of cell surface
expression of CD69, implying that the T cells had been further
activated by Shh signaling. The expression of CD25 on activated
T cells was also enhanced by exogenous Shh. These findings taken
together with the observation that Shh enhances the production of
IL-2, in part, may be an additional mechanism by which Shh is
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CD25 at 72 hrs
No antibody 5E1 50ng/ml
FIGURE 6. Anti-Shh Ab decreases the expres¬
sion ofCD25 and CD69 on activated CD4+ T cells.
Purified CD4"1 T cells were activated with immobi¬
lized anti-CD3 (1 pg/ml) and soluble anti-CD28 (5
fxg/ml) Abs in the presence of the anti-Shh Ab (5E1)
at 50 p.g/ml. Cell surface expression of CD25 (A)
and CD69 (B) at 72 h was compared with that on
anti-CD3/28-activated T cells in the absence of 5E1.
Representative experiment of n = 3 is presented.
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able to increase the proliferation of activated T cells. It also sug¬
gests that Shh signaling does not act by modulating the threshold
of TCR signaling (35). We observed that the addition of the neu¬
tralizing anti-Shh Ab was able to inhibit the production of IL-2 and
IFN-y, but not IL-10, in contrast to exogenous peptide, which en¬
hanced the synthesis of these cytokines. This suggests that IL-10
production can be regulated by TCR signaling independently of
Shh activation. Flowever, one effect of Shh on peripheral T cells
appears to be its ability to amplify cytokine production by acti¬
vated CD4+ T cells in a nonselective manner.
We demonstrate that the addition of a neutralizing anti-Shh Ab
to CD4+ T cells activated by anti-CD3/28 Ab treatment inhibits T
cell proliferation, IL-2 production, and the expression of the acti¬
vation Ags CD25 and CD69. These findings imply that induction
of Shh signaling is a physiological component of T cell activation
following the ligation of TCR and costimulatory receptors. Fur¬
thermore, this result suggests that Shh produced by CD4+ T cells
themselves in response to TCR-mediated activation functions in an
autocrine manner. In the thymus, Shh is expressed on epithelial
cells, and Ptc and Smo on the thymocytes (15), suggesting that Shh
signaling can also be delivered by APCs. We have also detected
Ptc and smo in macrophages (unpublished data). The expression of
receptors for Shh on both T cells and APCs would be consistent
with the concept that the effector function of both these cell pop¬
ulations can be modulated by Shh signaling. However, the effects
of Shh on APC function remain to be determined.
In summary, we show that the Shh signaling is functional in
peripheral CD4+ T cells. Both Shh and its receptor Ptc are ex¬
pressed on T cells, and they are up-regulated when the T cells are
activated by TCR and costimulatory receptor ligation. The func¬
tional consequences of this are that T cell proliferation is enhanced
and cell surface expression of the activation Ags CD25 and CD69
is increased, as is cytokine production. Furthermore, the ability of
a neutralizing Ab to directly inhibit the biological activity of ac¬
tivated T cells suggests that Shh signaling is a physiological com¬
ponent of CD4+ T cell responses.
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